

ACCESS DB # _____
PLEASE PRINT CLEARLY

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Sinta Robinson Examiner #: _____ Date: 3-17-09
Art Unit: 1625 Phone Number: 2- Serial Number: 10-550857
Location (Bldg/Room#): _____ (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

"For Sequence Searches Only" Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

See claims

INVENTOR SEARCH

=> fil hcapl
 FILE 'HCAPLUS' ENTERED AT 10:25:28 ON 20 MAR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2009 VOL 150 ISS 13
 FILE LAST UPDATED: 19 Mar 2009 (20090319/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

```
=> d que nos 181
L12      STR
L13 (    23983)SEA FILE=REGISTRY SSS FUL L12
L14      STR
L15      STR
L16 (    20832)SEA FILE=REGISTRY SUB=L13 SSS FUL (L14 OR L15)
L17 (    695)SEA FILE=HCAPLUS SPE=ON  ABB=ON  L16
L18 (      1)SEA FILE=HCAPLUS SPE=ON  ABB=ON  US2006-550857/AP
L19 (    163)SEA FILE=HCAPLUS SPE=ON  ABB=ON  ETO N7/AU
L20 (    114)SEA FILE=HCAPLUS SPE=ON  ABB=ON  NAGAO R7/AU
L21 (    361)SEA FILE=HCAPLUS SPE=ON  ABB=ON  KAZAMA T7/AU
L22      2 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L18 OR L19 OR L20 OR L21)
        AND L17
L23      1 SEA FILE=REGISTRY SPE=ON  ABB=ON  7723-14-0 =PHOSPHOROUS
L24      3439 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PRURITUS/CT
L25      7680 SEA FILE=HCAPLUS SPE=ON  ABB=ON  IMMUNODEFICIENCY/CT
L26      1825 SEA FILE=HCAPLUS SPE=ON  ABB=ON  SKIN/OBI(L)ULCER?/OBI
L27      6853 SEA FILE=HCAPLUS SPE=ON  ABB=ON  HYPERLIPIDEMIA/CT
L28      30922 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANEMIA/OBI
L29      7980 SEA FILE=HCAPLUS SPE=ON  ABB=ON  SEX?/OBI(L) (DISORDER#/OBI OR
        DYSFUNCTION?/OBI)
L30      299 SEA FILE=HCAPLUS SPE=ON  ABB=ON  RED/OBI(L)EYE#/OBI
L31      227 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (BIOLOGICAL TRANSPORT/CT OR
        BLOOD/OBI OR SERUM/OBI) (L)PHOSPHOROUS/OBI
L32      7512 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CALCIFICATION/OBI
L33      2484 SEA FILE=HCAPLUS SPE=ON  ABB=ON  GROWTH/CW(L) (RETARD?/OBI OR
```

L34 6287 SEA FILE=HCAPLUS SPE=ON ABB=ON BONE#/OBI (L) (FRACTURE/OBI OR
 DEFORM#/OBI)
 L35 1236 SEA FILE=HCAPLUS SPE=ON ABB=ON (CARDIAC/OBI OR HEART/OBI) (L)C
 ONDUCTION/OBI
 L36 1695 SEA FILE=HCAPLUS SPE=ON ABB=ON PAIN/OBI (L) (BONE/OBI OR
 JOINT#/OBI)
 L37 287 SEA FILE=HCAPLUS SPE=ON ABB=ON (NERVE/CT OR CENTRAL NERVOUS
 SYSTEM+NT/CT) (L) (PTH/OBI OR VITAMIN D/OBI OR PARATHYROID
 HORMONE/OBI)
 L38 6 SEA FILE=HCAPLUS SPE=ON ABB=ON PERIPHERAL NERVOUS SYSTEM+NT/C
 T (L) (PTH/OBI OR VITAMIN D/OBI OR PARATHYROID HORMONE/OBI)
 L39 23531 SEA FILE=HCAPLUS SPE=ON ABB=ON (KIDNEY#/OBI OR RENAL/OBI) (L)F
 AILURE/OBI
 L40 75591 SEA FILE=HCAPLUS SPE=ON ABB=ON HEART, DISEASE/CT OR CARDIOMYO
 PATH/OBI
 L41 3608 SEA FILE=HCAPLUS SPE=ON ABB=ON HYPERPARATHYROID#/OBI
 L42 593 SEA FILE=HCAPLUS SPE=ON ABB=ON HYPERPHOSPHATEMI#/OBI
 L43 829 SEA FILE=HCAPLUS SPE=ON ABB=ON OSTEALGIA/OBI OR ARTHRALGIA/OB
 I
 L44 2493 SEA FILE=HCAPLUS SPE=ON ABB=ON CARBOHYDRATE METABOLISM/CT
 L45 197 SEA FILE=HCAPLUS SPE=ON ABB=ON TENDON/CT (L) (TORN/OBI OR
 RUPTURE#/OBI OR INJUR#/OBI OR TEAR#/OBI)
 L46 21292 SEA FILE=HCAPLUS SPE=ON ABB=ON BONE/CT (L) (DISEASE/OBI OR
 DISORDER#/OBI)
 L47 1114 SEA FILE=HCAPLUS SPE=ON ABB=ON OSTEODYSTROPH#/OBI OR
 OSTEOPATH#/OBI
 L48 10271 SEA FILE=HCAPLUS SPE=ON ABB=ON ARTERIOSCLEROSIS/CT
 L49 170 SEA FILE=HCAPLUS SPE=ON ABB=ON VASCULOPATH#/OBI (L)DIABET#/OBI
 L50 225 SEA FILE=HCAPLUS SPE=ON ABB=ON (LUNG/OBI OR PULMONARY/OBI) (L)
 (EXPANSION/OBI OR DIFFUS#/OBI) (L) (DISEASE#/OBI OR DISORDER#/OBI
 OR IMPAIR#/OBI)
 L51 46938 SEA FILE=HCAPLUS SPE=ON ABB=ON (HEART/OBI OR CARDIAC/OBI) (L) (I
 NFACT#/OBI OR FAILURE/OBI OR MURMUR/OBI)
 L52 344 SEA FILE=HCAPLUS SPE=ON ABB=ON NERVOUS SYSTEM+NT/CT (L) (PTH/OB
 I OR VITAMIN D/OBI OR PARATHYROID HORMONE/OBI)
 L53 203624 SEA FILE=HCAPLUS SPE=ON ABB=ON L23
 L54 1477 SEA FILE=HCAPLUS SPE=ON ABB=ON L53 (L) (TRANSPORT#/OBI)
 L81 2 SEA FILE=HCAPLUS SPE=ON ABB=ON L22 OR (L22 AND (L24 OR L25
 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34
 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43
 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52
 OR L54))

=> d ibib abs hitind hitstr l81 1-2

L81 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:584604 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:9944


TITLE: Preparation of condensed pyrimidines, their use as
 serum phosphorus level-lowering agents and phosphoric
 acid-transport inhibitors, and their pharmaceutical
 compositions

INVENTOR(S): Eto, Nobuaki; Nagao, Pika; Sakai,
 Teruyuki; Kato, Shinichiro
 PATENT ASSIGNEE(S): Kirin Brewery Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 108pp.
 CODEN: JKXXAF

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007131532	A	20070531	JP 2001-303288	20010928
PRIORITY APPLN. INFO.:			JP 2001-303288	20010928
OTHER SOURCE(S):	MARPAT 147:9944			

GI



- AB Title compds. I [A = (un)substituted 5- to 9-membered (hetero)cyclic ring; R5 = (un)substituted C1-6 alkyl(oxy), aryl(oxy), C1-6 alkylamino, arylthio, heterocyclyl, etc.; R6, R7 = H, (un)substituted C1-6 alkyl, aryl C2-6 alkenyl, C2-6 alkynyl, aryl, heterocyclyl], their pharmacol. acceptable salts, or solvates are prepared. Thus, Me 2-aminobenzoate was amidated with 3,4-dimethoxybenzoyl chloride, cyclized with NH₂NH₂.H₂O, and reacted with trans-cinnamaldehyde to give I (A = benzene residue, R5 = 3,4-dimethoxyphenyl, R6 = H, R7 = trans-PhCH:CH), which inhibited Na-dependent phosphate transport with IC₅₀ value of 9.11 μM.
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
- ST phosphoric acid transport inhibitor pyrimidine prepn; kidney failure hyperphosphatemia treatment
- IT Kidney, disease
 (failure, chronic; preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)
- IT Kidney, disease
 (hyperphosphatemia; preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)
- IT Hyperparathyroidism
 (primary; preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)
- IT Hyperparathyroidism
 (secondary; preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)
- IT 7723-14-6, Phosphorus, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)
- IT 73861-01-5P 166873-11-4P 166873-12-5P
 328033-29-6P 937706-65-5P 937706-66-6P
 937706-67-7P 937706-68-8P 937706-69-9P
 937706-70-2P 937706-71-3P 937706-72-4P
 937706-73-5P 937706-74-6P 937706-75-7P

937706-76-8P 937706-77-9P 937706-78-0P
937706-79-1P 937706-80-4P 937706-81-5P
937706-82-6P 937706-83-7P 937706-84-8P
937706-85-9P 937706-86-0P 937706-87-1P
937706-88-2P 937706-89-3P 937706-90-6P
937706-91-7P 937706-92-9P 937706-93-9P
937706-94-0P 937706-95-1P 937706-96-2P
937706-97-3P 937706-98-4P 937706-99-5P
937707-00-1P 937707-01-2P 937707-02-3P
937707-03-4P 937707-04-5P 937707-05-6P
937707-06-7P 937707-07-6P 937707-08-9P
937707-09-0P 937707-10-3P 937707-11-4P
937707-12-5P 937707-13-6P 937707-14-7P
937707-15-8P 937707-16-9P 937707-17-0P
937707-18-1P 937707-19-2P 937707-20-5P
937707-21-6P 937707-22-7P 937707-23-6P
937707-24-9P 937707-25-0P 937707-26-1P
937707-27-2P 937707-28-3P 937707-29-4P
937707-30-7P 937707-31-8P 937707-32-9P
937707-33-0P 937707-34-1P 937707-35-2P
937707-36-3P 937707-37-4P 937707-38-5P
937707-39-6P 937707-40-9P 937707-41-0P
937707-42-1P 937707-43-2P 937707-44-3P
937707-45-1P 937707-46-5P 937707-47-6P
937707-48-7P 937707-49-8P 937707-50-1P
937707-51-2P 937707-52-3P 937707-53-4P
937707-54-5P 937707-55-6P 937707-56-7P
937707-57-8P 937707-58-9P 937707-59-0P
937707-60-3P 937707-61-4P 937707-62-5P
937707-63-6P 937707-64-7P 937707-65-8P
937707-66-9P 937707-67-0P 937707-68-1P
937707-69-2P 937707-70-5P 937707-71-6P
937707-72-7P 937707-73-8P 937707-74-9P
937707-75-0P 937707-76-1P 937707-77-2P
937707-78-3P 937707-79-4P 937707-80-7P
937707-81-8P 937707-82-9P 937707-83-0P
937707-84-1P 937707-85-2P 937707-86-3P
937707-87-4P 937707-88-5P 937707-89-6P
937707-90-9P 937707-91-0P 937707-92-1P
937707-93-2P 937707-94-3P 937707-95-4P
937707-96-5P 937707-97-6P 937707-98-7P
937707-99-8P 937708-00-4P 937708-01-5P
937708-02-6P 937708-03-7P 937708-04-8P
937708-05-9P 937708-06-0P 937708-07-1P
937708-08-2P 937708-09-3P 937708-10-6P
937708-11-7P 937708-12-8P 937708-13-9P
937708-14-0P 937708-15-1P 937708-16-2P
937708-17-3P 937708-18-4P 937708-19-5P
937708-20-8P 937708-21-9P 937708-22-0P
937708-23-1P 937708-24-2P 937708-25-3P
937708-26-4P 937708-27-5P 937708-28-6P
937708-29-7P 937708-30-0P 937708-31-1P
937708-32-2P 937708-33-3P 937708-34-4P
937708-35-5P 937708-36-6P 937708-37-7P
937708-38-8P 937708-39-9P 937708-40-0P
937708-41-3P 937708-42-4P 937708-43-5P
937708-44-6P 937708-45-7P 937708-46-8P
937708-47-9P 937708-48-0P 937708-49-1P
937708-50-4P 937708-51-5P 937708-52-6P
937708-53-7P 937708-54-8P 937708-55-9P

937708-56-0P 937708-57-1P 937708-58-2P
 937708-59-3P 937708-60-6P 937708-61-7P
 937708-62-8P 937708-63-9P 937708-64-0P
 937708-65-1P 937708-66-2P 937708-67-3P
 937708-68-4P 937708-69-5P 937708-70-6P
 937708-71-9P 937708-72-0P 937708-73-1P
 937708-74-2P 937708-75-3P 937708-76-4P
 937708-77-5P 937708-78-6P 937708-79-7P
 937708-80-0P 937708-81-1P 937708-82-2P
 937708-83-3P 937708-84-4P 937708-85-5P
 937708-86-6P 937708-87-7P 937708-88-8P
 937708-89-9P 937708-90-2P 937708-91-3P
 937708-92-4P 937708-93-5P 937708-94-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)

IT 937708-95-7P 937708-96-8P 937708-97-9P
 937708-98-0P 937708-99-1P 937709-00-7P
 937709-01-8P 937709-02-9P 937709-03-0P
 937709-04-1P 937709-05-2P 937709-06-3P
 937709-07-4P 937709-08-5P 937709-09-6P
 937709-10-9P 937709-11-0P 937709-12-1P
 937709-13-2P 937709-14-3P 937709-15-4P
 937709-16-5P 937709-17-6P 937709-18-7P
 937709-19-8P 937709-20-1P 937709-21-2P
 937709-22-3P 937709-35-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)

IT 134-20-3, Methyl 2-aminobenzoate 302-01-2, Hydrazine, reactions
 456-48-4, 3-Fluorobenzaldehyde 3535-37-3, 3,4-Dimethoxybenzoyl chloride
 4556-23-4, 4-Mercaptopyridine 4584-46-7,
 N-(2-Chloroethyl)-N,N-dimethylamine hydrochloride 14371-10-9,
 trans-Cinnamaldehyde 20260-53-1, Nicotinoyl chloride hydrochloride
 52727-57-8, Methyl 2-amino-5-bromobenzoate 937709-23-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)

IT 7723-14-0, Phosphorus, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)

RN 7723-14-0 HCAPLUS

CN Phosphorus (CA INDEX NAME)

P

IT 73361-01-5P 106873-11-4P 106873-12-5P
 328033-29-0P 937706-65-5P 937706-66-6P
 937706-67-7P 937706-68-8P 937706-69-9P
 937706-70-2P 937706-71-3P 937706-72-4P
 937706-73-5P 937706-74-6P 937706-75-7P
 937706-76-8P 937706-77-9P 937706-78-0P

937706-79-1P 937706-80-4P 937706-81-5P
 937706-82-6P 937706-83-7P 937706-84-8P
 937706-85-9P 937706-86-0P 937706-87-1P
 937706-88-2P 937706-89-3P 937706-90-6P
 937706-91-7P 937706-92-8P 937706-93-9P
 937706-94-0P 937706-95-1P 937706-96-2P
 937706-97-3P 937706-98-4P 937706-99-5P
 937707-00-1P 937707-01-2P 937707-02-3P
 937707-03-4P 937707-04-5P 937707-05-6P
 937707-06-7P 937707-07-8P 937707-08-9P
 937707-09-0P 937707-10-3P 937707-11-4P
 937707-12-5P 937707-13-6P 937707-14-7P
 937707-15-8P 937707-16-9P 937707-17-0P
 937707-18-1P 937707-19-2P 937707-20-5P
 937707-21-6P 937707-22-7P 937707-23-6P
 937707-24-9P 937707-25-0P 937707-26-1P
 937707-27-2P 937707-28-3P 937707-29-4P
 937707-30-7P 937707-31-9P 937707-32-5P
 937707-33-0P 937707-34-1P 937707-35-2P
 937707-36-3P 937707-37-4P 937707-38-5P
 937707-39-6P 937707-40-9P 937707-41-0P
 937707-42-1P 937707-43-2P 937707-44-3P
 937707-45-4P 937707-46-5P 937707-47-6P
 937707-48-7P 937707-49-8P 937707-50-1P
 937707-51-2P 937707-52-3P 937707-53-4P
 937707-54-5P 937707-55-6P 937707-56-7P
 937707-57-8P 937707-58-9P 937707-59-0P
 937707-60-3P 937707-61-4P 937707-62-5P
 937707-63-6P 937707-64-7P 937707-65-8P
 937707-66-9P 937707-67-0P 937707-68-1P
 937707-69-2P 937707-70-5P 937707-71-6P
 937707-72-7P 937707-73-8P 937707-74-9P
 937707-75-0P 937707-76-1P 937707-77-2P
 937707-78-3P 937707-79-4P 937707-80-7P
 937707-81-8P 937707-82-9P 937707-83-0P
 937707-84-1P 937707-85-2P 937707-86-3P
 937707-87-4P 937707-88-5P 937707-89-6P
 937707-90-9P 937707-91-0P 937707-92-1P
 937707-93-2P 937707-94-3P 937707-95-4P
 937707-96-5P 937707-97-6P 937707-98-7P
 937707-99-8P 937708-00-4P 937708-01-5P
 937708-02-6P 937708-03-7P 937708-04-8P
 937708-05-9P 937708-06-0P 937708-07-1P
 937708-08-2P 937708-09-3P 937708-10-6P
 937708-11-7P 937708-12-8P 937708-13-9P
 937708-14-0P 937708-15-1P 937708-16-2P
 937708-17-3P 937708-18-4P 937708-19-5P
 937708-20-8P 937708-21-9P 937708-22-0P
 937708-23-1P 937708-24-2P 937708-25-3P
 937708-26-4P 937708-27-5P 937708-28-6P
 937708-29-7P 937708-30-0P 937708-31-1P
 937708-32-2P 937708-33-3P 937708-34-4P
 937708-35-5P 937708-36-6P 937708-37-7P
 937708-38-8P 937708-39-9P 937708-40-2P
 937708-41-3P 937708-42-4P 937708-43-5P
 937708-44-6P 937708-45-7P 937708-46-8P
 937708-47-9P 937708-48-0P 937708-49-1P
 937708-50-4P 937708-51-5P 937708-52-6P
 937708-53-7P 937708-54-8P 937708-55-9P
 937708-56-0P 937708-57-1P 937708-58-2P


937708-59-3P 937708-60-6P 937708-61-7P
 937708-62-8P 937708-63-9P 937708-64-0P
 937708-65-1P 937708-66-2P 937708-67-3P
 937708-68-4P 937708-69-5P 937708-70-6P
 937708-71-9P 937708-72-0P 937708-73-1P
 937708-74-2P 937708-75-3P 937708-76-4P
 937708-77-5P 937708-78-6P 937708-79-7P
 937708-80-6P 937708-81-1P 937708-82-2P
 937708-83-3P 937708-84-4P 937708-85-5P
 937708-86-6P 937708-87-7P 937708-88-8P
 937708-89-9P 937708-90-2P 937708-91-3P
 937708-92-4P 937708-93-5P 937708-94-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for
 treatment of diseases)


RN 73861-01-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-phenyl-3-[(phenylmethylene)amino]- (CA INDEX NAME)




RN 106873-11-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-fluorophenyl)methylene]amino]-2-phenyl- (CA
 INDEX NAME)




RN 106873-12-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(3-fluorophenyl)methylene]amino]-2-phenyl- (CA
 INDEX NAME)



RN 328033-29-0 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[(2-bromophenyl)methylene]amino]-2-(3,4-
 dimethoxyphenyl)- (CA INDEX NAME)



RN 937706-65-5 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2E)-3-phenyl-2-propen-1-ylidene]amino]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 937706-66-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-67-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-68-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(2-methoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-69-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-methoxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 937706-70-2 HCAPLUS


CN 4(3H)-Quinazolinone, 2-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-71-3 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]amino]- (CA INDEX NAME)


Double bond geometry as described by E or Z.




RN 937706-72-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3,5-bis(trifluoromethyl)phenyl]methylene]amino]-
2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)

RN 937706-73-5 HCAPLUS



CN Benzonitrile, 3-[[[2-(3,4-dimethoxyphenyl)-4-oxo-3(4H)-
quinazolinyl]imino]methyl]- (CA INDEX NAME)

RN 937706-74-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[4-hydroxy-3-
methoxyphenyl]methylene]amino]- (CA INDEX NAME)

RN 937706-75-7 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[3,4,5-
trimethoxyphenyl]methylene]amino]- (CA INDEX NAME)



RN 937706-76-8 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[(2E)-3-phenyl-2-propen-1-ylidene]amino]- (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 937706-77-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(2-bromophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-78-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-79-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-80-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(phenylmethylene)amino]- (CA INDEX NAME)




RN 937706-81-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-82-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-83-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-84-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(2-furanylmethylene)amino]- (CA INDEX NAME)




RN 937706-85-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(5-methyl-2-furanyl)methylene]amino]- (CA INDEX NAME)




RN 937706-86-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(2-thienylmethylene)amino]- (CA INDEX NAME)




RN 937706-87-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-thienylmethylene)amino]-
(CA INDEX NAME)




RN 937706-88-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(2,4-dihydroxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-89-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3,4-dihydroxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-90-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[(phenylmethylene)amino]- (CA INDEX NAME)




RN 937706-91-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[2-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-92-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-93-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[2-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-94-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-95-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3-chloro-4-fluorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-96-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[4-(trifluoromethoxy)phenyl)methylene]amino]- (CA INDEX NAME)




RN 937706-97-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937706-98-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(3-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937706-99-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(4-hydroxy-3,5-dimethylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-00-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-ethoxy-4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-01-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[(4-fluorophenyl)methyleneamino]- (CA INDEX NAME)




RN 937707-02-3 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[(3-hydroxyphenyl)methyleneamino]- (CA INDEX NAME)



RN 937707-03-4 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[(4-methylphenyl)methyleneamino]- (CA INDEX NAME)



RN 937707-04-5 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-

(trifluoromethyl)phenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA
INDEX NAME)




RN 937707-05-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-((3,4-dimethoxyphenyl)-3-[[4-hydroxy-3-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-06-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-((3,4-dimethoxyphenyl)-3-[[2,5-dimethylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-07-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-((3,4-dimethoxyphenyl)-3-[[2-fluoro-5-(trifluoromethyl)phenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-08-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-((2-fluorophenyl)methyleneamino)-3-(((4-hydroxy-3-methylphenyl)methyleneamino)- (CA INDEX NAME)





RN 937707-09-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-(((2,5-dimethylphenyl)methyleneamino)-2-((2-fluorophenyl)- (CA INDEX NAME)




RN 937707-10-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-(((3-fluorophenyl)methyleneamino)-2-((4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-11-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-fluorophenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-12-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-13-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-hydroxyphenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-14-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-15-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-(2-propen-1-yloxy)phenyl]methylene]amino]- (CA INDEX NAME)





RN 937707-16-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3,5-dimethoxyphenyl]methylene]amino]- (CA INDEX NAME)




RN 937707-17-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[3-(trifluoromethyl)phenoxy]phenyl]methylene]amino]- (CA INDEX NAME)




RN 937707-18-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-19-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-20-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-21-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-22-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(4-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-23-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(4-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937707-24-9 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-25-0 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-(4-

methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-26-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-27-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-28-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-29-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-30-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-31-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-32-9 HCAPLUS


CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-33-0 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[(4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-34-1 HCAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)



RN 937707-35-2 HCAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-36-3 HCAPLUS
 CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-37-4 HCAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-38-5 HCAPLUS

CN 4(3H)-Quinazolinone, 7-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-39-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-40-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-41-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-42-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-43-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-44-3 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-45-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-46-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-47-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-48-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[3-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-49-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-50-1 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)





RN 937707-51-2 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937707-52-3 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)





RN 937707-53-4 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)





RN 937707-54-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[(3,4-dimethylphenyl)methyleneamino]- (CA INDEX NAME)





RN 937707-55-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[(3,4-dimethylphenyl)methyleneamino]- (CA INDEX NAME)





RN 937707-56-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[[(3,4-dimethylphenyl)methyleneamino]- (CA INDEX NAME)




RN 937707-57-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3,4-dimethylphenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-58-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3,4-dimethylphenyl)methylene]amino]-2-(3-fluorophenyl)- (CA INDEX NAME)





RN 937707-59-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3,4-dimethylphenyl)methylene]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)





RN 937707-60-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-61-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-6-chloro-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-62-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-63-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 937707-64-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 937707-65-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-bromo-4-methoxyphenyl)methylene]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 937707-66-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3-nitrophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-67-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-(dimethylamino)phenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-68-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-fluorophenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-69-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-fluorophenyl)-3-[[4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-70-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(4-fluorophenyl)methylene]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 937707-71-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-chlorophenyl)methylene]amino]-2-(4-chlorophenyl)- (CA INDEX NAME)




RN 937707-72-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-fluorophenyl)-3-[[3-(4-hydroxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-73-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[3-(4-pyridinyl)methylene]amino]- (CA INDEX NAME)




RN 937707-74-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(3-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937707-75-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[(3-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937707-76-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(3-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937707-77-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-78-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-((3,5-dimethoxyphenyl)methyleneamino)-3-((4-fluorophenyl)methyleneamino)- (CA INDEX NAME)




RN 937707-79-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-(((3-chlorophenyl)methyleneamino)-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-80-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-(((4-chlorophenyl)methyleneamino)-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 937707-81-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[3-(4-chlorophenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-82-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[3-(4-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937707-83-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(3-fluorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)





RN 937707-84-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-fluorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 937707-85-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(3-chlorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 937707-86-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-chlorophenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 937707-87-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-methylphenyl)methylene]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 937707-88-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-[3-(dimethylamino)propoxy]-3-[[4-(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-89-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[3,4-dimethoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 937707-90-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[(3,4-dimethoxyphenyl)methyleneamino]- (CA INDEX NAME)




RN 937707-91-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,5-dimethoxyphenyl)-3-[[(3,4-dimethoxyphenyl)methyleneamino]- (CA INDEX NAME)




RN 937707-92-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-fluorophenyl)methyleneamino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937707-93-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-fluorophenyl)methylene]amino]-2-(3-pyridinyl)-
(CA INDEX NAME)




RN 937707-94-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-methylphenyl)methylene]amino]-2-(3-pyridinyl)-
(CA INDEX NAME)




RN 937707-95-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-methylphenyl)methylene]amino]-2-(3-pyridinyl)-
(CA INDEX NAME)




RN 937707-96-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3,4-dimethylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937707-97-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-fluorophenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937707-98-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-fluorophenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937707-99-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-methylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-00-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-methylphenyl)methylene]amino]-2-(4-pyridinyl)-
(CA INDEX NAME)




RN 937708-01-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-[[(3,4-dimethylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-02-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-[2-(dimethylamino)ethoxy]-3-[[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-03-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-[2-(diethylamino)ethoxy]-2-(3,4-dimethoxyphenyl)-3-[[(4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-04-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(3-fluorophenyl)methylene]amino]-6-methoxy- (CA INDEX NAME)




RN 937708-05-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[(4-fluorophenyl)methylene]amino]-6-methoxy- (CA INDEX NAME)




RN 937708-06-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methoxy-3-[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-07-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methoxy-3-[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-08-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3,4-dimethylphenyl)methylene]amino]-6-methoxy- (CA INDEX NAME)




RN 937708-09-3 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(3-fluorophenyl)methylene]amino]-6-methyl- (CA INDEX NAME)




RN 937708-10-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-fluorophenyl)methylene]amino]-6-methyl- (CA INDEX NAME)




RN 937708-11-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methyl-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-12-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-methyl-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-13-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3,4-dimethylphenyl)methylene]amino]-6-methyl- (CA INDEX NAME)




RN 937708-14-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(3-fluorophenyl)methylene]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 937708-15-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-fluorophenyl)methylene]amino]-2-(2-furanyl)- (CA INDEX NAME)



RN 937708-16-2 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(2-furanyl)-3-[[3-(3-methylphenyl)methylene]amino]- (CA INDEX NAME)



RN 937708-17-3 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-2-(2-furanyl)-3-[[4-(4-

methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-18-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3,4-dimethylphenyl)methylene]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 937708-19-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 937708-20-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-fluorophenyl)methylene]amino]-2-(2-thienyl)- (CA INDEX NAME)




RN 937708-21-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-fluorophenyl)methylene]amino]-2-(2-thienyl)- (CA INDEX NAME)




RN 937708-22-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-methylphenyl)methylene]amino]-2-(2-thienyl)- (CA INDEX NAME)




RN 937708-23-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-methylphenyl)methylene]amino]-2-(2-thienyl)- (CA INDEX NAME)




RN 937708-24-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3,4-dimethylphenyl)methylene]amino]-2-(2-thienyl)- (CA INDEX NAME)




RN 937708-25-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(2-thienyl)- (CA INDEX NAME)



RN 937708-26-4 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(4-dimethylphenyl)methylene]amino]-2-(4-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 937708-27-5 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(4-methylphenyl)methylene]amino]-2-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 937708-28-6 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[3-(3,4-dimethylphenyl)methylene]amino]-2-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 937708-29-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3-fluorophenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-30-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4-fluorophenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-31-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3-methylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-32-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4-methylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-33-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3,4-dimethylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-34-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-35-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(3-fluorophenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-36-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-fluorophenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-37-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(3-methylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-38-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-methylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-39-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3,4-dimethylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)





RN 937708-40-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-41-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[3-fluorophenyl)methylene]amino]- (CA INDEX NAME)





RN 937708-42-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[4-fluorophenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-43-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(4-ethylphenyl)-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-44-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[(4-ethylphenyl)-3-[[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-45-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3,4-dimethylphenyl)methylene]amino]-2-(4-ethylphenyl)- (CA INDEX NAME)




RN 937708-46-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-(4-ethylphenyl)- (CA INDEX NAME)




RN 937708-47-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[(3-fluorophenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-48-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[4-fluorophenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-49-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[3-methylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-50-4 HCAPLUS


CN 4(3H)-Quinazolinone, 6-chloro-3-[[4-methylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-51-5 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[[(3,4-dimethylphenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-52-6 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)



RN 937708-53-7 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[[(4-fluorophenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-54-8 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[[(3-methylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-55-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[4-methylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-56-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[3,4-dimethylphenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-57-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-58-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3-fluorophenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-59-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4-fluorophenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-60-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3-methylphenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-61-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4-methylphenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-62-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3,4-dimethylphenyl)methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-63-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-[3-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937708-64-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[1-methyl-1H-pyrrol-2-yl]methylene]amino]- (CA INDEX NAME)




RN 937708-65-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[[4,5-dimethyl-2-furanyl]methylene]amino]- (CA INDEX NAME)



RN 937708-66-2 HCAPLUS


CN 4-(3H)-Quinazolinone, 3-[[4-methylphenyl)methylene]amino]-2-(4-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 937708-67-3 HCAPLUS

CN 4-(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-fluorophenyl)methylene]amino]-6-iodo- (CA INDEX NAME)




RN 937708-68-4 HCAPLUS

CN 4-(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-fluorophenyl)methylene]amino]-6-iodo- (CA INDEX NAME)




RN 937708-69-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-iodo-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-70-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6-iodo-3-[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-71-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[3,4-dimethylphenyl)methylene]amino]-6-iodo- (CA INDEX NAME)




RN 937708-72-0 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)-6-iodo- (CA INDEX NAME)




RN 937708-73-1 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[(1-methyl-1H-pyrrol-2-yl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)



RN 937708-74-2 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-3-[[(1-methyl-1H-pyrrol-2-yl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-75-3 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-chloro-3-[[(1-methyl-1H-pyrrol-2-yl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-76-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[1-(3-fluorophenyl)ethylidene]amino]- (CA INDEX NAME)




RN 937708-77-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[[1-(3-fluorophenyl)ethylidene]amino]- (CA INDEX NAME)




RN 937708-78-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[1-(3-methylphenyl)ethylidene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-79-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[1-(4-methylphenyl)ethylidene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-80-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[1-(4-methylphenyl)ethylidene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-81-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4,5-dimethyl-2-furanyl)methylene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937708-82-2 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(4,5-dimethyl-2-furanyl)methylene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-83-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4,5-dimethyl-2-furanyl)methylene]amino]-
2-(3-pyridinyl)- (CA INDEX NAME)

RN 937708-84-4 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[(4,5-dimethyl-2-furanyl)methylene]amino]-
2-(4-pyridinyl)- (CA INDEX NAME)

RN 937708-85-5 HCAPLUS


CN 4(3H)-Quinazolinone, 6-chloro-3-[[(4,5-dimethyl-2-furanyl)methylene]amino]-
2-(3-pyridinyl)- (CA INDEX NAME)

RN 937708-86-6 HCAPLUS


CN 4(3H)-Quinazolinone, 6-chloro-3-[[(4,5-dimethyl-2-furanyl)methylene]amino]-
2-(4-pyridinyl)- (CA INDEX NAME)




RN 937708-87-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3-
[(phenylmethylene)amino]- (CA INDEX NAME)

RN 937708-88-8 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[(2-bromophenyl)methylene]amino]-2-phenyl- (CA
INDEX NAME)

RN 937708-89-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(2-methylphenyl)methylene]amino]-2-phenyl- (CA
INDEX NAME)


RN 937708-90-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3-[[(2-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-91-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(2-chlorophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 937708-92-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[(6-methoxy-2-naphthalenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-93-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(1,1'-biphenyl)-4-ylmethylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



RN 937708-94-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methylene]amino]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




IT 937708-95-7P 937708-96-8P 937708-97-9P
 937708-98-0P 937708-99-1P 937709-00-7P
 937709-01-8P 937709-02-9P 937709-03-0P
 937709-04-1P 937709-05-2P 937709-06-3P
 937709-07-4P 937709-08-5P 937709-09-6P
 937709-10-9P 937709-11-0P 937709-12-1P
 937709-13-2P 937709-14-3P 937709-15-4P
 937709-16-5P 937709-17-6P 937709-18-7P
 937709-19-8P 937709-20-1P 937709-21-2P
 937709-22-3P 937709-35-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)


RN 937708-95-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937708-96-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(1,1-dimethylethyl)-2-hydroxyphenyl)methylene]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 937708-97-9 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[[4-nitrophenyl)methylene]amino]- (CA INDEX NAME)



RN 937708-98-0 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[4-(diethylamino)phenyl)methylene]amino]-2-(3,4-

dimethoxyphenyl)- (CA INDEX NAME)




RN 937708-99-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,5-dimethoxyphenyl)-3-[(3-fluorophenyl)methylene]amino]-6-hydroxy- (CA INDEX NAME)




RN 937709-00-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-(3,4-dimethoxyphenyl)-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937709-01-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937709-02-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 937709-03-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-2-(3,4-dimethoxyphenyl)-3-[[6-methyl-2-pyridinyl)methylene]amino]- (CA INDEX NAME)





RN 937709-04-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[6-methyl-2-pyridinyl)methylene]amino]- (CA INDEX NAME)




RN 937709-05-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-(1,1-dimethylethyl)phenyl]-3-[[3-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937709-06-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(3-methylphenyl)ethylidene]amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 937709-07-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-chloro-3-[[1-(3-methylphenyl)ethylidene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 937709-08-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[1-(4-methylphenyl)ethylidene]amino]-2-(3-pyridinyl)- (CA INDEX NAME)



RN 937709-09-6 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-methylphenyl)methylene]amino]-2-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 937709-10-9 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(3-methylphenyl)methylene]amino]-2-(4-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 937709-11-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3-fluorophenyl)methylene]amino]-2-[4-(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-12-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-fluorophenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-13-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(4-fluorophenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-14-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-methylphenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-15-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-(4-dimethylphenyl)methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-16-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-[4-[(4-pyridinylthio)methyl]phenyl]- (CA INDEX NAME)




RN 937709-17-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[3-fluorophenyl]methylene]amino]-2-[4-[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)





RN 937709-18-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-fluorophenyl]methylene]amino]-2-[4-[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)





RN 937709-19-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[(2-hydroxyethyl)thio]methyl]phenyl]-3-[[(3-methylphenyl)methylene]amino]- (CA INDEX NAME)





RN 937709-20-1 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[(2-hydroxyethyl)thio]methyl]phenyl]-3-[[(4-methylphenyl)methylene]amino]- (CA INDEX NAME)




RN 937709-21-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[(3,4-dimethylphenyl)methylene]amino]-2-[4-[[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)




RN 937709-22-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-[4-[[(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)



RN 937709-35-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[3-(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)




IT 937709-23-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidines as phosphoric acid-transport inhibitors for treatment of diseases)

RN 937709-23-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3,4-dimethoxyphenyl)-3-[[4-(4-fluorophenyl)methylene]amino]-6-hydroxy- (CA INDEX NAME)



L81 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:817853 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:331920

TITLE: Preparation of benzamide compounds as phosphorus transport inhibitors

INVENTOR(S): Eto, Nobuaki; Nagao, Rika; Miyazaki, Tetsuko

PATENT ASSIGNEE(S): Kirin Beer Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 787 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085382	A1	20041007	WO 2004-JP4427	20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1614676	A1	20060111	EP 2004-724132	20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 20060217426	A1	20060928	US 2006-550857	20060410 <--
PRIORITY APPLN. INFO.:			JP 2003-89173	A 20030327
			WO 2004-JP4427	W 20040329
OTHER SOURCE(S): MARPAT 141:331920				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [A = (un)substituted unsatd. carbocycle, heterocycle; dotted line indicates single or double bond; Z = N:CR6R7, etc.; R6, R7 = H, alkyl, etc.; R1 and R2 in combination represents oxo and R3 = R4 = H or R1 and R4 in combination represents a bond and R2 and R3 in combination represents a bond; R5 = alkyl, etc.] were prepared For example, condensation of N-(2-hydrazinocarbonylphenyl)-3,4-dimethoxybenzaldehyde, e.g., prepared from Me 2-aminobenzoate in 2 steps, with trans-cinnamaldehyde afforded compound II in 57% yield. In sodium-dependency inhibition assays, the IC50 value of compound II was 9.11 μ M. Compds. I are claimed useful for the treatment of renal insufficiency, hyperthyroidism, etc.
- IC ICM C07C251-80
 ICS C07C251-86; C07C317-44; C07C323-25; C07C323-60; C07C323-66;
 C07D207-18; C07D211-46; C07D211-58; C07D211-60; C07D213-32;
 C07D213-44; C07D213-81; C07D231-04; C07D241-04; C07D243-08;
 C07D261-18; C07D249-12; C07D257-04; C07D295-08
- CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
- IT Heart, disease
 (angina pectoris, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Disease, animal
 Pain
 (arthralgia, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Ulcer
 (cutaneous, skin ischemic ulcer, treatment of;
 preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Joint, anatomical
 (disease, arthralgia, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)

- IT Kidney, disease
(failure, chronic, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Heart, disease
Kidney, disease
(failure, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Bone, disease
(fracture, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Heart, disease
(infection, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Nerve, disease
(neuropathy, treatment of peripheral nerve failure associated to PTH increase, vitamin D decrease; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Calcification
(of blood vessel, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Pain
(of bone and joint, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Calcification
(of soft tissue, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Bone, disease
(osteopenia, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Bone, disease
(renal bone abnormal nutrition disease, treatment of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Carbohydrate metabolism
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of anomaly of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Bone, disease
(treatment of bone deformation; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Central nervous system, disease
(treatment of central nerve failure associated to PTH increase, vitamin D decrease; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Heart, disease
(treatment of conduction disorder; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Growth
(treatment of delay of; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Lung, disease
(treatment of expansion disorder; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Calcification
(treatment of heterotopia; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Blood, disease
(treatment of high phosphorous; preparation of benzamide compds. as phosphorus transport inhibitors)
- IT Tendon
(treatment of injury; preparation of benzamide compds. as

phosphorus transport inhibitors)

IT Eye, disease
(treatment of red eye; preparation of benzamide compds.
as phosphorus transport inhibitors)

IT Calcification
(treatment of transferable; preparation of benzamide compds. as phosphorus
transport inhibitors)

IT Anemia (disease)
Arteriosclerosis
Immuno deficiency
Pruritus
Sexual disorders
(treatment of; preparation of benzamide compds. as phosphorus transport
inhibitors)

IT Hyperlipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of; preparation of benzamide compds. as phosphorus transport
inhibitors)

IT Skin, disease
(ulcer, skin ischemic ulcer, treatment
of; preparation of benzamide compds. as phosphorus transport inhibitors)

IT 773061-09-9P 773061-77-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzamide compds. as phosphorus transport inhibitors)

IT 339217-94-6P 345997-47-9P 382166-94-1P
393155-66-3P 393527-06-5P 393856-19-4P
394698-30-7P 394702-69-3P 394715-67-4P
395094-86-3P 396109-24-3P 396116-18-0P
396126-68-4P 396127-91-6P 396128-00-0P
396642-91-4P 396643-53-1P 396657-63-9P
396656-64-3P 396663-37-6P 397281-92-4E
397289-21-3P 397289-49-5P 397289-56-4P
397304-66-4P 478383-59-4P 478504-55-1P
595570-97-1P 597529-23-2P 597529-25-4P
597529-29-8P 773060-68-7P 773060-69-8P
773060-70-1P 773060-71-2P 773060-72-3P
773060-73-4P 773060-74-5P 773060-75-6P
773060-76-7P 773060-77-8P 773060-78-9P
773060-79-0P 773060-80-3P 773060-81-4P
773060-82-5P 773060-83-6P 773060-84-7P
773060-85-8P 773060-86-9P 773060-87-0P
773060-88-1P 773060-89-2P 773060-90-5P
773060-91-6P 773060-92-7P 773060-93-8P
773060-94-9P 773060-95-0P 773060-96-1P
773060-97-2P 773060-98-3P 773060-99-4P
773061-00-0P 773061-01-1P 773061-02-2P
773061-03-3P 773061-04-4P 773061-05-5P
773061-06-6P 773061-07-7P 773061-08-8P
773061-10-2P 773061-11-3P 773061-12-4P
773061-13-5P 773061-14-6P 773061-15-7P
773061-16-8P 773061-17-9P 773061-18-0P
773061-19-1P 773061-20-4P 773061-21-5P
773061-22-6P 773061-23-7P 773061-24-8P
773061-25-9P 773061-26-0P 773061-27-1P
773061-28-2P 773061-29-3P 773061-30-6P
773061-31-7P 773061-32-8P 773061-33-9P
773061-34-0P 773061-35-1P 773061-36-2P
773061-37-3P 773061-38-4P 773061-39-5P

773061-40-8P 773061-41-9P 773061-42-0P
 773061-43-1P 773061-44-2P 773061-45-3P
 773061-46-4P 773061-47-5P 773061-48-6P
 773061-49-7P 773061-50-8P 773061-51-1P
 773061-52-2P 773061-53-3P 773061-54-4P
 773061-55-5P 773061-56-6P 773061-57-7P
 773061-58-8P 773061-59-9P 773061-60-2P
 773061-61-3P 773061-62-4P 773061-63-5P
 773061-64-6P 773061-65-7P 773061-66-8P
 773061-67-9P 773061-68-0P 773061-69-1P
 773061-70-4P 773061-71-5P 773061-72-6P
 773061-73-7P 773061-74-8P 773061-75-9P
 773061-76-0P 773061-78-2P 773061-79-3P
 773061-80-6P 773061-81-7P 773061-82-8P
 773061-83-9P 773061-84-0P 773061-85-1P
 773061-86-2P 773061-87-3P 773061-88-4P
 773061-89-5P 773061-90-8P 773061-91-9P
 773061-92-0P 773061-93-1P 773061-94-2P
 773061-95-3P 773061-96-4P 773061-97-5P
 773061-98-6P 773061-99-7P 773062-00-3P
 773062-01-4P 773062-02-5P 773062-03-6P
 773062-04-7P 773062-05-8P 773062-06-9P
 773062-07-0P 773062-08-1P 773062-09-2P
 773062-10-5P 773062-11-6P 773062-12-7P
 773062-13-8P 773062-14-9P 773062-15-0P
 773062-16-1P 773062-17-2P 773062-18-3P
 773062-19-4P 773062-20-7P 773062-21-8P
 773062-22-9P 773062-23-0P 773062-24-1P
 773062-25-2P 773062-26-3P 773062-27-4P
 773062-28-5P 773062-29-6P 773062-30-9P
 773062-31-0P 773062-32-1P 773062-33-2P
 773062-34-3P 773062-35-4P 773062-36-5P
 773062-37-6P 773062-38-7P 773062-39-8P
 773062-40-1P 773062-41-2P 773062-42-3P
 773062-43-4P 773062-44-5P 773062-45-6P
 773062-46-7P 773062-47-8P 773062-48-9P
 773062-49-0P 773062-50-3P 773062-51-4P
 773062-52-5P 773062-53-6P 773062-54-7P
 773062-55-8P 773062-56-9P 773062-57-0P
 773062-58-1P 773062-59-2P 773062-60-5P
 773062-61-6P 773062-62-7P 773062-63-8P
 773062-64-9P 773062-65-0P 773062-66-1P
 773062-67-2P 773062-68-3P 773062-69-4P
 773062-70-7P 773062-71-8P 773062-72-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)

IT 773062-73-0P 773062-74-1P 773062-75-2P
 773062-76-3P 773062-77-4P 773062-78-5P
 773062-79-6P 773062-80-9P 773062-81-0P
 773062-82-1P 773062-83-2P 773062-84-3P
 773062-85-4P 773062-86-5P 773062-87-6P
 773062-88-7P 773062-89-8P 773062-90-1P
 773062-91-2P 773062-92-3P 773062-93-4P
 773062-94-5P 773062-95-6P 773062-96-7P
 773062-97-8P 773062-98-9P 773062-99-0P
 773063-00-6P 773063-01-7P 773063-02-8P
 773063-03-9P 773063-04-0P 773063-05-1P
 773063-06-2P 773063-07-3P 773063-08-4P

773063-09-5P 773063-10-8P 773063-11-9P
 773063-12-0P 773063-13-1P 773063-14-2P
 773063-15-3P 773063-16-4P 773063-17-5P
 773063-18-6P 773063-19-7P 773063-20-0P
 773063-21-1P 773063-22-2P 773063-23-3P
 773063-24-4P 773063-25-5P 773063-26-6P
 773063-27-7P 773063-28-8P 773063-29-9P
 773063-30-2P 773063-31-3P 773063-32-4P
 773063-33-5P 773063-34-6P 773063-35-7P
 773063-36-8P 773063-37-9P 773063-38-0P
 773063-39-1P 773063-40-4P 773063-41-5P
 773063-42-6P 773063-43-7P 773063-44-8P
 773063-45-9P 773063-46-0P 773063-47-1P
 773063-48-2P 773063-49-3P 773063-50-6P
 773063-51-7P 773063-52-8P 773063-53-9P
 773063-54-0P 773063-55-1P 773063-56-2P
 773063-57-3P 773063-58-4P 773063-59-5P
 773063-60-8P 773063-61-9P 773063-62-0P
 773063-63-1P 773063-64-2P 773063-65-3P
 773063-66-4P 773063-67-5P 773063-68-6P
 773063-69-7P 773063-70-0P 773063-71-1P
 773063-72-2P 773063-73-3P 773063-74-4P
 773063-75-5P 773063-76-6P 773063-77-7P
 773063-78-8P 773063-79-9P 773063-80-2P
 773063-81-3P 773063-82-4P 773063-83-5P
 773063-84-6P 773063-85-7P 773063-86-8P
 773063-87-9P 773063-88-0P 773063-89-1P
 773063-90-4P 773063-91-5P 773063-92-6P
 773063-93-7P 773063-94-8P 773063-95-9P
 773063-96-0P 773063-97-1P 773063-98-2P
 773063-99-3P 773064-00-9P 773064-01-0P
 773064-02-1P 773064-03-2P 773064-04-3P
 773064-05-4P 773064-06-5P 773064-07-6P
 773064-08-7P 773064-09-8P 773064-10-1P
 773064-11-2P 773064-12-3P 773064-13-4P
 773064-14-5P 773064-15-6P 773064-16-7P
 773064-17-8P 773064-18-9P 773064-19-0P
 773064-20-3P 773064-21-4P 773064-22-5P
 773064-23-6P 773064-24-7P 773064-25-8P
 773064-26-9P 773064-27-0P 773064-28-1P
 773064-29-2P 773064-30-5P 773064-31-6P
 773064-32-7P 773064-33-8P 773064-34-9P
 773064-35-0P 773064-36-1P 773064-37-2P
 773064-38-3P 773064-39-4P 773064-40-7P
 773064-41-8P 773064-42-9P 773064-43-0P
 773064-44-1P 773064-45-2P 773064-46-3P
 773064-47-4P 773064-48-5P 773064-49-6P
 773064-50-9P 773064-51-0P 773064-52-1P
 773064-53-2P 773064-54-3P 773064-55-4P
 773064-56-5P 773064-57-6P 773064-58-7P
 773064-59-8P 773064-60-1P 773064-61-2P
 773064-62-3P 773064-63-4P 773064-64-5P
 773064-65-6P 773064-66-7P 773064-67-8P
 773064-68-9P 773064-69-0P 773064-70-3P
 773064-71-4P 773064-72-5P 773064-73-6P
 773064-74-7P 773064-75-8P 773064-76-9P
 773064-77-0P 773064-78-1P 773064-79-2P
 773064-80-5P 773064-81-6P 773064-82-7P
 773064-83-8P 773064-84-9P 773064-85-0P
 773064-86-1P 773064-87-2P 773064-88-3P

773064-89-4P 773064-90-7P 773064-91-8P
 773064-92-9P 773064-93-0P 773064-94-1P
 773064-95-2P 773064-96-3P 773064-97-4P
 773064-98-5P 773064-99-6P 773065-00-2P
 773065-01-3P 773065-02-4P 773065-03-5P
 773065-04-6P 773065-05-7P 773065-06-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)

IT 773065-07-9P 773065-08-0P 773065-09-1P
 773065-10-4P 773065-11-5P 773065-12-6P
 773065-13-7P 773065-14-8P 773065-15-9P
 773065-16-0P 773065-17-1P 773065-18-2P
 773065-19-3P 773065-20-6P 773065-21-7P
 773065-22-8P 773065-23-9P 773065-24-0P
 773065-25-1P 773065-26-2P 773065-27-3P
 773065-28-4P 773065-29-5P 773065-30-8P
 773065-31-9P 773065-32-0P 773065-33-1P
 773065-34-2P 773065-35-3P 773065-36-4P
 773065-37-5P 773065-38-6P 773065-39-7P
 773065-40-0P 773065-41-1P 773065-42-2P
 773065-43-3P 773065-44-4P 773065-45-5P
 773065-46-6P 773065-47-7P 773065-48-8P
 773065-49-9P 773065-50-2P 773065-51-3P
 773065-52-4P 773065-53-5P 773065-54-6P
 773065-55-7P 773065-56-8P 773065-57-9P
 773065-58-0P 773065-59-1P 773065-60-4P
 773065-61-5P 773065-62-6P 773065-63-7P
 773065-64-8P 773065-65-9P 773065-66-0P
 773065-67-1P 773065-68-2P 773065-69-3P
 773065-70-6P 773065-71-7P 773065-72-8P
 773065-73-9P 773065-74-0P 773065-75-1P
 773065-76-2P 773065-77-3P 773065-78-4P
 773065-79-5P 773065-80-8P 773065-81-9P
 773065-82-0P 773065-83-1P 773065-84-2P
 773065-85-3P 773065-86-4P 773065-87-5P
 773065-88-6P 773065-89-7P 773065-90-0P
 773065-91-1P 773065-92-2P 773065-93-3P
 773065-94-4P 773065-95-5P 773065-96-6P
 773065-97-7P 773065-98-8P 773065-99-9P
 773066-00-5P 773066-01-6P 773066-02-7P
 773066-03-8P 773066-04-9P 773066-05-0P
 773066-06-1P 773066-07-2P 773066-08-3P
 773066-09-4P 773066-10-7P 773066-11-8P
 773066-12-9P 773066-13-0P 773066-14-1P
 773066-15-2P 773066-16-3P 773066-17-4P
 773066-18-5P 773066-20-9P 773066-21-0P
 773066-22-1P 773066-23-2P 773066-24-3P
 773066-25-4P 773066-26-5P 773066-27-6P
 773066-28-7P 773066-29-8P 773066-30-1P
 773066-31-2P 773066-32-3P 773066-33-4P
 773066-34-5P 773066-35-6P 773066-36-7P
 773066-37-8P 773066-39-0P 773066-40-3P
 773066-41-4P 773066-42-5P 773066-43-6P
 773066-44-7P 773066-45-8P 773066-46-9P
 773066-47-0P 773066-48-1P 773066-49-2P
 773066-50-5P 773066-51-6P 773066-52-7P
 773066-53-8P 773066-54-9P 773066-55-0P
 773066-56-1P 773066-57-2P 773066-58-3P

773066-59-4P 773066-60-7P 773066-61-8P
 773066-62-9P 773066-63-0P 773066-64-1P
 773066-65-2P 773066-66-3P 773066-67-4P
 773066-68-5P 773066-69-6P 773066-70-9P
 773066-71-0P 773066-72-1P 773066-73-2P
 773066-74-3P 773066-75-4P 773066-76-5P
 773066-77-6P 773066-78-7P 773066-79-8P
 773066-80-1P 773066-81-2P 773066-82-3P
 773066-83-4P 773066-84-5P 773066-85-6P
 773066-86-7P 773066-87-8P 773066-88-9P
 773066-89-0P 773066-90-3P 773066-91-4P
 773066-92-5P 773066-93-6P 773066-94-7P
 773066-95-8P 773066-96-9P 773066-97-0P
 773066-98-1P 773066-99-2P 773067-00-6P
 773067-01-9P 773067-02-0P 773067-03-1P
 773067-04-2P 773067-05-3P 773067-06-4P
 773067-07-5P 773067-08-6P 773067-09-7P
 773067-10-0P 773067-11-1P 773067-12-2P
 773067-13-3P 773067-14-4P 773067-15-5P
 773067-16-6P 773067-17-7P 773067-18-8P
 773067-19-9P 773067-20-2P 773067-21-3P
 773067-22-4P 773067-23-5P 773067-24-6P
 773067-25-7P 773067-26-8P 773067-27-9P
 773067-28-0P 773067-29-1P 773067-30-4P
 773067-31-5P 773067-32-6P 773067-33-7P
 773067-34-8P 773067-35-9P 773067-36-0P
 773067-37-1P 773067-38-2P 773067-39-3P
 773067-40-6P 773067-41-7P 773067-42-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)

IT 773067-43-9P 773067-44-0P 773067-45-1P
 773067-46-2P 773067-47-3P 773067-48-4P
 773067-49-5P 773067-50-8P 773067-51-9P
 773067-52-0P 773067-53-1P 773067-54-2P
 773067-55-3P 773067-56-4P 773067-57-5P
 773067-58-6P 773067-59-7P 773067-60-0P
 773067-61-1P 773067-62-2P 773067-63-3P
 773067-64-4P 773067-65-5P 773067-66-6P
 773067-67-7P 773067-68-8P 773067-69-9P
 773067-70-2P 773067-71-3P 773067-72-4P
 773067-73-5P 773067-74-6P 773067-75-7P
 773067-76-8P 773067-77-9P 773067-78-0P
 773067-79-1P 773067-80-4P 773067-81-5P
 773067-82-6P 773067-83-7P 773067-84-8P
 773067-85-9P 773067-86-0P 773067-87-1P
 773067-88-2P 773067-89-3P 773067-90-6P
 773067-91-7P 773067-92-9P 773067-94-0P
 773067-95-1P 773067-96-2P 773067-97-3P
 773067-98-4P 773067-99-5P 773068-00-1P
 773068-01-2P 773068-02-3P 773068-03-4P
 773068-04-5P 773068-05-6P 773068-06-7P
 773068-07-8P 773068-08-9P 773068-09-0P
 773068-10-3P 773068-11-4P 773068-12-5P
 773068-13-6P 773068-14-7P 773068-15-8P
 773068-16-9P 773068-17-0P 773068-18-1P
 773068-19-2P 773068-20-5P 773068-21-6P
 773068-22-7P 773068-23-8P 773068-24-9P
 773068-25-0P 773068-26-1P 773068-27-2P

773068-26-3P 773068-29-4P 773068-30-7P
 773068-31-8P 773068-32-9P 773068-33-0P
 773068-34-1P 773068-35-2P 773068-36-3P
 773068-37-4P 773068-38-5P 773068-39-6P
 773068-40-9P 773068-41-0P 773068-42-1P
 773068-43-2P 773068-44-3P 773068-45-4P
 773068-46-5P 773068-47-6P 773068-48-7P
 773068-49-8P 773068-50-1P 773068-51-2P
 773068-52-3P 773068-53-4P 773068-54-5P
 773068-55-6P 773068-56-7P 773068-57-8P
 773068-58-9P 773068-59-0P 773068-60-3P
 773068-61-4P 773068-62-5P 773068-63-6P
 773068-64-7P 773068-65-8P 773068-66-9P
 773068-67-0P 773068-68-1P 773068-69-2P
 773068-70-5P 773068-71-6P 773068-72-7P
 773068-73-8P 773068-74-9P 773068-75-0P
 773068-76-1P 773068-77-2P 773068-78-3P
 773068-79-4P 773068-80-7P 773068-81-8P
 773068-82-9P 773068-83-0P 773068-84-1P
 773068-85-2P 773068-86-3P 773068-87-4P
 773068-88-5P 773068-89-6P 773068-90-9P
 773068-91-0P 773068-92-1P 773068-93-2P
 773068-94-3P 773068-95-4P 773068-96-5P
 773068-97-6P 773068-98-7P 773068-99-8P
 773069-00-4P 773069-01-5P 773069-02-6P
 773069-03-7P 773069-04-8P 773069-05-9P
 773069-06-0P 773069-07-1P 773069-08-2P
 773069-09-3P 773069-10-6P 773069-11-7P
 773069-12-8P 773069-13-9P 773069-14-0P
 773069-15-1P 773069-16-2P 773069-17-3P
 773069-18-4P 773069-19-5P 773069-20-8P
 773069-21-9P 773069-22-0P 773069-23-1P
 773069-24-2P 773069-25-3P 773069-26-4P
 773069-27-5P 773069-28-6P 773069-29-7P
 773069-30-0P 773069-32-2P 773069-34-4P
 773069-35-5P 773069-36-6P 773069-37-7P
 773069-38-8P 773069-39-9P 773069-40-2P
 773069-41-3P 773069-42-4P 773069-43-5P
 773069-44-6P 773069-45-7P 773069-46-8P
 773069-47-9P 773069-48-0P 773069-49-1P
 773069-50-4P 773069-51-5P 773069-52-6P
 773069-53-7P 773069-54-8P 773069-55-9P
 773069-56-0P 773069-57-1P 773069-58-2P
 773069-59-3P 773069-60-6P 773069-61-7P
 773069-62-8P 773069-63-9P 773069-64-0P
 773069-65-1P 773069-66-2P 773069-67-3P
 773069-68-4P 773069-69-5P 773069-70-8P
 773069-71-9P 773069-72-0P 773069-73-1P
 773069-74-2P 773069-75-3P 773069-76-4P
 773069-77-5P 773069-78-6P 773069-79-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)

IT 773069-80-0P 773069-81-1P 773069-82-2P
 773069-83-3P 773069-84-4P 773069-85-5P
 773069-86-6P 773069-87-7P 773069-88-8P
 773069-89-9P 773069-90-2P 773069-91-3P
 773069-92-4P 773069-93-5P 773069-94-6P
 773069-95-7P 773069-96-8P 773069-97-9P

773069-96-0P 773069-99-1P 773070-00-1P
 773070-01-2P 773070-02-3P 773070-03-4P
 773070-04-5P 773070-05-6P 773070-06-7P
 773070-07-8P 773070-08-9P 773070-09-0P
 773070-10-3P 773070-11-4P 773070-12-5P
 773070-13-6P 773070-14-7P 773070-15-8P
 773070-16-9P 773070-17-0P 773070-18-1P
 773070-19-2P 773070-20-5P 773070-21-6P
 773070-22-7P 773070-23-8P 773070-24-9P
 773070-25-0P 773070-26-1P 773070-27-2P
 773070-28-3P 773070-29-4P 773070-30-7P
 773070-31-8P 773070-32-9P 773070-33-0P
 773070-34-1P 773070-35-2P 773070-36-3P
 773070-37-4P 773070-38-5P 773070-39-6P
 773070-40-9P 773070-41-0P 773070-42-1P
 773070-43-2P 773070-44-3P 773070-45-4P
 773070-46-5P 773070-47-6P 773070-48-7P
 773070-49-8P 773070-50-1P 773070-51-2P
 773070-52-3P 773070-53-4P 773070-54-5P
 773070-55-6P 773070-56-7P 773070-57-8P
 773070-59-0P 773070-61-4P 773070-62-5P
 773070-63-6P 773070-64-7P 773070-65-8P
 773070-66-9P 773070-67-0P 773070-68-1P
 773070-69-2P 773070-70-5P 773070-71-6P
 773070-72-7P 773070-73-8P 773070-74-9P
 773070-75-0P 773070-76-1P 773070-77-2P
 773070-78-3P 773070-79-4P 773070-80-7P
 773070-81-8P 773070-82-9P 773070-83-0P
 773070-84-1P 773070-85-2P 773070-86-3P
 773070-87-4P 773070-88-5P 773070-89-6P
 773070-90-9P 773070-91-0P 773070-92-1P
 773070-93-2P 773070-94-3P 773070-95-4P
 773070-96-5P 773070-97-6P 773070-98-7P
 773070-99-8P 773071-00-4P 773071-01-5P
 773071-02-6P 773104-21-5P 773104-22-6P
 773104-23-7P 773104-24-8P 773104-25-9P
 773104-26-0P 773104-27-1P 773104-28-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)


IT 773061-09-9P 773061-77-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of benzamide compds. as phosphorus transport inhibitors)

RN 773061-09-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-77-1 HCAPLUS
 CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



IT 339217-94-6P 345997-47-9P 382166-94-1E
 393155-66-3P 393527-06-5P 393656-19-4E
 394698-30-7P 394702-69-3P 394715-67-4E
 395084-86-3P 396109-24-3P 396116-18-0P
 396126-68-4P 396127-91-6P 396128-00-0P
 396642-91-4P 396643-53-1P 396657-63-9P
 396658-64-3P 396662-37-6P 397281-92-4P
 397289-21-3P 397289-49-5P 397289-56-4P
 397304-66-4P 478383-59-4P 478504-55-1P
 595570-97-1P 597529-23-2P 597529-25-4P
 597529-29-8P 773060-68-7P 773060-69-8P
 773060-70-1P 773060-71-2P 773060-72-3P
 773060-73-4P 773060-74-5P 773060-75-6P
 773060-76-7P 773060-77-8P 773060-78-9P
 773060-79-0P 773060-80-3P 773060-81-4P
 773060-82-5P 773060-83-6P 773060-84-7P
 773060-85-8P 773060-86-9P 773060-87-0P
 773060-88-1P 773060-89-2P 773060-90-5P
 773060-91-6P 773060-92-7P 773060-93-8P
 773060-94-9P 773060-95-0P 773060-96-1P
 773060-97-2P 773060-98-3P 773060-99-4P
 773061-00-0P 773061-01-1P 773061-02-2P
 773061-03-3P 773061-04-4P 773061-05-5P
 773061-06-6P 773061-07-7P 773061-08-8P
 773061-10-2P 773061-11-3P 773061-12-4P
 773061-13-5P 773061-14-6P 773061-15-7P
 773061-16-8P 773061-17-9P 773061-18-0P
 773061-19-1P 773061-20-4P 773061-21-5P
 773061-22-6P 773061-23-7P 773061-24-8P
 773061-25-9P 773061-26-0P 773061-27-1P
 773061-28-2P 773061-29-3P 773061-30-6P
 773061-31-7P 773061-32-8P 773061-33-9P
 773061-34-0P 773061-35-1P 773061-36-2P
 773061-37-3P 773061-38-4P 773061-39-5P
 773061-40-8P 773061-41-9P 773061-42-0P
 773061-43-1P 773061-44-2P 773061-45-3P
 773061-46-4P 773061-47-5P 773061-48-6P
 773061-49-7P 773061-50-0P 773061-51-1P
 773061-52-2P 773061-53-3P 773061-54-4P
 773061-55-5P 773061-56-6P 773061-57-7P
 773061-58-8P 773061-59-9P 773061-60-2P
 773061-61-3P 773061-62-4P 773061-63-5P
 773061-64-6P 773061-65-7P 773061-66-8P
 773061-67-9P 773061-68-0P 773061-69-1P


773061-70-4P 773061-71-5P 773061-72-6P
 773061-73-7P 773061-74-6P 773061-75-9P
 773061-76-0P 773061-78-2P 773061-79-3P
 773061-80-6P 773061-81-7P 773061-82-8P
 773061-83-9P 773061-84-0P 773061-85-1P
 773061-86-2P 773061-87-3P 773061-88-4P
 773061-89-5P 773061-90-8P 773061-91-9P
 773061-92-0P 773061-93-1P 773061-94-2P
 773061-95-3P 773061-96-4P 773061-97-5P
 773061-98-6P 773061-99-7P 773062-00-3P
 773062-01-4P 773062-02-5P 773062-03-6P
 773062-04-7P 773062-05-8P 773062-06-9P
 773062-07-0P 773062-08-1P 773062-09-2P
 773062-10-5P 773062-11-6P 773062-12-7P
 773062-13-8P 773062-14-9P 773062-15-0P
 773062-16-1P 773062-17-2P 773062-18-3P
 773062-19-4P 773062-20-7P 773062-21-8P
 773062-22-9P 773062-23-0P 773062-24-1P
 773062-25-2P 773062-26-3P 773062-27-4P
 773062-28-5P 773062-29-6P 773062-30-9P
 773062-31-0P 773062-32-1P 773062-33-2P
 773062-34-3P 773062-35-4P 773062-36-5P
 773062-37-6P 773062-38-7P 773062-39-8P
 773062-40-1P 773062-41-2P 773062-42-3P
 773062-43-4P 773062-44-5P 773062-45-6P
 773062-46-7P 773062-47-8P 773062-48-9P
 773062-49-0P 773062-50-3P 773062-51-4P
 773062-52-5P 773062-53-6P 773062-54-7P
 773062-55-8P 773062-56-9P 773062-57-0P
 773062-58-1P 773062-59-2P 773062-60-5P
 773062-61-6P 773062-62-7P 773062-63-8P
 773062-64-9P 773062-65-0P 773062-66-1P
 773062-67-2P 773062-68-3P 773062-69-4P
 773062-70-7P 773062-71-8P 773062-72-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)


RN 339217-94-6 HCAPLUS

CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 345997-47-9 HCAPLUS


CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 382166-94-1 HCAPLUS
 CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 393155-66-3 HCAPLUS
 CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
 2-[(5-methyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)




RN 393527-06-5 HCAPLUS
 CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 393856-19-4 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-bromophenyl)methylene]hydrazide (CA INDEX NAME)

RN 394698-30-7 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-(2-pyridinylmethylene)hydrazide (CA INDEX NAME)

RN 394702-69-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-(2-furanylmethylene)hydrazide (CA INDEX NAME)


RN 394715-67-4 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 395084-86-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3,4,5-trimethoxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 396109-24-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-chlorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 396116-18-0 HCAPLUS



CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-(dimethylamino)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 396126-68-4 HCAPLUS
 CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
 2-[(3-nitrophenyl)methylene]hydrazide (CA INDEX NAME)



RN 396127-91-6 HCAPLUS
 CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
 2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)





RN 396128-00-0 HCAPLUS
 CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
 2-[(2-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 396642-91-4 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 396643-53-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-bromophenyl)methylene]hydrazide (CA INDEX NAME)





RN 396657-63-9 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-(2-thienylmethylene)hydrazide (CA INDEX NAME)





RN 396658-64-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 396662-37-6 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-nitrophenyl)methylene]hydrazide (CA INDEX NAME)




RN 397281-92-4 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 397289-21-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-hydroxy-3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 397289-49-5 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(2-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 397289-56-4 HCAPLUS



CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 397304-66-4 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)

RN 478383-59-4 HCAPLUS



CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 478504-55-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2,4-dihydroxyphenyl)methylene]hydrazide (CA INDEX NAME)


RN 595570-97-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2,4-dihydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 597529-23-2 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 597529-25-4 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)



RN 597529-29-8 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)



RN 773060-68-7 HCAPLUS



CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 773060-69-8 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773060-70-1 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]hydrazide (CA
INDEX NAME)



RN 773060-71-2 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2Z)-2-methyl-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)

Double bond geometry as described by E or Z.





RN 773060-72-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[3,5-bis(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773060-73-4 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[3-cyanophenyl]methylene]hydrazide (CA INDEX NAME)




RN 773060-74-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2Z)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)



Double bond geometry as described by E or Z.





RN 773060-75-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-bromophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773060-76-7 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773060-77-8 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773060-78-9 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-(3-thienylmethylene)hydrazide (CA INDEX NAME)




RN 773060-79-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-80-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-81-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773060-82-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-83-6 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-chloro-4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-84-7 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-(trifluoromethoxy)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773060-85-8 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773060-86-9 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-chlorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773060-87-0 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-hydroxy-3,5-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773060-88-1 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-ethoxy-3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-89-2 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773060-90-5 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)


RN 773060-91-6 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-hydroxy-3-methylphenyl]methylene]hydrazide (CA INDEX NAME)


RN 773060-92-7 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(2,5-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773060-93-8 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[2-fluoro-5-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

RN 773060-94-9 HCAPLUS


CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(4-hydroxy-3-methylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773060-95-0 HCAPLUS


CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(2,5-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-96-1 HCAPLUS
 CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-97-2 HCAPLUS
 CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-98-3 HCAPLUS
 CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773060-99-4 HCAPLUS
 CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
 2-[(4-(2-propen-1-yloxy)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-00-0 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3,5-dimethoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-01-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methylene]hydrazide (CA INDEX
NAME)



RN 773061-02-2 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-03-3 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-04-4 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-05-5 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-06-6 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,

2-[(3-chlorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-07-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-08-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-10-2 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-11-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,

2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-12-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-13-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-14-6 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-15-7 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,

2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-16-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-17-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-18-0 HCAPLUS


CN Benzoic acid, 4-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-19-1 HCAPLUS


CN Benzoic acid, 4-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,

2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-20-4 HCAPLUS

CN Benzoic acid, 4-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-21-5 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-22-6 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-23-7 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-24-8 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-25-9 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-26-0 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-27-1 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-28-2 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-29-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)



RN 773061-30-6 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)



RN 773061-31-7 HCAPLUS


CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX

(NAME)




RN 773061-32-8 HCAPLUS

CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773061-33-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-34-0 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-35-1 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-36-2 HCAPLUS

CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-37-3 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-38-4 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-39-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-40-8 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-41-9 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-42-0 HCAPLUS

CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-43-1 HCAPLUS

CN Benzoic acid, 2-[(3-fluorobenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-44-2 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-,
2-[(3-bromo-4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-45-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(4-fluorobenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-46-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-fluorobenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-47-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-fluorobenzoyl)amino]-,
2-[(3-chlorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-48-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-fluorobenzoyl)amino]-,
2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-49-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-fluorobenzoyl)amino]-,
2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-50-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)


RN 773061-51-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)


RN 773061-52-2 HCAPLUS

CN Benzoic acid, 2-[(4-methoxybenzoyl)amino]-,
2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)


RN 773061-53-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-54-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-55-5 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3-chlorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-56-6 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-57-7 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-58-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-59-9 HCAPLUS

CN Benzoic acid, 2-[[3-(trifluoromethoxy)benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-60-2 HCAPLUS

CN Benzoic acid, 2-[[3-(trifluoromethoxy)benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-61-3 HCAPLUS

CN Benzoic acid, 2-[[3-(trifluoromethoxy)benzoyl]amino]-,
2-[(3-chlorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-62-4 HCAPLUS


CN Benzoic acid, 2-[[3-(trifluoromethoxy)benzoyl]amino]-,
2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-63-5 HCAPLUS


CN Benzoic acid, 2-[[3-(trifluoromethoxy)benzoyl]amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-64-6 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-[3-(dimethylamino)propoxy]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-65-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3,4-dimethoxyphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-66-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(3,4-dimethoxyphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-67-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,5-dimethoxybenzoyl)amino]-,
2-[(3,4-dimethoxyphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-68-0 HCAPLUS


CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,

2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-69-1 HCAPLUS

CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-70-4 HCAPLUS

CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-71-5 HCAPLUS

CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-72-6 HCAPLUS


CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-73-7 HCAPLUS
 CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-74-8 HCAPLUS
 CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-75-9 HCAPLUS
 CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-76-0 HCAPLUS
 CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-78-2 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-[2-(dimethylamino)ethoxy]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-79-3 HCAPLUS

CN Benzoic acid, 5-[2-(diethylamino)ethoxy]-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-80-6 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methoxy-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-81-7 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methoxy-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-82-8 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methoxy-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-83-9 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methoxy-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773061-84-0 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methoxy-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773061-85-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methyl-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-86-2 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methyl-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-87-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methyl-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-88-4 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methyl-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-89-5 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methyl-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-90-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-furanylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-91-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-furanylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-92-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-furanylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-93-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-furanylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-94-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-furanylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-95-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-furanylcarbonyl)amino]-,
2-[(4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX
NAME)



RN 773061-96-4 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(2-thienylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773061-97-5 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(2-thienylcarbonyl)amino]-,

2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-98-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-thienylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773061-99-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-thienylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-00-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(2-thienylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-01-4 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(2-thienylcarbonyl)amino]-,

2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)



RN 773062-02-5 HCAPLUS


CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX
NAME)



● HCl

RN 773062-03-6 HCAPLUS


CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX
NAME)



● HCl

RN 773062-04-7 HCAPLUS


CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX
NAME)



● HCl


RN 773062-05-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-06-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-07-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-08-1 HCAPLUS



CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773062-09-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)

RN 773062-10-5 HCAPLUS



CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773062-11-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-12-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773062-13-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773062-14-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-15-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773062-16-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethylbenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-17-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethylbenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-18-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethylbenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-19-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethylbenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-20-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethylbenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-21-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethylbenzoyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)





RN 773062-22-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773062-23-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773062-24-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773062-25-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-26-3 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-27-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)


RN 773062-28-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773062-29-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773062-30-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773062-31-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773062-32-1 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

RN 773062-33-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773062-34-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-35-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-36-5 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-37-6 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-,

2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-38-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773062-39-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(1-methyl-1H-pyrrol-2-yl)methylene]hydrazide (CA INDEX NAME)




RN 773062-40-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-41-2 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX
NAME)



● HCl


RN 773062-42-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-iodo-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-43-4 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-iodo-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-44-5 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-iodo-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773062-45-6 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-iodo-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773062-46-7 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-iodo-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

RN 773062-47-8 HCAPLUS


CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
2-[(1-methyl-1H-pyrrol-2-yl)methylene]hydrazide (CA INDEX NAME)




RN 773062-48-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(1-methyl-1H-pyrrol-2-yl)methylene]hydrazide (CA INDEX NAME)

RN 773062-49-0 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(1-methyl-1H-pyrrol-2-yl)methylene]hydrazide (CA INDEX NAME)

RN 773062-50-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[1-(3-fluorophenyl)ethylidene]hydrazide (CA INDEX NAME)


RN 773062-51-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[1-(3-fluorophenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773062-52-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[1-(3-fluorophenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773062-53-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[1-(3-methylphenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773062-54-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[1-(4-methylphenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773062-55-8 HCAPLUS


CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-56-9 HCAPLUS
CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-57-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-58-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-59-2 HCAPLUS
CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,

2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-60-5 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(4,5-dimethyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)

RN 773062-61-6 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)




RN 773062-62-7 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[(2-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)


RN 773062-63-8 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773062-64-9 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4,5-dimethoxy-,
2-(phenylmethylene)hydrazide (CA INDEX NAME)




RN 773062-65-0 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[(2-bromophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773062-66-1 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[(2-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773062-67-2 HCAPLUS



CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4,5-dimethoxy-,
2-[(2-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-68-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(7-methoxy-2-naphthalenyl)methylene]hydrazide (CA INDEX NAME)


RN 773062-69-4 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(1,1'-biphenyl)-4-ylmethylene]hydrazide (CA INDEX NAME)

RN 773062-70-7 HCAPLUS


CN Benzoic acid, 2-(benzoylamino)-, 2-[(2E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 773062-71-8 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773062-72-9 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



IT 773062-73-0P 773062-74-1P 773062-75-2P
773062-76-3P 773062-77-4P 773062-78-5P
773062-79-6P 773062-80-9P 773062-81-0P
773062-82-1P 773062-83-2P 773062-84-3P
773062-85-4P 773062-86-5P 773062-87-6P
773062-88-7P 773062-89-8P 773062-90-1P
773062-91-2P 773062-92-3P 773062-93-4P
773062-94-5P 773062-95-6P 773062-96-7P
773062-97-8P 773062-98-9P 773062-99-0P
773063-00-6P 773063-01-7P 773063-02-8P
773063-03-9P 773063-04-0P 773063-05-1P
773063-06-2P 773063-07-3P 773063-08-4P
773063-09-5P 773063-10-8P 773063-11-9P
773063-12-0P 773063-13-1P 773063-14-2P
773063-15-3P 773063-16-4P 773063-17-5P
773063-18-6P 773063-19-7P 773063-20-0P
773063-21-1P 773063-22-2P 773063-23-3P
773063-24-4P 773063-25-5P 773063-26-6P
773063-27-7P 773063-28-8P 773063-29-9P
773063-30-2P 773063-31-3P 773063-32-4P
773063-33-5P 773063-34-6P 773063-35-7P
773063-36-8P 773063-37-9P 773063-38-0P
773063-39-1P 773063-40-4P 773063-41-5P
773063-42-6P 773063-43-7P 773063-44-8P
773063-45-9P 773063-46-0P 773063-47-1P
773063-48-2P 773063-49-3P 773063-50-6P
773063-51-7P 773063-52-8P 773063-53-9P
773063-54-0P 773063-55-1P 773063-56-2P
773063-57-3P 773063-58-4P 773063-59-5P
773063-60-8P 773063-61-9P 773063-62-0P


773063-63-1P 773063-64-2P 773063-65-3P
 773063-66-4P 773063-67-5P 773063-68-6P
 773063-69-7P 773063-70-8P 773063-71-1P
 773063-72-2P 773063-73-3P 773063-74-4P
 773063-75-5P 773063-76-6P 773063-77-7P
 773063-78-8P 773063-79-9P 773063-80-2P
 773063-81-3P 773063-82-4P 773063-83-5P
 773063-84-6P 773063-85-7P 773063-86-8P
 773063-87-9P 773063-88-0P 773063-89-1P
 773063-90-4P 773063-91-5P 773063-92-6P
 773063-93-7P 773063-94-8P 773063-95-9P
 773063-96-0P 773063-97-1P 773063-98-2P
 773063-99-3P 773064-00-9P 773064-01-0P
 773064-02-1P 773064-03-2P 773064-04-3P
 773064-05-4P 773064-06-5P 773064-07-6P
 773064-08-7P 773064-09-8P 773064-10-1P
 773064-11-2P 773064-12-3P 773064-13-4P
 773064-14-5P 773064-15-6P 773064-16-7P
 773064-17-8P 773064-18-9P 773064-19-0P
 773064-20-3P 773064-21-4P 773064-22-5P
 773064-23-6P 773064-24-7P 773064-25-8P
 773064-26-9P 773064-27-0P 773064-28-1P
 773064-29-2P 773064-30-5P 773064-31-6P
 773064-32-7P 773064-33-8P 773064-34-9P
 773064-35-0P 773064-36-1P 773064-37-2P
 773064-38-3P 773064-39-4P 773064-40-7P
 773064-41-8P 773064-42-9P 773064-43-0P
 773064-44-1P 773064-45-2P 773064-46-3P
 773064-47-4P 773064-48-5P 773064-49-6P
 773064-50-9P 773064-51-0P 773064-52-1P
 773064-53-2P 773064-54-3P 773064-55-4P
 773064-56-5P 773064-57-6P 773064-58-7P
 773064-59-8P 773064-60-1P 773064-61-2P
 773064-62-3P 773064-63-4P 773064-64-5P
 773064-65-6P 773064-66-7P 773064-67-8P
 773064-68-9P 773064-69-0P 773064-70-3P
 773064-71-4P 773064-72-5P 773064-73-6P
 773064-74-7P 773064-75-8P 773064-76-9P
 773064-77-0P 773064-78-1P 773064-79-2P
 773064-80-5P 773064-81-6P 773064-82-7P
 773064-83-8P 773064-84-9P 773064-85-0P
 773064-86-1P 773064-87-2P 773064-88-3P
 773064-89-4P 773064-90-7P 773064-91-8P
 773064-92-9P 773064-93-0P 773064-94-1P
 773064-95-2P 773064-96-3P 773064-97-4P
 773064-98-5P 773064-99-6P 773065-00-2P
 773065-01-3P 773065-02-4P 773065-03-5P
 773065-04-6P 773065-05-7P 773065-06-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)


RN 773062-73-0 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-,
 2-[[3-(1,1-dimethylethyl)-2-hydroxyphenyl]methylene]hydrazide (CA INDEX
 NAME)




RN 773062-74-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[[4-(diethylamino)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773062-75-2 HCAPLUS

CN Benzoic acid, 2-[(3,5-dimethoxybenzoyl)amino]-5-hydroxy-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-76-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-(2-pyridinylmethylene)hydrazide (CA INDEX NAME)





RN 773062-77-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-(2-pyridinylmethylene)hydrazide (CA INDEX NAME)

RN 773062-78-5 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(6-methyl-2-pyridinyl)methylene]hydrazide (CA INDEX NAME)

RN 773062-79-6 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(6-methyl-2-pyridinyl)methylene]hydrazide (CA INDEX NAME)


RN 773062-80-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-(1,1-dimethylethyl)benzoyl]amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-81-0 HCAPLUS

CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
2-[1-(3-methylphenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773062-82-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[1-(3-methylphenyl)ethylidene]hydrazide (CA INDEX NAME)





RN 773062-83-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[1-(4-methylphenyl)ethylidene]hydrazide (CA INDEX NAME)



RN 773062-84-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[1-(4-methylphenyl)methylene]hydrazide, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

RN 773062-85-4 HCAPLUS


CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX
NAME)



● HCl


RN 773062-86-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-pyridinylthio)methyl]benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-87-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-pyridinylthio)methyl]benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-88-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-89-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-90-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-91-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-pyridinylthio)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773062-92-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-93-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-94-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-95-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-96-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-97-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773062-98-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773062-99-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-00-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-01-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-02-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-03-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-04-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(3-hydroxypropylthio)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-05-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(3-hydroxypropylthio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-06-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(3-hydroxypropylthio)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-07-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[3-(3-hydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[[4-(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-08-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[3-(3-hydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[[3-(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-09-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[3-(3-hydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-10-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773063-11-9 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773063-12-0 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[3-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-13-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-14-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-15-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-16-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-17-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-18-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-19-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-20-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-21-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-22-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-23-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-24-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-25-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[[4-fluorophenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-26-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[[4-fluorophenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-27-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-28-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-29-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-30-2 HCAPLUS

CN Benzoic acid, 2-[[4-[[[3-[bis(2-hydroxyethyl)amino]propyl]amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773063-31-3 HCAPLUS


CN Benzoic acid, 2-[[4-[[[3-[bis(2-hydroxyethyl)amino]propyl]amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773063-32-4 HCAPLUS


CN Benzoic acid, 2-[[4-[[[3-[bis(2-hydroxyethyl)amino]propyl]amino]methyl]benzoyl]amino]-5-bromo-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

(NAME)




RN 773063-33-5 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-34-6 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-35-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-36-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[[4-[[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-37-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[[4-[[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-38-0 HCAPLUS

CN Benzoic acid, 2-[[4-((1,4'-bipiperidin)-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-((3,4-dimethylphenyl)methylene)hydrazide (CA INDEX NAME)




RN 773063-39-1 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[[4-(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-40-4 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-41-5 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-42-6 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-43-7 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-44-8 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-45-9 HCAPLUS

CN Benzoic acid, 2-[[4-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-46-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-47-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-48-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-49-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-50-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-51-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-52-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-53-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-54-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-55-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-56-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-hydroxy-1-piperidiny)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-57-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-hydroxy-1-piperidiny)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-58-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-hydroxy-1-piperidiny)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-59-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-60-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-61-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-62-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(4-(hydroxymethyl)-1-piperidinyl)methyl]benzoyl]amino]-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-63-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-64-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide
(CA INDEX NAME)



RN 773063-65-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)



RN 773063-66-4 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-

piperidinyl)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773063-67-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-68-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-69-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773063-70-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-71-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[(1H-1,2,4-triazol-5-ylsulfinyl)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-72-2 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-73-3 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-74-4 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(diethylamino)ethyl)methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773063-75-5 HCAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4-methyl-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773063-76-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(2E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 773063-77-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(2E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 773063-78-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(2E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 773063-79-9 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(2E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 773063-80-2 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(3E)-3-phenyl-2-propen-1-ylidene]hydrazide (CA INDEX NAME)



RN 773063-81-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(2E)-3-(2-methoxyphenyl)-2-propen-1-ylidene]hydrazide (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 773063-82-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-pyridinylcarbonyl)amino]-,
2-[(2E)-3-(2-methoxyphenyl)-2-propen-1-ylidene]hydrazide (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 773063-83-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(3-pyridinylcarbonyl)amino]-,
2-[(2E)-3-(2-methoxyphenyl)-2-propen-1-ylidene]hydrazide (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 773063-84-6 HCAPLUS



CN Benzoic acid, 5-chloro-2-[(4-pyridinylcarbonyl)amino]-,
2-[(2E)-3-(2-methoxyphenyl)-2-propen-1-ylidene]hydrazide (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 773063-85-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX
NAME)



RN 773063-86-8 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[4-[[[(3-fluorophenyl)thio]methyl]benzoyl]amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773063-87-9 HCAPLUS



CN Benzoic acid, 2-[(3-pyridinylcarbonyl)amino]-,
2-[(2E)-3-[4-(dimethylamino)phenyl]-2-propen-1-ylidene]hydrazide (CA
INDEX NAME)

Double bond geometry as described by E or Z.





RN 773063-88-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-pyridinylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773063-89-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773063-90-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773063-91-5 HCAPLUS


CN Benzoic acid, 5-chloro-2-[(2-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-92-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-pyridinylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)

RN 773063-93-7 HCAPLUS


CN Benzoic acid, 5-chloro-2-[[3-[(4-pyridinylthio)methyl]benzoyl]amino]-,
2-[(3,4-dimethylphenyl)methyl]hydrazide (CA INDEX NAME)

RN 773063-94-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3,4-dimethoxybenzoyl)amino]-,
2-[(4-methylphenyl)methyl]hydrazide (CA INDEX NAME)


RN 773063-95-9 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoylamino]-5-chloro-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-96-0 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoylamino]-5-chloro-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-97-1 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoylamino]-5-chloro-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-98-2 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773063-99-3 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-00-9 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-01-0 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-02-1 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-03-2 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-04-3 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-chloro-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-05-4 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-bromo-, 2-[(3-methoxyphenyl)methyl]hydrazide (CA INDEX NAME)




RN 773064-06-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-07-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-08-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-09-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-10-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-11-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773064-12-3 HCAPLUS


CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773064-13-4 HCAPLUS


CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-,

2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-14-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-15-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-16-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-17-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-18-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-19-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-20-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-21-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-22-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-23-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-24-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[2-(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-25-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[2-(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-26-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[2-(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-27-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-28-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-29-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-30-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-31-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-32-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-33-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-34-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-35-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-36-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-37-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-38-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-39-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-40-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[(2-hydroxyethyl)methylamino)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-41-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[(2-hydroxyethyl)methylamino)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-42-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[(2-hydroxyethyl)methylamino)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-43-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[(2-hydroxyethyl)methylamino)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-44-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-45-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-46-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-47-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-48-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[(2-hydroxyethyl)methylamino]methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-49-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-50-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-51-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-52-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-53-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-54-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-55-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-56-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-57-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[[3-hydroxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-58-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-59-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-60-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-61-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-62-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-63-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-64-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-65-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-66-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-67-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[ethyl(2-hydroxyethyl)amino)methyl]benzoyl]amino]-2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-68-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[2-(diethylamino)ethyl]thio)methyl]benzoyl]amino]-2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-69-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-70-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-71-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-72-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-73-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-74-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-75-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-76-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[[3-hydroxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-77-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[4-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-78-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773064-79-2 HCAPLUS


CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773064-80-5 HCAPLUS


CN Benzoic acid, 5-chloro-2-[[3-[[[2-

(diethylamino)ethyl]thio)methyl]benzoyl]amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-81-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio)methyl]benzoyl]amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-82-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio)methyl]benzoyl]amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-83-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio)methyl]benzoyl]amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-84-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-85-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-86-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-87-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-88-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-89-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-90-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-91-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-92-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-93-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-94-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-95-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773064-96-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-97-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]benzoyl]amino]-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-98-5 HCAPLUS

CN Benzoic acid, 2-[[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773064-99-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-00-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-01-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-02-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-03-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-04-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-05-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773065-06-8 HCAPLUS
 CN Benzoic acid, 2-[[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-iodo-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)



IT 773065-07-9P 773065-08-0P 773065-09-1P
 773065-10-4P 773065-11-5P 773065-12-6P
 773065-13-7P 773065-14-8P 773065-15-9P
 773065-16-0P 773065-17-1P 773065-18-2P
 773065-19-3P 773065-20-6P 773065-21-7P
 773065-22-8P 773065-23-9P 773065-24-0E
 773065-25-1P 773065-26-2P 773065-27-3P
 773065-28-4P 773065-29-5P 773065-30-8P
 773065-31-9P 773065-32-0P 773065-33-1P
 773065-34-2P 773065-35-3P 773065-36-4P
 773065-37-5P 773065-38-6P 773065-39-7P
 773065-40-0P 773065-41-1P 773065-42-2P
 773065-43-3P 773065-44-4P 773065-45-5P
 773065-46-6P 773065-47-7P 773065-48-8P
 773065-49-9P 773065-50-2P 773065-51-3P
 773065-52-4P 773065-53-5P 773065-54-6E
 773065-55-7P 773065-56-8P 773065-57-9P
 773065-58-0P 773065-59-1P 773065-60-4P
 773065-61-5P 773065-62-6P 773065-63-7P
 773065-64-8P 773065-65-9P 773065-66-0P
 773065-67-1P 773065-68-2P 773065-69-3P
 773065-70-6P 773065-71-7P 773065-72-8P
 773065-73-9P 773065-74-0P 773065-75-1P
 773065-76-2P 773065-77-3P 773065-78-4P
 773065-79-5P 773065-80-6P 773065-81-9P
 773065-82-0P 773065-83-1P 773065-84-2P
 773065-85-3P 773065-86-4P 773065-87-5P
 773065-88-6P 773065-89-7P 773065-90-0P
 773065-91-1P 773065-92-2P 773065-93-3P
 773065-94-4P 773065-95-5P 773065-96-6P
 773065-97-7P 773065-98-8P 773065-99-9P
 773066-00-5P 773066-01-6P 773066-02-7P
 773066-03-8P 773066-04-9P 773066-05-0P


773066-06-1P 773066-07-2P 773066-08-3P
 773066-09-4P 773066-10-7P 773066-11-8P
 773066-12-9P 773066-13-0P 773066-14-1P
 773066-15-2P 773066-16-3P 773066-17-4P
 773066-18-5P 773066-20-9P 773066-21-0P
 773066-22-1P 773066-23-2P 773066-24-3P
 773066-25-4P 773066-26-5P 773066-27-6P
 773066-28-7P 773066-29-8P 773066-30-1P
 773066-31-2P 773066-32-3P 773066-33-4P
 773066-34-5P 773066-35-6P 773066-36-7P
 773066-37-8P 773066-39-0P 773066-40-3P
 773066-41-4P 773066-42-5P 773066-43-6P
 773066-44-7P 773066-45-8P 773066-46-9P
 773066-47-0P 773066-48-1P 773066-49-2P
 773066-50-5P 773066-51-6P 773066-52-7P
 773066-53-8P 773066-54-9P 773066-55-0P
 773066-56-1P 773066-57-2P 773066-58-3P
 773066-59-4P 773066-60-7P 773066-61-8P
 773066-62-9P 773066-63-0P 773066-64-1P
 773066-65-2P 773066-66-3P 773066-67-4P
 773066-68-5P 773066-69-6P 773066-70-9P
 773066-71-0P 773066-72-1P 773066-73-2P
 773066-74-3P 773066-75-4P 773066-76-5P
 773066-77-6P 773066-78-7P 773066-79-8P
 773066-80-1P 773066-81-2P 773066-82-3P
 773066-83-4P 773066-84-5P 773066-85-6P
 773066-86-7P 773066-87-8P 773066-88-9P
 773066-89-0P 773066-90-3P 773066-91-4P
 773066-92-5P 773066-93-6P 773066-94-7P
 773066-95-8P 773066-96-9P 773066-97-0P
 773066-98-1P 773066-99-2P 773067-00-8P
 773067-01-9P 773067-02-0P 773067-03-1P
 773067-04-2P 773067-05-3P 773067-06-4P
 773067-07-5P 773067-08-6P 773067-09-7P
 773067-10-0P 773067-11-1P 773067-12-2P
 773067-13-3P 773067-14-4P 773067-15-5P
 773067-16-6P 773067-17-7P 773067-18-8P
 773067-19-9P 773067-20-2P 773067-21-3P
 773067-22-4P 773067-23-5P 773067-24-6P
 773067-25-7P 773067-26-8P 773067-27-9P
 773067-28-0P 773067-29-1P 773067-30-4P
 773067-31-5P 773067-32-6P 773067-33-7P
 773067-34-8P 773067-35-9P 773067-36-0P
 773067-37-1P 773067-38-2P 773067-39-3P
 773067-40-6P 773067-41-7P 773067-42-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)


RN 773065-07-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]am
 ino]-5-iodo-, 2-[[4-(hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-08-0 HCAPLUS

CN Benzoic acid, 2-[[3-((1,4'-bipiperidin)-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-09-1 HCAPLUS

CN Benzoic acid, 2-[[3-((1,4'-bipiperidin)-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-10-4 HCAPLUS

CN Benzoic acid, 2-[[3-((1,4'-bipiperidin)-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-11-5 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-12-6 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-13-7 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-14-8 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-15-9 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-16-0 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(3-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-17-1 HCAPLUS

CN Benzoic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-5-iodo-, 2-[(4-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-18-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-19-3 HCAPLUS



CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773065-20-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-methylbenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773065-21-7 HCAPLUS



CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773065-22-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773065-23-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773065-24-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773065-25-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-26-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-27-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethoxybenzoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-28-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethoxybenzoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-29-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethoxybenzoyl)amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-30-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-ethoxybenzoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-31-9 HCAPLUS

CN Benzoic acid, 2-[(2-pyridinylcarbamoyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-32-0 HCAPLUS

CN Benzoic acid, 2-[(2-pyridinylcarbamoyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-33-1 HCAPLUS

CN Benzoic acid, 2-[(2-pyridinylcarbamoyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-34-2 HCAPLUS


CN Benzoic acid, 2-[(2-pyridinylcarbamoyl)amino]-,
2-[(4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX
NAME)




RN 773065-35-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(cyclohexylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773065-36-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(5-isoxazolylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773065-37-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(5-isoxazolylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773065-38-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(5-isoxazolylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

RN 773065-39-7 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(5-isoxazolylcarbonyl)amino]-,
2-[[3-chloro-4-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)

RN 773065-40-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2,5-dimethyl-3-furanylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 773065-41-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2,5-dimethyl-3-furanylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-42-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[2,5-dimethyl-3-furanyl]carbonyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-43-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-44-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4-methyl-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-45-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4-methyl-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-46-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4-methyl-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-47-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(3,4-dimethoxybenzoyl)amino]-4-methyl-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773065-48-8 HCAPLUS

CN 2-Thiophenecarboxylic acid, 4-methyl-3-[[3-[(1H-1,2,4-triazol-5-
ylthio)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773065-49-9 HCAPLUS

CN 2-Thiophenecarboxylic acid, 4-methyl-3-[[3-[(1H-1,2,4-triazol-5-
ylthio)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA
INDEX NAME)




RN 773065-50-2 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[(3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-51-3 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[(3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-52-4 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[(3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-53-5 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-54-6 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-55-7 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-56-8 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773065-57-9 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-58-0 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-59-1 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-60-4 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-61-5 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-62-6 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-63-7 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-64-8 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[3-[[[2-(diethylamino)ethyl]methyl]benzoyl]amino]-4-methyl-2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773065-65-9 HCAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[[3-[[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-2-[[4-methylphenyl]methylene]hydrazide (CA INDEX NAME)



RN 773065-66-0 HCAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[[3-[[[4-hydroxy-1-

piperidinyl)methyl]benzoyl]amino]-4-methyl-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-67-1 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-68-2 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-69-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(2-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methyl]hydrazide (CA INDEX NAME)




RN 773065-70-6 HCAPLUS

CN Benzoic acid, 2-[(4-pyridinylcarbonyl)amino]-,
2-[(4-methylphenyl)methyl]hydrazide (CA INDEX NAME)




RN 773065-71-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(3-[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-,
2-[(4-chloro-3-(trifluoromethyl)phenyl)methyl]hydrazide (CA INDEX NAME)




RN 773065-72-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methyl]hydrazide (CA INDEX NAME)




RN 773065-73-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3,4-dimethoxybenzoyl]amino]-, 2-[(3,4-dimethylphenyl)methyl]hydrazide (CA INDEX NAME)




RN 773065-74-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-75-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-76-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-77-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-78-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-79-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-80-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-81-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[(1H-1,2,4-triazol-5-ylthio)methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-82-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[[3-[(3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-83-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-84-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-85-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-86-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[3-hydroxypropyl)thio]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-87-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[3-hydroxypropyl]thio]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-88-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-89-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-90-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-91-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-92-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773065-93-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-94-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[1,4'-bipiperidin]-1'-ylmethyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-95-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(1,4'-bipiperidin)-1'-ylmethyl]benzoylamino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773065-96-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(1,4'-bipiperidin)-1'-ylmethyl]benzoylamino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773065-97-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773065-98-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773065-99-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-([3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino)-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773066-00-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-([3-([4-(2-hydroxyethyl)-1-piperazinyl)methyl]benzoyl]amino)-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-01-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-02-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-03-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-04-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-05-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-06-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-07-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-08-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-09-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-10-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-11-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-12-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-13-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-14-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-15-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-16-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-17-4 HCAPLUS


CN 3-Thiophenecarboxylic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773066-18-5 HCAPLUS
 CN 3-Thiophenecarboxylic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-,
 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-20-9 HCAPLUS
 CN 3-Thiophenecarboxylic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-,
 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-21-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-22-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-23-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-4-methyl-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-24-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-25-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-26-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-27-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-4-methyl-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-28-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-4-methyl-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 773066-29-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-30-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-[[3-[[[3-(hydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[(4-methoxy-3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-31-2 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[[3-hydroxypropyl]thio]methyl]benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-32-3 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[[3-hydroxypropyl]thio]methyl]benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-33-4 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[[3-hydroxypropyl]thio]methyl]benzoyl]amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-34-5 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-35-6 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-36-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-37-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-39-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide
(CA INDEX NAME)




RN 773066-40-3 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-41-4 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoylamino]-4,5,6,7-tetrahydro-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-42-5 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoylamino]-4,5,6,7-tetrahydro-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-43-6 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoylamino]-4,5,6,7-tetrahydro-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-44-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4,5,6,7-tetrahydro-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-45-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4,5,6,7-tetrahydro-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773066-46-9 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-([1,4'-bipiperidin]-1'-ylmethyl)benzoyl]amino]-4,5,6,7-tetrahydro-,
2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-47-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-48-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(2-hydroxyethyl)-1-
piperazinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773066-49-2 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(2-hydroxyethyl)-1-
piperazinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)



RN 773066-50-5 HCAPLUS


CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(2-hydroxyethyl)-1-
piperazinyl]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)



RN 773066-51-6 HCAPLUS


CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(2-hydroxyethyl)-1-

piperazinyl)methyl]benzoyl]amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773066-52-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(2-hydroxyethyl)-1-
piperazinyl)methyl]benzoyl]amino]-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-53-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-
, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-54-9 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-
, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-55-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-
, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-56-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-
, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-57-2 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773066-58-3 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-
2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-59-4 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-
2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-60-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-61-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-62-9 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-63-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-64-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-65-2 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-66-3 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773066-67-4 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773066-68-5 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(hydroxymethyl)-1-
piperidinyl)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773066-69-6 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(hydroxymethyl)-1-
piperidinyl)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]
methylene]hydrazide (CA INDEX NAME)



RN 773066-70-9 HCAPLUS


CN Benzo[b]thiophene-3-carboxylic acid,
4,5,6,7-tetrahydro-2-[[3-[[4-(hydroxymethyl)-1-
piperidinyl)methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]
methylene]hydrazide (CA INDEX NAME)



RN 773066-71-0 HCAPLUS


CN 3-Thiophenecarboxylic acid, 2-[[3-[[3-

hydroxypropyl)thio)methyl]benzoyl]amino]-4-methyl-,
2-[(3,4-dimethylphenyl)methyl]hydrazide (CA INDEX NAME)




RN 773066-72-1 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[[(3,4-dimethylphenyl)methylene]amino]-5,6,7,8-tetrahydro-2-[3-[(1H-1,2,4-triazol-5-ylthio)methyl]phenyl]- (CA INDEX NAME)




RN 773066-73-2 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[[[(4-methylphenyl)methylene]amino]-2-[3-[(1H-1,2,4-triazol-5-ylthio)methyl]phenyl]- (CA INDEX NAME)




RN 773066-74-3 HCAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[[(4-fluorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-[3-[(1H-1,2,4-triazol-5-ylthio)methyl]phenyl]- (CA INDEX NAME)




RN 773066-75-4 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[3-(3-fluorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-[3-[(1H-1,2,4-
triazol-5-ylthio)methyl]phenyl]- (CA INDEX NAME)

RN 773066-76-5 HCAPLUS



CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]amino]-5,6,7,8-
tetrahydro-2-[3-[(1H-1,2,4-triazol-5-ylthio)methyl]phenyl]- (CA INDEX
NAME)

RN 773066-77-6 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[[4-methoxyphenyl)methylene]amino]-2-[3-[(1H-1,2,4-
triazol-5-ylthio)methyl]phenyl]- (CA INDEX NAME)



RN 773066-78-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[3-[[acetyl[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-79-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[acetyl(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773066-80-1 HCAPLUS



CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[acetyl(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773066-81-2 HCAPLUS



CN Benzo[b]thiophene-3-carboxylic acid,

2-[[3-[[[acetyl[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-, 2-[[3-(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-82-3 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[acetyl[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773066-83-4 HCAPLUS


CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[acetyl[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-, 2-[[4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-84-5 HCAPLUS
 CN 3-Thiophenecarboxylic acid, 2-[[3-[(3-hydroxypropyl)thio)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773066-85-6 HCAPLUS
 CN 3-Thiophenecarboxylic acid, 2-[[3-[(3-hydroxypropyl)thio)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-86-7 HCAPLUS
 CN 3-Thiophenecarboxylic acid, 2-[[3-[(3-hydroxypropyl)thio)methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-87-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[3-(3-hydroxypropylthio)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-88-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[3-(3-hydroxypropylthio)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-89-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[3-hydroxypropyl]thio]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-90-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-91-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-92-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-93-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-94-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[[3-[[[2-(diethylamino)ethyl)methylamino]methyl]benzoyl]amino]-, 2-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773066-95-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-96-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-97-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773066-98-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773066-99-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773067-00-8 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-[3-[[2-(diethylamino)ethyl]methylamino]methyl]phenyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)




RN 773067-01-9 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
2-[3-[[[2-(diethylamino)ethyl]methylamino]methyl]phenyl]-5,6,7,8-
tetrahydro-3-[[4-methoxyphenyl]methylene]amino]- (CA INDEX NAME)




RN 773067-02-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(
hydroxyethyl)sulfonyl]methyl]benzoyl]amino]-,
2-[[4-methylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-03-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[[[2-(
hydroxyethyl)sulfinyl]methyl]benzoyl]amino]-,
2-[[4-methylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-04-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(2-hydroxyethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-05-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[3-[(2-hydroxyethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-06-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)thio]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-07-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)thio]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-08-6 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773067-09-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-10-0 HCAPLUS

CN Benzoic acid, 2,2'-[1,3-propanediylbis[(methylimino)methylene]-3,1-phenylenecarbonylimino]]bis[5-chloro-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)


bis[(2E)-[(3,4-dimethylphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 773067-11-1 HCAPLUS


CN Benzoic acid, 2,2'-[1,3-propanediylbis[(methylimino)methylene-3,1-phenylenecarbonylimino]]bis[5-chloro-, bis[(2E)-[(3-fluorophenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 773067-12-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[2-(furanylmethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-13-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[2-(furanylmethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-14-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773067-15-5 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)sulfonyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-16-6 HCAPLUS


CN Benzoic acid, 2,2'-[1,6-hexanediylbis[(methylimino)methylene-3,1-phenylenecarbonylimino]]bis[5-chloro-, bis[(2E)-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A




PAGE 1-B



PAGE 2-A




RN 773067-17-7 HCAPLUS
 CN Benzoic acid, 5-chloro-2-[[3-[[[(2-sulfoethyl)thio]methyl]benzoyl]amino]-, 1-[2-[(3-fluorophenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773067-18-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-sulfoethylthio)methyl]benzoyl]amino]-, 1-[2-[(3-methylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773067-19-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-sulfoethylthio)methyl]benzoyl]amino]-, 1-[2-[(4-methylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773067-20-2 HCAPLUS


CN Benzoic acid, 5-chloro-2-[[3-[(2-sulfoethylthio)methyl]benzoyl]amino]-, 1-[2-[(3,4-dimethylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773067-21-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(4-fluorophenyl)methylene]amino]-2-[3-
[[2-(hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)


RN 773067-22-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[3-[[2-(hydroxyethyl)thio]methyl]phenyl]-3-
[[4-methylphenyl)methylene]amino]- (CA INDEX NAME)

RN 773067-23-5 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(3,4-dimethylphenyl)methylene]amino]-2-[3-
[[2-(hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)

RN 773067-24-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(
(trifluoromethyl)phenyl)methylene]amino]-2-[3-[[2-
hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)


RN 773067-25-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)thio]methyl]benzoylamino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773067-26-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2-furanylmethyl)thio]methyl]benzoylamino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-27-9 HCAPLUS


CN Benzoic acid, 2,2'-[1,3-propanediylbis[(methylimino)methylene-3,1-phenylenecarbonylimino]]bis[5-chloro-, bis[(2E)-[(4-fluorophenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A




RN 773067-28-0 HCAPLUS


CN Benzoic acid, 2,2'-[1,3-propanediylbis[(methylimino)methylene-3,1-phenylenecarbonylimino]]bis[5-chloro-, bis[(2E)-[4-methylphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 773067-29-1 HCAPLUS

CN Ethanesulfonic acid, 2-[[[3-[6-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinoxaliny]phenyl]methyl]thio]- (CA INDEX NAME)




RN 773067-30-4 HCAPLUS


CN Benzoic acid, 2,2'-[1,6-hexanediylbis[(methylimino)methylene-3,1-phenylenecarbonylimino]]bis[5-chloro-, bis[(2E)-[(3-fluorophenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A




RN 773067-31-5 HCAPLUS


CN Benzoic acid, 2,2'-[1,6-hexanediylbis[(methylimino)methylene-3,1-phenylenecarbonylimino]]bis[5-chloro-, bis[(2E)-[(3-methylphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A




RN 773067-32-6 HCAPLUS


CN Benzoic acid, 2,2'-[1,6-hexanediylbis[(methylimino)methylene]-3,1-phenylenecarbonylimino]bis[5-chloro-, bis[(2E)-(4-methylphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 773067-33-7 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-34-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[(2-sulfoethyl)thio]methyl]benzoyl]amino]-, 1-[2-[[4-fluorophenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773067-35-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[(2-sulfoethyl)thio]methyl]benzoyl]amino]-, 1-[2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773067-36-0 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[[2-(4-chlorophenyl)carbamoyl]amino]-4-methyl-2-[[3-(methoxyphenyl)methylene]hydrazide]]methyl]methylamino]methyl]benzoyl]amino]-4-methyl-2-[[3-(methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-37-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[[3-(fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-38-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-39-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-40-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-41-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-fluorophenyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773067-42-8 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



IT 773067-43-9P 773067-44-0P 773067-45-1P
 773067-46-2P 773067-47-3P 773067-48-4P
 773067-49-5P 773067-50-6P 773067-51-9P
 773067-52-0P 773067-53-1P 773067-54-2P
 773067-55-3P 773067-56-4P 773067-57-5P
 773067-58-6P 773067-59-7P 773067-60-0P
 773067-61-1P 773067-62-2P 773067-63-3P
 773067-64-4P 773067-65-5P 773067-66-6P
 773067-67-7P 773067-68-8P 773067-69-9P
 773067-70-2P 773067-71-3P 773067-72-4P
 773067-73-5P 773067-74-6P 773067-75-7P
 773067-76-8P 773067-77-9P 773067-78-0P
 773067-79-1P 773067-80-4P 773067-81-5P
 773067-82-6P 773067-83-7P 773067-84-8P
 773067-85-9P 773067-86-0P 773067-87-1P
 773067-88-2P 773067-89-3P 773067-90-6P
 773067-91-7P 773067-93-9P 773067-94-0P
 773067-95-1P 773067-96-2P 773067-97-3P
 773067-99-4P 773067-99-5P 773068-00-1P
 773068-01-2P 773068-02-3P 773068-03-4P
 773068-04-5P 773068-05-6P 773068-06-7P
 773068-07-8P 773068-08-9P 773068-09-0P
 773068-10-3P 773068-11-4P 773068-12-5P
 773068-13-6P 773068-14-7P 773068-15-8P

773068-16-9P 773068-17-0P 773068-18-1P
 773068-19-2P 773068-20-5P 773068-21-6P
 773068-22-7P 773068-23-8P 773068-24-9P
 773068-25-0P 773068-26-1P 773068-27-2P
 773068-28-3P 773068-29-4P 773068-30-7P
 773068-31-8P 773068-32-9P 773068-33-0P
 773068-34-1P 773068-35-2P 773068-36-3P
 773068-37-4P 773068-38-5P 773068-39-6P
 773068-40-9P 773068-41-0P 773068-42-1P
 773068-43-2P 773068-44-3P 773068-45-4P
 773068-46-5P 773068-47-6P 773068-48-7P
 773068-49-8P 773068-50-1P 773068-51-2P
 773068-52-3P 773068-53-4P 773068-54-5P
 773068-55-6P 773068-56-7P 773068-57-8P
 773068-58-9P 773068-59-0P 773068-60-3P
 773068-61-4P 773068-62-5P 773068-63-6P
 773068-64-7P 773068-65-8P 773068-66-9P
 773068-67-0P 773068-68-1P 773068-69-2P
 773068-70-5P 773068-71-6P 773068-72-7P
 773068-73-8P 773068-74-9P 773068-75-0P
 773068-76-1P 773068-77-2P 773068-78-3P
 773068-79-4P 773068-80-7P 773068-81-8P
 773068-82-9P 773068-83-0P 773068-84-1P
 773068-85-2P 773068-86-3P 773068-87-4P
 773068-88-5P 773068-89-6P 773068-90-9P
 773068-91-0P 773068-92-1P 773068-93-2P
 773068-94-3P 773068-95-4P 773068-96-5P
 773068-97-6P 773068-98-7P 773068-99-8P
 773069-00-4P 773069-01-5P 773069-02-6P
 773069-03-7P 773069-04-8P 773069-05-9P
 773069-06-0P 773069-07-1P 773069-08-2P
 773069-09-3P 773069-10-6P 773069-11-7P
 773069-12-8P 773069-13-9P 773069-14-0P
 773069-15-1P 773069-16-2P 773069-17-3P
 773069-18-4P 773069-19-5P 773069-20-8P
 773069-21-9P 773069-22-0P 773069-23-1P
 773069-24-2P 773069-25-3P 773069-26-4P
 773069-27-5P 773069-28-6P 773069-29-7P
 773069-30-0P 773069-32-2P 773069-34-4P
 773069-35-5P 773069-36-6P 773069-37-7P
 773069-38-8P 773069-39-9P 773069-40-2P
 773069-41-3P 773069-42-4P 773069-43-5P
 773069-44-6P 773069-45-7P 773069-46-8P
 773069-47-9P 773069-48-0P 773069-49-1P
 773069-50-4P 773069-51-5P 773069-52-6P
 773069-53-7P 773069-54-8P 773069-55-9P
 773069-56-0P 773069-57-1P 773069-58-2P
 773069-59-3P 773069-60-6P 773069-61-7P
 773069-62-8P 773069-63-9P 773069-64-0P
 773069-65-1P 773069-66-2P 773069-67-3P
 773069-68-4P 773069-69-5P 773069-70-8P
 773069-71-9P 773069-72-0P 773069-73-1P
 773069-74-2P 773069-75-3P 773069-76-4P
 773069-77-5P 773069-78-6P 773069-79-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)

RN 773067-43-9 HCAPLUS


CN Benzoic acid, 2-[4-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-5-

bromo-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-44-0 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-45-1 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-46-2 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-47-3 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-48-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-49-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-50-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-51-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[3-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-52-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-methylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-53-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773067-54-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773067-55-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-56-4 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-57-5 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-58-6 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-59-7 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-60-0 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-61-1 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-62-2 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-63-3 HCAPLUS

CN Benzoic acid, 2-[[4-[[bis(2-ethoxyethyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-64-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773067-65-5 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 773067-66-6 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

(CA INDEX NAME)




RN 773067-67-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773067-68-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-69-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-hydroxyethyl)-1-piperidinyl]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-70-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)-1-phenylethyl]amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773067-71-3 HCAPLUS


CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)-1-phenylethyl]amino]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)



RN 773067-72-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(4-morpholinyl)-1-phenylethyl]amino]methyl]benzoyl]amino]-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 773067-73-5 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]-3-[(3,4-dimethylphenyl)methylene]amino]- (CA INDEX NAME)




RN 773067-74-6 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]-3-[(3-fluorophenyl)methylene]amino]- (CA INDEX NAME)



RN 773067-75-7 HCAPLUS


CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-2-[[4-[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]- (CA INDEX NAME)




RN 773067-76-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[1,2-diethyl-4-pyrazolidinyl)amino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 773067-77-9 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[4-[[[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 773067-78-0 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[4-[[[(1,2-diethyl-4-pyrazolidinyl)amino]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 773067-79-1 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[4-[[[3-(methylphenylamino)propyl]amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-80-4 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[4-[[[3-(methylphenylamino)propyl]amino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-81-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[3-(methylphenylamino)propyl]amino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-82-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[3-(3-fluorophenyl)propyl]amino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-83-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[3-(4-chloro-3-(trifluoromethyl)phenyl)propyl]amino]methyl]benzoyl]amino]-, 2-[(4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-84-8 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[3-(methylphenylamino)propyl]amino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-85-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[3-(methylphenylamino)propyl]amino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-86-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-87-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-88-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-89-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-90-6 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-91-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773067-93-9 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-94-0 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[2-(ethylthio)ethyl]amino]methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-95-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-96-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773067-97-3 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773067-98-4 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773067-99-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-00-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-01-2 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino-,
2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-02-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-03-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-04-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[2-sulfoethylthio]methyl]benzoyl]amino]-, 3-[2-[(4-methoxy-3-methylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773068-05-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[2-sulfoethyl)thio]methyl]benzoyl]amino]-, 3-[2-[(4-methylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773068-06-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[2-sulfoethyl)thio]methyl]benzoyl]amino]-, 3-[2-[(4-fluorophenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773068-07-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[[2-sulfoethyl]thio]methyl]benzoyl]amino]-, 3-[2-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773068-08-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[[2-sulfoethyl]thio]methyl]benzoyl]amino]-, 3-[2-[[[4-methoxyphenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773068-09-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-10-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-11-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-4-methyl-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-12-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxyethyl)amino]methyl]benzoyl]amino]-4-methyl-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-13-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxyethyl)amino)methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 773068-14-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxyethyl)amino)methyl]benzoyl]amino]-4-methyl-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773068-15-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773068-16-9 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-17-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-18-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-19-2 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773068-20-5 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-,
2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-21-6 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[4-(hydroxymethyl)-1-piperidiny]methyl]benzoyl]amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-22-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[4-(hydroxymethyl)-1-piperidiny]methyl]benzoyl]amino]-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-23-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[4-(hydroxymethyl)-1-piperidiny]methyl]benzoyl]amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-24-9 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[4-(hydroxymethyl)-1-piperidiny]methyl]benzoyl]amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-25-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[4-(hydroxymethyl)-1-piperidiny]methyl]benzoyl]amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 773068-26-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[4-(hydroxymethyl)-1-piperidiny]methyl]benzoyl]amino]-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-27-2 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-28-3 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-29-4 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-30-7 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[[4-fluorophenyl]methylene]hydrazide (CA INDEX NAME)





RN 773068-31-8 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)





RN 773068-32-9 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773068-33-0 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-34-1 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-35-2 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-36-3 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773068-37-4 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773068-38-5 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5,6-dihydro-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-39-6 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
5,6-dihydro-2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-
, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-40-9 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
5,6-dihydro-2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-
, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-41-0 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
5,6-dihydro-2-[[3-[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-
, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-42-1 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
5,6-dihydro-2-[[3-[[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-
, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-43-2 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
5,6-dihydro-2-[[3-[[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-
, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773068-44-3 HCAPLUS

CN 4H-Cyclopenta[b]thiophene-3-carboxylic acid,
5,6-dihydro-2-[[3-[[[4-(hydroxymethyl)-1-piperidinyl]methyl]benzoyl]amino]-
, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-45-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(dimethylamino)methyl]benzoyl]amino]-4-
methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-46-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(dimethylamino)methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-47-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(dimethylamino)methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-48-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(dimethylamino)methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-49-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-50-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-51-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773068-52-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773068-53-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-54-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-methyl-2-[[3-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-55-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylmethyl)benzoyl]amino]-4-methyl-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-56-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-(1,4-dioxaspiro[4.5]dec-8-ylmethyl)benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773068-57-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-(1,4-dioxaspiro[4.5]dec-8-ylmethyl)benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773068-58-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-(1,4-dioxaspiro[4.5]dec-8-ylmethyl)benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773068-59-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-(1,4-dioxaspiro[4.5]dec-8-ylmethyl)benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-60-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(1,4-dioxaspiro[4.5]dec-8-yl)methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773068-61-4 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-62-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-63-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-64-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-65-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-66-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-67-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-4,5-dimethyl-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-68-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5-dimethyl-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-69-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5-dimethyl-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-70-5 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5-dimethyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-71-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-4,5-dimethyl-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-72-7 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide
(CA INDEX NAME)




RN 773068-73-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-74-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-4-methyl-, 2-[(4-methoxyphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX NAME)




RN 773068-75-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-5-fluoro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide, hydrochloride (1:1) (CA INDEX NAME)



RN 773068-76-1 HCAPLUS


CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-5-fluoro-, 2-[(4-methoxyphenyl)methylene]hydrazide, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 773068-77-2 HCAPLUS



CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 773068-78-3 HCAPLUS


CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-methoxyphenyl]methylene]hydrazide, hydrochloride (1:1)
(CA INDEX NAME)



● HCl


RN 773068-79-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-fluoro-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-80-7 HCAPLUS


CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-81-8 HCAPLUS
 CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773068-82-9 HCAPLUS
 CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-83-0 HCAPLUS
 CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-84-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-85-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-86-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-87-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-88-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-89-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-90-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-91-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-92-1 HCAPLUS

CN Benzoic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-93-2 HCAPLUS

CN Benzoic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-94-3 HCAPLUS

CN Benzoic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-95-4 HCAPLUS

CN Benzoic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-96-5 HCAPLUS

CN Benzoic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-97-6 HCAPLUS

CN Benzoic acid, 2-[[3-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773068-98-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773068-99-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-00-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-01-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-02-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-03-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-04-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-05-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-06-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-07-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-08-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-carboxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[(3,4-dimethylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773069-09-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-carboxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[(4-methylphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773069-10-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-carboxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[(4-fluorophenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773069-11-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-carboxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773069-12-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-carboxyethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[[4-methoxyphenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773069-13-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(carboxymethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide] (CA INDEX NAME)




RN 773069-14-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(carboxymethyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 1-[2-[(4-methoxyphenyl)methylene]hydrazide] (CA INDEX NAME)




RN 773069-15-1 HCAPLUS

CN Benzoic acid, 2-[[3-[(8,9-dihydropyrido[2,3-b][1,6]naphthyridin-7(6H)-yl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-16-2 HCAPLUS

CN Benzoic acid, 2-[[3-[(8,9-dihydropyrido[2,3-b][1,6]naphthyridin-7(6H)-yl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-17-3 HCAPLUS

CN Benzoic acid, 2-[[3-[(8,9-dihydropyrido[2,3-b][1,6]naphthyridin-7(6H)-yl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-18-4 HCAPLUS

CN Benzoic acid, 2-[[3-[(8,9-dihydropyrido[2,3-b][1,6]naphthyridin-7(6H)-yl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-19-5 HCAPLUS

CN Benzoic acid, 2-[[3-[(8,9-dihydropyrido[2,3-b][1,6]naphthyridin-7(6H)-yl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-20-8 HCAPLUS

CN Benzoic acid, 2-[[3-[(8,9-dihydropyrido[2,3-b][1,6]naphthyridin-7(6H)-yl)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-21-9 HCAPLUS

CN Benzoic acid, 2-[[3-[(2,3-dihydroxypropylthio)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-22-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-23-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-24-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-25-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-26-4 HCAPLUS

CN Benzoic acid, 2-[[3-[(2,3-dihydroxypropylthio)methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-27-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-28-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-29-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-30-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-32-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-(diethylamino)ethyl)amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-34-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-35-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(dipropylamino)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-36-6 HCAPLUS

CN Benzoic acid, 2-[[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(dipropylamino)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-37-7 HCAPLUS

CN Benzoic acid, 2-[[[3-[[[2-[bis(2-hydroxyethyl)amino]ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-38-8 HCAPLUS

CN Benzoic acid, 2-[[[3-[[[2-[bis(2-hydroxyethyl)amino]ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-39-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-[bis(2-hydroxyethyl)amino]ethyl]amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-40-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-pyrrolidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-41-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-pyrrolidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-42-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(1-pyrrolidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-43-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(1-pyrrolidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-44-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(1-pyrrolidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-45-7 HCAPLUS

CN Benzoic acid, 2-[[[3-[[[2-(hydroxyethyl)thio]methyl]benzoyl]amino]-5-(1-pyrrolidinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-46-8 HCAPLUS

CN Benzoic acid, 2-[[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-47-9 HCAPLUS

CN Benzoic acid, 5-[4-(2-hydroxyethyl)-1-piperazinyl]-2-[[[3-[[[2-(hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-48-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-[4-(2-hydroxyethyl)-1-piperazinyl]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-49-1 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-[[[2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazinyl]carbonyl]-4-[[3-[[[2-hydroxyethyl]thio]methyl]benzoyl]amino]phenyl]- (CA INDEX NAME)




RN 773069-50-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-thiomorpholinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-51-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-thiomorpholinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-52-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-thiomorpholinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-53-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-thiomorpholinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-54-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 5-bromo-2-[[3-
[(dimethylamino)methyl]benzoyl]amino]-
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-55-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-56-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-chloro-3-(trifluoromethyl)phenyl]methylene]amino]-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-2-[4-[[2-(2-hydroxyethyl)thio]methyl]phenyl]- (CA INDEX NAME)




RN 773069-57-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-[4-[[2-(diethylamino)ethyl]methylamino]methyl]phenyl]-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[[[4-methoxyphenyl]methylene]amino]- (CA INDEX NAME)




RN 773069-58-2 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[3-[[2-(3,4-dimethylphenyl)methylene]hydrazinyl]carbonyl]-4-[[4-[[2-(2-hydroxyethyl)thio]methyl]benzoyl]amino]phenyl]- (CA INDEX NAME)




RN 773069-59-3 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-60-6 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(1-piperidinyl)-, 2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)



RN 773069-61-7 HCAPLUS


CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(1-piperidinyl)-,
2-[(1H-imidazol-2-ylmethylene)hydrazide] (CA INDEX NAME)

RN 773069-62-8 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(1-piperidinyl)-,
2-[(4-hydroxy-3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773069-63-9 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(4-morpholinyl)-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-64-0 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(4-morpholinyl)-,
2-[(4-hydroxy-3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-65-1 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-(4-morpholinyl)-,
2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-66-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[[4-methyl-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-67-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[2-(diethylamino)ethoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-68-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(2-oxo-1-pyrrolidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-69-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(2-oxo-1-pyrrolidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-70-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(2-oxo-1-pyrrolidinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-71-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(2-oxo-1-pyrrolidinyl)-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-72-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(2-oxo-1-pyrrolidinyl)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773069-73-1 HCAPLUS


CN Benzoic acid, 2-[[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[2-hydroxy-3-(1-piperidinyl)propoxy]-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)



RN 773069-74-2 HCAPLUS

CN Benzoic acid, 2-[[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[2-hydroxy-2-(1-piperidinyl)ethoxy]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 773069-75-3 HCAPLUS

CN Benzoic acid, 2-[[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[3-(diethylamino)-2-hydroxypropoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-76-4 HCAPLUS

CN Benzoic acid, 2-[[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[3-(diethylamino)-2-hydroxypropoxy]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-77-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[2-hydroxy-3-(4-morpholinyl)propoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-78-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-[2-hydroxy-3-(4-morpholinyl)propoxy]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773069-79-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-methyl-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



IT 773069-80-0P 773069-81-1P 773069-82-2P
 773069-83-3P 773069-84-4P 773069-85-5P
 773069-86-6P 773069-87-7P 773069-88-8P
 773069-89-9P 773069-90-2P 773069-91-3P
 773069-92-4P 773069-93-5P 773069-94-6P
 773069-95-7P 773069-96-8P 773069-97-9P
 773069-98-0P 773069-99-1P 773070-00-1P
 773070-01-2P 773070-02-3P 773070-03-4P
 773070-04-5P 773070-05-6P 773070-06-7P
 773070-07-8P 773070-08-9P 773070-09-0P
 773070-10-3P 773070-11-4P 773070-12-5P
 773070-13-6P 773070-14-7P 773070-15-8P
 773070-16-9P 773070-17-0P 773070-18-1P
 773070-19-2P 773070-20-5P 773070-21-6P
 773070-22-7P 773070-23-8P 773070-24-9P
 773070-25-0P 773070-26-1P 773070-27-2P
 773070-28-3P 773070-29-4P 773070-30-7P
 773070-31-8P 773070-32-9P 773070-33-0P
 773070-34-1P 773070-35-2P 773070-36-3P


773070-37-4P 773070-38-5P 773070-39-6P
 773070-40-9P 773070-41-0P 773070-42-1P
 773070-43-2P 773070-44-3P 773070-45-4P
 773070-46-5P 773070-47-6P 773070-48-7P
 773070-49-8P 773070-50-1P 773070-51-2P
 773070-52-3P 773070-53-4P 773070-54-5P
 773070-55-6P 773070-56-7P 773070-57-8P
 773070-59-0P 773070-61-4P 773070-62-5P
 773070-63-6P 773070-64-7P 773070-65-8P
 773070-66-9P 773070-67-0P 773070-68-1P
 773070-69-2P 773070-70-5P 773070-71-6P
 773070-72-7P 773070-73-8P 773070-74-9P
 773070-75-0P 773070-76-1P 773070-77-2P
 773070-78-3P 773070-79-4P 773070-80-7P
 773070-81-8P 773070-82-9P 773070-83-0P
 773070-84-1P 773070-85-2P 773070-86-3P
 773070-87-4P 773070-88-5P 773070-89-6P
 773070-90-9P 773070-91-0P 773070-92-1P
 773070-93-2P 773070-94-3P 773070-95-4P
 773070-96-5P 773070-97-6P 773070-98-7P
 773070-99-8P 773071-00-4P 773071-01-5P
 773071-02-6P 773104-21-5P 773104-22-6P
 773104-23-7P 773104-24-8P 773104-25-9P
 773104-26-0P 773104-27-1P 773104-28-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzamide compds. as phosphorus transport inhibitors)


RN 773069-80-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(diethylamino)methyl]benzoyl]amino]-4-
 methyl-5-(1-piperidinylmethyl)-, 2-[[4-chloro-3-
 (trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-81-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 2-[[3-[(diethylamino)methyl]benzoyl]amino]-4-
 methyl-5-(1-piperidinylmethyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide
 (CA INDEX NAME)





RN 773069-82-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-(1-piperidinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773069-83-3 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773069-84-4 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773069-85-5 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773069-86-6 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-87-7 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-88-8 HCAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[[3-fluorophenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-89-9 HCAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-90-2 HCAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773069-91-3 HCAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 773069-92-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 2-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773069-93-5 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773069-94-6 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)



RN 773069-95-7 HCAPLUS



CN 2-Naphthalenecarboxylic acid, 3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773069-96-8 HCAPLUS



CN 2-Naphthalenecarboxylic acid, 3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-97-9 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-98-0 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[[3-fluorophenyl]methylene]hydrazide (CA INDEX NAME)




RN 773069-99-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-00-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-01-2 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[bis(2-hydroxypropyl)amino)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-02-3 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 773070-03-4 HCAPLUS


CN 3-Thiophenecarboxylic acid, 4-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)



RN 773070-04-5 HCAPLUS


CN 3-Thiophenecarboxylic acid, 4-[[3-[[[4-(2-hydroxyethyl)-1-

piperazinyl)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773070-05-6 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl)methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773070-06-7 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl)methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-07-8 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-08-9 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)



RN 773070-09-0 HCAPLUS


CN Benzoic acid, 2-([3-([bis(2-hydroxypropyl)amino)methyl]benzoyl)amino]-5-fluoro-, 2-((3,4-dimethylphenyl)methylene)hydrazide (CA INDEX NAME)



RN 773070-10-3 HCAPLUS

CN Benzoic acid, 2-[[2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-fluorobenzoyl]amino]-5-fluoro-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 773070-11-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-fluoro-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-12-5 HCAPLUS

CN Benzoic acid, 2-[[2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-fluorobenzoyl]amino]-5-fluoro-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-13-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-fluoro-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-14-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-fluoro-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-15-8 HCAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1,1-dimethylethyl)-3-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-16-9 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-17-0 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-18-1 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[3-[(diethylamino)methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-19-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[1-(3-fluorophenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773070-20-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-bromo-, 2-[1-(4-methoxyphenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773070-21-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[bis(2-hydroxypropyl)amino]methyl]benzoyl]amino]-5-chloro-, 2-[[4-[3-(dimethylamino)propoxy]phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-22-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[4-[3-(dimethylamino)propoxy]phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-23-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[4-(carboxymethoxy)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-24-9 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-(trifluoromethoxy)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773070-25-0 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[4-(2-hydroxyethoxy)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773070-26-1 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid,
2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5,6,7-
tetrahydro-, 2-[[1-(3-fluorophenyl)ethylidene]hydrazide (CA INDEX NAME)




RN 773070-27-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-quinoxalinylylcarbonyl)amino]-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-28-3 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-quinoxalinylylcarbonyl)amino]-,
2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-29-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-quinoxalinylylcarbonyl)amino]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773070-30-7 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-31-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-32-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-33-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-34-1 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-35-2 HCAPLUS

CN Benzoic acid, 5-chloro-2-[[3-[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-, 2-[[4-(trifluoromethoxy)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-36-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-37-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-38-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-39-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-40-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-methoxy-, 2-[[3-fluorophenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-41-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-methoxy-, 2-[[4-methylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-42-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-methoxy-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-43-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-methoxy-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-44-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2,3-dihydroxypropyl)thio]methyl]benzoyl]amino]-5-methoxy-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-45-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-methoxy-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-46-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-methoxy-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-47-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-methoxy-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-48-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(2-methoxyethoxy)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-49-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(2-methoxyethoxy)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-50-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(2-methoxyethoxy)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-51-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[(3-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773070-52-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[(4-methylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773070-53-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide
(CA INDEX NAME)




RN 773070-54-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 773070-55-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-4,5-bis(2-methoxyethoxy)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773070-56-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-[2-(2-methoxyethoxy)ethoxy]-, 2-[[3-fluorophenyl]methylene]hydrazide (CA INDEX NAME)





RN 773070-57-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-[2-(2-methoxyethoxy)ethoxy]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773070-59-0 HCAPLUS


CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-[2-(2-methoxyethoxy)ethoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773070-61-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-[2-(2-methoxyethoxy)ethoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)


ino]-5-[2-(2-methoxyethoxy)ethoxy]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




—NEt₂

PAGE 1-B

RN 773070-62-5 HCAPLUS
CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]am
ino]-5-[2-(2-methoxyethoxy)ethoxy]-,
2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-63-6 HCAPLUS
CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]am
ino]-5-[3-(1-piperidinyl)propoxy]-,
2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX
NAME)




RN 773070-64-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-[3-(1-piperidinyl)propoxy]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-65-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-[3-(1-piperidinyl)propoxy]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-66-9 HCAPLUS

CN Benzoic acid, 2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-[3-(1-piperidinyl)propoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-67-0 HCAPLUS

CN Benzoic acid, 2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-[2-(1-piperidinyl)ethoxy]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-68-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-[2-(1-piperidinyl)ethoxy]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-69-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-[2-(1-piperidinyl)ethoxy]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)



RN 773070-70-5 HCAPLUS


CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-[2-(1-piperidinylethoxy)]-2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773070-71-6 HCAPLUS

CN Benzoic acid, 5-(cyclohexylmethoxy)-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 773070-72-7 HCAPLUS
 CN Benzoic acid, 5-(cyclohexylmethoxy)-2-[[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 773070-73-8 HCAPLUS
 CN Benzoic acid, 5-(cyclohexylmethoxy)-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 773070-74-9 HCAPLUS
 CN Benzoic acid, 5-(cyclohexylmethoxy)-2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 773070-75-0 HCAPLUS

CN Benzoic acid, 5-(cyclohexylmethoxy)-2-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 773070-76-1 HCAPLUS

CN Benzoic acid, 5-(4-fluorobutoxy)-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-77-2 HCAPLUS

CN Benzoic acid, 5-(4-fluorobutoxy)-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-78-3 HCAPLUS

CN Benzoic acid, 5-(4-fluorobutoxy)-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-79-4 HCAPLUS

CN Benzoic acid, 5-(4-fluorobutoxy)-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)





RN 773070-80-7 HCAPLUS

CN Benzoic acid, 5-(4-fluorobutoxy)-2-[[3-[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773070-81-8 HCAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 2-[[3-[[bis[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-4,5,6,7-tetrahydro-, 2-[[4-methylphenyl]methylene]hydrazide (CA INDEX NAME)





RN 773070-82-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-fluorobutoxy)-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-83-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-fluorobutoxy)-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-84-1 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-fluorobutoxy)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)





RN 773070-85-2 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-fluorobutoxy)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-86-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-fluorobutoxy)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-87-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(4-hydroxy-1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-88-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-[4-(hydroxymethyl)-1-piperidinyl]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-89-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(4-morpholinyl)-, 2-[[3,4-dimethylphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-90-9 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(4-morpholinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-91-0 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio)methyl]benzoyl]amino]-5-(4-morpholinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-94-3 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-methyl-1-piperidinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-95-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-methyl-1-piperidinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773070-96-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-methyl-1-piperidiny)]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-97-6 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-methyl-1-piperidiny)]-, 2-[[4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-98-7 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-hydroxyethyl)thio]methyl]benzoyl]amino]-5-(4-methyl-1-piperazinyl)-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773070-99-8 HCAPLUS

CN Benzoic acid, 2-[[3-[[[(2-(diethylamino)ethyl)methylamino]methyl]benzoyl]amino]-5-(4-morpholinyl)-, 2-[(3,4-dimethylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 773071-00-4 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-morpholinyl)-, 2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazide (CA INDEX NAME)




RN 773071-01-5 HCAPLUS

CN Benzoic acid, 2-[[3-[[2-(diethylamino)ethyl]methylamino]methyl]benzoyl]amino]-5-(4-morpholinyl)-, 2-[[4-methoxyphenyl]methylene]hydrazide (CA INDEX NAME)




RN 773071-02-6 HCAPLUS

CN Benamide, 5-chloro-2-[[3-[(diethylamino)methyl]benzoyl]amino]-N-(phenylmethoxy)- (CA INDEX NAME)




RN 773104-21-5 HCAPLUS

CN Benzoic acid, 4-chloro-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773104-22-6 HCAPLUS


CN Benzoic acid, 4-chloro-2-[(3,4-dimethoxybenzoyl)amino]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 773104-23-7 HCAPLUS

CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)



RN 773104-24-8 HCAPLUS

CN Benzoic acid, 2-[(3,4-dimethoxybenzoyl)amino]-5-iodo-,
2-[(3-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 773104-25-9 HCAPLUS


CN Benzoic acid, 5-bromo-2-[(4-pyridinylcarbonyl)amino]-,
2-[3-(2-hydroxyethoxy)phenyl]methylene]hydrazide (CA INDEX NAME)

RN 773104-26-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-pyridinylcarbonyl)amino]-,
2-[(3-methylphenyl)methylene]hydrazide (CA INDEX NAME)


RN 773104-27-1 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[4-[[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]methyl]benzoyl]amino]-, 2-[(4-fluorophenyl)methylene]hydrazide
(CA INDEX NAME)



RN 773104-28-2 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-[4-[[{(1,2-diethyl-4-pyrazolidinyl)amino]methyl]phenyl]-3-[[{(4-methoxyphenyl)methylene]amino]-
(CA INDEX NAME)



REFERENCE COUNT:

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

STRUCTURE SEARCH PART 1

=> fil reg; d stat que 19

FILE 'REGISTRY' ENTERED AT 10:27:52 ON 20 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAR 2009 HIGHEST RN 1123341-06-9

DICTIONARY FILE UPDATES: 18 MAR 2009 HIGHEST RN 1123341-06-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

L6 STR



VAR G1=11/13/15

VAR G5=C/CY/17/19/21/23/25/27

REP G10=(3-7) A

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L7 (23983)SEA FILE=REGISTRY SSS FUL L6

L8 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L9 8 SEA FILE=REGISTRY SUB=L7 SSS FUL L8

100.0% PROCESSED 13 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

=> fil hcapl; d que nos l10

FILE 'HCAPLUS' ENTERED AT 10:28:00 ON 20 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2009 VOL 150 ISS 13

FILE LAST UPDATED: 19 Mar 2009 (20090319/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

```
L6          STR
L7  (      23983)SEA FILE=REGISTRY SSS FUL L6
L8          STR
L9          8 SEA FILE=REGISTRY SUB=L7 SSS FUL L8
L10         1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L9
```

```
=> s l10 not l81
L82          0 L10 NOT L81      L81=INVENTOR SEARCH
```

```
=> s l10 and l81
L83          1 L10 AND L81
```

```
=> d scan ti      THIS REFERENCE WAS PRINTED IN FULL IN THE INVENTOR SEARCH
```

```
L83  1 ANSWERS  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI    Preparation of benzamide compounds as phosphorus transport inhibitors
```

ALL ANSWERS HAVE BEEN SCANNED

STRUCTURE SEARCH PART 2

=> fil reg; d stat que l5; fil hcapl; d que nos l55
 FILE 'REGISTRY' ENTERED AT 10:28:31 ON 20 MAR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAR 2009 HIGHEST RN 1123341-06-9
 DICTIONARY FILE UPDATES: 18 MAR 2009 HIGHEST RN 1123341-06-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>


L1 STR



VAR G1=11/13/15
 VAR G5=C/CY/17/19/21/23/25/27
 REP G10=(3-7) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 28


STEREO ATTRIBUTES: NONE
 L2 (23983)SEA FILE=REGISTRY SSS FUL L1
 L3 STR



VAR G1=11/13/15
 VAR G5=C/CY/17/19/21/23/25/27
 REP G10=(3-7) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE
 L4 STR



VAR G1=11/13/15
 VAR G5=C/CY/17/19/21/23/25/27
 REP G10=(3-7) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
 L5 20832 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)

100.0% PROCESSED 22461 ITERATIONS 20832 ANSWERS
 SEARCH TIME: 00.00.03

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2009 VOL 150 ISS 13
 FILE LAST UPDATED: 19 Mar 2009 (20090319/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

```

L1      STR
L2 (    23983)SEA FILE=REGISTRY SSS FUL L1
L3      STR
L4      STR
L5      20832 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)
L11     695 SEA FILE=HCAPLUS SPE=ON ABB=ON L5
L23     1 SEA FILE=REGISTRY SPE=ON ABB=ON 7723-14-0
L24     3439 SEA FILE=HCAPLUS SPE=ON ABB=ON PRURITUS/CT
L25     7680 SEA FILE=HCAPLUS SPE=ON ABB=ON IMMUNODEFICIENCY/CT
L26     1825 SEA FILE=HCAPLUS SPE=ON ABB=ON SKIN/OBI(L)ULCER?/OBI
L27     6853 SEA FILE=HCAPLUS SPE=ON ABB=ON HYPERLIPIDEMIA/CT
L28     30922 SEA FILE=HCAPLUS SPE=ON ABB=ON ANEMIA/OBI
L29     7980 SEA FILE=HCAPLUS SPE=ON ABB=ON SEX?/OBI(L) (DISORDER#/OBI OR
      DYSFUNCTION?/OBI)
L30     299 SEA FILE=HCAPLUS SPE=ON ABB=ON RED/OBI(L)EYE#/OBI
L31     227 SEA FILE=HCAPLUS SPE=ON ABB=ON (BIOLOGICAL TRANSPORT/CT OR
      BLOOD/OBI OR SERUM/OBI) (L)PHOSPHOROUS/OBI
L32     7512 SEA FILE=HCAPLUS SPE=ON ABB=ON CALCIFICATION/OBI
L33     2484 SEA FILE=HCAPLUS SPE=ON ABB=ON GROWTH/CW(L) (RETARD?/OBI OR
      DELAY?/OBI)
L34     6287 SEA FILE=HCAPLUS SPE=ON ABB=ON BONE#/OBI(L) (FRACTURE/OBI OR
      DEFORM?/OBI)
L35     1236 SEA FILE=HCAPLUS SPE=ON ABB=ON (CARDIAC/OBI OR HEART/OBI) (L)C
      ONDUCTION/OBI
L36     1695 SEA FILE=HCAPLUS SPE=ON ABB=ON PAIN/OBI(L) (BONE/OBI OR
      JOINT#/OBI)
L37     287 SEA FILE=HCAPLUS SPE=ON ABB=ON (NERVE/CT OR CENTRAL NERVOUS
      SYSTEM+NT/CT) (L) (PTH/OBI OR VITAMIN D/OBI OR PARATHYROID
      HORMONE/OBI)
L38     6 SEA FILE=HCAPLUS SPE=ON ABB=ON PERIPHERAL NERVOUS SYSTEM+NT/C
  
```

T(L) (PTH/OBI OR VITAMIN D/OBI OR PARATHYROID HORMONE/OBI)
 L39 23531 SEA FILE=HCAPLUS SPE=ON ABB=ON (KIDNEY#/OBI OR RENAL/OBI) (L) F
 AILURE/OBI
 L40 75591 SEA FILE=HCAPLUS SPE=ON ABB=ON HEART, DISEASE/CT OR CARDIOMYO
 PATH?/OBI
 L41 3608 SEA FILE=HCAPLUS SPE=ON ABB=ON HYPERPARATHYROID?/OBI
 L42 593 SEA FILE=HCAPLUS SPE=ON ABB=ON HYPERPHOSPHATEMI?/OBI
 L43 829 SEA FILE=HCAPLUS SPE=ON ABB=ON OSTEALGIA/OBI OR ARTHRALGIA/OB
 I
 L44 2493 SEA FILE=HCAPLUS SPE=ON ABB=ON CARBOHYDRATE METABOLISM/CT
 L45 197 SEA FILE=HCAPLUS SPE=ON ABB=ON TENDON/CT(L) (TORN/OBI OR
 RUPTURE#/OBI OR INJUR?/OBI OR TEAR?/OBI)
 L46 21292 SEA FILE=HCAPLUS SPE=ON ABB=ON BONE/CT(L) (DISEASE/OBI OR
 DISORDER#/OBI)
 L47 1114 SEA FILE=HCAPLUS SPE=ON ABB=ON OSTEODYSTROPH?/OBI OR
 OSTEOPATH?/OBI
 L48 10271 SEA FILE=HCAPLUS SPE=ON ABB=ON ARTERIOSCLEROSIS/CT
 L49 170 SEA FILE=HCAPLUS SPE=ON ABB=ON VASCULOPATH?/OBI (L) DIABET?/OBI
 L50 225 SEA FILE=HCAPLUS SPE=ON ABB=ON (LUNG/OBI OR PULMONARY/OBI) (L)
 (EXPANSION/OBI OR DIFFUS?/OBI) (L) (DISEASE#/OBI OR DISORDER#/OBI
 OR IMPAIR?/OBI)
 L51 46938 SEA FILE=HCAPLUS SPE=ON ABB=ON (HEART/OBI OR CARDIAC/OBI) (L) (I
 NFACT?/OBI OR FAILURE/OBI OR MURMUR/OBI)
 L52 344 SEA FILE=HCAPLUS SPE=ON ABB=ON NERVOUS SYSTEM+NT/CT(L) (PTH/OB
 I OR VITAMIN D/OBI OR PARATHYROID HORMONE/OBI)
 L53 203624 SEA FILE=HCAPLUS SPE=ON ABB=ON L23
 L54 1477 SEA FILE=HCAPLUS SPE=ON ABB=ON L53(L) (TRANSPORT?/OBI)
 L55 16 SEA FILE=HCAPLUS SPE=ON ABB=ON L11 AND (L24 OR L25 OR L26 OR
 L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
 L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR
 L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR L54)

=> s l55 not l81

L84 14 L55 NOT L81 L81=INVENTOR SEARCH ANSWER SET

=> d ibib abs hitind hitstr l84 1-14

L84 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:179418 HCAPLUS Full-text

DOCUMENT NUMBER: 150:229664

TITLE: Bis(cyanomethyl)benzene derivatives as aromatase
 inhibitors and their use in cancer therapy

INVENTOR(S): Scheefers, Hans

PATENT ASSIGNEE(S): Schebo Biotech AG, Germany

SOURCE: PCT Int. Appl., 94pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018811	A1	20090212	WO 2008-DE1262	20080725
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,			


MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

DE 2007-102007037372A 20070806

DE 2007-102007049993A 20071013

GI



AB The invention relates to bis(cyanomethyl)benzene derivs. of formula I, which are possible aromatase inhibitors. In compds. I, each R1 is independently H, cyano, nitro, trifluoromethyl, or C1-4 alkyl; and L is $-(CH_2)_n-$, where n is 0-4. The invention also relates to the use of the compds. for cancer therapy.

CC 1-6 (Pharmacology)

Section cross-reference(s): 25

IT Heart failure

Inflammation

Inflammatory bowel disease

(chronic, treatment of; bis(cyanomethyl)benzene derivs. as aromatase inhibitors and their use in cancer therapy)

IT AIDS (disease)

Allergy

Arthritis

Asthma

Autoimmune disease

Bacterial infection

Cachexia

Connective tissue disease

Crohn disease

Diabetes insipidus

Diabetes mellitus

Heart failure

Hematopoietic neoplasm

Inflammatory bowel disease

Multiple sclerosis

Myasthenia gravis

Neoplasm

Non-Hodgkin lymphoma

Obesity

Osteoarthritis

Psoriasis

Rheumatoid arthritis

Rhinitis
Sepsis
T-cell lymphoma
Urticaria
Uveitis

(treatment of; bis(cyanomethyl)benzene derivs. as aromatase inhibitors and their use in cancer therapy)

IT	1116680-46-6	1116680-47-7	1116680-48-8	1116680-49-9	1116680-50-2
	1116680-51-3	1116680-52-4	1116680-53-5	1116680-54-6	1116680-55-7
	1116680-56-8	1116680-57-9	1116680-58-0	1116680-59-1	1116680-60-4
	1116680-61-5	1116680-62-6	1116680-63-7	1116680-64-8	1116680-65-9
	1116680-66-0	1116680-67-1	1116680-68-2	1116680-69-3	
	1116680-70-6	1116680-71-7	1116680-72-8	1116680-73-9	
	1116680-74-0	1116680-75-1	1116680-76-2	1116680-77-3	1116680-78-4
	1116680-79-5	1116680-80-8	1116680-81-9	1116680-82-0	1116680-83-1
	1116680-85-3	1116680-86-4	1116680-87-5	1116680-88-6	1116680-89-7
	1116680-90-0	1116680-91-1	1116680-92-2	1116680-93-3	1116680-94-4
	1116680-95-5	1116680-97-7	1116680-99-9	1116681-01-6	1116681-03-8

RL: PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prophetic drug candidate; bis(cyanomethyl)benzene derivs. as aromatase inhibitors and their use in cancer therapy)


IT 1116680-69-3 1116680-70-6 1116680-71-7

RL: PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prophetic drug candidate; bis(cyanomethyl)benzene derivs. as aromatase inhibitors and their use in cancer therapy)


RN 1116680-69-3 HCAPLUS

CN Benzamide, N-[4-(aminooxy)butyl]-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethoxy)-2-quinazolinyl]-2-methylpropyl]- (CA INDEX NAME)




RN 1116680-70-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1116680-71-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:410465 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 148:403229

TITLE: Preparation of thiadiazolone derivatives as

INVENTOR(S): TNF- α converting enzyme (TACE) inhibitors
Kikuchi, Shinichi; Matsui, Takuya; Inoue, Teruhiko;
Terashita, Masakazu; Miura, Tomoya; Mimura, Takayuki;
Fukui, Kenji; Takahashi, Akihiko

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 620pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038841	A1	20080403	WO 2007-JP69519	20070928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2006-270144 A 20060930
US 2006-850626P P 20061010

OTHER SOURCE(S): MARPAT 148:403229

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The title compds. [I; Raal, Raa2 = H, C1-4 alkyl; na = 0-2; Lab1 = C(Rab5)(Rab6), Q, Q1, Q2, etc.; Rab5, Rab6 = H, C1-4 alkyl; Rab1-4 = H, halo, NO2, each (un)substituted OH, SH, NH2, CO2H, C1-4 alkyl, C3-12 carbocyclyl, or heterocyclyl, etc.; nb = 0-2; ring J1, J2 = each (un)substituted saturated monocyclic heterocyclic or nonarom. C3-8 carbocyclic ring; nc = 0,1; ring Lc = each (un)substituted C3-12 carbocyclic ring or saturated monocyclic heterocyclic ring; Lb = CON(Rba1)-Lba1, Lba6-N(Rba2)-CO-Lba2, S(O)N(Rba3), N(Rba4)S(O), COLba3, SO2Lba4, N(Rba5)Lba5; Rba1-5 = H, (un)substituted C1-4 alkyl, C1-7 alkanoyl, C6-12 aryl-C1-7 alkanoyl, C7-11 aroyl, etc.; Lba1-6 = a bond, (un)substituted C1-3 alkylene; Ld = (CHLd1)nd1-Xda-(CHLd2)nd2-Xdb; Xda, Xdb = a bond, O, (un)substituted NH, CO, CH(OH), S, S(O), SO2; nd1, nd2 = 0-2; Ld1, Ld2 = H, C1-4 alkyl; Ue = each (un)substituted C3-12 carbocyclyl, unsatd. fused heterocyclyl, C2-6 alkynyl; Rf = H, C1-4 alkyl] or pharmaceutically acceptable salts thereof or hydrates thereof are prepared. These compds. are excellent in inhibiting activity against TNF- α converting enzyme (TACE), also called as α disintegrin and metalloproteinase 17 (ADAM17) which cleaves pro-TNF- α to release TNF- α , and are selective inhibitors of TACE (ADAM17) over ADAM10 and ADAM14. Therefore, they are inhibitors of the production of TNF- α and can be used as pharmaceutical agents effective for the prevention or treatment of diseases associated with TNF- α such as inflammatory disease, autoimmune disease, allergic disease, atopic disease, transplant rejection, graft-vs.-host disease, cardiovascular disease, reperfusion, infection, osteoporosis, diabetes, hyperlipidemia, Alzheimer's disease, neuropathy, organ fibrosis, rheumatoid arthritis, malignant tumor, and inflammatory bowel disease (IBD). Thus, 0.062 g 5-(2-aminoethyl)-3H-[1,3,4]thiadiazol-2-one hydrobromide, 0.040 g 4-(2-Methylquinolin-4-ylmethoxy)benzoic acid, and 1.0 mL DMF were mixed, sequentially treated with 0.030 mL N-methylmorpholine, 0.042 g 1-hydroxybenzotriazole monohydrate, and 0.052 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and stirred at room temperature for 7 h to give 49% 4-(2-methylquinolin-4-ylmethoxy)-N-[2-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)ethyl]benzamide (II). II and 4-(2-methylquinolin-4-ylmethoxy)-N-[(1R,2S)-2-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)cyclohexyl]benzamide (III) in vitro showed IC50 of ≥ 0.01 - <10 and <0.01 μ M, resp., against recombinant human TACE (ADAM17). III in vitro inhibited the LPS-stimulated production of TNF- α in THP-1 cells with IC50 of <1 μ M.
- CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
- Section cross-reference(s): 1
- IT Alzheimer's disease
 Anti-Alzheimer's agents
 Anti-infective agents
 Anti-inflammatory agents
 Antidiabetic agents
 Antifibrotic agents
 Antiosteoporotic agents
 Antirheumatic agents
 Antitumor agents
 Autoimmune disease
 Cardiovascular agents
 Cardiovascular system, disease
 Diabetes mellitus
 Fibrosis
 Human
 Hyperlipidemia
 Hypolipemic agents
 Infection
 Inflammation
 Inflammatory bowel disease
 Neoplasm

Osteoporosis
Reperfusion
Rheumatoid arthritis

(preparation of thiadiazolone derivs. as TNF- α converting enzyme
(TACE) inhibitors)

IT 1828-66-6P, 4-Morpholinesulfonyl chloride 30431-99-3P,
4-Cyanotetrahydropyran-4-carboxylic acid ethyl ester 71233-25-5P,
1-(tert-Butoxycarbonyl)-3-Oxopiperidine-4-carboxylic acid ethyl ester
110503-79-2P, N'-[3-[(Benzyloxycarbonyl)amino]propanoyl]hydrazinecarboxylic
acid tert-butyl ester 127956-11-0P, 4-Oxotetrahydropyran-3-carboxylic
acid methyl ester 321174-91-8P, (S)-2-Hydroxyamino-2-phenylethanol
361367-97-7P, (2S,3R)-1-(tert-Butoxycarbonyl)-3-Azidopyrrolidine-2-
carboxylic acid methyl ester 362490-22-0P,
4-[(1R)-1-Phenylethyl]amino]-5,6-dihydro-2H-pyran-3-carboxylic acid
methyl ester 362490-23-1P, (3R,4R)-4-[(1R)-1-
Phenylethyl]amino]tetrahydropyran-3-carboxylic acid methyl ester
362492-34-0P, (2S,3R)-1-(tert-Butoxycarbonyl)-3-Aminopyrrolidine-2-
carboxylic acid methyl ester 372144-07-5P,
4-[1-[(Benzyloxycarbonyl)amino]-2-carboxyethyl]piperidine-1-carboxylic
acid tert-butyl ester 388108-92-7P,
(3S,4R)-1-(tert-Butoxycarbonyl)-4-[(Benzyloxycarbonyl)amino]piperidine-3-
carboxylic acid 461665-33-8P, 4-[(2-Trifluoromethylbenzimidazol-1-
yl)methyl]benzoic acid 477585-11-8P,
4-[(1R)-1-Phenylethyl]amino]tetrahydropyran-3-carboxylic acid methyl
ester 477585-26-5P, 4-[(2-Methylquinolin-4-yl)methoxy]benzenesulfonic
acid sodium salt 477585-31-2P, 4-[(2-Methylquinolin-4-
yl)methoxy]benzenesulfonyl chloride hydrochloride 503168-22-7P,
(3R,4R)-4-Aminotetrahydropyran-3-carboxylic acid methyl ester
683774-07-4P, (3R,4R)-4-[(1R)-1-Phenylethyl]amino]tetrahydropyran-3-
carboxylic acid methyl ester hydrobromide 897564-22-6P,
2-Methyl-6-trifluoromethoxyquinoline-4-carboxylic acid 1016257-56-9P,
4-[(2-Methyl-6-(trifluoromethoxy)quinolin-4-yl)methoxy]benzoic acid
1016257-59-2P, (2-Methyl-6-trifluoromethoxyquinolin-4-yl)methanol
hydrochloride 1016257-61-6P, 4-Bromomethyl-2-methyl-6-
trifluoromethoxyquinoline 1016257-63-8P,
4-[(2-Methyl-6-(trifluoromethoxy)quinolin-4-yl)methoxy]benzoic acid methyl
ester 1016257-65-0P, 4-[(2-(Pyridin-4-yl)quinolin-4-yl)methoxy]benzoic
acid 1016257-67-2P, 4-[(2-Chloroquinolin-4-yl)methoxy]benzoic acid
methyl ester 1016257-69-4P, 4-[(2-(Pyridin-4-yl)quinolin-4-
yl)methoxy]benzoic acid methyl ester 1016257-74-1P,
4-[(2-Trifluoromethylbenzimidazol-1-yl)methyl]benzoic acid methyl ester
1016257-76-3P, 4-[(7-Methyl-1,2,3,4-tetrahydroquinolin-5-
yl)methoxy]benzoic acid 1016257-78-5P, 7-Methylquinoline-5-carboxylic
acid 1016257-80-9P, 7-Methylquinoline-5-carboxylic acid methyl ester
1016257-82-1P, 7-Methyl-1,2,3,4-tetrahydroquinoline-5-carboxylic acid
methyl ester 1016257-84-3P, (7-Methyl-1,2,3,4-tetrahydroquinolin-5-
yl)methanol 1016257-86-5P, 4-[(7-Methyl-1,2,3,4-tetrahydroquinolin-5-
yl)methoxy]benzoic acid methyl ester 1016257-88-7P,
2-Fluoro-4-[(2-methyl-4,5,6,7-tetrahydroquinolin-4-yl)methoxy]benzoic acid
1016257-90-1P, 2-Methyl-5,6,7,8-tetrahydroquinoline-4-carboxylic acid
methyl ester 1016257-93-4P, (2-Methyl-5,6,7,8-tetrahydroquinolin-4-
yl)methanol 1016257-95-6P, 4-[(2-Methyl-4,5,6,7-tetrahydroquinolin-4-
yl)methoxy]benzoic acid 1016257-98-9P,
[2-(Hydrazinocarbonyl)ethyl]carbamic acid benzyl ester hydrochloride
1016258-00-6P, [3-[N'-(Methylsulfonylthiocarbonyl)hydrazino]-3-
oxopropyl]carbamic acid benzyl ester 1016258-02-8P,
[2-(5-Methylsulfonyl-[1,3,4]thiadiazol-2-yl)ethyl]carbamic acid benzyl
ester 1016258-04-0P, [2-(5-Methylsulfonyl-[1,3,4]thiadiazol-2-
yl)ethyl]carbamic acid benzyl ester 1016258-06-2P,
[2-(5-Oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)ethyl]carbamic acid benzyl

ester 1016258-08-4P, 5-(2-Aminoethyl)-3H-[1,3,4]thiadiazol-2-one
 monohydrobromide 1016258-10-8P, N-Benzyl[2-(5-methylsulfonyl-
 [1,3,4]thiadiazol-2-yl)ethyl]carbamic acid benzyl ester 1016258-12-0P,
 N-Benzyl[2-(5-methylsulfonyl-[1,3,4]thiadiazol-2-yl)ethyl]carbamic acid
 benzyl ester 1016258-14-2P, [1-(Benzylamino)cyclohexyl]acetic acid
 methyl ester 1016258-17-5P, (1-Aminocyclohexyl)acetic acid methyl ester
 hydrochloride 1016258-20-0P, 3-[(Benzylloxycarbonyl)amino]-4-
 hydroxybutyric acid tert-butyl ester 1016258-23-3P,
 3-[(Benzylloxycarbonyl)amino]-4-(2,2-dimethylpropionyloxy)butyric acid
 tert-butyl ester 1016258-25-5P, 3-[(Benzylloxycarbonyl)amino]-4-(2,2-
 dimethylpropionyloxy)butyric acid 1016258-27-7P, 2,2-Dimethylpropionic
 acid 2-[(benzylloxycarbonyl)amino]-4-[N'-(methoxythiocarbonyl)hydrazino]-4-
 oxobutyl ester 1016258-29-9P, 2,2-Dimethylpropionic acid
 2-[(Benzylloxycarbonyl)amino]-3-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-
 yl)propyl ester 1016258-31-3P, 2,2-Dimethylpropionic acid
 2-amino-3-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)propyl ester
 monohydrobromide 1016258-33-5P, [[4-[(2-Methylquinolin-4-
 yl)methoxy]benzoyl][2-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-
 yl)ethyl]amino]acetic acid methyl ester 1016258-35-7P,
 4-Aminomethyltetrahydropyran-4-carboxylic acid ethyl ester hydrochloride
 1016258-37-9P, 4-[[[(Benzylloxycarbonyl)amino]methyl]tetrahydropyran-4-
 carboxylic acid ethyl ester 1016258-39-1P,
 3-[(Benzylloxycarbonyl)amino]-4-(1,3-dioxo-1,3-dihydroisindol-2-yl)butyric
 acid tert-butyl ester 1016258-41-5P,
 3-[(Benzylloxycarbonyl)amino]-4-(1,3-dioxo-1,3-dihydroisindol-2-yl)butyric
 acid 1016258-43-7P, [1-[(1,3-Dioxo-1,3-dihydroisindol-2-yl)methyl]-3-
 [N'-(methoxythiocarbonyl)hydrazino]-3-oxopropyl]carbamic acid benzyl ester
 1016258-45-9P, [1-[(1,3-Dioxo-1,3-dihydroisindol-2-yl)methyl]-2-(5-oxo-
 4,5-dihydro-[1,3,4]thiadiazol-2-yl)ethyl]carbamic acid benzyl ester
 1016258-47-1P, 2-[2-Amino-3-(5-oxo-4,5-dihydro[1,3,4]thiadiazol-2-
 yl)propyl]isindole-1,3-dione monohydrobromide 1016258-49-3P,
 N-[1-[(1,3-Dioxo-1,3-dihydroisindol-2-yl)methyl]-2-(5-oxo-4,5-dihydro-
 [1,3,4]thiadiazol-2-yl)ethyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
 1016258-54-0P, (S)-1-(tert-Butoxycarbonyl)-3-oxopyrrolidine-2-carboxylic
 acid methyl ester 1016258-56-2P,
 [2-(5-Oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-1-[1-(2,2,2-
 trifluoroacetyl)piperidin-4-yl]ethyl]carbamic acid benzyl ester
 1016258-58-4P, 5-[2-Amino-2-[1-(2,2,2-trifluoroacetyl)piperidin-4-
 yl]ethyl]-3H-[1,3,4]thiadiazol-2-one monohydrobromide 1016258-60-8P,
 4-[(2-Methylquinolin-4-yl)methoxy]-N-[2-(5-oxo-4,5-dihydro-
 [1,3,4]thiadiazol-2-yl)-1-[1-(2,2,2-trifluoroacetyl)piperidin-4-
 yl]ethyl]benzamide 1016258-62-0P,
 4-[(2-Methylquinolin-4-yl)methoxy]-N-[2-(5-oxo-4,5-dihydro-
 [1,3,4]thiadiazol-2-yl)-1-(piperidin-1-yl)ethyl]benzamide 1016258-64-2P,
 4-[2-[5-[(tert-Butoxycarbonyl)oxy]-[1,3,4]thiadiazol-2-yl)-1-[4-[(2-
 methylquinolin-4-yl)methoxy]benzoylamino]ethyl]piperidine-1-carboxylic
 acid tert-butyl ester 1016258-66-4P,
 1-(tert-Butoxycarbonyl)-4-cyanopiperidine-4-carboxylic acid ethyl ester
 1016258-69-7P, 1-(tert-Butoxycarbonyl)-4-Aminomethylpiperidine-4-
 carboxylic acid ethyl ester 1016258-78-8P,
 (3R,4R)-4-Aminotetrahydropyran-3-carboxylic acid hydrochloride
 1016258-81-3P, (3R,4R)-4-[(Benzylloxycarbonyl)amino]tetrahydropyran-3-
 carboxylic acid 1016258-84-6P, (3R,4R)-3-Carbamoylethyltetrahydropyran-4-
 yl]carbamic acid benzyl ester 1016258-87-9P,
 [(3R,4R)-3-(5-Oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)tetrahydropyran-4-
 yl]carbamic acid benzyl ester 1016258-90-4P,
 4-[1-[(Benzylloxycarbonyl)amino]-2-carbamoyl]piperidine-1-carboxylic
 acid tert-butyl ester 1016258-95-9P,
 4-[1-[(Benzylloxycarbonyl)amino]-2-(5-methoxy-[1,3,4]thiadiazol-2-
 yl)ethyl]piperidine-1-carboxylic acid tert-butyl ester 1016258-99-3P,

[2-(5-Oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-1-(piperidin-1-yl)ethyl]carbamate acid benzyl ester monohydrochloride 1016259-02-1P,
 [1-(1-Isopropylpiperidin-4-yl)-2-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)ethyl]carbamate acid benzyl ester 1016259-05-4P,
 5-[2-Amino-2-(1-isopropylpiperidin-4-yl)ethyl]-3H-[1,3,4]thiadiazol-2-one monohydrobromide 1016259-08-7P, 3-[(Benzyloxycarbonyl)amino]-4-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 1016259-11-2P, [4-(5-Oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)piperidin-3-yl]carbamate acid benzyl ester monohydrochloride 1016259-14-5P, 3-[(tert-Butoxycarbonyl)amino]-4-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-4-oxobutanoic acid tert-butyl ester 1016259-20-3P, 3-[(tert-Butoxycarbonyl)amino]-4-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)butyric acid tert-butyl ester 1016259-23-6P, 2-[(tert-Butoxycarbonyl)methyl]-5-oxopyrrolidine-1-carboxylic acid tert-butyl ester 1016259-26-9P 1016259-29-2P 1016259-33-8P 1016259-35-0P 1016259-38-3P, 4-[(Benzyloxycarbonyl)amino]-6-[N'-(methoxythiocarbonyl)hydrazino]-6-oxohexanoic acid methyl ester 1016259-41-8P, 4-[(Benzyloxycarbonyl)amino]-5-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)pentanoic acid methyl ester 1016259-44-1P, 4-Amino-5-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)pentanoic acid methyl ester monohydrobromide 1016259-52-1P, 1-(tert-Butoxycarbonyl)-5-(1-Phenylethylamino)-3,6-dihydro-2H-pyridine-4-carboxylic acid ethyl ester 1016259-54-3P, 1-(tert-Butoxycarbonyl)-3-(1-Phenylethylamino)piperidine-4-carboxylic acid ethyl ester 1016259-56-5P, 3-Amino-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid ethyl ester hydrochloride 1016259-59-8P, 1-(tert-Butoxycarbonyl)-3-[(Benzyloxycarbonyl)amino]piperidine-4-carboxylic acid ethyl ester 1016259-61-2P, 1-(tert-Butoxycarbonyl)-3-[(Benzyloxycarbonyl)amino]piperidine-4-carboxylic acid 1016259-63-4P, 3-[(Benzyloxycarbonyl)amino]-4-[N'-(methylsulfonyl)thiocarbonyl]hydrazino]carbonyl]piperidine-1-carboxylic acid tert-butyl ester 1016259-65-6P, 3-[(Benzyloxycarbonyl)amino]-4-(5-methylsulfonyl-[1,3,4]thiadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 1016259-67-8P, 3-[(Benzyloxycarbonyl)amino]-4-(5-methylsulfonyl-[1,3,4]thiadiazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester 1016259-69-0P, [4-(5-Methylsulfonyl-[1,3,4]thiadiazol-2-yl)piperidin-3-yl]carbamate acid benzyl ester monohydrochloride 1016259-71-4P, [4-(5-Methylsulfonyl-[1,3,4]thiadiazol-2-yl)-1-(2-methoxyethyl)piperidin-3-yl]carbamate acid benzyl ester 1016259-73-6P, [1-(2-Methoxyethyl)-4-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)piperidin-3-yl]carbamate acid benzyl ester 1016259-75-8P, [trans-1-(2-Methoxyethyl)-4-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)piperidin-3-yl]carbamate acid benzyl ester 1016259-77-0P, [2-(5-Oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-1-(1-thiocarbamoylpiperidin-4-yl)ethyl]carbamate acid benzyl ester 1016259-80-5P, [1-[1-(4-Methylthiazol-2-yl)piperidin-4-yl]-2-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)ethyl]carbamate acid benzyl ester 1016259-82-7P, 5-[2-Amino-2-[1-(4-methylthiazol-2-yl)piperidin-4-yl]ethyl]-3H-[1,3,4]thiadiazol-2-one monohydrobromide 1016259-84-9P, [1-[(Morpholin-4-yl)sulfonyl]-3-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)piperidin-4-yl]carbamate acid benzyl ester 1016259-85-0P, 5-[4-Amino-1-[(morpholin-4-yl)sulfonyl]piperidin-3-yl]-3H-[1,3,4]thiadiazol-2-one monohydrobromide 1016259-86-1P, (3aS,6aS)-1-[(1S)-2-Hydroxy-1-phenylethyl]tetrahydropyrrolo[3,4-c]isoxazole-5-carboxylic acid tert-butyl ester 1016259-87-2P, (3S,4S)-3-Amino-4-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester 1016259-88-3P, (3S,4S)-3-[(Benzyloxycarbonyl)amino]-4-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester

1016259-89-4P 1016259-90-7P, 1-(tert-Butoxycarbonyl)-4-oxopiperidine-3-carboxylic acid benzyl ester 1016259-91-8P,
 1-(tert-Butoxycarbonyl)-4-[(1R)-1-phenylethyl]amino]-5,6-dihydro-2H-pyridine-3-carboxylic acid benzyl ester 1016259-92-9P,
 1-(tert-Butoxycarbonyl)-4-[(1R)-1-phenylethyl]amino]piperidine-3-carboxylic acid benzyl ester 1016259-94-1P,
 (3S,4R)-1-(tert-Butoxycarbonyl)-4-[(1R)-1-Phenylethyl]amino]piperidine-3-carboxylic acid benzyl ester p-toluenesulfonate 1016259-96-3P
 1016259-97-4P, (3S,4S)-3-[[4-[(2-Methylquinolin-4-yl)methoxy]benzoyl]amino]-4-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)pyrrolidine-1-carboxylic acid 4-nitrophenyl ester 1016259-98-5P,
 4-[(2-Methylquinolin-4-yl)methoxy]-N-[(3S,4S)-4-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)pyrrolidin-3-yl]benzamide monohydrochloride
 1016259-99-6P, 5-((3S,4R)-4-Amino-1-methylpiperidin-3-yl)-3H-[1,3,4]thiadiazol-2-one dihydrobromide 1016260-00-6P,
 5-((3S,4S)-4-Amino-1-methylpyrrolidin-3-yl)-3H-[1,3,4]thiadiazol-2-one dihydrobromide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of thiadiazolone derivs. as TNF- α converting enzyme (TACE) inhibitors)

IT 1016259-63-4P, 3-[(Benzyloxycarbonyl)amino]-4-[[N'-(methylsulfanyl)thiocarbonyl]hydrazino]carbonyl]piperidine-1-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of thiadiazolone derivs. as TNF- α converting enzyme (TACE) inhibitors)

RN 1016259-63-4 HCAPLUS

CN 1,4-Piperidinedicarboxylic acid, 3-[(phenylmethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, 4-[2-[(methylthio)thioxomethyl]hydrazide] (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1060874 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:386007

TITLE: Preparation of quinazolinones and their use as potassium channels activators

INVENTOR(S): Brown, William Dalby; Jessen, Carsten; Demnitz, Joachim; Dyhring, Tino; Stroebaek, Dorte

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 30pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007104717	A1	20070920	WO 2007-EP52239	20070309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1996560	A1	20081203	EP 2007-726760	20070309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
US 20090036473	A1	20090205	US 2008-278091	20080801
PRIORITY APPLN. INFO.:				
			DK 2006-368	A 20060315
			US 2006-782529P	P 20060316
			WO 2007-EP52239	W 20070309

OTHER SOURCE(S): MARPAT 147:386007
GI



- AB This invention relates to novel quinazolinone derivs. I [R1, R2 = H, alkyl, cycloalkyl, etc.; R3 = alkyl, cycloalkyl, alkoxy; R4, R5 = H, alkyl, cycloalkyl, etc.] having medical utility, to use of I for the manufacture of a medicament, to pharmaceutical compns. comprising I, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of Kv7 channels. Thus, reacting trans-2-phenyl-1-cyclopropanecarboxylic acid with 3-amino-2-isopropyl-3H-quinazolin-4-one (preparation given) afforded 39% trans-2-phenylcyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)amide which induces an increase in current amplitude in the order 190% at a concentration of 3 μ M, which is an indication of its potent Kv72+3 activating activity.
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
- IT Section cross-reference(s): 1, 63
Aging, animal
Alzheimer's disease
Amyotrophic lateral sclerosis
Analgesics
Anti-AIDS agents
Anti-Alzheimer's agents

Anti-inflammatory agents
 Anti-ischemic agents
 Antiarrhythmics
 Antiasthmatics
 Anticonvulsants
 Antidepressants
 Antifibrotic agents
 Antimigraine agents
 Antiparkinsonian agents
 Antipsychotics
 Antiulcer agents
 Anxiety
 Anxiolytics
 Asbestosis
 Asthma
 Bipolar disorders
 Bladder, disease
 Cardiac arrhythmia
 Cardiomyopathy
 Cardiovascular agents
 Cardiovascular system, disease
 Central nervous system agents
 Chronic obstructive pulmonary disease
 Cognition enhancers
 Cognitive disorders
 Convulsion
 Crohn disease
 Cystic fibrosis
 Dementia
 Depression
 Down's syndrome
 Drug dependence
 Eating disorders
 Epilepsy
 Eye, disease
 Heart failure
 Human
 Inflammation
 Inflammatory bowel disease
 Learning disorders
 Long QT syndrome
 Mania
 Memory disorders
 Mood disorders
 Mood disorders
 Motion sickness
 Multiple sclerosis
 Muscle relaxants
 Myasthenia gravis
 Myocardial ischemia
 Nervous system agents
 Neuroprotective agents
 Obsessive-compulsive disorders
 Pain
 Parkinson's disease
 Phobia
 Pneumoconiosis
 Potassium channel openers
 Prodrugs
 Prophylaxis

Psychosis
Schizophrenia
Seizures
Silicosis
Sleep disorders
Stroke
Tinnitus
Tremor

Ulcerative colitis

(preparation of novel quinazolinones as potassium channel activators useful in treatment and prevention of diseases)

IT 950588-73-5P 950588-74-6P 950588-75-7P
950588-76-8P 950588-77-9P 950588-78-0P
950588-79-1P 950588-80-4P 950588-82-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinazolinones as potassium channel activators useful in treatment and prevention of diseases)

IT 950588-73-5P 950588-74-6P 950588-75-7P
950588-76-8P 950588-77-9P 950588-78-0P
950588-79-1P 950588-80-4P 950588-82-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinazolinones as potassium channel activators useful in treatment and prevention of diseases)

RN 950588-73-5 HCAPLUS

CN Cyclopropanecarboxamide, 2-(4-chlorophenyl)-N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-74-6 HCAPLUS

CN Cyclopropanecarboxamide, 2-(4-fluorophenyl)-N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-75-7 HCAPLUS

CN Cyclopropanecarboxamide, 2-(4-chlorophenyl)-N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-76-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-2-phenyl-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-77-9 HCAPLUS

CN Cyclopropanecarboxamide, 2-(4-fluorophenyl)-N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-78-0 HCAPLUS

CN Cyclopropanecarboxamide, 2-(3-fluorophenyl)-N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-79-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-2-(4-methylphenyl)-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-80-4 HCAPLUS

CN Cyclopropanecarboxamide, 2-(3-fluoro-4-methylphenyl)-N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 950588-82-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[2-(1-methylethyl)-4-oxo-3(4H)-quinazolinyl]-2-(4-methylphenyl)-, (1R,2S)-rel- (CA INDEX NAME)



Relative stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:740676 HCAPLUS Full-text
DOCUMENT NUMBER: 145:188900
TITLE: Preparation of tricyclic compounds as mGluR1
antagonists
INVENTOR(S): Matasi, Julius J.; Tulshian, Deen; Burnett, Duane A.;
Wu, Wen-Lian; Korakas, Peter; Silverman, Lisa S.;
Sasikumar, Thavalakulamgara K.; Qiang, Li; Domalski,
Martin S.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 366 pp., Cont.-in-part of U.S.
Ser. No. 152,535.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060167029	A1	20060727	US 2005-301672	20051213
US 20060009477	A1	20060112	US 2005-152535	20050614
US 7485648	B2	20090203		
CA 2633093	A1	20070621	CA 2006-2633093	20061211
WO 2007070393	A2	20070621	WO 2006-US46943	20061211
WO 2007070393	A3	20071025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1966220	A2	20080910	EP 2006-848624	20061211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
MX 2008007797	A	20080820	MX 2008-7797	20080613
PRIORITY APPLN. INFO.:				
			US 2004-579920P	P 20040615
			US 2005-152535	A2 20050614
			US 2005-301672	A 20051213
			WO 2006-US46943	W 20061211
OTHER SOURCE(S): MARPAT 145:188900				
GI				



II



III

AB The title compds. I [J1-J4 = independently N, N(O) or C(R), provided that 0-2 of J1-J4 are N or N(O); R = H, halo, amino, CHF₂O, etc.; X = O, S, C(O), (un)substituted CH₂ or NH; R1 = H, halo, alkyl, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, aryl, etc.; R4 = H, :O, :S, alkyl, etc.; R5 = R3 or is absent; and pharmaceutically acceptable salts or solvates thereof] were prepared as metabotropic glutamate receptor (mGluR1) antagonists. Thus, reacting II with 2-fluoro-4-methoxyaniline in the presence of glacial acetic acid in toluene afforded 13% III. Compds. I were tested for inhibition of hmGluR1 (data given). Compds. I and their pharmaceutical compns. are useful for treatment of mGluR1 associated diseases, such as pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease (no data).

INCL 514267000; 544250000

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Heart, disease

(arrest, treating; preparation of tricyclic compds. as mGluR1 antagonists)

IT	872887-74-6P	872887-75-7P	872887-76-8P	872887-77-9P	872887-78-0P
	872887-79-1P	872887-80-4P	872887-81-5P	872887-82-6P	872887-83-7P
	872887-84-8P	872887-85-9P	872887-86-0P	872887-87-1P	872887-88-2P
	872887-89-3P	872887-90-6P	872887-91-7P	872887-92-8P	872887-93-9P
	872887-94-0P	872887-95-1P	872887-96-2P	872887-97-3P	872887-98-4P
	872887-99-5P	872888-00-1P	872888-01-2P	872888-02-3P	872888-03-4P
	872888-04-5P	872888-05-6P	872888-06-7P	872888-07-8P	872888-08-9P
	872888-09-0P	872888-10-3P	872888-11-4P	872888-12-5P	872888-13-6P
	872888-14-7P	872888-15-8P	872888-16-9P	872888-17-0P	872888-18-1P
	872888-19-2P	872888-20-5P	872888-21-6P	872888-22-7P	872888-23-8P
	872888-24-9P	872888-25-0P	872888-27-2P	872888-29-4P	872888-30-7P
	872888-32-9P	872888-33-0P	872888-34-1P	872888-35-2P	872888-36-3P
	872888-37-4P	872888-38-5P	872888-39-6P	872888-40-9P	872888-41-0P
	872888-42-1P	872888-43-2P	872888-46-5P	872888-47-6P	872888-48-7P
	872888-49-8P	872888-50-1P	872888-51-2P	872888-52-3P	872888-53-4P
	872888-54-5P	872888-55-6P	872888-56-7P	872888-57-8P	872888-58-9P
	872888-59-0P	872888-60-3P	872888-61-4P	872888-62-5P	872888-63-6P
	872888-64-7P	872888-65-8P	872888-66-9P	872888-67-0P	
	872888-68-1P	872888-69-2P	872888-70-5P	872888-71-6P	
	872888-72-7P	872888-73-8P	872888-74-9P	872888-75-0P	872888-76-1P
	872888-78-3P	872888-79-4P	872888-80-7P	872888-81-8P	872888-82-9P
	872888-83-0P	872888-85-2P	872888-86-3P	872888-87-4P	872888-88-5P
	872888-89-6P	872888-90-9P	872888-91-0P	872888-92-1P	872888-94-3P
	872888-95-4P	872888-96-5P	872888-97-6P	872889-01-5P	872889-02-6P
	872889-03-7P	872889-04-8P	872889-05-9P	872889-06-0P	872889-07-1P
	872889-08-2P	872889-09-3P	872889-10-6P	872889-11-7P	872889-12-8P

872889-13-9P 872889-14-0P 872889-15-1P 872889-16-2P 872889-17-3P
 872889-18-4P 872889-19-5P 872889-20-8P 872889-21-9P 872889-22-0P
 872889-23-1P 872889-24-2P 872889-25-3P 872889-26-4P 872889-27-5P
 872889-28-6P 872889-29-7P 872889-30-0P 872889-31-1P 872889-32-2P
 872889-33-3P 872889-34-4P 872889-35-5P 872889-36-6P 872889-37-7P
 872889-38-8P 872889-39-9P 872889-40-2P 872889-41-3P 872889-42-4P
 872889-43-5P 872889-44-6P 872889-45-7P 872889-46-8P 872889-47-9P
 872889-48-0P 872889-51-5P 872889-52-6P 872889-53-7P 872889-54-8P
 872889-55-9P 872889-56-0P 872889-57-1P 872889-58-2P 872889-59-3P
 872889-60-6P 872889-61-7P 872889-62-8P 872889-63-9P 872889-64-0P
 872889-66-2P 872889-67-3P 872889-68-4P 872889-69-5P 872889-70-8P
 872889-71-9P 872889-72-0P 872889-73-1P 872889-74-2P 872889-75-3P
 872889-76-4P 872889-77-5P 872889-78-6P 872889-79-7P 872889-83-3P
 872889-84-4P 872889-85-5P 872889-86-6P 872890-42-1P 872890-43-2P
 872890-44-3P 902745-59-9P 902745-60-2P 902745-61-3P 902745-62-4P
 902745-63-5P 902745-64-6P 902745-65-7P 902745-66-8P 902745-68-0P
 902745-69-1P 902745-71-5P 902745-73-7P 902745-74-8P 902745-75-9P
 902745-76-0P 902745-77-1P 902745-78-2P 902745-79-3P 902745-80-6P
 902745-81-7P 902745-82-8P 902745-83-9P 902745-84-0P 902745-85-1P
 902745-86-2P 902745-87-3P 902745-88-4P 902745-89-5P 902745-90-8P
 902745-91-9P 902745-92-0P 902745-93-1P 902745-94-2P 902745-95-3P
 902745-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of tricyclic compds. as mGluR1 antagonists)


IT 872888-66-9P 872888-67-0P 872888-68-1P
 872888-69-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of tricyclic compds. as mGluR1 antagonists)


RN 872888-66-9 HCAPLUS

CN Acetamide, N-[9-(dimethylamino)-2-methyl-4-oxopyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]- (CA INDEX NAME)




RN 872888-67-0 HCAPLUS


CN Acetamide, N-[9-(dimethylamino)-4-oxo-2-(trifluoromethyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 872888-68-1 HCAPLUS
 CN Cyclopropanecarboxamide, N-[2-cyclopropyl-9-(dimethylamino)-4-oxopyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]- (CA INDEX NAME)




RN 872888-69-2 HCAPLUS
 CN Cyclobutanecarboxamide, N-[2-cyclobutyl-9-(dimethylamino)-4-oxopyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]- (CA INDEX NAME)



L84 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:366878 HCAPLUS Full-text
 DOCUMENT NUMBER: 144:412379
 TITLE: Preparation of
 2-(4-carbamimidoylphenylamino)-2-phenylacetic acid
 hydrazide derivatives as preventives or therapeutic
 agents for diseases caused by thrombus formation
 INVENTOR(S): Clark, Richard; Hirota, Shinsuke; Azuma, Hiroshi;
 Kira, Kazunobu; Watanabe, Nobuhisa; Nagakura, Tadashi;
 Horizoe, Tatsuo
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 281 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041119	A1	20060420	WO 2005-JP18853	20051013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1810965 A1 20070725 EP 2005-793650 20051013
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU
 US 20080132507 A1 20080605 US 2007-665385 20070413
 PRIORITY APPLN. INFO.: JP 2004-298379 A 20041013
 WO 2005-JP18853 W 20051013
 OTHER SOURCE(S): MARPAT 144:412379
 GI



I

- AB Compds. represented by the general formula (I) or salts thereof, or hydrates of both [R1a, R1b, R1c, R1d = H, halo, C1-6 alkyl; R2 = (un)substituted Ph; R3 = H, C1-6, each (un)substituted C3-8 cycloalkyl, 5- or 6-membered nonarom. heterocyclyl, C6-10 aryl, 5- or 6-membered heteroaryl, C6-10 arylmethyl, C6-10 arylamino, 5- to 10-membered heteroarylmethyl, or 5- to 10-membered heteroarylamino; Z1, Z2, Z3 = H, C1-6 alkyl; X = a single bond, S(O)2, CO, C(S)] are prepared These compds. are safe and have moderate physicochem. stability and useful as preventive or therapeutic agents for diseases caused by thrombus formation including thrombosis, deep venous thrombosis, pulmonary embolism, cerebral infarction, myocardial infarction, vascular stenosis, disseminated intravascular coagulation, and malignant tumor. Thus, a mixture of 3-chloroisonicotinic acid 5.2, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 6.1, 1-hydroxybenzotriazole monohydrate 4.9, and 0.6 mL DMF was stirred at 0° for 1 h, treated with 15 mg 4-[[[N'-[3-ethoxy-4-(2-methoxyethoxy)phenyl]hydrazino]carbonyl]methyl]amino]benzamidinium dihydrochloride, and stirred at room temperature overnight to give 28% 4-[[2-[N'-[3-(3-chloropyridin-4-yl)carbonyl]hydrazino]-1-[3-ethoxy-4-(2-methoxyethoxy)phenyl]-2-oxoethyl]amino]benzamidinium trifluoroacetate (II). II in vitro showed IC50 of 0.049 mM against blood coagulation factor VIIa.
- CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 25, 28
- IT Brain, disease
 Heart, disease
 (infarction; preparation of
 2-(carbamimidoylphenylamino)-2-phenylacetic acid hydrazide derivs. as
 preventives or therapeutic agents for diseases caused by thrombus
 formation)
- IT 883574-17-2P 883574-21-8P 883574-23-0P 883574-25-2P 883574-30-9P
 883574-32-1P 883574-36-5P 883574-38-7P 883574-40-1P 883574-42-3P
 883574-44-5P 883574-47-8P 883574-51-4P 883574-53-6P 883574-59-2P

883574-61-6P	883574-63-8P	883574-65-0P	883574-67-2P	883574-69-4P
883574-72-9P	883574-74-1P	883574-76-3P	883574-78-5P	883574-80-9P
883574-82-1P	883574-84-3P	883574-86-5P	883574-88-7P	883574-90-1P
883574-92-3P	883574-94-5P	883574-96-7P	883574-98-9P	883575-00-6P
883575-02-8P	883575-04-0P	883575-06-2P	883575-08-4P	883575-10-8P
883575-12-0P	883575-14-2P	883575-16-4P	883575-18-6P	883575-20-0P
883575-30-2P	883575-34-6P	883575-38-0P	883575-42-6P	883575-44-8P
883575-46-0P	883575-51-7P	883575-53-9P	883575-56-2P	883575-59-5P
883575-62-0P	883575-65-3P	883575-70-0P	883575-73-3P	883575-76-6P
883575-78-8P	883575-80-2P	883575-82-4P	883575-88-0P	883575-90-4P
883575-94-8P	883575-99-3P	883576-01-0P	883576-03-2P	883576-05-4P
883576-08-7P	883576-10-1P	883576-14-5P	883576-16-7P	883576-18-9P
883576-20-3P	883576-22-5P	883576-24-7P	883576-26-9P	883576-28-1P
883576-35-0P	883576-37-2P	883576-39-4P	883576-41-8P	883576-43-0P
883576-45-2P	883576-47-4P	883576-49-6P	883576-51-0P	883576-53-2P
883576-55-4P	883576-57-6P	883576-59-8P	883576-61-2P	883576-63-4P
883576-65-6P	883576-67-8P	883576-69-0P	883576-71-4P	883576-75-8P
883576-77-0P	883576-79-2P	883576-81-6P	883576-83-8P	883576-85-0P
883576-87-2P	883576-89-4P	883576-91-8P	883576-93-0P	883576-95-2P
883576-97-4P	883576-99-6P	883577-01-3P	883577-03-5P	883577-05-7P
883577-07-9P	883577-09-1P	883577-11-5P	883577-13-7P	883577-15-9P
883577-17-1P	883577-19-3P	883577-21-7P	883577-23-9P	883577-25-1P
883577-27-3P	883577-29-5P	883577-31-9P	883577-33-1P	883577-35-3P
883577-37-5P	883577-39-7P	883577-41-1P	883577-43-3P	883577-45-5P
883577-47-7P	883577-49-9P	883577-51-3P	883577-53-5P	
883577-55-7P	883577-57-9P	883577-59-1P	883577-61-5P	883577-63-7P
883577-65-9P	883577-67-1P	883577-69-3P	883577-71-7P	883577-73-9P
883577-75-1P	883577-77-3P	883577-79-5P	883577-81-9P	883577-83-1P
883577-85-3P	883577-87-5P	883577-89-7P	883577-91-1P	883577-93-3P
883577-95-5P	883577-97-7P	883577-99-9P	883578-01-6P	883578-03-8P
883578-05-0P	883578-07-2P	883578-09-4P	883578-11-8P	883578-13-0P
883578-15-2P	883578-17-4P	883578-19-6P	883578-21-0P	883578-23-2P
883578-25-4P	883578-27-6P	883578-29-8P	883578-31-2P	883578-33-4P
883578-35-6P	883578-37-8P	883578-39-0P	883578-41-4P	883578-43-6P
883578-45-8P	883578-47-0P	883578-49-2P	883578-51-6P	883578-53-8P
883578-55-0P	883578-57-2P	883578-59-4P	883578-62-9P	883578-65-2P
883578-68-5P	883578-71-0P	883578-74-3P	883578-77-6P	883578-79-8P
883578-81-2P	883578-83-4P	883578-85-6P	883578-87-8P	883578-89-0P
883578-91-4P	883578-93-6P	883578-95-8P	883578-97-0P	883578-99-2P
883579-01-9P	883579-03-1P	883579-05-3P	883579-07-5P	883579-09-7P
883579-11-1P	883579-13-3P	883579-15-5P	883579-17-7P	883579-19-9P
883579-21-3P	883579-23-5P	883579-25-7P	883579-27-9P	883579-29-1P
883579-31-5P	883579-33-7P	883579-35-9P	883579-37-1P	883579-39-3P
883579-41-7P	883579-43-9P	883579-45-1P	883579-47-3P	883579-49-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(carbamimidoylphenylamino)-2-phenylacetic acid hydrazide derivs. as preventives or therapeutic agents for diseases caused by thrombus formation)

IT 883577-51-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(carbamimidoylphenylamino)-2-phenylacetic acid hydrazide derivs. as preventives or therapeutic agents for diseases caused by thrombus formation)

RN 883577-51-3 HCAPLUS


CN 4-Pyridinecarboxylic acid, 3-(acetylaminomethyl)-, 2-[2-[[4-(aminomethyl)phenyl]amino]-2-[3-ethoxy-4-(1-

methylethoxy)phenyl]acetyl]hydrazide, 2,2,2-trifluoroacetate (1:1) (CA
INDEX NAME)

CM 1

CRN 883577-50-2

CMF C28 H33 N7 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:15100 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:108348

TITLE: Preparation of tricyclic compounds as mGluR1
antagonists

INVENTOR(S): Matasi, Julius J.; Tulshian, Deen; Burnett, Duane A.;
Wu, Wen-Lian; Korakas, Peter; Silverman, Lisa S.;
Sasikumar, Thavalakulamgara K.; Qiang, Li; Domalski,
Martin S.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 309 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002051	A1	20060105	WO 2005-US20972	20050614

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CA 2571012 A1 20060105 CA 2005-2571012 20050614

EP 1765829 A1 20070328 EP 2005-761566 20050614

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

CN 101001862 A 20070718 CN 2005-80027420 20050614

JP 2008502693 T 20080131 JP 2007-516647 20050614


MX 2006014913 A 20070321 MX 2006-14913 20061215

PRIORITY APPLN. INFO.: US 2004-579920P P 20040615


WO 2005-US20972 W 20050614

OTHER SOURCE(S): CASREACT 144:108348; MARPAT 144:108348

GI



I



II

AB Title compds. represented by the formula I [wherein J1-J4 = independently N, N→O or C(R), provided that 0-2 of J1-J4 are N or N→O; R = H, halo, amino, CHF2, etc.; X = O, S, amino, C=O or (un)substituted C; R1-R5 = independently H, halo, alkyl, etc.; and pharmaceutically acceptable salts or solvates thereof] were prepared as metabotropic glutamate receptor (mGluR1) antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of cyanoacetamide with dimethylacetamide dimethylacetal. I were tested for inhibition of hmGluR1. Thus, I and their pharmaceutical compds. are useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, for treatment of mGluR associated diseases, such as pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease (no data).

IC ICM C07D495-14

ICS C07D491-14; C07D495-04; C07D471-14; A61K031-519; A61P025-00;

C07D333-00; C07D239-00; C07D221-00; C07D307-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT Heart, disease

(arrest; preparation of tricyclic compds. as mGluR1 antagonists)

IT 872887-87-1P 872887-88-2P 872887-89-3P 872887-90-6P 872887-91-7P

872887-92-8P 872887-93-9P 872887-94-0P 872887-95-1P 872887-96-2P

872887-97-3P	872887-98-4P	872887-99-5P	872888-00-1P	872888-01-2P
872888-02-3P	872888-03-4P	872888-04-5P	872888-05-6P	872888-06-7P
872888-07-8P	872888-08-9P	872888-09-0P	872888-10-3P	872888-11-4P
872888-12-5P	872888-13-6P	872888-14-7P	872888-15-8P	872888-16-9P
872888-17-0P	872888-18-1P	872888-19-2P	872888-20-5P	872888-21-6P
872888-22-7P	872888-23-8P	872888-24-9P	872888-25-0P	872888-27-2P
872888-29-4P	872888-30-7P	872888-32-9P	872888-33-0P	872888-34-1P
872888-35-2P	872888-36-3P	872888-37-4P	872888-38-5P	872888-39-6P
872888-40-9P	872888-41-0P	872888-42-1P	872888-43-2P	872888-45-4P
872888-46-5P	872888-47-6P	872888-48-7P	872888-49-8P	872888-50-1P
872888-51-2P	872888-52-3P	872888-53-4P	872888-54-5P	872888-55-6P
872888-56-7P	872888-57-8P	872888-58-9P	872888-59-0P	872888-60-3P
872888-61-4P	872888-62-5P	872888-63-6P	872888-64-7P	872888-65-8P
872888-66-9P	872888-67-0P	872888-68-1P		
872888-69-2P	872888-70-5P	872888-71-6P	872888-72-7P	
872888-73-8P	872888-74-9P	872888-75-0P	872888-76-1P	872888-78-3P
872888-79-4P	872888-80-7P	872888-81-8P	872888-82-9P	872888-83-0P
872888-84-1P	872888-85-2P	872888-86-3P	872888-87-4P	872888-88-5P
872888-89-6P	872888-90-9P	872888-91-0P	872888-92-1P	872888-94-3P
872888-95-4P	872888-96-5P	872888-97-6P	872889-01-5P	872889-02-6P
872889-03-7P	872889-04-8P	872889-05-9P	872889-06-0P	872889-07-1P
872889-08-2P	872889-09-3P	872889-10-6P	872889-11-7P	872889-12-8P
872889-13-9P	872889-14-0P	872889-15-1P	872889-16-2P	872889-17-3P
872889-18-4P	872889-19-5P	872889-20-8P	872889-21-9P	872889-22-0P
872889-23-1P	872889-24-2P	872889-25-3P	872889-26-4P	872889-27-5P
872889-28-6P	872889-29-7P	872889-30-0P	872889-31-1P	872889-32-2P
872889-33-3P	872889-34-4P	872889-35-5P	872889-36-6P	872889-37-7P
872889-38-8P	872889-39-9P	872889-40-2P	872889-41-3P	872889-42-4P
872889-43-5P	872889-44-6P	872889-45-7P	872889-46-8P	872889-47-9P
872889-48-0P	872889-51-5P	872889-52-6P	872889-53-7P	872889-54-8P
872889-55-9P	872889-56-0P	872889-57-1P	872889-58-2P	872889-59-3P
872889-60-6P	872889-61-7P	872889-62-8P	872889-63-9P	872889-64-0P
872889-66-2P	872889-67-3P	872889-68-4P	872889-69-5P	872889-70-8P
872889-71-9P	872889-72-0P	872889-73-1P	872889-74-2P	872889-75-3P
872889-76-4P	872889-77-5P	872889-78-6P	872889-79-7P	872889-83-3P
872889-84-4P	872889-85-5P	872889-86-6P	872889-87-7P	872890-42-1P
872890-43-2P	872890-44-3P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic compds. as mGluR1 antagonists)

IT 872888-66-9P 872888-67-0P 872888-68-1P


872888-69-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic compds. as mGluR1 antagonists)


RN 872888-66-9 HCAPLUS

CN Acetamide, N-[9-(dimethylamino)-2-methyl-4-oxopyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]- (CA INDEX NAME)




RN 872888-67-0 HCAPLUS

CN Acetamide, N-[9-(dimethylamino)-4-oxo-2-(trifluoromethyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 872888-68-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[2-cyclopropyl-9-(dimethylamino)-4-oxopyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]- (CA INDEX NAME)



RN 872888-69-2 HCAPLUS

CN Cyclobutanecarboxamide, N-[2-cyclobutyl-9-(dimethylamino)-4-oxopyrido[3',2':4,5]thieno[3,2-d]pyrimidin-3(4H)-yl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:979639 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:286443

TITLE: Preparation of pyrimidine derivatives as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A



INVENTOR(S): Sato, Michitaka; Matsui, Teruaki; Asagarasu, Akira; Hayashi, Hiroyuki; Araki, Seiichi; Tamaoki, Satoru; Takahashi, Nobuyuki; Yamauchi, Yukinao; Yamamoto, Yoshiko; Yamamoto, Norio; Ogawa, Chisato

PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan

SOURCE: PCT Int. Appl., 261 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082887	A1	20050909	WO 2005-JP3691	20050225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005217320	A1	20050909	AU 2005-217320	20050225
CA 2557541	A1	20050909	CA 2005-2557541	20050225
EP 1724267	A1	20061122	EP 2005-719969	20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1922171	A	20070228	CN 2005-80005603	20050225
KR 2006127156	A	20061211	KR 2006-717068	20060824
US 20070197551	A1	20070823	US 2006-590707	20060825
PRIORITY APPLN. INFO.:			JP 2004-52040	A 20040226
			JP 2004-322858	A 20041105
			WO 2005-JP3691	W 20050225

OTHER SOURCE(S): MARPAT 143:286443
 GI



AB Title compds. I [ring A = carbocyclic group, etc.; X1 = H, amino, etc.; X2 = H, alkyl; Y = bond, etc.; n = 0-4; Ar = optionally substituted II with halo, etc.; Z = O, etc.; B = moiety required for completing mono-, poly-heterocyclic ring containing N together with N-C-Z; dotted line indicates single, double bond] were prepared. For example, treatment of potassium 3-amino-5,6-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-thiolate with 2-[4-(3-chloropropyl)piperazin-1-yl]quinoline, e.g., prepared from piperazine in 2

steps, afforded 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one (III) in 50% yield. In 5-HT₃ receptor affinity assay (in vitro), compound III exhibited the antagonistic activity of 94% at 10⁻⁷ M. Compds. I are claimed useful for the treatment of anxiety, depression, etc. Formulation is given.

- IC ICM C07D401-12
- ICS A61K031-496; A61K031-4985; A61K031-517; A61K031-519; A61K031-5395; A61K045-00; A61K045-06; A61P001-00; A61P001-04; A61P003-04; A61P007-00; A61P009-10; A61P009-12; A61P011-00; A61P011-14; A61P013-00; A61P013-02; A61P013-08; A61P015-00
- CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
- IT Bone, disease
Necrosis
(bone necrosis; preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)
- IT Bone, disease
Cartilage, disease
Inflammation
(osteoarthritis dissecans; preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)
- IT Alcoholism
Allergy inhibitors
Alzheimer's disease
Analgesics
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Anticonvulsants
Antidepressants
Antiemetics
Antiglaucoma agents
Antihypertensives
Antiobesity agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antiulcer agents
Anxiety
Anxiolytics
Apnea
Cartilage, neoplasm
Cognition enhancers
Cognitive disorders
Connective tissue, disease
Convulsion
Cough
Disease, animal
Drug dependence
Drug withdrawal
Eating disorders
Epilepsy
Gastrointestinal agents
Glaucoma (disease)
Granuloma
Human
Mental and behavioral disorders

Nausea
Nervous system agents
Obesity
Pain
Parkinson's disease
Pneumoconiosis
Prostate gland, neoplasm
Schizophrenia
Sexual disorders
Sleep disorders
Tremor
Vomiting

(preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)

IT	863665-85-4P	863665-89-8P	864385-05-7P	864385-12-6P	864385-49-9P
	864385-51-3P	864385-58-0P	864385-61-5P	864385-71-7P	864385-72-8P
	864385-90-0P	864385-93-3P	864386-59-4P	864386-60-7P	
	864386-62-9P				

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)

IT	864386-22-1P	864386-23-2P	864386-24-3P	864386-25-4P	864386-26-5P
	864386-27-6P	864386-28-7P	864386-29-8P	864386-30-1P	864386-31-2P
	864386-32-3P	864386-33-4P	864386-34-5P	864386-35-6P	864386-36-7P
	864386-37-8P	864386-38-9P	864386-39-0P	864386-40-3P	864386-41-4P
	864386-42-5P	864386-43-6P	864386-44-7P	864386-45-8P	864386-46-9P
	864386-47-0P	864386-48-1P	864386-49-2P	864386-50-5P	864386-51-6P
	864386-52-7P	864386-53-8P	864386-54-9P	864386-55-0P	864386-56-1P
	864386-57-2P	864386-58-3P	864386-61-3P	864386-63-0P	
	864386-64-1P	864386-65-2P	864386-66-3P	864386-67-4P	864386-68-5P
	864386-69-6P	864386-70-9P	864386-71-0P	864386-72-1P	864386-73-2P
	864386-74-3P	864386-75-4P	864386-76-5P	864386-77-6P	864386-78-7P
	864386-79-8P	864386-80-1P	864386-81-2P	864386-82-3P	864386-83-4P
	864386-84-5P	864386-85-6P	864386-86-7P	864386-87-8P	864386-88-9P
	864386-89-0P	864386-90-3P	864386-91-4P	864386-92-5P	864386-93-6P
	864386-94-7P	864386-95-8P	864386-96-9P	864386-97-0P	864386-98-1P
	864386-99-2P	864387-00-8P	864387-01-9P	864387-02-0P	864387-03-1P
	864387-04-2P	864387-05-3P	864387-06-4P	864387-07-5P	864387-09-7P
	864387-10-0P	864387-11-1P	864390-04-5P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)


IT 864386-60-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrimidine derivs. as 5-HT₃ receptor antagonists having agonistic activity on 5-HT_{1A} for treatment of anxiety, depression, etc.)

RN 864386-60-7 HCAPLUS

CN Spiro[1,3-dioxolane-2,6' (4'H)-quinazolin]-4'-one,
3',5',7',8'-tetrahydro-3'-[(1-methylethylidene)amino]-2'-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)




IT 864386-61-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as 5-HT3 receptor antagonists having agonistic activity on 5-HT1A for treatment of anxiety, depression, etc.)

RN 864386-61-8 HCAPLUS

CN Spiro[1,3-dioxolane-2,6'-(4'H)-quinazolin]-4'-one, 3',5',7',8'-tetrahydro-3'-[(1-methylethyl)amino]-2'-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523406 HCAPLUS Full-text

DOCUMENT NUMBER: 143:59676

TITLE: Preparation of novel hydroxamic acid esters for inhibiting angiogenesis

INVENTOR(S): Fensholdt, Jeff; Thorhauge, Jacob; Norremark, Bjarne

PATENT ASSIGNEE(S): Leo Pharma A/S, Den.

SOURCE: PCT Int. Appl., 351 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054179	A2	20050616	WO 2004-DK840	20041202
WO 2005054179	A3	20050804		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG


AU 2004295022	A1	20050616	AU 2004-295022	20041202
CA 2549242	A1	20050616	CA 2004-2549242	20041202
EP 1697312	A2	20060906	EP 2004-801164	20041202

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU


CN 1906155	A	20070131	CN 2004-80040898	20041202
BR 2004017158	A	20070306	BR 2004-17158	20041202
JP 2007513098	T	20070524	JP 2006-541802	20041202
MX 2006006210	A	20060825	MX 2006-6210	20060601
KR 2007026337	A	20070308	KR 2006-710826	20060602
IN 2006DN03191	A	20070831	IN 2006-DN3191	20060602
NO 2006002905	A	20060621	NO 2006-2905	20060621
US 20070244117	A1	20071018	US 2007-580967	20070312

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 143:59676; MARPAT 143:59676
 GI



I



II

AB The invention relates to compds. I [R1 = H, alkyl, cycloalkyl, etc.; D = N, CR2; E = N, CR3; F = N, CR4; G = N, CR5; R2-R5 = H, halo, OH, etc.; W = O, S, H2, NOR6, NR6; R6 = H, cycloalkyl, aryl, etc.; X, Y = (CH2)n, (CH2)pCH:CH(CH2)q, etc.; n, p, q = 0-6; B = aryl, heteroaryl, cycloalkyl, etc.; R8 = H, halo, OH, etc.; A = alkyl, cycloalkyl, heteroaryl, etc.; R9 = H, oxo, halo, etc.; with provision], for use-alone or in combination with one or more other pharmaceutically active compds.- in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer. Over 400 compds. I were prepared. Thus, reacting 2-[(pyridin-4-ylmethyl)amino]benzoic acid (preparation given) with O-benzylhydroxylamine hydrochloride afforded II which showed -logIC50 of 7.1 in an assay for in vitro KDR inhibition.

IC ICM C07C259-10

ICS A61K031-165; C07D213-84; C07D401-12; C07D413-06

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1, 63


IT Bone

(osteophyte, treating or ameliorating a condition or disease characterized by osteophyte formation; preparation of novel hydroxamic acid esters for inhibiting angiogenesis)

IT Bone, disease


(treating or ameliorating a condition or disease characterized by bone and cartilage destruction; preparation of novel

hydroxamic acid esters for inhibiting angiogenesis)					
IT	854380-02-2P	854380-03-3P	854380-04-4P	854380-05-5P	854380-06-6P
	854380-07-7P	854380-08-8P	854380-09-9P	854380-10-2P	854380-11-3P
	854380-12-4P	854380-13-5P	854380-14-6P	854380-15-7P	854380-16-8P
	854380-17-9P	854380-18-0P	854380-19-1P	854380-20-4P	854380-21-5P
	854380-22-6P	854380-23-7P	854380-24-8P	854380-25-9P	854380-26-0P
	854380-27-1P	854380-28-2P	854380-29-3P	854380-30-6P	854380-31-7P
	854380-32-8P	854380-33-9P	854380-34-0P	854380-35-1P	854380-36-2P
	854380-37-3P	854380-38-4P	854380-39-5P	854380-40-8P	854380-41-9P
	854380-42-0P	854380-43-1P	854380-44-2P	854380-45-3P	854380-46-4P
	854380-47-5P	854380-48-6P	854380-49-7P	854380-50-0P	854380-51-1P
	854380-52-2P	854380-53-3P	854380-54-4P	854380-55-5P	854380-56-6P
	854380-57-7P	854380-58-8P	854380-59-9P	854380-60-2P	854380-61-3P
	854380-62-4P	854380-63-5P	854380-64-6P	854380-65-7P	854380-66-8P
	854380-67-9P	854380-68-0P	854380-69-1P	854380-70-4P	854380-71-5P
	854380-72-6P	854380-73-7P	854380-74-8P	854380-75-9P	854380-76-0P
	854380-77-1P	854380-78-2P	854380-79-3P	854380-80-6P	854380-81-7P
	854380-82-8P	854380-83-9P	854380-84-0P	854380-85-1P	854380-86-2P
	854380-87-3P	854380-88-4P	854380-89-5P	854380-90-8P	854380-91-9P
	854380-92-0P	854380-93-1P	854380-94-2P	854380-95-3P	854380-96-4P
	854380-97-5P	854380-98-6P	854380-99-7P	854381-00-3P	854381-01-4P
	854381-02-5P	854381-03-6P	854381-04-7P	854381-05-8P	854381-06-9P
	854381-07-0P	854381-08-1P	854381-09-2P	854381-10-5P	854381-11-6P
	854381-12-7P	854381-13-8P	854381-14-9P	854381-15-0P	854381-16-1P
	854381-17-2P	854381-18-3P	854381-19-4P	854381-20-7P	854381-21-8P
	854381-22-9P	854381-23-0P	854381-24-1P	854381-25-2P	854381-26-3P
	854381-27-4P	854381-28-5P	854381-29-6P	854381-30-9P	854381-31-0P
	854381-32-1P	854381-33-2P	854381-34-3P	854381-35-4P	854381-36-5P
	854381-38-7P	854381-40-1P	854381-42-3P	854381-43-4P	854381-44-5P
	854381-45-6P	854381-46-7P	854381-47-8P	854381-48-9P	
	854381-49-0P	854381-50-3P	854381-51-4P	854381-52-5P	854381-53-6P
	854381-55-8P	854381-56-9P	854381-57-0P	854381-58-1P	854381-59-2P
	854381-60-5P	854381-61-6P	854381-62-7P	854381-63-8P	854381-64-9P
	854381-65-0P	854381-66-1P	854381-67-2P	854381-68-3P	854381-69-4P
	854381-70-7P	854381-71-8P	854381-72-9P	854381-73-0P	854381-74-1P
	854381-75-2P	854381-76-3P	854381-77-4P	854381-78-5P	854381-79-6P
	854381-80-9P	854381-81-0P	854381-82-1P	854406-06-7P	
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
(preparation of novel hydroxamic acid esters for inhibiting angiogenesis)					
IT	854381-47-8P	854381-48-9P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
(preparation of novel hydroxamic acid esters for inhibiting angiogenesis)					
RN	854381-47-8	HCAPLUS			
CN	4-Pyridinecarboxamide, N-[2-[[phenylmethoxy]amino]carbonyl]phenyl]- (CA INDEX NAME)				



RN 854381-48-9 HCAPLUS

CN 4-Pyridineacetamide, N-[2-[(phenylmethoxy)amino]carbonyl]phenyl]- (CA
INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:369265 HCAPLUS Full-text

DOCUMENT NUMBER: 142:423892

TITLE: Alanyl aminopeptidase inhibitors for functionally
influencing different cells and treating
immunological, inflammatory, neuronal, and other
diseases

INVENTOR(S): Ansorge, Siegfried; Bank, Ute; Nordhoff, Karsten;
Tager, Michael; Striggow, Frank

PATENT ASSIGNEE(S): Institut Fur Medizintechnologie Magdeburg GmbH IMT,
Germany; Keyneurotek AG

SOURCE: PCT Int. Appl., 332 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037257	A2	20050428	WO 2004-EP11643	20041015
WO 2005037257	A3	20060914		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10348023	A1	20050519	DE 2003-10348023	20031015
AU 2004281536	A1	20050428	AU 2004-281536	20041015
CA 2542723	A1	20050428	CA 2004-2542723	20041015
EP 1673075	A2	20060628	EP 2004-790485	20041015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1897928	A	20070117	CN 2004-80036456	20041015
JP 2007508349	T	20070405	JP 2006-534706	20041015
US 20070037752	A1	20070215	US 2006-575882	20060915
PRIORITY APPLN. INFO.:			DE 2003-10348023	A 20031015
			WO 2004-EP11643	W 20041015

OTHER SOURCE(S): MARPAT 142:423892

AB The invention discloses substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further discloses the use of at least one such substance or at least one pharmaceutical or cosmetic composition containing such a substance for preventing and treating diseases, especially diseases with an overshooting immune response (autoimmune diseases, allergies, and transplant rejections), other chronic inflammatory diseases, neuronal diseases, brain damage, skin diseases (acne and psoriasis, among others), tumors, and special viral infections (including SARS).

IC ICM A61K031-00
ICS A61K31-4015

CC 1-12 (Pharmacology)
Section cross-reference(s): 62, 63

IT Heart, disease
(failure; alanylaminopeptidase inhibitors for treatment of immunol., inflammatory, neuronal, and other diseases)

IT Heart, disease
(infarction; alanylaminopeptidase inhibitors for treatment of immunol., inflammatory, neuronal, and other diseases)

IT 712-80-1 717-21-5 795-25-5 1670-21-9 4311-88-0 4332-95-0
4332-97-2 5159-24-0 5347-94-4 5419-96-5 5789-24-2 7164-71-8
13359-18-7 13359-22-3 15267-82-0 16237-73-3 18298-50-5
21190-16-9 22596-74-3 24617-55-8 25671-98-1 29635-97-0
31364-86-0 31404-08-7 32502-21-9 32704-58-8 35559-16-1
36301-90-3 40291-26-7 41377-63-3 41834-27-9 42285-84-7
49749-89-5 50508-40-2 52119-08-1 54147-04-5 57845-74-6
60664-22-4 62011-88-5 62214-31-7 63958-93-0 67189-39-3
68462-61-3 68943-85-1 74245-83-3 86791-05-1 86817-89-2
90916-79-3 90920-35-7 91026-77-6 91330-52-8 91568-04-6
92902-61-9 92905-85-6 92971-05-6 93417-98-2 93418-01-0
93418-03-2 93418-05-4 93444-96-3 96733-82-3 97420-70-7
99368-66-8 99873-43-5 100136-52-5 100724-25-2 102248-96-4
108695-55-2 110548-95-3 110973-83-6 113906-16-4 113906-17-5
113906-46-0 113906-68-6 113906-79-9 113908-24-0 117824-92-7
118082-70-5 125721-73-5 134589-88-1 137205-09-5 139047-73-7
143038-20-4 148320-70-1 149452-96-0 150649-09-5 152342-23-9
159416-02-1 160382-74-1 160382-79-6 162331-09-1 162331-15-9
189129-24-6 198762-63-9 215779-02-5 215779-06-9 220428-37-5
223676-17-3 254753-65-6 256377-35-2 259856-54-7 287383-59-9
290366-55-1 292170-16-2 292869-34-2 294852-06-5 294889-87-5
297135-24-1 298685-68-4 298685-88-8 300803-85-4 301227-59-8
301232-74-6 302801-96-3 302821-70-1 302823-16-1 302909-12-2
302909-66-6 303085-70-3 303108-03-4 303202-78-0 303203-44-3
303214-65-5 303228-10-6 303969-87-1 304452-40-2 304480-29-3
304481-72-9 304507-23-1 304665-31-4 304872-60-4 304906-81-8
304908-39-2 306302-11-4 306732-84-3 306969-52-8 307322-97-0
307323-24-6 307338-88-1 307495-44-9 307509-90-6 308106-08-3
309925-10-8 309939-82-0 310437-29-7 310439-28-2 310440-06-3
311314-98-4 311793-32-5 312277-47-7 312498-76-3 312517-83-2
312733-59-4 312732-76-6 313232-22-3 313248-34-9 313394-22-8
314028-42-7 314068-86-5 314074-38-9 315194-10-6 315205-82-4
315206-23-6 315211-35-9 315213-87-7 315213-93-5 315218-00-9
315226-84-7 315232-45-2 316132-19-1 316154-86-6 317374-57-5
318245-72-6 318260-81-0 318263-38-6 318265-84-8 321964-32-3
321964-42-5 322665-64-5 324009-72-5 324020-27-1 324021-20-7
324033-48-9 324525-49-7 325474-53-1 325483-86-1 325777-55-7
325990-34-9 325990-45-2 325998-92-3 325999-25-5 326007-44-7
326019-99-2 326914-03-8 327031-60-7 327042-81-9 327047-60-9
327992-85-8 328002-81-9 328032-45-7 328033-53-0 328043-46-5
328113-76-4 328129-86-8 328538-99-4 328541-47-5 328555-28-8

328914-84-7	329043-63-2	329045-85-4	329047-06-5	329048-03-5
329049-25-4	329050-96-6	329051-25-4	329051-82-3	329051-89-0
329052-18-8	329052-54-2	329052-57-5	329053-28-3	329053-44-3
329193-66-0	329194-12-9	329194-22-1	329194-54-9	329709-94-6
329962-08-5	329962-14-3	329962-48-3	329963-39-5	330219-61-9
330220-00-3	330220-02-5	330589-69-0		

RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alanil aminopeptidase inhibitors for treatment of immunol., inflammatory, neuronal, and other diseases)

IT	330591-49-6	330592-57-9	330594-12-2	330631-56-6	330820-94-5
	330833-82-4	330839-34-4	331817-85-7	332074-14-3	332103-43-2
	332391-91-0	332394-04-4	332413-08-8	333443-85-9	335402-85-2
	337926-60-0	339012-53-2	339021-52-2	339089-79-1	339090-12-9
	339095-28-2	339107-75-4	339116-36-8	339166-31-3	
	339188-49-7	339192-11-9	339207-52-2	339225-69-3	339226-81-2
	339226-93-6	339231-52-6	339245-18-0	339254-63-6	339257-00-0
	339258-39-8	339258-55-8	339295-37-3	339302-08-8	339311-51-2
	339317-89-4	339322-12-2	341493-43-4	341493-51-4	342034-57-5
	342780-74-9	345953-02-8	349087-50-9	349457-95-0	349567-11-9
	350475-18-2	350492-82-9	352215-74-8	352453-15-7	352555-11-4
	352663-14-0	353245-60-0	353462-07-4	353492-38-3	353494-83-4
	354121-04-3	354761-03-8	354788-01-5	354788-09-3	355419-11-3
	355245-78-4	356039-52-6	357623-72-4	357933-08-5	360069-98-3
	361369-04-2	361369-36-0	364051-60-5	364053-32-7	364053-35-0
	364053-37-2	364054-43-3	364381-13-5	368841-13-8	371214-58-3
	371215-51-9	371942-02-8	373639-72-6	376613-29-5	380427-32-7
	381206-47-9	384857-41-4	388083-63-4	400064-19-9	400064-25-7
	401611-02-7	401827-78-9	402487-43-8	402509-13-1	402517-99-1
	402727-99-5	403649-76-3	403650-17-9	403663-38-7	403664-11-9
	403664-12-0	405105-04-6	406173-97-5	406174-14-9	406177-51-3
	406177-54-6	413573-38-3	423752-27-6	428835-86-3	431070-21-2
	410175-99-9	433942-04-2	433947-19-4	438033-47-7	439138-58-6
	440335-55-7	440627-83-8	443781-01-9	444338-78-7	444597-56-2
	444681-56-5	445395-27-7	445395-34-6	445403-00-9	445404-11-5
	445404-12-6	445404-14-8	445404-15-9	445459-03-0	445459-06-3
	445459-83-6	445473-38-1	446029-45-4	447409-86-1	447409-98-5
	448190-21-4	448192-49-2	451462-06-9	461438-77-7	470472-81-2
	474651-42-8	476635-95-7	477515-13-2	478642-17-0	483327-47-5
	490031-71-5	494191-40-1	514822-02-7	514822-17-4	514822-27-6
	514822-48-1	519169-92-7	519169-93-8	524036-28-0	540763-48-2
	553629-28-0	575448-00-9	591239-60-0	591239-62-2	591239-64-0
	591239-65-5	591239-70-2	608494-44-6	612047-65-1	625412-82-4
	634887-06-2	634894-98-7	634895-14-0	677738-55-5	678189-71-4
	680600-06-0	680989-02-0	685097-43-2	685891-27-4	697273-23-7
	698975-97-2	698995-07-2	698995-09-4	700350-25-0	700350-56-7
	700357-84-2	700358-03-8	700358-04-9	700358-05-0	700358-06-1
	700358-29-8	700358-33-4	700358-35-6	730240-46-7	738612-79-8
	753388-59-9	775578-77-3	850607-07-7	850607-08-8	850607-09-9
	850607-10-2	850607-11-3	850607-12-4	850607-13-5	850607-14-6
	850607-15-7	850607-16-8	850607-17-9	850607-18-0	
	850607-19-1	850607-20-4	850607-21-5	850607-22-6	850607-23-7
	850607-24-8	850607-25-9	850607-26-0	850607-27-1	850607-28-2
	850607-29-3	850607-30-6	850607-31-7	850607-32-8	850607-33-9
	850607-34-0	850607-35-1	850607-36-2	850607-37-3	850607-38-4
	850607-39-5	850607-40-8	850607-41-9	850607-42-0	850607-43-1
	850607-44-2	850607-45-3	850620-72-3	850620-78-9	850620-82-5
	850620-84-7	850620-85-8			

RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alanyl aminopeptidase inhibitors for treatment of immunol.,
inflammatory, neuronal, and other diseases)


IT 329048-03-5 339107-75-4 850607-17-9

RL: DEV (Device component use); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(alanyl aminopeptidase inhibitors for treatment of immunol.,
inflammatory, neuronal, and other diseases)


RN 329048-03-5 HCAPLUS

CN Benzoic acid, 2-[(2,4-dichlorobenzoyl)amino]-,
2-(2-furanylmethylene)hydrazide (CA INDEX NAME)




RN 339107-75-4 HCAPLUS

CN Benzoic acid, 2-[(2-chlorobenzoyl)amino]-, 2-(2-furanylmethylene)hydrazide
(CA INDEX NAME)



RN 850607-17-9 HCAPLUS

CN Benzoic acid, 2-[(2,3-dichlorobenzoyl)amino]-,
2-(2-furanylmethylene)hydrazide (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:331915 HCAPLUS [Full-text](#)


DOCUMENT NUMBER: 140:357353

TITLE: Preparation of triazolone and triazoloethione
inhibitors of matrix metalloproteinases and/or
TNF- α converting enzyme as anti-inflammatory
agents


INVENTOR(S): King, Bryan W.; Sheppeck, James; Gilmore, John L.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032846	A2	20040422	WO 2003-US31537	20031003
WO 2004032846	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2003284001 A1 20040504 AU 2003-284001 20031003 US 20040116491 A1 20040617 US 2003-678331 20031003 US 7074810 B2 20060711 EP 1558581 A2 20050803 EP 2003-776228 20031003 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK PRIORITY APPLN. INFO.: US 2002-416709P P 20021007 WO 2003-US31537 W 20031003 OTHER SOURCE(S): MARPAT 140:357353 GI				



I



II

AB The present application describes novel hydantoin derivs. (shown as I; A = O, S; L-R11 represents a very large variety of substituents and is defined in the claims; e.g. II) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF- α converting enzyme (TACE), aggrecanase, or a combination thereof. Some examples of I exhibit Ki's <10 μ M but individual data are not presented. Although the methods of preparation are not claimed, 37 example preps. are

included. For example, II was prepared in 4 steps (100, 66, 73 and 82%, resp.) starting with condensation of Et 4-aminobutyrate hydrochloride with 4-(2-methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride followed by base hydrolysis to the acid, followed by hydrazide formation with thiosemicarbazide followed by cyclization.

IC ICM A61K

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT Heart, disease

(failure; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme as anti-inflammatory agents)

IT Bone, disease

Inflammation

(polychondritis, relapsing; preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme as anti-inflammatory agents)

IT 362488-46-8P 362489-83-6P 362489-93-8P 503168-49-8P 681283-80-7P
 681283-81-8P 681283-83-0P 681283-85-2P 681283-86-3P 681283-87-4P
 681283-89-6P 681283-90-9P 681283-93-2P 681283-96-5P 681283-97-6P
 681284-01-5P 681284-02-6P 681284-05-9P 681284-08-2P 681284-09-3P
 681284-11-7P 681284-12-8P 681284-13-9P 681284-15-1P 681284-16-2P
 681284-17-3P 681284-19-5P 681284-20-8P 681284-21-9P
 681284-24-2P 681284-25-3P 681284-26-4P 681284-29-7P
 681284-30-0P 681284-31-1P 681284-33-3P 681284-34-4P
 681284-38-8P 681284-39-9P 681284-40-2P 681284-43-5P
 681284-44-6P 681284-47-9P 681284-48-0P 681284-53-7P
 681284-55-9P 681284-60-6P 681284-64-0P 681284-65-1P
 681284-66-2P 681284-69-5P 681284-74-2P 681284-76-4P
 681284-78-6P 681284-85-5P 681284-87-7P 681284-89-9P
 681284-95-7P 681284-97-9P 681285-10-9P 681285-12-1P
 681285-14-3P 681285-18-7P 681285-19-8P 681285-20-1P
 681285-25-6P 681285-27-8P 681285-31-4P 681285-33-6P
 681285-34-7P 681285-37-0P 681285-38-1P
 681285-42-7P 681285-45-0P 681285-46-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme as anti-inflammatory agents)

IT 681284-17-3P 681284-21-9P 681284-26-4P
 681284-34-4P 681284-40-2P 681284-44-6P
 681284-48-0P 681284-55-9P 681284-65-1P
 681284-78-6P 681284-87-7P 681284-97-9P
 681285-14-3P 681285-20-1P 681285-27-8P
 681285-34-7P 681285-38-1P 681285-42-7P
 681285-45-0P 681285-48-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme as anti-inflammatory agents)

RN 681284-17-3 HCAPLUS

CN Cyclopentanecarboxylic acid, 2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 681284-21-9 HCAPLUS

CN Cyclopentanecarboxylic acid, 2-[[4-[[2-(1-methylethyl)-1H-benzimidazol-1-yl]methyl]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 681284-26-4 HCAPLUS

CN Cyclopentanecarboxylic acid, 2-[[4-[(2-methyl-4-quinolinyl)methyl]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 681284-34-4 HCAPLUS

CN 2H-Pyran-3-carboxylic acid, tetrahydro-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (3R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681284-40-2 HCAPLUS

CN 2H-Pyran-3-carboxylic acid, tetrahydro-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (3R,4S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 681284-44-6 HCAPLUS

CN 1-Oxaspiro[4.4]nonane-7-carboxylic acid,
8-[[4-[(2-methyl-4-quinolinyloxy)methoxy]benzoyl]amino]-,
2-(aminothioxomethyl)hydrazide, (5R, 7S, 8R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681284-48-0 HCAPLUS

CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[4-[(2-methyl-4-quinolinyloxy)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester,
3-[2-(aminothioxomethyl)hydrazide], (3R, 4R)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 681284-55-9 HCAPLUS

CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[4-[(2,3-dihydro-1,1-dioxido-4H-1,4-benzothiazin-4-yl)methyl]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 3-[2-(aminothioxomethyl)hydrazide], (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 681284-65-1 HCAPLUS

CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester,

3-[2-(aminothioxomethyl)hydrazide], (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681284-78-6 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-propyl-,
2-(aminothioxomethyl)hydrazide, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 681284-87-7 HCAPLUS
 CN 1,3-Pyrrolidinededicarboxylic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 3-[2-(aminothioxomethyl)hydrazide], (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681284-97-9 HCAPLUS

CN 1,4-Piperidinedicarboxylic acid, 3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 4-[2-(aminothioxomethyl)hydrazide], (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681285-14-3 HCAPLUS

CN 4-Piperidinecarboxylic acid, 3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-propyl-, 2-(aminothioxomethyl)hydrazide, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681285-20-1 HCAPLUS

CN 4-Piperidinecarboxylic acid, 3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(methylsulfonyl)-, 2-(aminothioxomethyl)hydrazide, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681285-27-8 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-(1-methylethyl)-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681285-34-7 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-methyl-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminothioxomethyl)hydrazide, (3S,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 681285-38-1 HCAPLUS

CN 1,3-Piperidinedicarboxylic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 3-[2-(aminothioxomethyl)hydrazide], (3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 681285-42-7 HCAPLUS
 CN Cyclopentanecarboxylic acid, 2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminocarbonyl)hydrazide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 681285-41-6
 CMF C25 H27 N5 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 681285-45-0 HCAPLUS
 CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 3-[2-(aminocarbonyl)hydrazide] (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 681285-48-3 HCAPLUS
 CN 2H-Pyran-3-carboxylic acid, tetrahydro-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-, 2-(aminocarbonyl)hydrazide (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:356418 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 138:368761
 TITLE: Preparation of indole derivatives as inhibitors of human liver glycogen phosphorylase a
 INVENTOR(S): Nakamura, Takeshi; Takagi, Masaki; Ueda, Nobuhisa
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
 SOURCE: PCT Int. Appl., 237 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037864	A1	20030508	WO 2002-JP11234	20021029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465382	A1	20030508	CA 2002-2465382	20021029
AU 2002344600	A1	20030512	AU 2002-344600	20021029
JP 2003201279	A	20030718	JP 2002-315100	20021029
EP 1452526	A1	20040901	EP 2002-777995	20021029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20050054696	A1	20050310	US 2004-493853	20041021
PRIORITY APPLN. INFO.:			JP 2001-331501	A 20011029
			WO 2002-JP11234	W 20021029

OTHER SOURCE(S): MARPAT 138:368761
 GI



- AB The title compds. I [R1 = H, alkyl, etc.; R2 = H, halo; R3 = halo, alkyl, etc.; R4 = H, alkyl; R5 = H, alkyl, alkoxy carbonyl; R6 = H, alkyl, etc.; R7 = C(:X)AB; X = O, etc.; A = NR8, etc.; R8 = H, alkyl, etc.; B = (un)substituted Ph, etc.] are prepared I are useful in the treatment of diabetes. Compds. of this invention in vitro showed IC50 values of 0.010 μ M to > 0.1 μ M against human liver glycogen phosphorylase a.
- IC ICM C07D209-42
 ICS C07D401-12; C07D401-14; C07D403-12; C07D405-12; C07D409-12; C07D413-12; C07D417-12; C07D487-04; C07D495-04; C07D409-04; C07D409-14; A61K031-404; A61K031-407; A61K031-41; A61K031-4178; A61K031-4188; A61K031-4196; A61K031-4155; A61K031-427

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 28

IT Hyperlipidemia
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation and bioeffect of indole derivs. or salts or prodrugs thereof
 with human liver glycogen phosphorylase inhibiting activity)

IT 37574-79-1P 521960-49-6P 521960-50-9P 521960-51-0P
 521960-52-1P 521960-53-2P 521960-54-3P 521960-55-4P
 521960-56-5P 521960-57-6P 521960-58-7P 521960-59-8P 521960-60-1P
 521960-61-2P 521960-62-3P 521960-63-4P 521960-65-6P 521960-66-7P
 521960-67-8P 521960-68-9P 521960-69-0P 521960-70-3P 521960-71-4P
 521960-72-5P 521960-73-6P 521960-74-7P 521960-75-8P 521960-76-9P
 521960-77-0P 521960-78-1P 521960-79-2P 521960-81-6P 521960-82-7P
 521960-84-9P 521960-85-0P 521960-87-2P 521960-89-4P 521960-91-8P
 521960-92-9P 521960-94-1P 521960-96-3P 521960-98-5P 521961-00-2P
 521961-03-5P 521961-05-7P 521961-07-9P 521961-09-1P
 521961-10-4P 521961-11-5P 521961-12-6P 521961-13-7P
 521961-14-8P 521961-15-9P 521961-16-0P 521961-17-1P 521961-18-2P
 521961-19-3P 521961-20-6P 521961-21-7P 521961-22-8P 521961-23-9P
 521961-24-0P 521961-25-1P 521961-26-2P 521961-27-3P
 521961-28-4P 521961-29-5P 521961-30-8P 521961-31-9P 521961-32-0P
 521961-33-1P 521961-34-2P 521961-35-3P 521961-36-4P 521961-37-5P
 521961-38-6P 521961-39-7P 521961-40-0P 521961-41-1P
 521961-42-2P 521961-43-3P 521961-44-4P 521961-45-5P 521961-46-6P
 521961-47-7P 521961-48-8P 521961-49-9P 521961-50-2P 521961-51-3P
 521961-52-4P 521961-53-5P 521961-54-6P 521961-55-7P 521961-56-8P
 521961-57-9P 521961-58-0P 521961-59-1P 521961-60-4P 521961-61-5P
 521961-62-6P 521961-63-7P 521961-64-8P 521961-65-9P 521961-66-0P
 521961-67-1P 521961-68-2P 521961-69-3P 521961-70-6P
 521961-71-7P 521961-72-8P 521961-73-9P
 521961-74-0P 521961-75-1P 521961-76-2P
 521961-77-3P 521961-78-4P 521961-79-5P 521961-80-8P
 521961-81-9P 521961-82-0P 521961-83-1P 521961-84-2P 521961-85-3P
 521961-86-4P 521961-87-5P 521961-88-6P 521961-89-7P 521961-90-0P
 521961-91-1P 521961-92-2P 521961-93-3P 521961-94-4P 521961-95-5P
 521961-96-6P 521961-97-7P 521961-98-8P 521961-99-9P 521962-00-5P
 521962-01-6P 521962-02-7P 521962-03-8P 521962-04-9P 521962-05-0P
 521962-06-1P 521962-07-2P 521962-08-3P 521962-09-4P
 521962-10-7P 521962-11-8P 521962-12-9P 521962-13-0P 521962-14-1P
 521962-15-2P 521962-16-3P 521962-17-4P 521962-18-5P 521962-19-6P
 521962-20-9P 521962-21-0P 521962-22-1P 521962-23-2P 521962-24-3P
 521962-25-4P 521962-26-5P 521962-27-6P 521962-28-7P 521962-29-8P
 521962-30-1P 521962-31-2P 521962-32-3P 521962-33-4P 521962-34-5P
 521962-35-6P 521962-36-7P 521962-37-8P 521962-38-9P 521962-39-0P
 521962-40-3P 521962-41-4P 521962-42-5P 521962-43-6P 521962-44-7P
 521962-45-8P 521962-46-9P 521962-47-0P 521962-48-1P 521962-49-2P
 521962-50-5P 521962-51-6P 521962-52-7P 521962-53-8P 521962-54-9P
 521962-55-0P 521962-56-1P 521962-57-2P 521962-58-3P 521962-59-4P
 521962-60-7P 521962-61-8P 521962-62-9P 521962-63-0P 521962-64-1P
 521962-65-2P 521962-66-3P 521962-67-4P 521962-68-5P 521962-69-6P
 521962-70-9P 521962-71-0P 521962-72-1P 521962-73-2P 521962-74-3P
 521962-75-4P 521962-76-5P 521962-77-6P 521962-78-7P 521962-79-8P
 521962-80-1P 521962-81-2P 521962-82-3P 521962-83-4P 521962-84-5P
 521962-85-6P 521962-87-8P 521962-88-9P 521962-89-0P
 521962-90-3P 521962-91-4P 521962-92-5P 521962-93-6P 521962-94-7P
 521962-95-8P 521962-96-9P 521962-98-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of indole derivs. as inhibitors of human liver glycogen

phosphorylase a)

IT 1483-24-5P 1664-54-6P 17701-61-0P 20948-67-8P 41981-24-2P
 97132-93-9P 521963-23-5P 521963-24-6P 521963-25-7P
 521963-26-8P 521963-27-9P 521963-28-0P 521963-29-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of indole derivs. as inhibitors of human liver glycogen
 phosphorylase a)


IT 521960-52-1P 521961-10-4P 521961-27-3P
 521961-36-6P 521961-39-7P 521961-68-2P
 521961-71-7P 521961-72-8P 521961-73-9P
 521961-74-0P 521961-75-1P 521961-76-2P
 521961-77-3P 521962-06-1P 521962-87-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of indole derivs. as inhibitors of human liver glycogen
 phosphorylase a)


RN 521960-52-1 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
 2-[2-[(2-carboxy-2-methylpropoxy)carbonyl]amino]benzoyl]hydrazide (CA
 INDEX NAME)




RN 521961-10-4 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
 2-[2-[(2-acetylamino)benzoyl]hydrazide (CA INDEX NAME)




RN 521961-27-3 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-methyl-,
 2-[2-[(methoxycarbonyl)amino]benzoyl]hydrazide (CA INDEX NAME)




RN 521961-38-6 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[[[2-hydroxy-1-(hydroxymethyl)ethoxy]carbonyl]amino]benzoyl]hydrazide
(CA INDEX NAME)




RN 521961-39-7 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[[[1-(1-carboxy-1-methylethoxy)carbonyl]amino]benzoyl]hydrazide (CA
INDEX NAME)




RN 521961-68-2 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-fluoro-,
2-[2-[[[methoxycarbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)




RN 521961-71-7 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[[[phenoxycarbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)




RN 521961-72-8 HCAPLUS


CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[[[phenylmethoxy]carbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)




RN 521961-73-9 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[(2-hydroxyethoxy)carbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)

RN 521961-74-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[(3-hydroxypropoxy)carbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)


RN 521961-75-1 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 5-chloro-,
2-[2-[(carboxymethoxy)carbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)


RN 521961-76-2 HCAPLUS

CN Propanedioic acid, 2-[[[2-[[2-[(5-chloro-1H-indol-2-yl)carbonyl]hydrazinyl]carbonyl]phenyl]amino]carbonyl]oxy]methyl]-2-methyl-
(CA INDEX NAME)

CMF C7 H8 O3 S



IT 521963-24-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of indole derivs. as inhibitors of human liver glycogen
 phosphorylase a)
 RN 521963-24-6 HCAPLUS
 CN 1H-Indole-2-carboxylic acid, 5-chloro-,
 2-[2-[[[2,2-dimethyl-3-oxo-3-
 (phenylmethoxy)propoxy]carbonyl]amino]benzoyl]hydrazide (CA INDEX NAME)



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:725990 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 130:125051

TITLE: Synthesis of 2-substituted-10H-[1,2,4]triazino[6,1-b]quinazoline-10-ones and
 8,13,14,16-

AUTHOR(S): tetrahydronaphtho[2',3':3,4][1,2,5]triazepino[7,1-b]quinazoline-8,13,16-triones with biological interest
 Hassanein, Abu-Zeid A.; Nassar, Omama M.; Zahran,
 Medhat A.; Ali, Ahmad H.

CORPORATE SOURCE: Department of Chemistry Faculty of Education, Suez
 Canal University, Al-Arish, Egypt

SOURCE: Al-Azhar Bulletin of Science (1997), 8(2), 417-434
 CODEN: ABSCE7; ISSN: 1110-2535

PUBLISHER: Al-Azhar University, Faculty of Science


DOCUMENT TYPE: Journal

LANGUAGE: English



AB A number of novel 2-substituted-10H-[1,2,4]triazino[6,1-b]quinazoline-10-ones
 tetrahydronaphtho[2',3':3,4][1,2,5]triazepino[7,1-b]quinazolinetrione, and a
 [1,2,5]triazepino[7,1-b]quinazolinone derivative were obtained via
 nucleophilic interaction of 3-amino-2-[arylsulfonamido-methyl]quinazoline-4-
 [3H]one with different reagents. Whereas in case of 3-amino-2-
 (arylcaboxamidomethyl)quinazolin-4-[3H]one, acyclic derivs. were obtained.
 The biochem. studies of some of these products showed promising effect on the
 immune system and no toxic effect on rat liver.

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1



- IT Immunodeficiency
(preparation and biol. activity of triazinoquinazolinones and naphthotriazepinoquinazolinetriones)
- IT 219970-95-3P 219970-96-4P 219970-97-5P 219970-98-6P 219970-99-7P
219971-00-3P 219971-01-4P 219971-02-5P 219971-03-6P 219971-04-7P
219971-05-8P 219971-06-9P 219971-07-0P 219971-08-1P 219971-09-2P
219971-10-5P 219971-11-6P 219971-12-7P 219971-13-8P
219971-14-9P 219971-15-0P 219971-16-1P
219971-17-2P 219971-18-3P 219971-19-4P 219971-20-7P
219971-21-8P 219971-22-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and biol. activity of triazinoquinazolinones and naphthotriazepinoquinazolinetriones)
- IT 219971-13-8P 219971-14-9P 219971-15-0P
219971-16-1P 219971-17-2P 219971-18-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and biol. activity of triazinoquinazolinones and naphthotriazepinoquinazolinetriones)
- RN 219971-13-8 HCAPLUS
- CN Benzamide, N-[[3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]methyl]- (CA INDEX NAME)



- RN 219971-14-9 HCAPLUS
- CN Benzamide, N-[[3-[[[(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (CA INDEX NAME)





- RN 219971-15-0 HCAPLUS
- CN Benzamide, N-[[3,4-dihydro-3-[[[(4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]methyl]- (CA INDEX NAME)




RN 219971-16-1 HCAPLUS

CN Benzamide, N-[[3,4-dihydro-4-oxo-3-[[3,4,5-trimethoxyphenyl)methylene]amino]-2-quinazolinyl)methyl]- (CA INDEX NAME)




RN 219971-17-2 HCAPLUS

CN Benzamide, 2-chloro-N-[[3,4-dihydro-3-[[4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl)methyl]- (CA INDEX NAME)



RN 219971-18-3 HCAPLUS

CN Benzamide, 4-chloro-N-[[3,4-dihydro-4-oxo-3-[[3,4,5-trimethoxyphenyl)methylene]amino]-2-quinazolinyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:268348 HCAPLUS Full-text

DOCUMENT NUMBER: 128:321662

ORIGINAL REFERENCE NO.: 128:63765a

TITLE: Compositions and methods for treating bone deficit conditions

INVENTOR(S): Orme, Mark W.; Baidur, Nand; Robbins, Kirk G.; et al.

PATENT ASSIGNEE(S): Zymogenetics, Inc., USA; Osteoscreen, Inc.

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817267	A1	19980430	WO 1997-US18864	19971023
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5990169	A	19991123	US 1997-806771	19970226
US 6153631	A	20001128	US 1997-806768	19970226
US 6251901	B1	20010626	US 1997-806769	19970226
US 5919808	A	19990706	US 1997-808743	19970228
US 5922753	A	19990713	US 1997-808742	19970228
US 5948776	A	19990907	US 1997-808739	19970228
US 5994358	A	19991130	US 1997-808744	19970228
US 6342514	B1	20020129	US 1997-808741	19970228
US 5965573	A	19991012	US 1997-812141	19970306
AU 9749889	A	19980515	AU 1997-49889	19971023
EP 973513	A1	20000126	EP 1997-912787	19971023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001510450	T	20010731	JP 1998-519529	19971023
US 6649631	B1	20031118	US 1999-297188	19991119
PRIORITY APPLN. INFO.:			US 1996-735870	A2 19961023
			US 1996-735873	A2 19961023
			US 1996-735874	A2 19961023
			US 1996-735876	A2 19961023
			US 1996-735881	A2 19961023
			US 1996-736220	A2 19961023
			US 1996-736221	A2 19961023
			US 1996-736222	A2 19961023
			US 1996-736228	A2 19961023
			US 1996-736318	A2 19961023
			US 1996-736319	A2 19961023
			WO 1997-US18864	W 19971023

OTHER SOURCE(S): MARPAT 128:321662

GI



AB Compds. containing 2 covalently linked aromatic systems, i.e. Ar1LAr2 [I; Ar1, Ar2 = (un)substituted Ph, naphthyl, or 5- or 6-membered aromatic heterocyclyl; L = linker (atoms or covalent bond per se) so as to space the aromatic systems at a distance of 1.5-15 Å] are effective in treating conditions associated with bone deficits. The compds. can be administered to vertebrate subjects alone or in combination with addnl. agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems. A variety of compds. were prepared and/or tested by high-throughput screening. For instance, title compound II was prepared by condensation of 2-chloro-5-(trifluoromethyl)pyridine with ethylenediamine in the presence of EtN(Pr-iso)₂ at reflux. At 5-50 µg/kg/day in ovariectomized rats, II stimulated bone growth with volume increases of 21-71% observed in a calvarial bone growth assay, another compound I induced a 4-fold increase in width of new calvarial bone vs. controls.

IC ICM A61K031-165

ICS A61K031-215; A61K031-33; A61K031-405; A61K031-415; A61K031-42;
A61K031-425; A61K031-44; A61K031-47; A61K031-505; A61K031-53;
A61K031-535; A61K031-54

CC 28-20 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 25, 27

IT Bone, disease
(fracture, treatment; preparation of (hetero)aromatic compds. for
treating bone deficit conditions)

IT Bone, disease
Hyperparathyroidism
(treatment; preparation of (hetero)aromatic compds. for treating bone
deficit conditions)

IT	479-13-0	619-67-0	961-60-4	1138-15-4	1694-45-7	2390-54-7
	4765-56-4	6019-43-8	7477-43-2	7477-46-5	10205-62-6	10360-31-3
	15826-37-6	19736-41-5	22765-52-2	22765-57-7	28620-82-8	
	33357-46-9	33757-75-4	34580-14-8	37052-98-5	38101-69-8	
	38101-92-7	48189-64-6	49582-19-6	52869-16-6	53846-93-8	
	57601-14-6	62225-55-2	73548-13-7	77038-70-1	77143-59-0	
	77669-19-3	80998-91-0	84088-42-6	93873-08-6	108608-01-1	
	110490-58-9	112535-18-9	116249-87-7	129855-33-0	131136-84-0	
	133124-80-8	133928-85-5	139233-22-0	143816-39-1	145603-02-7	
	182572-98-1	190436-20-5	190436-27-2	190436-31-8	190436-32-9	
	190436-35-2	190436-38-5	190436-40-9	190436-44-3	190436-47-6	
	190436-51-2	190436-55-6	190436-58-9	190436-62-5	190436-67-0	
	190436-71-6	190436-74-9	190436-78-3	190436-79-4	190436-83-0	
	190436-87-4	190436-90-9	190436-93-2	190436-96-5	190437-08-2	
	190437-12-8	190437-16-2	190437-20-8	190437-23-1	190437-26-4	
	190437-29-7	190437-36-6	190437-38-8	190437-39-9	190437-40-2	
	190437-41-3	190437-42-4	190437-43-5	190437-44-6	190437-45-7	
	190437-46-8	190437-47-9	190437-48-0	190437-49-1		
	190437-50-4	190437-51-5	190437-52-6	190437-53-7	190437-54-8	

190437-55-9 190437-56-0 190437-57-1 190437-59-3 190437-60-6
 190437-61-7 190437-62-8 190437-63-9 190437-64-0 190437-65-1
 190437-66-2 190437-67-3 190437-68-4 190437-69-5 190437-70-8
 190437-71-9 190437-72-0 190437-73-1 190437-74-2 190437-75-3
 190437-76-4 190437-77-5 190437-78-6 190437-79-7 190437-80-0
 190437-82-2 190437-83-3 190437-84-4 190437-85-5 190437-86-6
 190437-87-7 190437-88-8 190437-89-9 190437-91-3 190437-92-4
 190437-93-5 190437-94-6 190437-95-7 190437-96-8 190437-98-0
 190437-99-1 190438-00-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of (hetero)aromatic compds. for treating bone deficit conditions)

IT 190437-49-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of (hetero)aromatic compds. for treating bone deficit conditions)

RN 190437-49-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(E)-[(2,3-dihydro-1H-inden-5-yl)methylene]amino]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L84 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:397336 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 127:17703

ORIGINAL REFERENCE NO.: 127:3581a,3584a

TITLE: Preparation of (hetero)aromatic compounds for treating bone deficit conditions.

INVENTOR(S): Petrie, Charles; Orme, Mark W.; Baidur, Nand; Robbins, Kirk G.; Harris, Scott M.; Kontoyianni, Maria; Hurley, Laurence H.; Kerwin, Sean M.; Mundy, Gregory R.

PATENT ASSIGNEE(S): Zymogenetics, Inc., USA; Osteoscreen, Inc.; University of Texas At Austin

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715308	A1	19970501	WO 1996-US17019	19961023
W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL,				

IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO,
 NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KZ, RU, TJ, TM
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
 MR, NE, SN, TD, TG

CA 2235481	A1	19970501	CA 1996-2235481	19961023
AU 9674710	A	19970515	AU 1996-74710	19961023
AU 706262	B2	19990610		
EP 866710	A1	19980930	EP 1996-936906	19961023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1201393	A	19981209	CN 1996-197827	19961023
HU 9802319	A2	19990201	HU 1998-2319	19961023
HU 9802319	A3	19991228		
BR 9611210	A	19991228	BR 1996-11210	19961023
JP 2000513324	T	20001010	JP 1997-516761	19961023
US 6008208	A	19991228	US 1997-878868	19970619
NO 9801810	A	19980622	NO 1998-1810	19980422
US 6413998	B1	20020702	US 1999-453828	19991202
PRIORITY APPLN. INFO.:			US 1995-5830P	P 19951023
			US 1996-735875	B1 19961023
			WO 1996-US17019	W 19961023
			US 1997-878868	A3 19970619

OTHER SOURCE(S): MARPAT 127:17703
 GI



- AB A method for treating deficient bone growth and/or undesirable bone resorption comprises administration of compds. comprising 2 (substituted) aromatic systems spaced apart by a linker of 1.5-15 Å, is claimed. Thus, dithizone was refluxed in EtOH/HOAc for 18 h to give 25% title compound (I). In a calvarial bone growth assay, I induced a 4-fold increase in width of new calvarial bone vs. controls.
- IC ICM A61K031-54
- CC 28-20 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 25, 27
- IT Bone, disease
 (fracture, treatment; preparation of (hetero)aromatic compds. for treating bone deficit conditions)
- IT Bone, disease
 Hyperparathyroidism
 Osteoporosis
 (treatment; preparation of (hetero)aromatic compds. for treating bone deficit conditions)
- IT 100-10-7 479-13-0 619-67-0 961-60-4 1138-15-4 1694-45-7
 2390-54-7 4765-56-4 6019-43-8 7477-43-2 7477-46-5 10205-62-6
 10360-31-3 15826-37-6 19736-41-5 22765-52-2 22765-57-7
 28620-82-8 33357-46-9 33757-75-4 34580-14-8 37052-98-5
 38101-69-8 38101-92-7 48189-64-6 49582-19-6 52869-16-6
 53846-93-8 57601-14-6 62225-55-2 73548-13-7 77038-70-1
 77143-59-0 77669-19-3 80998-91-0 84088-42-6 93873-08-6

108608-01-1	110490-58-9	112535-18-9	116249-87-7	129855-33-0
131136-84-0	133124-80-8	133928-85-5	139233-22-0	143816-39-1
143816-41-5	145603-02-7	182572-98-1	190436-20-5	190436-27-2
190436-31-8	190436-32-9	190436-35-2	190436-38-5	190436-40-9
190436-44-3	190436-47-6	190436-51-2	190436-55-6	190436-58-9
190436-62-5	190436-67-0	190436-71-6	190436-74-9	190436-78-3
190436-79-4	190436-83-0	190436-87-4	190436-90-9	190436-93-2
190436-96-5	190436-99-8	190437-08-2	190437-12-8	190437-16-2
190437-20-8	190437-23-1	190437-26-4	190437-29-7	190437-34-4
190437-36-6	190437-38-8	190437-39-9	190437-40-2	190437-41-3
190437-42-4	190437-43-5	190437-44-6	190437-45-7	190437-46-8
190437-47-9	190437-48-0	190437-49-1	190437-50-4	
190437-51-5	190437-52-6	190437-53-7	190437-54-8	190437-55-9
190437-56-0	190437-57-1	190437-59-3	190437-60-6	190437-61-7
190437-62-8	190437-63-9	190437-64-0	190437-65-1	190437-66-2
190437-67-3	190437-68-4	190437-69-5	190437-70-8	190437-71-9
190437-72-0	190437-73-1	190437-74-2	190437-75-3	190437-76-4
190437-77-5	190437-78-6	190437-79-7	190437-80-0	190437-81-1
190437-82-2	190437-83-3	190437-84-4	190437-85-5	190437-86-6
190437-87-7	190437-88-8	190437-89-9	190437-90-2	190437-91-3
190437-92-4	190437-93-5	190437-94-6	190437-95-7	190437-96-8
190437-98-0	190437-99-1	190438-00-7		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of (hetero)aromatic compds. for treating bone deficit conditions)

IT 190437-49-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of (hetero)aromatic compds. for treating bone deficit conditions)

RN 190437-49-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(E)-[(2,3-dihydro-1H-inden-5-yl)methylene]amino]-2-methyl- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

STRUCTURE SEARCH PART 3

=> fil reg; d stat que l64; fil hcapl; d que nos l80
 FILE 'REGISTRY' ENTERED AT 10:29:26 ON 20 MAR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAR 2009 HIGHEST RN 1123341-06-9
 DICTIONARY FILE UPDATES: 18 MAR 2009 HIGHEST RN 1123341-06-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>


L1 STR



VAR G1=11/13/15
 VAR G5=C/CY/17/19/21/23/25/27
 REP G10=(3-7) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE
 L2 (23983)SEA FILE=REGISTRY SSS FUL L1
 L3 STR



```

VAR G1=11/13/15
VAR G5=C/CY/17/19/21/23/25/27
REP G10=(3-7) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28

```

```

STEREO ATTRIBUTES: NONE
L4 STR

```



```

VAR G1=11/13/15
VAR G5=C/CY/17/19/21/23/25/27
REP G10=(3-7) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```






GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 29

```

```



STEREO ATTRIBUTES: NONE
L5 20832 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)
L58 STR

```



N @76 Ak @82

Page 1-A



Page 2-A

VAR G1=11/13/15

VAR G2=H/X/OH/82/69/77/74/76/77/80/71

REP G3=(1-3) C

VAR G10=32-7 31-4/38-7 37-4/52-7 53-4/53-7 54-4/53-7 52-4/47-7 48-4

NODE ATTRIBUTES:

NSPEC IS R AT 76

CONNECT IS E1 RC AT 70

CONNECT IS E1 RC AT 78

CONNECT IS E1 RC AT 79

CONNECT IS E1 RC AT 81

CONNECT IS E1 RC AT 82

DEFAULT MLEVEL IS ATOM

DEFAULT ELEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 58

STEREO ATTRIBUTES: NONE

L60 STR



VAR G1=11/13/15/20/17/23/26/29/32

VAR G6=H/38/CY/39

REP G10=(3-7) A

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 38

CONNECT IS E2 RC AT 39

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 40

DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L64 9996 SEA FILE=REGISTRY SUB=L5 SSS FUL L58 AND L60

100.0% PROCESSED 20819 ITERATIONS

9996 ANSWERS

SEARCH TIME: 00.00.04

FILE 'HCAPLUS' ENTERED AT 10:29:27 ON 20 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Mar 2009 VOL 150 ISS 13

FILE LAST UPDATED: 19 Mar 2009 (20090319/ED)

HCAPlus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

```

L1          STR
L2 (        23983)SEA FILE=REGISTRY SSS FUL L1
L3          STR
L4          STR
L5          20832 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)
L58         STR
L60         STR
L64         9996 SEA FILE=REGISTRY SUB=L5 SSS FUL L58 AND L60
L65         122 SEA FILE=HCAPLUS SPE=ON ABB=ON L64
L72         47 SEA FILE=HCAPLUS SPE=ON ABB=ON L65 AND PHARMAC?/SC, SX
L73         44 SEA FILE=HCAPLUS SPE=ON ABB=ON L65 (L) (THU OR BAC OR PAC OR
          PKT OR DMA)/RL
L74         59 SEA FILE=HCAPLUS SPE=ON ABB=ON (L72 OR L73)
L76         19 SEA FILE=HCAPLUS SPE=ON ABB=ON L74 AND PATENT/DT
L77         40 SEA FILE=HCAPLUS SPE=ON ABB=ON L74 NOT L76
L78         33 SEA FILE=HCAPLUS SPE=ON ABB=ON L77 AND PY<2007
L79         19 SEA FILE=HCAPLUS SPE=ON ABB=ON L76 AND (PD<20070620 OR
          AD<20070620 OR PRD<20070620)
L80         52 SEA FILE=HCAPLUS SPE=ON ABB=ON (L78 OR L79)

```

```

=> s l80 not l81,l84
L85         48 L80 NOT (L81 OR L84)          L81,L84 WERE PREVIOUSLY PRINTED

```

```

=> d ibib abs hitstr 1-48; fil hom

```

```

L85 ANSWER 1 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:674922 HCAPLUS Full-text
DOCUMENT NUMBER: 149:10043
TITLE: Preparation of quinazolinone modulators of TGR5 for
treatment of metabolic, cardiovascular and
inflammatory diseases
INVENTOR(S): Pinkerton, Anthony B.; Kabakibi, Ayman; Hoffman,
Timothy Z.; Siegel, Dana L.; Noble, Stewart A.
PATENT ASSIGNEE(S): Kalypsys, Inc., USA
SOURCE: PCT Int. Appl., 147pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008067219	A2	20080605	WO 2007-US85225	20071120 <--
WO 2008067219	A3	20080717		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20090035306 A1 20090205 US 2007-943097 20071120 <--
 PRIORITY APPLN. INFO.: US 2006-867783P P 20061129 <--
 US 2007-975561P P 20070927
 OTHER SOURCE(S): MARPAT 149:10043
 GI



I




II

AB The present invention relates to quinazolinone compds. of general structure I (wherein X is (un)substituted C1-2alkyl; R6 and R7 are independently alkyl, alkenyl, alkynyl, etc.; R8, R10 are aryl, heteroaryl, cycloalkyl, etc.; R9 is H, alkyl, acyl, etc.) useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting 2-(4-Fluorophenyl)-4H-benzo[d][1,3]oxazin-4-one with hydrazine to provide 3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one which was subsequently reacted with 4-bromobenzyl bromide. In an assay that measured cAMP production by HEK-293 cells transfected with TGR5, II had an EC50 of $\leq 10 \mu\text{M}$.


IT 389576-52-7P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one 1029981-17-6P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-7-methoxyquinazolin-4(3H)-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of quinazolinone modulators of TGR5 for treatment of metabolic, cardiovascular and inflammatory diseases)

RN 389576-52-7 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[(4-bromophenyl)methylamino]-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 1029981-17-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(4-bromophenyl)methylamino]-2-(4-fluorophenyl)-7-methoxy- (CA INDEX NAME)



IT 61107-41-7P, 3-(Benzylamino)-2-phenylquinazolin-4(3H)-one
 361180-56-5P, 2-(4-Fluorophenyl)-3-[(4-isopropylbenzyl)amino]quinazolin-4(3H)-one 389577-36-0P,
 3-[(3-Bromobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one
 389577-38-2P, 3-[(2,4-Dichlorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 389577-40-6P,
 3-[(4-Bromobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one
 1029980-88-3P, 3-[(2,4-Difluorobenzyl)amino]-2-(3-fluorophenyl)quinazolin-4(3H)-one 1029980-89-9P,
 3-[(4-Bromobenzyl)amino]-2-[2-(trifluoromethyl)phenyl]quinazolin-4(3H)-one
 1029980-90-2P, 3-[(4-Bromobenzyl)amino]-2-[4-(trifluoromethyl)phenyl]quinazolin-4(3H)-one 1029980-91-3P,
 3-[(4-Bromobenzyl)amino]-2-(2-chlorophenyl)quinazolin-4(3H)-one
 1029980-92-4P, 3-[(4-tert-Butylbenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-93-5P,
 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one
 1029980-94-6P, 3-[(3,5-Difluorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029980-95-7P,
 3-[(3,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one
 1029980-96-8P, 3-[(4-Bromobenzyl)amino]-2-(o-tolyl)quinazolin-4(3H)-one 1029980-98-0P,
 2-(2-Fluorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one
 1029980-99-1P, 3-[(3-Chlorobenzyl)amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029981-00-7P,
 3-[(4-Bromobenzyl)amino]-2-(2-methoxyphenyl)quinazolin-4(3H)-one
 1029981-01-8P, 2-(2-Fluorophenyl)-3-[[3-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-02-9P,
 3-[[3-Fluoro-4-(trifluoromethyl)benzyl]amino]-2-(2-fluorophenyl)quinazolin-4(3H)-one 1029981-03-0P,
 2-(2-Fluorophenyl)-3-[(4-methylbenzyl)amino]quinazolin-4(3H)-one
 1029981-04-1P, 2-(2-Fluorophenyl)-3-[[4-(trifluoromethoxy)benzyl]amino]quinazolin-4(3H)-one 1029981-05-2P,
 3-[(4-Bromobenzyl)amino]-2-(2-fluorophenyl)-7-methylquinazolin-4(3H)-one
 1029981-06-3P, 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)-7-methylquinazolin-4(3H)-one 1029981-07-4P,
 3-[(4-Bromobenzyl)amino]-2-(2-fluorophenyl)-6-methoxyquinazolin-4(3H)-one
 1029981-08-5P, 3-[(2,4-Difluorobenzyl)amino]-2-(2-fluorophenyl)-6-methoxyquinazolin-4(3H)-one 1029981-14-3P,

3-[(4-Bromobenzyl)amino]-2-(pyridin-2-yl)quinazolin-4(3H)-one 1029981-19-8P, 3-[(2,4-Difluorobenzyl)amino]-2-(4-fluorophenyl)-7-methoxyquinazolin-4(3H)-one 1029981-21-2P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)-7-methoxyquinazolin-4(3H)-one 1029981-23-4P, 2-(4-Fluorophenyl)-7-methoxy-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-25-6P, 2-(4-Fluorophenyl)-3-[[pyridin-3-yl)methyl]amino]quinazolin-4(3H)-one 1029981-27-8P, 2-(4-Fluorophenyl)-3-[[naphthalen-2-yl)methyl]amino]quinazolin-4(3H)-one 1029981-30-3P, 2-(4-Fluorophenyl)-3-(4-morpholinobutylamino)quinazolin-4(3H)-one 1029981-32-5P, 3-[(4-Bromobenzyl)amino]-2-(furan-2-yl)quinazolin-4(3H)-one 1029981-36-9P, 3-[(4-Bromobenzyl)amino]-2-[4-(dimethylamino)phenyl]quinazolin-4(3H)-one 1029981-38-1P, 3-[(4-Chlorobenzyl)amino]-2-[4-(dimethylamino)phenyl]quinazolin-4(3H)-one 1029981-40-5P, 3-[(4-Bromobenzyl)amino]-2-cyclohexylquinazolin-4(3H)-one 1029981-43-8P, 3-[(4-Chlorobenzyl)amino]-2-cyclohexylquinazolin-4(3H)-one 1029981-45-0P, 3-[(4-Bromobenzyl)amino]-2-(3-chlorophenyl)quinazolin-4(3H)-one 1029981-47-2P, 3-[(4-Bromobenzyl)amino]-2-(4-chlorophenyl)quinazolin-4(3H)-one 1029981-49-4P, 3-[(4-Chlorobenzyl)amino]-2-(3-chlorophenyl)quinazolin-4(3H)-one 1029981-51-8P, 2-(3-Chlorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-53-0P, 2-(3-Chlorophenyl)-3-[(3,4-difluorobenzyl)amino]quinazolin-4(3H)-one 1029981-55-2P, 3-[(4-Chlorobenzyl)amino]-2-(4-chlorophenyl)quinazolin-4(3H)-one 1029981-57-4P, 2-(4-Chlorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-59-6P, 2-(4-Chlorophenyl)-3-[(3,4-difluorobenzyl)amino]quinazolin-4(3H)-one 1029981-61-0P, 3-[(4-Bromobenzyl)amino]-2-(4-fluoro-3-methylphenyl)quinazolin-4(3H)-one 1029981-63-2P, 3-[(4-Bromobenzyl)amino]-2-(3-methoxyphenyl)quinazolin-4(3H)-one 1029981-65-4P, 3-[(4-Chlorobenzyl)amino]-2-(3-methoxyphenyl)quinazolin-4(3H)-one 1029981-67-6P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluoro-3-methylphenyl)quinazolin-4(3H)-one 1029981-69-8P, 3-[(4-Bromobenzyl)amino]-2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one 1029981-71-2P, 3-[(4-Chlorobenzyl)amino]-2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one 1029981-73-4P, 3-[(4-Bromobenzyl)amino]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 1029981-75-6P, 3-[(4-Chlorobenzyl)amino]-2-[3-(trifluoromethoxy)phenyl]quinazolin-4(3H)-one 1029981-77-8P, 3-[(4-Chlorobenzyl)amino]-2-(3,4-dimethoxyphenyl)quinazolin-4(3H)-one 1029981-79-0P, 2-(Benzo[d][1,3]dioxol-5-yl)-3-[(4-bromobenzyl)amino]quinazolin-4(3H)-one 1029981-81-4P, 2-(Benzo[d][1,3]dioxol-5-yl)-3-[(4-chlorobenzyl)amino]quinazolin-4(3H)-one 1029981-84-7P, 3-[(4-Bromobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one 1029981-86-9P, 3-[(4-Chlorobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one 1029981-88-1P, 3-[(4-Fluorobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one 1029981-90-5P, 2-(3-Methoxy-4-methylphenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one 1029981-92-7P, 3-[(3,4-Difluorobenzyl)amino]-2-(3-methoxy-4-methylphenyl)quinazolin-4(3H)-one 1029981-96-3P, 3-[(4-Bromobenzyl)amino]-2-(4-fluoro-3-methoxyphenyl)quinazolin-4(3H)-one 1029982-00-0P, 3-[(4-Chlorobenzyl)amino]-2-(4-fluoro-3-methoxyphenyl)quinazolin-4(3H)-one 1029982-02-2P, 3-[(4-Bromobenzyl)amino]-2-(4-chloro-3-methoxyphenyl)-3H-quinazolin-4-one 1029982-04-4P, 3-[(4-Chlorobenzyl)amino]-2-(4-chloro-3-

methoxyphenyl)-3H-quinazolin-4-one 1029982-10-2F,
 2-(4-Fluorophenyl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-
 one 1029982-12-4F, 3-[(4-Chlorobenzyl)amino]-2-(4-
 fluorophenyl)quinazolin-4(3H)-one 1029982-13-6F,
 3-[(2,4-Difluorobenzyl)amino]-2-(4-fluorophenyl)quinazolin-4(3H)-one
 1029982-16-8F, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-7-
 methylquinazolin-4(3H)-one 1029982-18-0P,
 2-(4-Fluorophenyl)-7-methyl-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-
 4(3H)-one 1029982-20-4F,
 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-6,7-dimethoxyquinazolin-4(3H)-
 one 1029982-22-6P, 3-(3-Bromophenethylamino)-2-(4-
 fluorophenyl)quinazolin-4(3H)-one 1029982-24-8F,
 3-(4-Bromophenethylamino)-2-(4-fluorophenyl)quinazolin-4(3H)-one
 1029982-26-0F, 3-[(4-Bromobenzyl)amino]-2-(thiophen-2-
 yl)quinazolin-4(3H)-one 1029982-28-2F,
 2-(Thiophen-2-yl)-3-[[4-(trifluoromethyl)benzyl]amino]quinazolin-4(3H)-one
 1029982-32-8F, 3-[(4-Bromobenzyl)amino]-2-(thiophen-3-
 yl)quinazolin-4(3H)-one 1029982-36-2P,
 3-[[3,5-Bis(trifluoromethyl)benzyl]amino]-2-(4-fluorophenyl)quinazolin-
 4(3H)-one 1029982-38-4F,
 3-[(4-Bromobenzyl)amino]-2-(3,4-difluorophenyl)quinazolin-4(3H)-one
 1029982-44-2P, 3-[(4-Bromobenzyl)amino]-2-(4-fluorophenyl)-7-
 hydroxyquinazolin-4(3H)-one 1029982-46-4P,
 3-[(4-Bromobenzyl)amino]-2-(3-hydroxyphenyl)quinazolin-4(3H)-one
 1029982-48-6P, 3-[(4-Bromobenzyl)amino]-2-(4-
 hydroxyphenyl)quinazolin-4(3H)-one 1029982-50-0P,
 3-[(4-Chlorobenzyl)amino]-2-(4-fluorophenyl)-6-hydroxyquinazolin-4(3H)-one
 1029982-52-2P, 3-[(4-Bromobenzyl)amino]-2-(4-hydroxy-3-
 methoxyphenyl)quinazolin-4(3H)-one 1029982-54-4P,
 3-[(4-Chlorobenzyl)amino]-2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-
 one 1029982-56-6P 1029982-64-6F,
 3-(Benzylamino)-6-fluoro-2-(3-fluorophenyl)quinazolin-4(3H)-one
 1029982-67-9F, 3-[(4-Bromobenzyl)amino]-2-phenylquinazolin-4(3H)-
 one 1029982-70-4P, 3-[(4-Bromobenzyl)amino]-2-(3-
 fluorophenyl)quinazolin-4(3H)-one 1029982-72-6P,
 3-[(4-Bromobenzyl)amino]-6-fluoro-2-(3-fluorophenyl)quinazolin-4(3H)-one
 1029982-74-8P, 3-[[4-Fluoro-3-(trifluoromethyl)benzyl]amino]-2-(3-
 fluorophenyl)quinazolin-4(3H)-one 1029982-76-0P,
 3-[(4-Chlorobenzyl)amino]-7-fluoro-2-(4-fluorophenyl)quinazolin-4(3H)-one
 1029982-78-2F, 3-[(4-Bromobenzyl)amino]-2-(3-chloro-4-
 methylphenyl)quinazolin-4(3H)-one 1029982-80-6P,
 2-(3-Chloro-4-methylphenyl)-3-[(4-chlorobenzyl)amino]quinazolin-4(3H)-one
 1029982-90-8P, 3-[(4-Bromobenzyl)amino]-2-(6-methoxypyridin-3-
 yl)quinazolin-4(3H)-one 1029982-92-0F,
 3-[(4-Bromobenzyl)amino]-2-(6-hydroxypyridin-3-yl)quinazolin-4(3H)-one
 1029982-94-2P, 3-[(4-Bromobenzyl)amino]-2-(3-hydroxy-4-
 methoxyphenyl)quinazolin-4(3H)-one 1029982-96-4P,
 3-[(4-Chlorobenzyl)amino]-2-(3-hydroxy-4-methoxyphenyl)quinazolin-4(3H)-
 one 1029982-52-1F

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(drug candidate; preparation of quinazolinone modulators of TGR5 for
 treatment of metabolic, cardiovascular and inflammatory diseases)


RN 81107-41-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-phenyl-3-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 361180-56-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-(1-methylethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 389577-36-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(3-bromophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 389577-38-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(2,4-dichlorophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 389577-40-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-88-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(4-bromophenyl)methyl]amino]-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 1029980-89-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(bromophenyl)methyl]amino]-2-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1029980-90-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(bromophenyl)methyl]amino]-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 1029980-91-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(bromophenyl)methyl]amino]-2-(2-chlorophenyl)- (CA INDEX NAME)




RN 1029980-92-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-93-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[2,4-difluorophenyl]methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-94-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3,5-difluorophenyl]methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-95-7 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[3,4-difluorophenyl]methyl]amino]-2-(2-fluorophenyl)- (CA INDEX NAME)




RN 1029980-96-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(2-fluorophenyl)methyl]amino]-2-(2-fluorophenyl)-
(CA INDEX NAME)

RN 1029980-98-0 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(2-bromophenyl)-3-[[4-(4-methylphenyl)methyl]amino]-
(CA INDEX NAME)

RN 1029980-99-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-(trifluoromethyl)phenyl)-3-[[4-(2-fluorophenyl)methyl]amino]-
(CA INDEX NAME)


RN 1029981-00-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-methoxyphenyl)-
(CA INDEX NAME)




RN 1029981-01-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-02-9 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-03-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[4-methylphenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-04-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-fluorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-05-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(2-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 1029981-06-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2,4-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 1029981-07-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(2-fluorophenyl)-6-methoxy- (CA INDEX NAME)




RN 1029981-08-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2,4-difluorophenyl)methyl]amino]-2-(2-fluorophenyl)-6-methoxy- (CA INDEX NAME)




RN 1029981-14-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(2-fluorophenyl)methyl]amino]-2-(2-pyridinyl)-
(CA INDEX NAME)




RN 1029981-19-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(4-difluorophenyl)methyl]amino]-2-(4-fluorophenyl)-7-methoxy- (CA INDEX NAME)




RN 1029981-21-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)-7-methoxy- (CA INDEX NAME)




RN 1029981-23-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-7-methoxy-3-[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029981-25-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)




RN 1029981-27-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[(2-naphthalenylmethyl)amino]- (CA INDEX NAME)




RN 1029981-30-3 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[4-(4-morpholinyl)butyl]amino]- (CA INDEX NAME)




RN 1029981-32-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(2-furanyl)- (CA INDEX NAME)




RN 1029981-36-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 1029981-38-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 1029981-40-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-cyclohexyl- (CA INDEX NAME)




RN 1029981-43-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-cyclohexyl- (CA INDEX NAME)




RN 1029981-45-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(3-chlorophenyl)-
(CA INDEX NAME)




RN 1029981-47-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-chlorophenyl)-
(CA INDEX NAME)




RN 1029981-49-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-[[4-(4-chlorophenyl)methyl]amino]-
(CA INDEX NAME)




RN 1029981-51-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-[[4-(trifluoromethyl)phenyl]methyl]amino]-
(CA INDEX NAME)




RN 1029981-53-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chlorophenyl)-3-([(3,4-difluorophenyl)methyl]amino)- (CA INDEX NAME)




RN 1029981-55-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-([(4-chlorophenyl)methyl]amino)- (CA INDEX NAME)



RN 1029981-57-4 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-([(4-(trifluoromethyl)phenyl)methyl]amino)- (CA INDEX NAME)



RN 1029981-59-6 HCAPLUS


CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-([(3,4-

difluorophenyl)methyl]amino]- (CA INDEX NAME)




RN 1029981-61-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-fluoro-3-methylphenyl)- (CA INDEX NAME)





RN 1029981-63-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 1029981-65-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-(3-methoxyphenyl)- (CA INDEX NAME)




RN 1029981-67-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methyl]amino]-2-(4-fluoro-3-methylphenyl)- (CA INDEX NAME)




RN 1029981-69-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methyl]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-71-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methyl]amino]-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-73-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1029981-75-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1029981-77-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-[[4-(4-chlorophenyl)methyl]amino]-3-(3,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 1029981-79-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(1,3-benzodioxol-5-yl)-3-[[4-(4-bromophenyl)methyl]amino]- (CA INDEX NAME)




RN 1029981-81-4 HCAPLUS

CN 4(3H)-Quinazolinone, 2-((4-benzodioxol-5-yl)-3-((4-chlorophenyl)methyl)amino)- (CA INDEX NAME)




RN 1029981-84-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)




RN 1029981-86-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)




RN 1029981-88-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-fluorophenyl)methyl]amino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)




RN 1029981-90-5 HCAPLUS

CN 4-(3H)-Quinazolinone, 2-[(3-methoxy-4-methylphenyl)-3-[[4-(trifluoromethyl)phenyl]methylamino]- (CA INDEX NAME)




RN 1029981-92-7 HCAPLUS

CN 4-(3H)-Quinazolinone, 3-[[3,4-difluorophenyl]methylamino]-2-(3-methoxy-4-methylphenyl)- (CA INDEX NAME)



RN 1029981-98-3 HCAPLUS


CN 4-(3H)-Quinazolinone, 3-[[4-bromophenyl]methylamino]-2-(4-fluoro-3-methoxyphenyl)- (CA INDEX NAME)



RN 1029982-00-0 HCAPLUS


CN 4-(3H)-Quinazolinone, 3-[[4-chlorophenyl]methylamino]-2-(4-fluoro-3-

methoxyphenyl)- (CA INDEX NAME)




RN 1029982-02-2 HCAPLUS

CN 4-(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methylamino]-2-(4-chloro-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-04-4 HCAPLUS

CN 4-(3H)-Quinazolinone, 2-(4-chloro-3-methoxyphenyl)-3-[[[(4-chlorophenyl)methylamino]- (CA INDEX NAME)




RN 1029982-10-2 HCAPLUS

CN 4-(3H)-Quinazolinone, 2-(4-fluorophenyl)-3-[[[(4-(trifluoromethyl)phenyl)methylamino]- (CA INDEX NAME)




RN 1029982-12-4 HCAPLUS

CN 4-(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methylamino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-14-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(4-difluorophenyl)methyl]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-16-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-7-methyl- (CA INDEX NAME)




RN 1029982-18-0 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-fluorophenyl)-7-methyl-3-[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029982-20-4 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-6,7-dimethoxy- (CA INDEX NAME)




RN 1029982-22-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[2-(3-bromophenyl)ethyl]amino]-2-(4-fluorophenyl)-
(CA INDEX NAME)

RN 1029982-24-8 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[2-(4-bromophenyl)ethyl]amino]-2-(4-fluorophenyl)-
(CA INDEX NAME)

RN 1029982-26-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(2-thienyl)- (CA
INDEX NAME)


RN 1029982-28-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(2-thienyl)-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 1029982-32-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(3-thienyl)- (CA INDEX NAME)




RN 1029982-36-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-38-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(3,4-difluorophenyl)- (CA INDEX NAME)




RN 1029982-44-2 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methyl]amino]-2-(4-fluorophenyl)-7-hydroxy- (CA INDEX NAME)




RN 1029982-46-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(3-hydroxyphenyl)-
(CA INDEX NAME)

RN 1029982-48-6 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-hydroxyphenyl)-
(CA INDEX NAME)

RN 1029982-50-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-(4-fluorophenyl)-
6-hydroxy- (CA INDEX NAME)


RN 1029982-52-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-(4-hydroxy-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-54-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methyl]amino]-2-(4-hydroxy-3-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-56-6 HCAPLUS

CN Benzoic acid, 4-[[[2-(3-fluorophenyl)-4-oxo-3(4H)-quinazolinyl]amino]methyl]- (CA INDEX NAME)




RN 1029982-64-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-fluoro-2-(3-fluorophenyl)-3-[(phenylmethyl)amino]- (CA INDEX NAME)




RN 1029982-67-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-bromophenyl)methyl]amino]-2-phenyl- (CA INDEX NAME)




RN 1029982-70-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methylamino]-2-(3-fluorophenyl)-
(CA INDEX NAME)


RN 1029982-72-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-bromophenyl)methylamino]-6-fluoro-2-(3-fluorophenyl)- (CA INDEX NAME)




RN 1029982-74-8 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-fluorophenyl)-3-[[(4-fluoro-3-(trifluoromethyl)phenyl)methylamino]- (CA INDEX NAME)




RN 1029982-76-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-7-fluoro-2-(4-fluorophenyl)- (CA INDEX NAME)




RN 1029982-78-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(3-chloro-4-methylphenyl)- (CA INDEX NAME)




RN 1029982-80-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(3-chloro-4-methylphenyl)-3-[[[(4-chlorophenyl)methyl]amino]- (CA INDEX NAME)



RN 1029982-90-8 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(6-methoxy-3-pyridinyl)- (CA INDEX NAME)



RN 1029982-92-0 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(1,6-dihydro-6-oxo-

3-pyridinyl)- (CA INDEX NAME)




RN 1029982-94-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-bromophenyl)methyl]amino]-2-(3-hydroxy-4-methoxyphenyl)- (CA INDEX NAME)




RN 1029982-96-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)methyl]amino]-2-(3-hydroxy-4-methoxyphenyl)- (CA INDEX NAME)



RN 1029998-52-4 HCAPLUS


CN Benzonitrile, 4-[[[2-(4-fluorophenyl)-4-oxo-3(4H)-quinazolinyl]amino]methyl]- (CA INDEX NAME)





IT 1029982-58-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of quinazolinone modulators of TGR5 for treatment of metabolic, cardiovascular and inflammatory diseases)
 RN 1029982-58-8 HCAPLUS
 CN Benzoic acid, 4-[[[2-(3-fluorophenyl)-4-oxo-3(4H)-quinazolinyl]amino]methyl]-, methyl ester (CA INDEX NAME)



L85 ANSWER 2 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:1054629 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 147:31048
 TITLE: Synthesis and antimicrobial activity of newer quinazolinones
 AUTHOR(S): Patel, J. A.; Mistry, B. D.; Desai, K. R.
 CORPORATE SOURCE: Department of Chemistry, B. K. M. Science College, Valsad, 396001, India
 SOURCE: E-Journal of Chemistry (2006), 3(10 & 11), 97-102
 CODEN: ECJHAO
 PUBLISHER: WWW Publications
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:31048
 GI




AB Quinazolinones I (R1 = Me, Ph; R2 = H, 2-, 3-, 4-OMe, -Br, -Cl, -NO2, -Me) were prepared by reaction of imines II (R1 = Me, Ph) with benzenediazonium chlorides. I were tested for antibacterial activity in vitro; no activity against the yeast *Candida albicans* was observed
 IT 842504-86-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and antibacterial and antifungal activity of
 [(aryldiazenyl)benzylidene]amino]bromoquinazolinones from
 (benzylideneamino)bromoquinazolinones and diazotized anilines)

RN 848504-06-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-phenyl-3-[(phenylmethylene)amino]- (CA
 INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 3 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:930205 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:301087

TITLE: Synthesis of some new
 2-furyl-3-(4-oxo-1,3-thiazolidin-3-yl)-2-
 aryl/heteroaryl-4(3H)-quinazolinones as antimicrobial
 agents

AUTHOR(S): Singh, S.; Tripathi, O. P.; Singh, Sanjay
 CORPORATE SOURCE: Department of Chemistry, T.D.P.G. College, Jaunpur,
 222002, India

SOURCE: Journal of Ultra Chemistry (2006), 2(1),
 85-90

CODEN: JUCOAL; ISSN: 0973-3450

PUBLISHER: Journal of Ultra Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:301087

AB Anthranilic acid was treated with aroyl chlorides in pyridine to give 2-
 aryl/heteroaryl-3,1-benzoxazin-4-ones. These were treated with hydrazine
 hydrochloride in ethanol to result 3-amino-2-aryl/heteroaryl-4(3H)-
 quinazolinones. These compds. reacted with furfural and yielded 3-
 furylidenamino-2-aryl/heteroaryl-4(3H)- quinazolinones. These were treated
 with mercaptoacetic acid in benzene to give 2-furyl-3-(4-oxo-thiazolidin-3-
 yl)-2-aryl/heteroaryl-4(3H)- quinazolinones. A representative number of
 synthesized compds. were evaluated for their antimicrobial activities.


IT 137605-84-6P 947238-20-2P 947238-21-3P
 947238-22-4P 947238-23-5P 947238-24-6P
 947238-25-7P 947238-27-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of some new 2-furyl-3-(4-oxo-1,3-thiazolidin-3-yl)-2-aryl-

4(3H)-
 quinazolinones as antimicrobial agents)


RN 137605-84-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-phenyl- (CA INDEX
 NAME)




RN 947238-20-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-(4-pyridinyl)- (CA INDEX NAME)




RN 947238-21-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-(3-pyridinyl)- (CA INDEX NAME)




RN 947238-22-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 947238-23-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-chlorophenyl)-3-[(2-furanylmethylene)amino]- (CA INDEX NAME)




RN 947238-24-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-(2-nitrophenyl)- (CA INDEX NAME)




RN 947238-25-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-(4-nitrophenyl)- (CA INDEX NAME)



RN 947238-27-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(2-furanylmethylene)amino]-2-(4-methylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 4 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:447129 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:130435

TITLE: Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity

AUTHOR(S): Rodrigues, Paula C. A.; Roth, Thomas; Fiebig, Heinz H.; Unger, Clemens; Muelhaupt, Rolf; Kratz, Felix

CORPORATE SOURCE: Department of Medical Oncology, Clinical Research,
Tumor Biology Center, Freiburg, D-79106, Germany

SOURCE: Bioorganic & Medicinal Chemistry (2006),
14(12), 4110-4117
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:130435


AB Polyethylene glycol conjugates with linkers of varying acid-sensitivity were prepared by reacting five maleimide derivs. of daunorubicin containing an amide bond (1) or acid-sensitive carboxylic hydrazone bonds (2-5) with α -methoxy-poly(ethylene glycol)-thiopropionic acid amide (MW 20000) or α,ω -bis-thiopropionic acid amide poly(ethylene glycol) (MW 20000). The polymer drug derivs. were designed to release daunorubicin inside the tumor cell by acid-cleavage of the hydrazone bond after uptake of the conjugate by endocytosis. In subsequent cell culture expts., the order of antitumor activity of the PEG daunorubicin conjugates correlated with their acid-sensitivity as determined by HPLC (cell lines: BXF T24 bladder carcinoma and LXFL 529L lung cancer cell line; assay: propidium iodide fluorescence assay). The acid-sensitivity of the link between PEG and daunorubicin is therefore an important parameter for in vitro efficacy.

IT 997014-43-6P 997014-44-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(correlation of acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity)

RN 997014-43-6 HCAPLUS

CN Benzoic acid, 2-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)benzoyl]amino]-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● HC1


RN 997014-44-7 HCAPLUS

CN Benzoic acid, 2-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)benzoyl]amino]-4,5-difluoro-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-

dioxo-2-naphthacenyl]ethylidene]hydrazide, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A

● HCl


IT 897014-55-0 897014-56-1 897014-59-4
897014-60-7

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(correlation of acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity)


RN 897014-55-0 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -[2-[[3-[[1-[3-[[[2-[[[1-[[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazino]carbonyl]phenyl]amino]carbonyl]phenyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]amino]ethyl]-6-methoxy-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 897014-56-1 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -[2-[[3-[[1-[3-[[[2-[[[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazino]carbonyl]-4,5-difluorophenyl]amino]carbonyl]phenyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]amino]ethyl]- ω -methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 897014-59-4 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α-[2-[[3-[[1-[3-[[[2-[[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthaceny]ethylidene]hydrazino]carbonyl]phenyl]amino]carbonyl]phenyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]amino]ethyl]-ω-[2-[[3-[[1-[3-[[[2-[[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthaceny]ethylidene]hydrazino]carbonyl]phenyl]amino]carbonyl]phenyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]amino]ethoxy]- (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 2-C




RN 897014-60-7 HCAPLUS


CN Poly(oxy-1,2-ethanediyl), α -[2-[3-[1-[3-[1-[2-[1-[1-(2S,4S)-4-(3-

amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazino]carbonyl]-4,5-difluorophenyl]amino]carbonyl]phenyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]amino]ethyl]- α -[2-[1-[3-[1-[3-[1-[2-[1-[1-(2S,4S)-4-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazino]carbonyl]-4,5-difluorophenyl]amino]carbonyl]phenyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]amino]ethoxy]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 1-C




PAGE 2-C




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L85 ANSWER 5 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:119217 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:274313
 TITLE: Heterocyclic compounds from 4H-3,1-benzoxazin-4-one derivatives as anticancer agent
 AUTHOR(S): Abdel-Rahman, Taha. M.
 CORPORATE SOURCE: Faculty of Specific Education, Ain-Shams University, Cairo, Egypt
 SOURCE: Bollettino Chimico Farmaceutico (2005), 144(3), 104-123
 CODEN: BCFAAI; ISSN: 0006-6648
 PUBLISHER: Societa Editoriale Farmaceutica
 DOCUMENT TYPE: Journal; (computer optical disk)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:274313
 GI



- AB The behavior of 2-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-benzoic acid towards some nitrogen nucleophiles has been investigated. Thus, series of various substituted and fused quinazoline derivs. have been prepared and further transformed using appropriate reagents. IR, ¹H NMR, ¹³C NMR and mass spectra were in a good accord with the proposed structures. Some of the newly synthesized compds., e.g., I (R = Ph or NHPh), exhibited in vitro anticancer activity.
- IT 873555-58-9P 873555-59-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antitumor activity of various substituted and fused quinazoline derivs. via condensation and heterocyclization of benzoxazinonyl benzoic acid with nitrogen nucleophiles followed by derivatization with appropriate reagents)
- RN 873555-58-9 HCAPLUS
- CN Benzoic acid, 2-[3-[[[2-(benzoylamino)phenyl]thio]phenylmethyl]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



- RN 873555-59-0 HCAPLUS
- CN Benzoic acid, 2-[3,4-dihydro-3-[[[2-[[[4-methylphenyl]sulfonyl]amino]phenyl]thio]phenylmethyl]amino]-4-oxo-2-quinazolinyl]- (CA INDEX NAME)




IT 873555-35-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antitumor activity of various substituted and fused quinazoline derivs. via condensation and heterocyclization of benzoxazinonyl benzoic acid with nitrogen nucleophiles followed by derivatization with appropriate reagents)

RN 873555-35-2 HCAPLUS

CN Benzoic acid, 2-[3-[[[(2-aminophenyl)thio]phenylmethyl]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



IT 873555-34-1P 873555-37-4P 873555-38-5P


873555-56-7P 873555-57-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and antitumor activity of various substituted and fused quinazoline derivs. via condensation and heterocyclization of benzoxazinonyl benzoic acid with nitrogen nucleophiles followed by derivatization with appropriate reagents)

RN 873555-34-1 HCAPLUS


CN Benzoic acid, 2-[3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]- (CA INDEX NAME)



RN 873555-37-4 HCAPLUS


CN Benzoic acid, 2-[3-[[[2-(acetylamino)phenyl]thio]phenylmethyl]amino]-3,4-

dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)




RN 873555-38-5 HCAPLUS

CN Benzoic acid, 2-[3,4-dihydro-4-oxo-3-[[phenyl][2-[(phenylsulfonyl)amino]phenyl]thio]methyl]amino]-2-quinazolinyl]- (CA INDEX NAME)




RN 873555-56-7 HCAPLUS

CN Benzoic acid, 2-[3-[[[(2-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



RN 873555-57-8 HCAPLUS

CN Benzoic acid, 2-[3,4-dihydro-3-[[[(4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 6 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1263570 HCAPLUS Full-text

DOCUMENT NUMBER: 144:128930

TITLE: Heterocyclic compounds from 4H-3,1-benzoxazin-4-one derivatives as anticancer agent

AUTHOR(S): Abdel-Rahman, Taha M.

CORPORATE SOURCE: Faculty of Specific Education, Ain-Shams University, Cairo, Egypt

SOURCE: Journal of Heterocyclic Chemistry (2005), 42(7), 1257-1265

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:128930

AB Behavior of 2-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)benzoic acid towards nitrogen nucleophiles namely, hydrazine hydrate, in different solvents, ammonium acetate, and o-phenylenediamine has been investigated to give aminoquinazolin-4-one, benzotriazepinone, spiro-type compound, and nitrogen bridgehead compds. Also, reactivity of the aminoquinazolin-4-one towards carbon electrophiles such as Et acetoacetate, Et phenylacetate, Et chloroacetate, and aromatic aldehydes has been discussed. Reaction of a Schiff's base derived from 2-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)benzoic acid with sulfur nucleophiles, namely o-aminothiophenol and/or thioglycolic acid, afforded Michael type adducts. Structural assignments, of the heterocyclic products have been confirmed by elemental anal. and spectral data (1H- and 13C-NMR and MS fragmentation). The bioassay indicates that some of the target compds. obtained have good selective anticancer activity.

IT 873555-58-9P 873555-59-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


BIOL (Biological study); PREP (Preparation)

(preparation of heterocyclic compds. from 4H-3,1-benzoxazin-4-one derivs.

as anticancer agents)


RN 873555-58-9 HCAPLUS

CN Benzoic acid, 2-[3-[[[2-(benzoylamino)phenyl]thio]phenylmethyl]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)




RN 873555-59-0 HCAPLUS


CN Benzoic acid, 2-[3,4-dihydro-3-[[[2-[[[4-methylphenyl]sulfonyl]amino]phenyl]thio]phenylmethyl]amino]-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



IT 873555-34-1P 873555-35-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of heterocyclic compds. from 4H-3,1-benzoxazin-4-one derivs.
 as anticancer agents)
 RN 873555-34-1 HCAPLUS
 CN Benzoic acid, 2-[3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-
 quinazolinyl]- (CA INDEX NAME)




RN 873555-35-2 HCAPLUS
 CN Benzoic acid, 2-[3-[[[(2-aminophenyl)thio]phenylmethyl]amino]-3,4-dihydro-
 4-oxo-2-quinazolinyl]- (CA INDEX NAME)




IT 873555-37-4P 873555-38-5P 873555-56-7P
 873555-57-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of heterocyclic compds. from 4H-3,1-benzoxazin-4-one derivs.
 as anticancer agents)
 RN 873555-37-4 HCAPLUS
 CN Benzoic acid, 2-[3-[[[2-(acetylamino)phenyl]thio]phenylmethyl]amino]-3,4-

dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)




RN 873555-38-5 HCAPLUS

CN Benzoic acid, 2-[3,4-dihydro-4-oxo-3-[[phenyl][2-[(phenylsulfonyl)amino]phenyl]thio]methyl]amino]-2-quinazolinyl]- (CA INDEX NAME)




RN 873555-56-7 HCAPLUS

CN Benzoic acid, 2-[3-[[[(2-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



RN 873555-57-8 HCAPLUS

CN Benzoic acid, 2-[3,4-dihydro-3-[[[(4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 7 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:291437 HCAPLUS Full-text

DOCUMENT NUMBER: 143:5993

TITLE: Differential inhibition of inducible T cell cytokine secretion by potent iron chelators

AUTHOR(S): Leung, Stewart; Holbrook, April; King, Beverly; Lu, Hong-Tao; Evans, Vincent; Miyamoto, Neil; Mallari, Cornell; Harvey, Susan; Davey, Dave; Ho, Elena; Li, Wei-Wei; Parkinson, John; Horuk, Richard; Jaroch, Stefan; Berger, Markus; Skuballa, Werner; West, Christopher; Pulk, Rebecca; Phillips, Gary; Bryant, Judi; Subramanyam, Babu; Schaefer, Caralee; Salamon, Hugh; Lyons, Eric; Schilling, Daniela; Seidel, Henrik; Kraetzschmar, Joern; Snider, Michael; Perez, Daniel

CORPORATE SOURCE: Berlex Biosciences, Richmond, CA, USA

SOURCE: Journal of Biomolecular Screening (2005), 10(2), 157-167

CODEN: JBISF3; ISSN: 1087-0571

PUBLISHER: Sage Publications

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Effector functions and proliferation of T helper (Th) cells are influenced by cytokines in the environment. Th1 cells respond to a synergistic effect of interleukin-12 (IL-12) and interleukin-18 (IL-18) to secrete interferon-gamma (IFN- γ). In contrast, Th2 cells respond to interleukin-4 (IL-4) to secrete IL-4, interleukin-13 (IL-13), interleukin-5 (IL-5), and interleukin-10 (IL-10). The authors were interested in identifying nonpeptide inhibitors of the Th1 response selective for the IL-12/IL-18-mediated secretion of IFN- γ while leaving the IL-4-mediated Th2 cytokine secretion relatively intact. The authors established a screening protocol using human peripheral blood mononuclear cells (PBMCs) and identified the hydrazino anthranilate compound 1 as a potent inhibitor of IL-12/IL-18-mediated IFN- γ secretion from CD3+ cells with an IC50 around 200 nM. The inhibitor was specific because it had virtually no effect on IL-4-mediated IL-13 release from the same population of cells. Further work established that compound 1 was a potent intracellular iron chelator that inhibited both IL-12/IL-18- and IL-4-mediated T cell proliferation. Iron chelation affects multiple cellular pathways in T cells. Thus, the IL-12/IL-18-mediated proliferation and IFN- γ secretion are very sensitive to intracellular iron concentration. However, the IL-4-mediated IL-13 secretion does not correlate with proliferation and is partially resistant to potent iron chelation.

IT 852316-38-2

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(differential inhibition of inducible T cell cytokine secretion by potent iron chelators)


RN 852316-38-2 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[(2-hydroxy-5-methylphenyl)methylene]hydrazide (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 8 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:38232 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:336322
 TITLE: Synthesis and biological activity of some substituted 2-phenyl-quinazolin-4-ones
 AUTHOR(S): Raghavendra, N. M.; Niranjan, M. S.; Venkatesh, P.; Kumar, B. R. Prashantha; Gowda, Narendra B.; Sripathi, M. S.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Government College of Pharmacy, Bangalore, 560 027, India
 SOURCE: Asian Journal of Chemistry (2005), 17(1), 57-65
 CODEN: AJCHEW; ISSN: 0970-7077
 PUBLISHER: Asian Journal of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:336322
 GI




- AB Synthesis of nine 2,3,6-trisubstituted quinazolin-4-ones I (R= amino, phenylmethyleamino, 4-Cl-phenylmethyleamino, 2-Cl-phenylmethyleamino, 4-MeO-phenylmethyleamino, dimethylaminophenylmethyleamino, 3-NO2-phenylmethyleamino, 4-COOH-phenylmethyleamino, 4-OH-3-MeO-phenylmethyleamino) is reported. The synthesized compds. were screened for their anticancerous activity by evaluating the percentage increase in life span in mice bearing Ehrlich ascites carcinoma at different dose, viz., 2, 50, 100 and 250 µg/mouse/day on alternate days for a total period of 10 days. Synthesized compds. were also investigated for their antimicrobial activity against two gram + and two gram - microorganisms using agar cup diffusion method.
- IT 115754-10-6P 848504-06-3P 848504-07-4P
 818504-08-5P 848504-09-6P 848504-10-9P
 848504-11-0P 848504-12-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)

(preparation of substituted arylbromoquinazolinones and their anticancerous and antimicrobial activity)


RN 115754-70-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-chlorophenyl)methylene]amino]-2-phenyl-
(CA INDEX NAME)




RN 848504-06-3 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-2-phenyl-3-[(phenylmethylene)amino]- (CA INDEX NAME)




RN 848504-07-4 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[2-(2-chlorophenyl)methylene]amino]-2-phenyl-
(CA INDEX NAME)




RN 848504-08-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-methoxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 848504-09-6 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[[4-(dimethylamino)phenyl]methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 848504-10-9 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[4-(4-hydroxy-3-methoxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 848504-11-0 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-[[3-nitrophenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)



RN 848504-12-1 HCAPLUS

CN Benzoic acid, 4-[[6-bromo-4-oxo-2-phenyl-3(4H)-quinazolinyl]imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 9 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:308434 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:339338

TITLE: Preparation of quinazolin-4-one derivatives as PGD2 synthetase inhibitors

INVENTOR(S): Itai, Akiko; Muto, Susumu; Inoue, Tsuyoshi; Urade, Yoshihiro

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan

SOURCE: PCT Int. Appl., 96 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2503674	A1	20040415	CA 2003-2503674	20031002 <--
AU 2003268735	A1	20040423	AU 2003-268735	20031002 <--
GB 2410025	A	20050720	GB 2005-7682	20031002 <--
GB 2410025	B	20070328		
US 20060229324	A1	20061012	US 2005-529946	20051004 <--
PRIORITY APPLN. INFO.:			JP 2002-291114	A 20021003 <--
			WO 2003-JP12648	W 20031002 <--
OTHER SOURCE(S):	MARPAT 140:339338			
GI				




I




II

- AB The title compds. I [wherein X = (un)substituted N=CH or NHCH₂; R₁-R₄ = independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH₂] or pharmaceutically acceptable salts, hydrates, or solvates thereof are prepared as prostaglandin D₂ synthase (PGD₂) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compds. I showed strong inhibitory effect against human PGD₂.
- IT 679843-49-3P 679843-55-1P 679843-56-2P
679843-57-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD₂ synthetase inhibitors)
- RN 679843-49-3 HCAPLUS
- CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 679843-55-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)




RN 679843-56-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(3-methoxyphenyl)- (CA INDEX NAME)



RN 679843-57-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(2-methoxyphenyl)- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 10 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:198513 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 140:210829
 TITLE: Chromene derivatives as preventives of vascular endothelium proliferation
 INVENTOR(S): Fujita, Takashi; Oguchi, Minoru; Yokoyama, Tomihisa; Inoue, Tatsuya; Nagasawa, Yasuo
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 161 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004075614	A	20040311	JP 2002-238686	20020820 <--
PRIORITY APPLN. INFO.:			JP 2002-238686	20020820 <--
OTHER SOURCE(S):	MARPAT	140:210829		

GI




AB The invention provides chromene derivs. I (R1 = H, optionally substituted C1-6 alkyl, C6-10 aryl, or C1-12 acyl; R2, R3, R4, and R5 = H, halogeno, C1-6 alkyl, C3-6 cycloalkyl, etc.; R6 = H, halogeno, optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R7 and R8 = H, halogeno, C1-6 alkyl, C3-6 cycloalkyl, optionally substituted C6-10 aryl, or an optionally substituted 5-10-membered heterocyclic group; the dotted line indicates a double bond or a single bond; and Ar = optionally substituted C6-10 aryl or an optionally substituted 5-10-membered heterocyclic group) as preventives of vascular endothelium proliferation, suitable for use for treatment of diabetic retinopathy, cancer, and rheumatism, etc. A compound 3-[(6,7-dimethoxy-2H-chromene-3-carbonyl)amino]benzoic acid Et ester was prepared, and its effect on human umbilical cord venous endothelial cell proliferation was examined. A tablet containing 2-[(6-acetoxy-5,7,8-trimethyl-2H-chromene-3-carbonyl)amino]benzoic acid 100 mg/490 mg tablet was formulated.

IT 452077-19-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of chromene derivs. as preventives of vascular endothelium proliferation for treatment of related disease)

RN 452077-19-9 HCAPLUS

CN 2H-1-Benzopyran-3-carboxamide, 6-(acetyloxy)-5,7,8-trimethyl-N-[2-[[(phenylmethoxy)amino]carbonyl]phenyl]- (CA INDEX NAME)



L85 ANSWER 11 OF 48 HCAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2004:17804 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:94056

TITLE: Preparation of [(quinazolinonyl)benzyl]phosphonate diesters and their use as acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) inhibitors

INVENTOR(S): Sakai, Yasuhiro; Miyata, Kazuyoshi; Tomoyasu, Takahiro; Kuroda, Terunori; Inoue, Yasuhide; Hagi, Akifumi; Miki, Shinya; Yoshinaga, Yoshihiro; Doi, Masako; Tsuda, Yoshihiko

PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004002214	A	20040108	JP 2002-131479	20020507 <--
JP 4110371	B2	20080702		
PRIORITY APPLN. INFO.:			JP 2002-106534	A 20020409 <--
OTHER SOURCE(S):	MARPAT	140:94056		

GI



AB The title compds. I [R1-R4 = H, halo, lower alkyl, lower alkoxy; R5 = (un)substituted Ph, benzodioxolanyl, naphthyl, etc.], useful as antiarteriosclerotic and anticholesteremic agents, are prepared Thus, condensation of di-Et [4-(3-amino-7-chloro-4(3H)-quinazolinon-2-yl)benzyl]phosphonate with p-tolualdehyde gave I (R1 = R2 = R4 = H, R3 = Cl, R5 = 4-C6H4Me), which inhibited 75% ACAT-1 activity.

IT 642463-77-2P 642463-78-3P 642463-79-4P
642463-80-7P 642463-81-8P 642463-82-9P
642463-83-0P 642463-84-1P 642463-85-2P


642463-66-3P 642463-67-4P 642463-68-5P
 642463-69-6P 642463-90-9P 642463-91-0P
 642463-92-1P 642463-93-2P 642463-94-3P
 642463-95-1P 642463-96-5P 642463-97-6P
 642463-98-7P 642464-00-4P 642464-02-6P
 642464-04-8P 642464-06-0P 642464-08-2P
 642464-10-6P 642464-12-9P 642464-13-9P
 642464-15-1P 642464-17-3P 642464-18-4P
 642464-19-5P 642464-20-8P 642464-21-9P
 642464-22-0P 642464-23-1P 642464-24-2P
 642464-25-3P 642464-26-4P 642464-27-5P
 642464-28-6P 642464-29-7P 642464-30-0P
 642464-31-1P 642464-32-2P 642464-33-3P
 642464-34-4P 642464-35-5P 642464-36-6P
 642464-37-7P 642464-38-8P 642464-39-9P
 642464-40-2P 642464-41-3P 642464-42-4P
 642464-43-5P 642464-44-6P 642464-45-7P
 642464-46-8P 642464-47-9P 642464-48-0P
 642464-49-1P 642464-50-4P 642464-51-5P
 642464-52-6P 642464-53-7P 642464-54-8P
 642464-55-9P 642464-56-0P 642464-57-1P
 642464-58-2P 642464-59-3P 642464-60-6P
 642464-61-7P 642464-62-8P 642464-63-9P
 642464-64-0P 642464-65-1P 642464-66-2P
 642464-67-3P 642464-68-4P 642464-69-5P
 642464-69-5P 642464-69-5P 642464-69-5P
 642464-70-6P 642464-71-7P 642464-72-8P
 642464-73-8P 642464-74-9P 642464-75-0P
 642464-76-1P 642464-77-2P 642464-78-3P
 642464-79-4P 642464-80-5P 642464-81-6P
 642464-82-7P 642464-83-8P 642464-84-9P
 642464-85-0P 642464-86-1P 642464-87-2P
 642464-88-3P 642464-89-4P 642464-90-5P
 642464-91-6P 642464-92-7P 642464-93-8P
 642464-94-9P 642464-95-0P 642464-96-1P
 642464-97-2P 642464-98-3P 642464-99-4P
 642465-00-5P 642465-01-6P 642465-02-7P
 642465-03-8P 642465-04-9P 642465-05-0P
 642465-06-1P 642465-07-2P 642465-08-3P
 642465-09-4P 642465-10-5P 642465-11-6P
 642465-12-7P 642465-13-8P 642465-14-9P
 642465-15-0P 642465-16-1P 642465-17-2P
 642465-18-3P 642465-19-4P 642465-20-5P
 642465-21-6P 642465-22-7P 642465-23-8P
 642465-24-9P 642465-25-0P 642465-26-1P
 642465-27-2P 642465-28-3P 642465-29-4P
 642465-30-5P 642465-31-6P 642465-32-7P
 642465-33-8P 642465-34-9P 642465-35-0P
 642465-36-1P 642465-37-2P 642465-38-3P
 642465-39-4P 642465-40-5P 642465-41-6P
 642465-42-7P 642465-43-8P 642465-44-9P
 642465-45-0P 642465-46-1P 642465-47-2P
 642465-48-3P 642465-49-4P 642465-50-5P
 642465-51-6P 642465-52-7P 642465-53-8P
 642465-54-9P 642465-55-0P 642465-56-1P
 642465-57-2P 642465-58-3P 642465-59-4P
 642465-60-5P 642465-61-6P 642465-62-7P
 642465-63-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(preparation of [(quinazolinonyl)benzyl]phosphonate diesters as
 acyl-CoA:cholesterol acyltransferase-1 inhibitors for
 antiarteriosclerotic and anticholesteremic agents)


RN 642463-77-2 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-(4-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-78-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-79-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-80-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-ethylphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-81-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-(1-methylethyl)phenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-82-9 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[[4-(1,1-dimethylethyl)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-83-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[4-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-84-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[3-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-85-2 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[4-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-86-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[4-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-87-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[3-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-88-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[2-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-89-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[4-(phenoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-90-9 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[3-phenoxyphenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-91-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[4-(phenylmethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-92-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[3-(phenylmethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-93-2 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[2-(phenylmethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-94-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-95-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-96-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-97-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642463-98-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[3-(3-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-00-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2-(2-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-02-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-04-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[3-(fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-06-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2-(fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-08-2 HCAPLUS

CN Phosphonic acid, [[4-[3-[(2-bromophenyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-10-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-12-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-13-9 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-15-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[[4-(methylthio)phenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-17-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[[4-(dimethylamino)phenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-18-4 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(acetylamino)phenyl]methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-19-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[4-(1-pyrrolidinyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-20-8 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[1,1'-biphenyl]-4-ylmethylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-21-9 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-22-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-23-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2,5-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-24-2 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(2,3-dichlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-25-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(2,4-dichlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-26-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(3,4-dichlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-27-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-28-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-29-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-5-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-30-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-6-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-31-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-methoxy-3-(phenylmethoxy)phenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-32-2 HCAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-33-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1-naphthalenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-34-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-naphthalenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-35-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(2-hydroxy-1-naphthalenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-36-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(2,3,4-trimethoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-37-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-38-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1-oxido-4-pyridinyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-39-9 HCAPLUS

CN Phosphonic acid, [[4-[[7-chloro-3,4-dihydro-3-[[6-methyl-2-pyridinyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-40-2 HCAPLUS

CN Phosphonic acid, [[4-[[7-chloro-3,4-dihydro-4-oxo-3-[(2-thienyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-41-3 HCAPLUS

CN Phosphonic acid, [[4-[[7-chloro-3,4-dihydro-4-oxo-3-[(3-thienyl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-42-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-methyl-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-43-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(3-methyl-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-44-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(5-chloro-2-thienyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-45-7 HCAPLUS

CN Phosphonic acid, [[4-[3-[(5-bromo-2-thienyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-46-8 HCAPLUS

CN Phosphonic acid, [[4-[3-[[4-bromo-2-thienyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-47-9 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[5-nitro-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-48-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[5-nitro-2-thienyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-49-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(2-furanylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-50-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[(3-furanylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-51-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[5-methyl-2-furanyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-52-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4,5-dimethyl-2-furanyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-53-7 HCAPLUS

CN Phosphonic acid, [[4-[3-[(5-bromo-2-furanyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-54-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-nitro-2-furanyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-55-9 HCAPLUS

CN Phosphonic acid, [[4-[3-[(2-benzofuranylmethylene)amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-56-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-57-1 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(1H-pyrrol-2-yl)methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-58-2 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[[1-methyl-1H-pyrrol-2-yl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-59-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1H-imidazol-4-yl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-60-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1H-imidazol-2-yl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-61-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-62-8 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[(4-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-63-9 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[3-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-64-0 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[2-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-65-1 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3-[[4-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-66-2 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3-[[3-(3-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-67-3 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3-[[4-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-68-4 HCAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-6-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-69-5 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-95-7 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[4-(4-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-97-9 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[3-(4-methylphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642464-99-1 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[4-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-01-8 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[4-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-03-0 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[2-(4-hydroxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-05-2 HCAPLUS

CN Phosphonic acid, [[4-[3-[[4-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-07-4 HCAPLUS

CN Phosphonic acid, [[4-[3-[[3-(4-chlorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-09-6 HCAPLUS

CN Phosphonic acid, [[4-[3-[[4-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-10-9 HCAPLUS

CN Phosphonic acid, [[4-[3-[[3-(4-fluorophenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-12-1 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[4-(4-nitrophenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-13-2 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[4-(methylthio)phenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-15-4 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(dimethylamino)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-17-6 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(acetylamino)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-20-1 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[4-(3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-22-3 HCAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-25-6 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[6-methyl-2-pyridinyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-27-8 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[(2-thienylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-28-9 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-29-0 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-6-methyl-4-oxo-3-[[3-(trifluoromethoxy)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-30-3 HCAPLUS

CN Phosphonic acid, [[4-[3-[(3-chlorophenyl)methylene]amino]-3,4-dihydro-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-31-4 HCAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-32-5 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-6-methyl-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-39-2 HCAPLUS

CN Phosphonic acid, [[4-[3-[(3-chlorophenyl)methylene]amino]-7-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-41-6 HCAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-7-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-43-8 HCAPLUS

CN Phosphonic acid, [[4-[7-fluoro-3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-51-8 HCAPLUS

CN Phosphonic acid, [[4-[3-[(1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6-methoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-52-9 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[(1H-imidazol-2-ylmethylene)amino]-6-methoxy-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-55-2 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[3,4-dimethoxyphenyl)methylene]amino]-3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-56-3 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[1,3-benzodioxol-5-ylmethylene)amino]-3,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-57-4 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[1H-imidazol-2-ylmethylene)amino]-6,7-dimethoxy-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-60-9 HCAPLUS

CN Phosphonic acid, [[4-[3-[[[4-bromophenyl)methylene]amino]-7-chloro-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-61-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[(1H-indol-2-ylmethylene)amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642465-62-1 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[[3-(trifluoromethyl)phenyl]methylene]amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642465-63-2 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[1-oxido-4-pyridinyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L85 ANSWER 12 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:17803 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:87712

TITLE: Acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) inhibitors containing [(quinazolinonyl)benzyl]phosphonate diester derivatives

INVENTOR(S): Sakai, Yasuhiro; Miyata, Kazuyoshi; Tomoyasu, Takahiro; Kuroda, Terunori; Inoue, Yasuhide; Shu, Akifumi; Miki, Shinya; Yoshinaga, Yoshihiro; Doi, Masako; Tsuda, Yoshihiko

PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004002213	A	20040108	JP 2002-131208	20020507 <--
PRIORITY APPLN. INFO.:			JP 2002-106526	A 20020409 <--
OTHER SOURCE(S):	MARPAT 140:87712			
GI				



AB The title inhibitors, useful as antiarteriosclerotic and anticholesteremic agents, contain [(quinazolinonyl)benzyl]phosphonate diesters I [R1-R4 = H, halo, lower alkyl; R5 = (lower alkoxy-substituted) Ph, pyridyl; R6 = lower alkyl] as active ingredients are prepared Thus, I (R1 = R2 = R4 = H, R3 = Cl, R5 = 3-C6H4OMe) inhibited 82% ACAT-1 activity.

IT 173019-00-6P 173019-01-7P 173019-02-8P
 642097-06-3P 642097-09-0P 642097-08-3P
 642097-01-4P 642097-02-5P 642097-03-6P
 642097-04-7P 642097-05-8P 642097-06-9P
 642097-07-0P 642097-08-1P 642097-09-2P


642098-04-2P 642098-05-3P 642098-06-4P
 642098-07-5P 642098-08-6P 642098-09-7P
 642098-11-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(preparation [(quinazolinonyl)benzyl]phosphonate diesters as
 acyl-CoA:cholesterol acyltransferase-1 inhibitors)


RN 173019-00-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-
 [(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester
 (9CI) (CA INDEX NAME)




RN 173019-01-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-
 methoxyphenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-,
 diethyl ester (9CI) (CA INDEX NAME)




RN 173019-02-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(2-
 pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester
 (9CI) (CA INDEX NAME)




RN 642097-88-9 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-89-0 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[2-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-90-3 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[4-(ethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-91-4 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[2-(ethoxyphenyl)methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-92-5 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[[4-(1-methylethoxy)phenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-93-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3-[[[4-(1,1-dimethylethoxy)phenyl]methylene]amino]-3,4-dihydro-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-94-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[[[4-(pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-95-8 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(3-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-96-9 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-97-0 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[4-(4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-98-1 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642097-99-2 HCAPLUS

CN Phosphonic acid, [[4-[6-chloro-3,4-dihydro-4-oxo-3-[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-04-2 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-05-3 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[4-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-06-4 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[[(3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-07-5 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[[(4-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-08-6 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-4-oxo-3-[[[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 642098-09-7 HCAPLUS

CN Phosphonic acid, [[4-[3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-6-methyl-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 642098-11-1 HCAPLUS

CN Phosphonic acid, [[4-[7-fluoro-3,4-dihydro-3-[[3-methoxyphenyl)methylene]amino]-4-oxo-2-quinazolinyl]phenyl)methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L85 ANSWER 13 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:929559 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:396057

TITLE: Preparation of phosphonate diesters as ACAT-1 inhibitors

INVENTOR(S): Tomoyasu, Takahiro; Miyata, Kazuyoshi; Sakai, Yasuhiro; Kuroda, Terunori; Inoue, Yasuhide; Hagi, Akifumi; Miki, Shinya; Yoshinaga, Yoshihiro; Doi, Masako; Tsuda, Yoshihiko

PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335789	A	20031128	JP 2002-146831	20020521 <--
JP 4038662	B2	20080130		
PRIORITY APPLN. INFO.:			JP 2002-146831	20020521 <--
OTHER SOURCE(S):	MARPAT 139:396057			

GI




AB Title compds. I (R1 = NR7R8; R7, R8 = H, alkylpyridyl, NR7R8 = N-methylpiperazinyl, morpholino, etc.; R3, R4, R5, R6 = H, halo), useful as ACAT-1 inhibitors, are prepared. Thus, reaction of di-Et 4-(6-bromo-4H-3,1-benzoxazin-4-on-2-yl)benzylphosphonate with 3-(aminomethyl)pyridine in THF at room temperature for 12 h gave I (R1 = 3-pyridinylmethylamino, R2 = Et, R3 = R4 = R6 = H, R5 = Br) (II). II showed good inhibitory activity against ACAT-1. Formulation are given.

IT 625831-35-8P 625831-36-9P 625831-37-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of phosphonate diesters as ACAT-1 inhibitors)


RN 625831-35-8 HCAPLUS

CN Benzoic acid, 4-chloro-2-[[4-[(diethoxyphosphinyl)methyl]benzoyl]amino]-, 2-[(2-chlorophenyl)methylene]hydrazide (CA INDEX NAME)




RN 625831-36-9 HCAPLUS

CN Benzoic acid, 4-chloro-2-[[4-[(diethoxyphosphinyl)methyl]benzoyl]amino]-, 2-[(3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



RN 625831-37-0 HCAPLUS

CN Benzoic acid, 4-chloro-2-[[4-[(diethoxyphosphinyl)methyl]benzoyl]amino]-, 2-[(2-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



L85 ANSWER 14 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:318870 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:214421

TITLE: Synthesis and pharmacological investigation of some novel 2,3-disubstituted quinazolin-4(3H)-ones as analgesic and antiinflammatory agents

AUTHOR(S): Alagarsamy, V.; Meena, S.; Vijayakumar, S.; Ramseshu, K. V.; Revathi, R.

CORPORATE SOURCE: Medicinal Chemistry Laboratory, S. B. College of Pharmacy, Sivakasi, 626130, India

SOURCE: Pharmazie (2003), 58(4), 233-236

CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:214421

AB A series of novel 2-substituted quinazolin-4(3H)-ones have been synthesized by condensing the aromatic primary amine of 2-substituted quinazolines with different aldehydes and ketones. The synthesized compds. were confirmed by their spectral data (IR, NMR and MS) and the purity was ascertained by elemental anal. Some compds. were evaluated for analgesic and antiinflammatory activities in which they exhibited more potent activities than diclofenac sodium. The activity values were found to be significant as compared to those of controls.

IT 56158-78-2P 588698-08-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(preparation of disubstituted quinazolinones via condensation of amines of substituted quinazolines with various aldehydes and ketones and their analgesic and antiinflammatory activities)


RN 56158-78-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-phenyl-3-[(3-phenyl-2-propen-1-ylidene)amino]- (CA INDEX NAME)



RN 588698-08-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(1-methylpropylidene)amino]-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 15 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:80408 HCAPLUS Full-text

DOCUMENT NUMBER: 139:273459

TITLE: Antibacterial and antifungal activities of some novel 2,3-disubstituted quinazolin-4(3H)-ones

AUTHOR(S): Alagarsamy, V.

CORPORATE SOURCE: Medicinal Chemistry Laboratory, S. B. College of Pharmacy, Sivakasi, 626 130, India

SOURCE: Indian Journal of Pharmaceutical Sciences (2002), 64(6), 600-603

CODEN: IJSDW; ISSN: 0250-474X

PUBLISHER: Indian Pharmaceutical Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of novel 2,3-disubstituted quinazolin-4(3H)-ones was synthesized by condensing the aromatic primary amino group of quinazoline with different aldehydes and ketones. When these compds. were evaluated for antibacterial and antifungal activities, all the compds. inhibited the growth of bacteria and fungi significantly. Compds. VII and IX exhibited equipotent activity with the standard ciprofloxacin against *Shigella flexneri* and *Pseudomonas aeruginosa*, and compound VIII exhibited equivalent activity to ciprofloxacin against *Bacillus subtilis* and *Citrobacter ferundii*. Compds. V, VI and IX were equipotent with the standard clotrimazole against *Aspergillus niger* and *Microsporum gypseum*; and compound VI was equipotent with standard clotrimazole against *Trichophyton mentagrophytes*.

IT 56158-78-2P 588698-08-2P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(antibacterial and antifungal activities of novel 2,3-disubstituted quinazolin-4(3H)-ones)


RN 56158-78-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-phenyl-3-[(3-phenyl-2-propen-1-ylidene)amino]- (CA INDEX NAME)



RN 588698-08-2 HCAPLUS


CN 4(3H)-Quinazolinone, 3-[(1-methylpropylidene)amino]-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 16 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:658103 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:185514
 TITLE: Preparation of chromene derivatives for treatment and prevention of retinopathy and diabetic retinopathy
 INVENTOR(S): Fujita, Takashi; Oguchi, Minoru; Yokoyama, Tomihisa; Inoue, Tatsuya
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
 SOURCE: PCT Int. Appl., 245 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066454	A1	20020829	WO 2002-JP1501	20020220 <--
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2002234893	A1	20020904	AU 2002-234893	20020220 <--
JP 2002322169	A	20021108	JP 2002-42721	20020220 <--
PRIORITY APPLN. INFO.:				
			JP 2001-45256	A 20010221 <--
			WO 2002-JP1501	W 20020220 <--
OTHER SOURCE(S): MARPAT 137:185514				
GI				



AB The title compds. I [R1 represents hydrogen, optionally substituted C1-6 alkyl, C6-10 aryl, or C1-12 acyl; R2, R3, R4, and R5 are the same or different and each represents hydrogen, halogeno, C1-6 alkyl, C3-6 cycloalkyl, etc.; R6 represents hydrogen, halogeno, optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R7 and R8 are the same or different and each represents hydrogen, halogeno, C1-6 alkyl, C3-6 cycloalkyl, optionally substituted C6-10 aryl, or an optionally substituted five- to ten-membered heterocyclic group; the dotted line indicates a double bond or a single bond; and Ar represents optionally substituted C6-10 aryl or an optionally

substituted five- to ten-membered heterocyclic group] are prepared. In an *in vitro* test, the antiproliferative activity of 16 compds. of this invention was ≥ 30 times that of the known tranilast. Formulations are given.

IT 452077-19-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chromene derivs. for treatment and prevention of retinopathy

and diabetic retinopathy)

RN 452077-19-9 HCAPLUS

CN 2H-1-Benzopyran-3-carboxamide, 6-(acetyloxy)-5,7,8-trimethyl-N-[2-[[(phenylmethoxy)amino]carbonyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 17 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:560149 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:24692

TITLE: Some reactions with quinoxaline-2,3-dicarboxylic acid anhydride: Novel synthesis of thieno[2,3-d]pyrimidines and pyrrolo[3,4-b]quinoxalines as antimicrobial agents
AUTHOR(S): Ammar, Y. A.; Ismail, M. M. F.; El-Gaby, M. S. A.; Zahran, M. A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Egypt

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2002), 41B(7), 1486-1491
CODEN: IJSEDB; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:24692

AB The reactivity of quinoxaline-2,3-dicarboxylic anhydride (I) towards some heterocyclic amines as N nucleophiles was studied. E.g., treatment of I with 2-aminobenzo[b]thiophenes led to preparation of polyheterocyclic compds. such as pyrroloquinoxalines and thieno[2,3-d]pyrimidines. Some quinoxaline derivs. were tested for their antibacterial and antifungal activity. None of the tested compds. showed activity superior to that of Streptomycin or Mycostatin.


IT 478060-51-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of quinoxalinylnbenzothienopyrimidines)

RN 478060-51-4 HCAPLUS


CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[[(4-methoxyphenyl)methylene]amino]-2-(2-
quinoxaliny)- (CA INDEX NAME)



IT 478060-49-0P 478060-53-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction of quinoxaline-2,3-dicarboxylic anhydride with
aminobenzothiophenes)
RN 478060-49-0 HCAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[[(2-hydroxyphenyl)methylene]amino]-2-(2-
quinoxaliny)- (CA INDEX NAME)



RN 478060-53-6 HCAPLUS
CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[(4-chlorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-quinoxaliny)-
(CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 18 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:390137 HCAPLUS [Full-text](#)
DOCUMENT NUMBER: 137:263004
TITLE: Synthesis and pharmacological investigation of some

novel 2-phenyl-3-(substituted methyl amino)
quinazolin-4(3H)-ones as H1-receptor blockers

AUTHOR(S): Alagarsamy, V.; Venkatesaperumal, R.; Vijayakumar, S.;
Angayarkanni, T.; Pounammal, P.; Senthilganes, S.;
Kandeeban, S.

CORPORATE SOURCE: Medicinal Chemistry Laboratory, S.B. College of
Pharmacy, Sivakasi, 626 130, India

SOURCE: Pharmazie (2002), 57(5), 306-307
CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 137:263004

AB A series of 3-[(aminomethyl)amino]-2-phenyl-2-4(3H)-quinazolinones were
prepared from 3-amino-2-phenyl-4(3H)-quinazolinone. When tested for H1-
receptor blocking activity on isolated guinea pig ileum all the test compds.
inhibited histamine induced contraction whereas 3-
[[[(dimethylamino)methyl]amino]-2-phenyl-4(3H)-quinazolinone (IC50 0.59 + 103
ng/mL) and 3-[(1-piperazinylmethyl)amino]-2-phenyl-4(3H)-quinazolinone (IC50
0.49 + 103 ng/mL) were found to be two fold potent when compared to standard
chlorpheniramine maleate. These compds. have less sedative activity than a
standard. Hence, they could serve as prototype mols. for future development.

IT 462659-73-0P, 3-[[[(Dimethylamino)methyl]amino]-2-phenyl-4(3H)-
quinazolinone 462659-74-1P 462659-75-2P
462659-76-3P 462659-77-4P 462659-78-5P
462659-79-6P 462659-80-9P 462659-81-0P
462659-82-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of
3-[(aminomethyl)amino]-2-phenyl-2-4(3H)-quinazolinones as H1-receptor
blockers)


RN 462659-73-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(dimethylamino)methyl]amino]-2-phenyl- (CA INDEX
NAME)




RN 462659-74-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(diethylamino)methyl]amino]-2-phenyl- (CA INDEX
NAME)




RN 462659-75-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2-phenyl-3-[(1-pyrrolidinylmethyl)amino]- (CA INDEX
NAME)




RN 462659-76-3 HCAPLUS

CN 4 (3H)-Quinazolinone, 3-[(4-morpholinylmethyl)amino]-2-phenyl- (CA INDEX NAME)




RN 462659-77-4 HCAPLUS

CN 4 (3H)-Quinazolinone, 2-phenyl-3-[(1-piperazinylmethyl)amino]- (CA INDEX NAME)




RN 462659-78-5 HCAPLUS

CN 4 (3H)-Quinazolinone, 2-phenyl-3-[(phenylamino)methylamino]- (CA INDEX NAME)




RN 462659-79-6 HCAPLUS

CN 4 (3H)-Quinazolinone, 3-[[[(4-methoxyphenyl)amino]methyl]amino]-2-phenyl- (CA INDEX NAME)




RN 462659-80-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(3-methylphenyl)amino]methyl]amino]-2-phenyl-
(CA INDEX NAME)




RN 462659-81-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(1H-benzimidazol-1-ylmethyl)amino]-2-phenyl- (CA
INDEX NAME)



RN 462659-82-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(1H-benzotriazol-1-ylmethyl)amino]-2-phenyl- (CA
INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 19 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:600056 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:167344

TITLE: Synthesis of some new substituted quinazoline
derivatives and their antimicrobial screening

AUTHOR(S): Abdel-Hamde, Sami G.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, College of
Pharmacy, King Saud University, Riyadh, 11451, Saudi
Arabia

SOURCE: Saudi Pharmaceutical Journal (2001), 9(2),
72-84

CODEN: SPJOEM; ISSN: 1319-0164

PUBLISHER: Saudi Pharmaceutical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:167344

AB A new series of 4-oxo-6-iodo-3H-quinazoline and its fused heterocyclic analogs
were prepared and screened for their antimicrobial activity. Some of the
comps. showed remarkable broad spectrum antimicrobial activity. The fused
heterocycles 1,2,4-triazino[3,4-c]quinazoline, 1,2,4-triazolo[2,3-

c]quinazoline and pyrazolo[1,5-c]quinazoline proved to contribute for activity. The detailed synthesis and their antimicrobial screening are reported.

IT 329699-24-3P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of quinazolines)
 RN 329699-24-3 HCAPLUS
 CN Acetonitrile, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazoliny]amino]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 20 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:785234 HCAPLUS Full-text

DOCUMENT NUMBER: 134:95112

TITLE: Synthesis, antitumor activity, and anti-HIV-1 testing of certain heterocyclic systems containing an adamantane nucleus

AUTHOR(S): El-Sherbeny, Magda A.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Riyadh, 11495, Saudi Arabia

SOURCE: Archiv der Pharmazie (Weinheim, Germany) (2000), 333(10), 323-328

CODEN: ARPMAS; ISSN: 0365-6233

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:95112


AB A new series of substituted 2-(1-adamantyl)-4H-3,1-benzoxazin-4-ones and 2-(1-adamantyl)-3-amino or alkyl-3,4-dihydroquinazolin-4-ones have been synthesized and tested for their antitumor and antiviral activities. Two of the tested compds. exhibited a broad spectrum antitumor activity with full panel (MG-MID) median growth inhibition (GI50) values of 3.2 and 4.9 μ M resp. Moderate selectivity towards leukemia cell lines was observed with several of the compds. Two compds. possessed moderate anti-HIV-1 potency with EC50 values of 50.3 and 69.2 μ M resp. Detailed synthesis, spectroscopic, and biol. data are reported.

IT 318499-78-4P 318499-79-5P 318499-80-6P 318499-81-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis, antitumor activity, and anti-HIV-1 testing of heterocyclics containing an adamantane nucleus)


RN 318499-78-4 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]-, 2-(2-thienylmethylene)hydrazide (CA INDEX NAME)




RN 318499-79-5 HCAPLUS

CN Benzoic acid, 5-methyl-2-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-, 2-(2-thienylmethylene)hydrazide (CA INDEX NAME)




RN 318499-80-8 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-, 2-[(5-methyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)



RN 318499-81-9 HCAPLUS

CN Benzoic acid, 5-methyl-2-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-, 2-[(5-methyl-2-furanyl)methylene]hydrazide (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 21 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:645870 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 133:217704
 TITLE: Small molecules having GLP-2 like activity, and their therapeutic use
 INVENTOR(S): Lee, David K. H.; Treasurywala, Adi
 PATENT ASSIGNEE(S): NPS Allelix Corp., Can.
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053208	A2	20000914	WO 2000-CA245	20000309 <--
WO 2000053208	A3	20010809		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, MN, SN, TD, TG

PRIORITY APPLN. INFO.: GB 1999-5416 A 19990309 <--

OTHER SOURCE(S): MARPAT 133:217704


AB Non-peptide agonists of the GLP-2 receptor are provided. In accordance with one aspect of the invention, there is provided, for use to treat subjects for which treatment with a GLP-2 peptide is indicated, a compound characterized as having a mol. weight of from about 100 Daltons to less than about 1000 Daltons and which possesses GLP-2 receptor agonist activity. Preparation of e.g. 2-(benzoylamino)- α -[(4-chlorobenzylidene)hydrazino]benzaldehyde is described.

IT 292142-91-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (GLP-2 receptor nonpeptide agonists, and therapeutic use)

RN 292142-91-7 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)




IT 195066-45-6 292142-92-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GLP-2 receptor nonpeptide agonists, and therapeutic use)


RN 195066-45-6 HCAPLUS

CN Benzoic acid, 2-(benzoylamino)-, 2-[[4-(dimethylamino)phenyl]methylene]hydrazide (CA INDEX NAME)



RN 292142-92-8 HCAPLUS

CN Benzoic acid, 2-[(4-chlorobenzoyl)amino]-, 2-[(4-hydroxy-3-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 22 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:92318 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 132:279169

TITLE: Synthesis and reactions of 2-[2-(2,4,6-trimethylbenzoyl)vinyl]-4H-3,1-benzoxazin-4-one of expected biological activity

AUTHOR(S): Abdel-Fattah, M. E.; Soliman, E. A.; Soliman, S. M. A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt

SOURCE: Egyptian Journal of Chemistry (1999), 42(6), 499-516

CODEN: EGJCA3; ISSN: 0449-2285

PUBLISHER: National Information and Documentation Centre

DOCUMENT TYPE: Journal

LANGUAGE: English

AB β -(2,4,6-Trimethylbenzoyl)acryloyl chloride reacts with anthranilic acid to give theamide which is easily cyclized by acetic anhydride to give the title benzoxazinone (I). I was cyclized with N₂H₄ to give the 3-aryl-5-pyrazolylbenzoxazinone. The behavior of this compound towards aromatic aldehydes, ketones, phthalic anhydride and phthalylamino acid chlorides has been investigated. Reactions of I with o-phenylenediamine, ammonia, Grignard reagents, Friedel-Crafts reagents and bromine are described. The products showed a range of antibacterial activity.


IT 234103-34-5P 234103-36-7P 234103-46-3P

RL: EAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of trimethylbenzoylvinylbenzoxazinones and pyrazolylbenzoxazinones with bactericidal activity)


RN 234103-34-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-[[4,5-dihydro-3-(2,4,6-trimethylphenyl)-1H-pyrazol-5-yl]-3-[[4-methoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 234103-36-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methylene]amino]-2-[4,5-dihydro-3-(2,4,6-trimethylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 234103-40-3 HCAPLUS

CN 4(3H)-Quinazolinone, 2-[4,5-dihydro-3-(2,4,6-trimethylphenyl)-1H-pyrazol-5-yl]-3-[(1-methylethylidene)amino]- (CA INDEX NAME)



REFERENCE COUNT:

21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 23 OF 48 HCAPLUS

COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:733031 HCAPLUS Full-text
 DOCUMENT NUMBER: 131:337358
 TITLE: Preparation of dolastatin 15 derivatives as anticancer agents
 INVENTOR(S): Ritter, Kurt; Janssen, Bernd; Haupt, Andreas; Kling, Andreas; Barlozzari, Teresa; Amberg, Wilhelm
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: U.S., 42 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985837	A	19991116	US 1998-112249	19980708 <--
CA 2332641	A1	20000120	CA 1999-2332641	19990623 <--
WO 200002906	A1	20000120	WO 1999-US14099	19990623 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9947081	A	20000201	AU 1999-47081	19990623 <--
EP 1093460	A1	20010425	EP 1999-930569	19990623 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9911932	A	20011016	BR 1999-11932	19990623 <--
HU 2001003560	A2	20020228	HU 2001-3560	19990623 <--
HU 2001003560	A3	20020528		
JP 2002520335	T	20020709	JP 2000-559135	19990623 <--
NO 2001000046	A	20010302	NO 2001-46	20010104 <--
MX 2001000033	A	20010521	MX 2001-33	20010108 <--
US 20010018422	A1	20010830	US 2001-756593	20010108 <--
ZA 2001000169	A	20020108	ZA 2001-169	20010108 <--
PRIORITY APPLN. INFO.:				
			US 1998-112249	A 19980708 <--
			WO 1999-US14099	W 19990623 <--

OTHER SOURCE(S): MARPAT 131:337358

AB Dolastatin 15 derivs. A-B-D-E-F-G [A, B, D, E are certain amino acid residues; F is an aminocycloalkane-carboxylic acid residue; G is (un)substituted amino, hydrazido, aminoxy, oximato, arylalkyl, heteroarylalkyl, aryl, heteroaryl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonylalkyl, aminocarbonyl, alkylcarbonylalkyl, alkylcarbonyl, arylcarbonylalkyl, arylcarbonyl, alkylsulfinylalkyl, alkylsulfinyl, arylsulfinylalkyl, arylsulfinyl, alkylsulfonylalkyl, alkylsulfonyl, arylsulfonylalkyl, or arylsulfonyl] were prepared as anticancer agents. Thus, Me2Val-Val-MeVal-Pro-NHCH₂CH₂CONMe₂-2 (Me2Val = N,N-dimethylvaline, MeVal = N-methylvaline), prepared via amidation, showed IC₅₀ = 4 x 10⁻⁷ mol/L in a cytotoxicity assay using HT-29 colon carcinoma cells.

IT 1099579-20-0 1099579-75-5 1099580-16-1
 1099580-72-9 1099581-42-6 1099581-44-8
 1099581-46-0 1099581-49-3 1099581-50-6

RL: FRPH (Prophetic)


(Preparation of dolastatin 15 derivatives as anticancer agents)

RN 1099579-20-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1099581-42-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1099581-44-8 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1099581-46-0 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1099581-49-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1099581-50-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 24 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:511131 HCAPLUS Full-text

DOCUMENT NUMBER: 131:157643

TITLE: Preparation of hydrazones derivatives for treatment or prevention of diseases related to glucose metabolic pathways

INVENTOR(S): Jacobsen, Palle; Madsen, Peter; Westergaard, Niels

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940062	A1	19990812	WO 1999-DK53	19990203 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9926102	A	19990823	AU 1999-26102	19990203 <--
PRIORITY APPLN. INFO.:			DK 1998-159	A 19980205 <--
			US 1998-74001P	P 19980209 <--
			WO 1999-DK53	W 19990203 <--

OTHER SOURCE(S): MARPAT 131:157643


AB Hydrazone derivs. of formula R1R2C=NNR3R4 (I) or R1R2C=NN=CR3R4 (II) [R1-R4 = H, C1-8 alkyl, C3-8 cycloalkyl, OH, acyl, C1-6 alkoxy, NO2, cyano, (un)substituted carbonyl, (un)substituted amino, (un)substituted sulfonamide, (un)substituted (hetero)aryl, etc.; R1 and R2 or R3 and R4 may together form an (un)substituted hetero- or carbocycle], were prep'd for use as medicaments in therapy especially in the treatment of diseases related to glucose metabolic pathways. Specifically, claimed compds. I and II were prepared for use in the treatment or prevention of diseases of the endocrinol. system, preferably hyperglycemia, NIDDM, or diabetes, and for treatment of glycogen storage disease or hypoglycemia. Compns. of the invention are claimed to exhibit glucose-6-phosphatase inhibitory activity with IC50 values of less than 100 µM (no data). Thus, 4-chlorobenzaldehyde was added to N,N-dibenzylhydrazine in DMF followed by addition of tri-Et orthoformate to form N,N-dibenzyl-N'-(4-chlorobenzylidene)hydrazine, i.e., I (where R1 = H, R2 = C6H4-p-Cl, and R3 = R4 = CH2Ph), in 94% yield.

IT 73861-04-6P, 3-[(4-Methoxybenzylidene)amino]-2-phenyl-3H-quinazolin-4-one 106873-08-9P, 3-[(4-Dimethylaminobenzylidene)amino]-2-phenyl-3H-quinazolin-4-one 237403-40-6P, 3-[(Furan-3-ylmethylene)amino]-2-phenyl-3H-quinazolin-4-one 237403-41-7P, 2-(4-Bromophenyl)-3-[(3,4-dihydroxybenzylidene)amino]-3H-quinazolin-4-one RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TRQ (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydrazone derivs. for treatment or prevention of diseases of the endocrinol. system, preferably hyperglycemia, NIDDM, or diabetes, and for treatment of glycogen storage disease or hypoglycemia)


RN 73861-04-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-methoxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 106873-08-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-(dimethylamino)phenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 237403-40-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-furanylmethylene]amino]-2-phenyl- (CA INDEX NAME)



RN 237403-41-7 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-bromophenyl)-3-[[[3,4-dihydroxyphenyl)methylene]amino]- (CA INDEX NAME)



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 25 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1999:290179 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 131:31917
 TITLE: Synthesis of new quinazolin-4-ones of medicinal importance
 AUTHOR(S): Kawadkar, R. K.; Ghiya, B. J.
 CORPORATE SOURCE: Chemistry Department, Institute of Science, Nagpur, 440 001, India
 SOURCE: Asian Journal of Chemistry (1999), 11(2), 388-391
 CODEN: AJCHEW; ISSN: 0970-7077
 PUBLISHER: Asian Journal of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Some new quinazolin-4-ones have been synthesized using different amino compds., viz., ammonia, hydrazine hydrate, urea, thiourea, formamide, guanidine carbonate, etc., with benzoxazinones. Further condensations of these quinazolinones were carried out using piperazine-formaldehyde or Ph isothiocyanate. Significant antimicrobial activities were observed for some products.

IT 226879-18-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antibacterial activity of)


RN 226879-18-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3,3'-(1,4-piperazinediylbis(methyleneimino))bis[2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 26 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:285715 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 131:129961
 TITLE: Synthesis and reactions of 2-[2-(2,4,6-trimethylbenzoyl)vinyl]-4H-3,1-benzoxazin-4-one and antimicrobial activity
 AUTHOR(S): Abdel-Fattah, M. E.; Soliman, E. A.; Soliman, S. M. A.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Suez Canal University Ismailia, Cairo, Egypt
 SOURCE: Indian Journal of Heterocyclic Chemistry (1999), 8(3), 177-182
 CODEN: IJCHEI; ISSN: 0971-1627
 PUBLISHER: Prof. R. S. Varma
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:129961
 GI



AB β -(2,4,6-Trimethylbenzoyl)-acryloyl chloride reacts with anthranilic acid to give adduct I which is cyclized by the action of acetic anhydride to give the benzoxazinone II. Condensation of II with hydrazine hydrate gave pyrazole III. The behavior of III towards aromatic aldehydes, ketones, phthalic Anhydride, and amino acid chlorides has been investigated. Reaction of II with o-phenylenediamine, ammonia, Grignard reagents, Friedel-Crafts reaction and bromine has been described. Some of the compds. were tested for antibacterial activity; some were active against gram-neg. and gram-pos. bacterial.


IT 234103-34-5P 234103-36-7P 234103-46-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal activity of benzoxazinones and quinazolinones)


RN 234103-34-5 HCAPLUS

CN 4(3H)-Quinazolinone, 2-[[4,5-dihydro-3-(2,4,6-trimethylphenyl)-1H-pyrazol-5-yl]-3-[[4-methoxyphenyl)methylene]amino]- (CA INDEX NAME)




RN 234103-36-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methylene]amino]-2-[4,5-dihydro-3-(2,4,6-trimethylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RN 234103-40-3 HCAPLUS
 CN 4(3H)-Quinazolinone, 2-[4,5-dihydro-3-(2,4,6-trimethylphenyl)-1H-pyrazol-5-yl]-3-[(1-methylethylidene)amino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 27 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:41696 HCAPLUS Full-text

DOCUMENT NUMBER: 130:261484

TITLE: Synthesis and anti-HIV activity of some non-nucleoside 2,3-disubstituted quinazoline derivatives (part-V)
 AUTHOR(S): Desai, N. C.; Undavia, N. K.; Trivedi, P. B.; Dave, Dipika; Vyas, G. D.

CORPORATE SOURCE: Department of Chemistry, Bhavnagar University, Bhavnagar, 364 002, India

SOURCE: Indian Journal of Experimental Biology (1999), 36(12), 1280-1283
 CODEN: IJEBAA6; ISSN: 0019-5189

PUBLISHER: National Institute of Science Communication, CSIR

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several [2-phenyl-4(3H)-oxo-3-quinazolinylamino]-N-substituted- arylacetamides (1a-j) have been synthesized and tested at the National Cancer Institute, Bethesda, Maryland, USA, for their anti-HIV activity against susceptible human host cells (CEM cell line) over a wide range of concns. (6.35+10⁻⁸ to 2.00+10⁻⁴ M). The highest protection observed is 45.67%. The structures of these compds. have been established on the basis of elemental anal. and spectral data.

IT 222416-83-3P 222416-84-4P 222416-85-5P
 222416-86-6P 222416-87-7P 222416-88-8P
 222416-89-9P 222416-90-2P 222416-91-3P


222416-93-4P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(synthesis and anti-HIV activity of non-nucleoside disubstituted
quinazoline derivs. in relation to structure)


RN 222416-83-3 HCAPLUS

CN Acetamide, 2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-N-phenyl- (CA
INDEX NAME)




RN 222416-84-4 HCAPLUS

CN Acetamide, N-(4-methoxyphenyl)-2-[(4-oxo-2-phenyl-3(4H)-
quinazolinyl)amino]- (CA INDEX NAME)




RN 222416-85-5 HCAPLUS

CN Acetamide, 2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-N-(phenylmethyl)-
(CA INDEX NAME)




RN 222416-86-6 HCAPLUS

CN Acetamide, N-(2-methoxyphenyl)-2-[(4-oxo-2-phenyl-3(4H)-
quinazolinyl)amino]- (CA INDEX NAME)




RN 222416-87-7 HCAPLUS

CN Acetamide, N-(2,4-dimethylphenyl)-2-[(4-oxo-2-phenyl-3(4H)-
quinazolinyl)amino]- (CA INDEX NAME)




RN 222416-88-8 HCAPLUS

CN Acetamide, N-(2,5-dimethylphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)




RN 222416-89-9 HCAPLUS

CN Acetamide, N-(4-bromophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)




RN 222416-90-2 HCAPLUS

CN Acetamide, N-(2-chloro-4-nitrophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)




RN 222416-91-3 HCAPLUS

CN Acetamide, N-(2-chloro-5-nitrophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



RN 222416-92-4 HCAPLUS

CN Acetamide, N-(2,3-dimethyl-6-nitrophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 28 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:649561 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 130:38346

TITLE: Synthesis and anticonvulsant testing of some new 2-phenyl-6-iodo-3-substituted-4(3H)-quinazolinone derivatives

AUTHOR(S): Aziza, M. A. E.

CORPORATE SOURCE: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt

SOURCE: Al-Azhar Journal of Pharmaceutical Sciences (1987), 19, 129-135

CODEN: AAJFFT; ISSN: 1110-1644

PUBLISHER: Al-Azhar University, Faculty of Pharmacy

DOCUMENT TYPE: Journal

LANGUAGE: English


AB 6-Iodo-3-hydroxy-2-phenyl-4(3H)-quinazolinone was prepared. The salt of this compound was reacted with Et chloroacetate in DMF. By the reaction of the product with isopropylamine, n-hexylamine, 2-aminoethanol, n-butylamine, cyclohexylamine, n-propylamine, or hydrazine hydrate in DMF, the corresponding amides or hydrazides were obtained. Anticonvulsant activity of some of the new compds. was tested.

IT 216767-45-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and anticonvulsant testing of phenyliodoquinazolinones)

RN 216767-45-2 HCAPLUS

CN Acetic acid, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-, hydrazide (CA INDEX NAME)



IT 216767-39-4P 216767-41-8P 216767-44-1P


216767-46-3P 216767-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and anticonvulsant testing of phenyliodoquinazolinones)


RN 216767-39-4 HCAPLUS

CN Acetamide, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 216767-41-8 HCAPLUS

CN Acetamide, N-butyl-2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]- (CA INDEX NAME)




RN 216767-44-1 HCAPLUS

CN Acetamide, N-cyclohexyl-2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]- (CA INDEX NAME)




RN 216767-46-3 HCAPLUS

CN Acetic acid, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-, 2-[(4-methylphenyl)methylene]hydrazide (CA INDEX NAME)




RN 216767-47-4 HCAPLUS


CN Acetic acid, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-, 2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)




IT 216767-37-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and anticonvulsant testing of phenyliodoquinazolinones)
 RN 216767-37-2 HCAPLUS
 CN Acetic acid, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-, ethyl ester (CA INDEX NAME)




IT 216767-40-7P 216767-42-9P 216767-43-0P
 216767-48-5P 216767-49-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and anticonvulsant testing of phenyliodoquinazolinones)
 RN 216767-40-7 HCAPLUS
 CN Acetamide, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-N-propyl- (CA INDEX NAME)



RN 216767-42-9 HCAPLUS
 CN Acetamide, N-hexyl-2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]- (CA INDEX NAME)




RN 216767-43-0 HCAPLUS
 CN Acetamide, N-(2-hydroxyethyl)-2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]- (CA INDEX NAME)




RN 216767-48-5 HCAPLUS

CN Acetic acid, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]-, 2-[(2,4-dichlorophenyl)methylene]hydrazide (CA INDEX NAME)



RN 216767-49-6 HCAPLUS

CN Acetamide, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)oxy]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 29 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:424091 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:95502

ORIGINAL REFERENCE NO.: 129:19703a,19706a

TITLE: Preparation of fungicidal quinazolinones

INVENTOR(S): Bellina, Russell Frank; Bereznak, James Francis; Christensen, Joel Robert; Chang, Zen-Yu; Fawzi, Maged Mohamed; Marshall, Eric Allen; Moberg, William Karl; Rorer, Morris Padgett; Sternberg, Charlene Gross; Walker, Michael Paul; Zimmerman, William Thomas

PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826664	A1	19980625	WO 1997-US22779	19971215 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

BR 9714222 A 20000418 BR 1997-14222 19971211 <--
AU 9853803 A 19980715 AU 1998-53803 19971215 <--
EP 946095 A1 19991006 EP 1997-950927 19971215 <--

R: CH, DE, FR, GB, IT, LI

JP 2002513394 T 20020508 JP 1998-527831 19971215 <--


PRIORITY APPLN. INFO.: US 1996-33657P P 19961217 <--

US 1997-41964P P 19970403 <--

WO 1997-US22779 W 19971215 <--

OTHER SOURCE(S): MARPAT 129:95502

GI




AB The title compds. [I; R3 = Cl, Br, I, C1-8 alkyl, etc.; R4 = H, Cl, Br, I, etc.; when R3 and R4 are on adjacent atoms they can be OC(R16)20; W = O, S, SO, etc.; Q = O, S; R1 = C1-10 alkyl, C3-6 cycloalkyl, C3-10 cycloalkenyl, etc.; R2 = C1-10 alkyl, C3-7 cycloalkyl, C3-10 cycloalkenyl, etc.; R16 = H, halo, C1-4 alkyl, C1-6 haloalkyl; R19 = Cl, Br, I], useful for controlling plant diseases caused by fungal plant pathogens, were prepared Thus, treatment of 6-iodo-3-n-propyl-2-thio-4(3H)-quinazolinone with phosgene in Pr acetate afforded I [R1 = n-Pr; W = direct bond; R2 = Cl; R3 = 6-I; R4 = R19 = H] which showed 99% control against Erysiphe graminis f. sp. tritici at 200 ppm.

IT 209604-45-5P

RL: AGR (Agricultural use); EAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fungicidal quinazolinones)

RN 209604-45-5 HCAPLUS

CN 4(3H)-Quinazolinone, 6-bromo-3-ethoxy-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L85 ANSWER 30 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:2088 HCAPLUS Full-text

DOCUMENT NUMBER: 128:114924


ORIGINAL REFERENCE NO.: 128:22536h,22537a

TITLE: Synthesis and chemistry of some novel
3-heteroaryl-quinazolin-4-one derivatives and their
antimicrobial effects
AUTHOR(S): Abdel-Hamide, S. G.
CORPORATE SOURCE: Pharm. Chem. Dep., Fac. of Pharm., Al-Azhar Univ.,
Cairo, Egypt
SOURCE: Journal of the Indian Chemical Society (1997
) , 74(8), 619-623
CODEN: JICSAH; ISSN: 0019-4522
PUBLISHER: Indian Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:114924
GI




AB Some new heteroaryl-quinazolin-4-ones, e.g. I (X = H, 4-Cl, 4-Br, 4-F, 4-Me, 4-NMe₂, 4-OH, 2,3-Cl₂), have been synthesized via the interaction of 3-amino-2-phenyl-6-iodoquinazolin-4-one with some oxo-compds. Significant in vitro antimicrobial activities have been observed for some members of the series.

IT 201731-94-4P 201731-95-5P 201731-97-7P
201732-00-5P 201732-01-6P 201732-02-7P
201732-03-8P 201732-04-9P 201732-24-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 201731-94-4 HCAPLUS
CN 4(3H)-Quinazolinone, 6-iodo-3-[[4-(methylphenyl)methylene]amino]-2-phenyl-
(CA INDEX NAME)




RN 201731-95-5 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[[[4-(dimethylamino)phenyl]methylene]amino]-6-iodo-2-phenyl-
(CA INDEX NAME)




RN 201731-97-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(3,4-dichlorophenyl)methylene]amino]-6-iodo-2-phenyl- (CA INDEX NAME)




RN 201732-00-5 HCAPLUS

CN Benzeneacetonitrile, 2,4-dichloro- α -[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)


RN 201732-01-6 HCAPLUS

CN 4(3H)-Quinazolinone, 3-(2-buten-1-ylideneamino)-6-iodo-2-phenyl- (CA INDEX NAME)




RN 201732-02-7 HCAPLUS

CN 4(3H)-Quinazolinone, 6-iodo-2-phenyl-3-[(3-phenyl-2-propen-1-ylidene)amino]- (CA INDEX NAME)




RN 201732-03-8 HCAPLUS


CN 4(3H)-Quinazolinone, 6-iodo-2-phenyl-3-[(2-pyridinylmethylene)amino]- (CA INDEX NAME)




RN 201732-04-9 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-iodo-2-phenyl-3-[(2-thienylmethylene)amino]- (CA INDEX NAME)




RN 201732-24-3 HCAPLUS
 CN Ethanedioic acid, 1-ethyl ester, 2-[2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]methylene]hydrazide] (CA INDEX NAME)



IT 201731-90-0P 201731-96-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and chemical of novel heteroaryl quinazolinone derivs. and antimicrobial effects)
 RN 201731-90-0 HCAPLUS
 CN 4(3H)-Quinazolinone, 6-iodo-2-phenyl-3-[(phenylmethylene)amino]- (CA INDEX NAME)



RN 201731-96-6 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(4-hydroxyphenyl)methylene]amino]-6-iodo-2-phenyl- (CA INDEX NAME)




IT 201731-91-1P 201731-92-2P 201731-93-3P

201732-17-4P 201732-18-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and chemical of novel heteroaryl quinazolinone derivs. and antimicrobial effects)


RN 201731-91-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methylene]amino]-6-iodo-2-phenyl- (CA INDEX NAME)




RN 201731-92-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-bromophenyl)methylene]amino]-6-iodo-2-phenyl- (CA INDEX NAME)




RN 201731-93-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-fluorophenyl)methylene]amino]-6-iodo-2-phenyl- (CA INDEX NAME)




RN 201732-17-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)thio]methyl]amino]-6-iodo-2-phenyl- (CA INDEX NAME)



RN 201732-18-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-chlorophenyl)thio](4-fluorophenyl)methyl]amino]-6-iodo-2-phenyl- (CA INDEX NAME)




IT 201731-89-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and chemical of novel heteroaryl quinazolinone derivs. and antimicrobial effects)

RN 201731-89-7 HCAPLUS

CN Formamide, N-(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)- (CA INDEX NAME)




IT 201732-20-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and chemical of novel heteroaryl quinazolinone derivs. and antimicrobial effects)

RN 201732-20-9 HCAPLUS

CN Methanimidamide, N-(2-hydroxyethyl)-N'-(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 31 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:2043 HCAPLUS Full-text

DOCUMENT NUMBER: 128:88872

ORIGINAL REFERENCE NO.: 128:17361a,17364a

TITLE: Synthesis of some new heterocyclic systems bearing 2-phenyl-6-iodo-4(3H)-quinazolinon-3-yl moiety as antibacterial agents

AUTHOR(S): Abdel-Hamide, S. G.

CORPORATE SOURCE: Pharm. Chem. Dep., Al-Azhar Univ., Cairo, Nasr City, Egypt

SOURCE: Journal of the Indian Chemical Society (1997), 74(8), 613-618

CODEN: JICSAH; ISSN: 0019-4522

PUBLISHER: Indian Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A number of heterobicyclic systems bearing 2-phenyl-6-iodo-4(3H)-quinazolinon-3-yl moiety have been synthesized by interaction of 3-amino-3-phenyl-6-iodo-4(3H)-quinazolinone with bifunctional compds. followed by cyclization in different media. Some of the compds. possess high activity against bacteria.


IT 200947-76-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of new heterocyclic systems bearing phenyliodoquinazolinonyl moiety as antibacterial agents)

RN 200947-76-8 HCAPLUS

CN Acetic acid, 2-[(6-iodo-4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 32 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:218276 HCAPLUS Full-text

DOCUMENT NUMBER: 126:317357

ORIGINAL REFERENCE NO.: 126:61569a,61572a

TITLE: Synthesis and antimicrobial activity of some bis(quinazoline) derivatives

AUTHOR(S): Shiba, S. A.; El-Khamry, A. A.; Shaban, M. E.; Atia, K. S.

CORPORATE SOURCE: Faculty Science, Ain Shams University, Cairo, Egypt

SOURCE: Pharmazie (1997), 52(3), 189-194


CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




I

AB Bis[quinazolin-4-on-2-yl]-1,3-phenylene (I) and its 3-N-substituted derivs. were prepared from the corresponding bis[3,1-benzoxazin-4-on-2-yl]-1,3-phenylene as precursor. Quinazolinone I was converted into several derivs. such as bis[quinazolin-4-thioxo-2-yl]-, bis[4-chloroquinazolin-2-yl]-, and bis[4-hydrazinoquinazolin-2-yl]-1,3-phenylene. Some of the prepared compds. show activity against Gram-pos. and Gram-neg. bacteria and yeasts.

IT 189294-30-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of bis-quinazolines)

RN 189294-30-2 HCAPLUS

CN 4(3H)-Quinazolinone, 2,2'-(1,3-phenylene)bis[3-[(4-methoxyphenyl)methylene]amino]- (CA INDEX NAME)



L85 ANSWER 33 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:762413 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 126:42418

ORIGINAL REFERENCE NO.: 126:8221a,8224a

TITLE: Synthesis and antiinflammatory activity of certain thienopyrimidine derivatives

AUTHOR(S): El-Kerdawy, M. M.; Yousif, M. Y.; El-Emam, A. A.; Moustafa, M. A.; El-Sherbeny, M. A.

CORPORATE SOURCE: Dep. Med. Chem., Univ. Mansoura, Mansoura, 35516, Egypt

SOURCE: Bollettino Chimico Farmaceutico (1996), 135(5), 301-305

CODEN: BCFAAI; ISSN: 0006-6648

PUBLISHER: Societa Editoriale Farmaceutica

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Interaction of Et 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3- carboxylate with 2-thiophene carbonyl chloride afforded Et 2-(2-thenoylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate which upon cyclization yielded 2-(2-thienyl)-5,6,7,8-tetrahydrobenzo[b]- thieno[2,3-d]-4H-3,1-oxazin-4-one and 2-(2-thienyl)-3-amino-5,6,7,8-tetrahydrobenzo-[b]thieno[2,3-d]-3,4-


dihydropyrimidin-4-one. Some of the prepared compds. were screened for their antiinflammatory activity and several showed significant activity.

IT 184906-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and antiinflammatory activity of certain thienopyrimidine derivs.)

RN 184906-73-8 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[(4-chlorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)-
(CA INDEX NAME)



IT 184906-71-6P 184906-72-7P 184906-74-9P

184906-75-0P 184906-76-1P 184906-77-2P


184906-78-3P 184906-79-4P 184906-82-9P

184906-84-1P 184906-67-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and antiinflammatory activity of certain thienopyrimidine derivs.)


RN 184906-71-6 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[(4-fluorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)-
(CA INDEX NAME)




RN 184906-72-7 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[[(4-bromophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)- (CA
INDEX NAME)




RN 184906-74-9 HCAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one,
3-[[3,4-dichlorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)-
(CA INDEX NAME)




RN 184906-75-0 HCAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[[4-methoxyphenyl)methylene]amino]-2-(2-thienyl)-
(CA INDEX NAME)




RN 184906-76-1 HCAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one,
3-[[3,4-dimethoxyphenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)-
(CA INDEX NAME)




RN 184906-77-2 HCAPLUS

CN [1]Benzo[thieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[[4-nitrophenyl)methylene]amino]-2-(2-thienyl)-
(CA INDEX NAME)




RN 184906-78-3 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[(6-nitro-1,3-benzodioxol-5-yl)methylene]amino]-2-(2-
thienyl)- (CA INDEX NAME)




RN 184906-79-4 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-3-[(2-methoxy-1-naphthalenyl)methylene]amino]-2-(2-
thienyl)- (CA INDEX NAME)




RN 184906-82-9 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
5,6,7,8-tetrahydro-2-(2-thienyl)-3-[(2-thienylmethylene)amino]- (CA INDEX
NAME)




RN 184906-84-1 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[(2-furanyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)- (CA INDEX
NAME)



RN 184906-87-4 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrimidin-4(3H)-one,
3-[(2-chlorophenyl)methylene]amino]-5,6,7,8-tetrahydro-2-(2-thienyl)-
(CA INDEX NAME)



L85 ANSWER 34 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:995215 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 124:117098

ORIGINAL REFERENCE NO.: 124:21809a,21812a

TITLE: Preparation of pyridylanilide derivatives as
fungicides

INVENTOR(S): Riordan, Peter Dominic; Boddy, Ian Kenneth; Osbourn,
Susan Elisabeth

PATENT ASSIGNEE(S): Agrevo UK Ltd., UK

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9525723	A1	19950928	WO 1995-GB570	19950316 <--
W:	AU, BG, BR, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RO, RU, SD, SK, UA, US			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9518981	A	19951009	AU 1995-18981	19950316 <--
AU 688473	B2	19980312		
EP 750611	A1	19970102	EP 1995-911403	19950316 <--
EP 750611	B1	19980708		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			

CN 1143954	A	19970226	CN 1995-192131	19950316 <--
HU 74778	A2	19970228	HU 1996-2547	19950316 <--
HU 214292	B	19980302		
BR 9507105	A	19970909	BR 1995-7105	19950316 <--
JP 09510471	T	19971021	JP 1995-524455	19950316 <--
AT 168099	T	19980715	AT 1995-911403	19950316 <--
ZA 9502205	A	19951031	ZA 1995-2205	19950317 <--
US 5756524	A	19980526	US 1996-714149	19960918 <--
PRIORITY APPLN. INFO.:			GB 1994-5347	A 19940318 <--
			WO 1995-GB570	W 19950316 <--
OTHER SOURCE(S):	MARPAT 124:117098			
GI				




AB Title compds. I [X = O, S; R1, R2 = H, alkyl, cycloalkyl, alkenyl, etc.; R3 = (substituted) pyridyl, pyrimidinyl, pyrazinyl, etc.] were prepared. Condensation of 6-methoxynicotinoyl chloride with Me anthranilate in the presence of Et3N in THF afforded I (X = O; R1 = R2 = H; R3 = 6-methoxy-3-pyridyl) which showed activity against barley powdery mildew, rice blast and apple scab at ≤ 500 ppm.

IT 173055-91-9P 173056-97-8P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of anilide derivs. as fungicides)


RN 173055-91-9 HCAPLUS

CN 3-Pyridinecarboxamide, 6-methoxy-N-[2-[(methoxyamino)carbonyl]phenyl]- (CA INDEX NAME)



RN 173056-97-8 HCAPLUS

CN Benzoic acid, 2-[[[(6-methoxy-3-pyridinyl)carbonyl]amino]-, 2-(1-methylethylidene)hydrazide (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 35 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:994818 HCAPLUS Full-text

DOCUMENT NUMBER: 124:117591

ORIGINAL REFERENCE NO.: 124:21913a, 21916a

TITLE: Preparation and formulation of quinazolinonylbenzylphosphonic acid diester derivatives as hypolipemics, antihypertensives, and antidiabetics

INVENTOR(S): Kuroki, Yasuhisa; Miyata, Kazuyoshi; Tsuda, Yoshihiko; Inoue, Yasuhide; Kanaya, Jun; Sato, Keigo
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524410	A1	19950914	WO 1995-JP303	19950227 <--
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08143586	A	19960604	JP 1995-35261	19950223 <--
JP 3533542	B2	20040531		
CA 2184891	A1	19950914	CA 1995-2184891	19950227 <--
CA 2184891	C	20000926		
AU 9518244	A	19950925	AU 1995-18244	19950227 <--
AU 679344	B2	19970626		
EP 749974	A1	19961227	EP 1995-909996	19950227 <--
EP 749974	B1	20010627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1147257	A	19970409	CN 1995-192824	19950227 <--
CN 1066739	C	20010606		
AT 202567	T	20010715	AT 1995-909996	19950227 <--
TW 379225	B	20000111	TW 1995-84102161	19950307 <--
US 5798344	A	19980825	US 1996-704740	19960905 <--
PRIORITY APPLN. INFO.:				
			JP 1994-37361	A 19940308 <--
			JP 1994-126526	A 19940608 <--
			JP 1994-251484	A 19940919 <--
			WO 1995-JP303	W 19950227 <--

OTHER SOURCE(S): MARPAT 124:117591

GI



AB The title compds. I [R1, R2, R3 and R6 represent each independently hydrogen, lower alkyl, halogen, nitro, etc.; R4 represents Ph, lower alkyl, phenylalkyl, etc.; R5 represents lower alkyl; R7 represents lower alkoxy, hydroxy, Ph, or phenylated lower alkoxy or lower alkylamino wherein the Ph group may be halogenated; X1 and X2 represent each oxygen or sulfur; A represents oxygen or a single bond; and Z represents lower alkylene] are prepared The title compound II [R1 = F; R2 = H] at 100 mg/Kg orally decreased blood glucose in rats by 50%. The title compound II [R1 = H; R2 = Br] at 100 mg/Kg orally decreased plasma triglycerides in rats by 35%.


IT 173019-00-6P 173019-01-7P 173019-02-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazolinonylbenzylphosphonic acid diester derivs. as hypolipemics, antihypertensives, and antidiabetics)


RN 173019-00-6 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(phenylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 173019-01-7 HCAPLUS

CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-3-[[4-methoxyphenyl]methylene]amino]-4-oxo-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 173019-02-8 HCAPLUS
 CN Phosphonic acid, [[4-[7-chloro-3,4-dihydro-4-oxo-3-[(2-pyridinylmethylene)amino]-2-quinazolinyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 36 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:727893 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 123:339972

ORIGINAL REFERENCE NO.: 123:61015a,61018a

TITLE: Synthetic approaches and biological evaluation of some new sulfonate ester-containing quinazoline derivatives as potentially active antimicrobial agents

AUTHOR(S): Habib, O. M.; Girges, M. M.; Moawad, E. B.; El-Shafei, A. M.

CORPORATE SOURCE: Mansoura Faculty Science, Mansoura University, Mansura, 35516, Egypt

SOURCE: Bollettino Chimico Farmaceutico (1995), 134(4), 209-15

CODEN: BCFAAI; ISSN: 0006-6648

PUBLISHER: Societa Editoriale Farmaceutica

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several sulfonate ester-containing quinazolinone derivs. that are substituted with isolated or fused, aryl, hetaryl or hetarylphenyl ring systems were synthesized with a view to evaluate their efficacy as new bactericidal and/or fungicidal agents. Synthesis of these products involved prior preparation of the 2-[4'-(benzenesulfonyloxy)phenyl]-3,1,4(H)-benzoxazin-4-one derivative and subsequent reaction with several nitrogen nucleophiles. Most of the prepared compds. showed high antimicrobial activity, comparable to standard chemotherapeutic agents, when screened against different microorganisms.

IT 170876-06-9P 170876-07-0P 170876-08-1P

170876-09-2P 170876-10-5P


RL: EAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and bactericidal and fungicidal activity of sulfonate ester-containing quinazoline derivs.)


RN 170876-06-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(phenylmethylene)amino]-2-[4-(phenylsulfonyl)oxy]phenyl)- (CA INDEX NAME)




RN 170876-07-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methylene]amino]-2-[4-(phenylsulfonyl)oxy]phenyl)- (CA INDEX NAME)





RN 170876-08-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-nitrophenyl)methylene]amino]-2-[4-(phenylsulfonyl)oxy]phenyl)- (CA INDEX NAME)





RN 170876-09-2 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(3-nitrophenyl)methylene]amino]-2-[4-(phenylsulfonyl)oxy]phenyl)- (CA INDEX NAME)



RN 170876-10-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(4-methoxyphenyl)methylene]amino]-2-[4-(phenylsulfonyl)oxy]phenyl]- (CA INDEX NAME)



L85 ANSWER 37 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:612182 HCAPLUS Full-text

DOCUMENT NUMBER: 123:198652

ORIGINAL REFERENCE NO.: 123:35461a,35464a

TITLE: Synthesis of certain benzoxazine and quinazoline

derivatives as potential antiinflammatory agents

AUTHOR(S): Kerdawy, M. M. El; Yousif, M. Y.; Emam, A. A. El;

Moustafa, M. A.; El-Sherbeny, M. A.

CORPORATE SOURCE: Faculty Pharmacy, University Mansoura, Mansura, Egypt

SOURCE: Egyptian Journal of Pharmaceutical Sciences (

1994), 35(1-6), 1-20

CODEN: EJPSBZ; ISSN: 0301-5068

PUBLISHER: National Information and Documentation Centre

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Substituted 2-(2-thienyl)-4H-3,1-benzoxazin-4-ones have been synthesized.

Aminolysis of these compds. was achieved using 1-methylpiperazine, n-

propylamine, hydroxylamine hydrochloride, p-anisidine, p-phenetidine,

hydrazine hydrate, and ammonium acetate. Also prepared were

tetrazoloquinazoline, triazoloquinazoline, and

(thenyldenehydrazino)quinazoline derivs. Antiinflammatory screening for some

compds. were carried out.


IT 167995-27-3P 167995-28-6P

RL: SPN (Synthetic preparation); PREP (Preparation)


(synthesis and antiinflammatory activity of benzoxazine and quinazoline

derivs.)

RN 167995-27-9 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-thienylcarbonyl)amino]-,
2-[(4-fluorophenyl)methylene]hydrazide (CA INDEX NAME)

RN 167995-28-0 HCAPLUS

CN Benzoic acid, 5-chloro-2-[(2-thienylcarbonyl)amino]-,
2-[(4-bromophenyl)methylene]hydrazide (CA INDEX NAME)

L85 ANSWER 38 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:388996 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 123:33013

ORIGINAL REFERENCE NO.: 123:6103a,6106a

TITLE: Synthesis of 2,3-disubstituted-3,1-quinoxalin-4(4H)-
ones as potential anticancer and anti-HIV agents
AUTHOR(S): Shah, B. R.; Bhatt, J. J.; Patel, H. H.; Undavia, N.
K.; Trivedi, P. B.; Desai, N. C.CORPORATE SOURCE: Department Chemistry, Bhavnagar University, Bhavnagar,
364 002, IndiaSOURCE: Indian Journal of Chemistry, Section B: Organic
Chemistry Including Medicinal Chemistry (1995
) , 34B(3), 201-8

CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: Publications & Information Directorate, CSIR

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:33013

AB Several 3-(4,5-dihydro-4-arylidene-5-oxo-2-phenyl-1H-imidazol-1-yl)-2- phenyl-4(3H)-oxoquinazolines, [2-phenyl-4(3H)-oxo-3-quinazolinylamino]-N-substituted-arylacetamides, N1-(4-[4(3H)-oxo-2-phenylquinazolin-3-yl]aminocarbophenyl)-N2-alkyl/arylthiouras, N1-[4(3H)-oxo-2-phenylquinazolin-3-yl]-N2-arylthiouras, and N1-(4-[4(3H)-oxo-2-phenylquinazolin-3-yl]aminocarbophenyl)-N2- carboaryl/aryloxythiouras have been synthesized and tested for their antibacterial, antitubercular, anticancer and anti-HIV activities. The structures of these compds. have been established on the basis of elemental analyses and spectral data.

IT 164296-61-1P 164296-62-2P 164296-63-3P

164296-64-4P 164296-65-5P 164296-66-6P


164296-67-7P 164296-68-8P 164296-69-9P
 164296-70-2P 164296-71-3P 164296-72-4P
 164296-73-5P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)

(synthesis of disubstituted quinazolinones as potential antibacterial,
 antitubercular, anticancer and anti-HIV agents)


RN 164296-61-1 HCAPLUS

CN Acetamide, N-(2-chlorophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
 (CA INDEX NAME)




RN 164296-62-2 HCAPLUS

CN Acetamide, N-(3-chlorophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
 (CA INDEX NAME)




RN 164296-63-3 HCAPLUS

CN Acetamide, N-(4-chlorophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
 (CA INDEX NAME)




RN 164296-64-4 HCAPLUS

CN Acetamide, N-(2-nitrophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
 (CA INDEX NAME)




RN 164296-65-5 HCAPLUS

CN Acetamide, N-(3-nitrophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
 (CA INDEX NAME)




RN 164296-66-6 HCAPLUS


CN Acetamide, N-(4-nitrophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
(CA INDEX NAME)

RN 164296-67-7 HCAPLUS


CN Acetamide, N-(3-methoxyphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



RN 164296-68-8 HCAPLUS


CN Acetamide, N-(4-methylphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
(CA INDEX NAME)

RN 164296-69-9 HCAPLUS

CN Acetamide, N-(2-methylphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
(CA INDEX NAME)


RN 164296-70-2 HCAPLUS

CN Acetamide, N-(3-methylphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
(CA INDEX NAME)




RN 164296-71-3 HCAPLUS

CN Acetamide, N-(4-ethoxyphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]-
(CA INDEX NAME)




RN 164296-72-4 HCAPLUS

CN Acetamide, N-(2,4-dichlorophenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



RN 164296-73-5 HCAPLUS

CN Acetamide, N-(2,6-dimethylphenyl)-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



L85 ANSWER 39 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:409333 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 121:9333

ORIGINAL REFERENCE NO.: 121:1977a,1980a

TITLE: Chemistry and cyclization reactions of
3-aminothienoquinoxaline-2-carbohydrazide and
derivatives. Part II

AUTHOR(S): Badr, M. Z. A.; Maghoub, S. A.; Moustafa, O. S.; Abd
El-Latif, F. M.

CORPORATE SOURCE: Fac. Sci., Assiut Univ., Assiut, Egypt

SOURCE: Journal of the Chemical Society of Pakistan (

1993), 15(4), 264-9

CODEN: JCSPDF; ISSN: 0253-5106


DOCUMENT TYPE:

Journal

LANGUAGE:

English

GI




AB Condensation of 3-aminothieno[2,3-b]quinoxaline-2-carbohydrazide I (R = R₁ = H) with ArCHO (Ar = Ph, 4-MeOC₆H₄, 4-O₂NC₆H₄) give the corresponding 2-arylidenehydrazocarbonyl derivs. I (RR₁ = CHAr) (II). Treatment of II with benzoylchloride gave cyclocondensation products 2-phenyl-3-(arylidene amino)pyrimido[4',5':4,5]thieno[2,3-b]quinoxaline-4-ones III (R₂ = Ph). Also, II cyclize by refluxing with acetic anhydride to give the corresponding 2-methyl-3-(arylideneamino)pyrimidohienoquinoxalinones III (R₂ = Me). Acetylation of I (R = R₁ = H) with glacial acetic acid gives the corresponding 2-(β-N-acetyl hydrazo carbonyl) derivative I (R = H, R₁ = COMe).

IT 155303-45-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antimicrobial activity of)

RN 155303-45-0 HCAPLUS

CN Pyrimido[4',5':4,5]thieno[2,3-b]quinoxalin-4(3H)-one, 2-phenyl-3-[(phenylmethylene)amino]- (CA INDEX NAME)



L85 ANSWER 40 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:233993 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 118:233993

ORIGINAL REFERENCE NO.: 118:40531a,40534a

TITLE: Synthesis of some biologically active heterocycles. Reactions of the hydrazide of 2'-thienoylanthranilic acid and its 3,5-dibromo derivative

AUTHOR(S): Abdel-Hamid, Hoda A.; Shiba, Sayed A.; El-Khamry, Abdel Momen A.; Youssef, Ahmed S. A.

CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt


SOURCE: Phosphorus, Sulfur and Silicon and the Related

Elements (1992), 72(1-4), 237-47
 CODEN: PSSLEC; ISSN: 1042-6507
 Journal
 English
 CASREACT 118:233993


DOCUMENT TYPE:
 LANGUAGE:
 OTHER SOURCE(S):
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


- AB The hydrazide of 2-thienoylanthranilic acid and its 3,5-dibromo derivative were condensed with CS2 to give 1-(3-quinazolinyl)-2-thiono-5-(2-aminophenyl)-1,3,4-triazoles I (R = H, Br). When compds. I were treated with acetyl chloride, 3-N-acetamidoquinazolin-4-ones II (R = H, Br; R1 = 2-thienyl throughout this abstract) were formed. With aromatic aldehydes ArCHO (Ar = Ph, p-MeOC6H4, p-ClC6H4, p-O2NC6H4), the Schiff bases III and IV (R = H, Br, same Ar and R1 for both) were prepared. Reaction of I with potassium thiocyanate and Ph isothiocyanate gave semicarbazide derivs. while ammonium thiocyanate afforded the triazolethiones V (R = H, Br). Reaction of I with Et acetoacetate gave the pyrazole derivs. VI (R = H, Br); a dimethylpyrazole compound was formed from reaction of I (R = H) with acetylacetone. Eleven compds. were screened for their possible antibacterial activity against gram-pos. *Bacillus subtilis* and gram-neg. *Escherichia coli*. Only five of the compds. possessed antibacterial activity, two of them against both species.
- IT 126590-86-5P 120590-87-6P 120590-88-7P
 147435-61-8P 147435-62-9P 147435-65-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)
- RN 120590-86-5 HCAPLUS
- CN Benzoic acid, 2-[(2-thienylcarbonyl)amino]-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)




- RN 120590-87-6 HCAPLUS
- CN Benzoic acid, 2-[(2-thienylcarbonyl)amino]-, 2-[(4-methoxyphenyl)methylene]hydrazide (CA INDEX NAME)




RN 120590-88-7 HCAPLUS

CN Benzoic acid, 2-[(2-thienylcarbonyl)amino]-,
2-[(4-chlorophenyl)methylene]hydrazide (CA INDEX NAME)


RN 147435-61-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-methoxyphenyl)methylene]amino]-2-(2-thienyl)-
(CA INDEX NAME)


RN 147435-62-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-chlorophenyl)methylene]amino]-2-(2-thienyl)-
(CA INDEX NAME)


RN 147435-65-2 HCAPLUS

CN Benzoic acid, 2-[(2-thienylcarbonyl)amino]-,
2-[(4-nitrophenyl)methylene]hydrazide (CA INDEX NAME)


ACCESSION NUMBER: 1992:511567 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 117:111567
 ORIGINAL REFERENCE NO.: 117:19471a,19474a
 TITLE: Synthesis and biological activities of
 3-[N-(4-oxo-2-substituted-3-quinazolinyl)formimidoyl]chromones.
 AUTHOR(S): Achaliah, G.; Reddy, V. Malla
 CORPORATE SOURCE: Univ. Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506
 009, India
 SOURCE: Indian Journal of Pharmaceutical Sciences (1991), 53, 253-5
 CODEN: IJSIDW; ISSN: 0250-474X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A condensation of 4 different 3-formylchromones I (R1 = H, R2 = H, Cl, Me; R1 = Me, R2 = Cl) with 3-amino-4(3H)-quinazolinones II (R3 = Me, Ph, R4 = H; R3 = Me, R4 = Br) resulted in 12 new compds., which were characterized as 3-[N-(4-oxo-3-quinazolinyl)formimidoyl]chromones III, based on spectro-anal. properties. I were found to exhibit promising antibacterial and antifungal properties.
 IT 142917-61-1P 142917-62-2P 142917-63-3P
 142917-64-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 142917-61-1 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-oxo-4H-1-benzopyran-3-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 142917-62-2 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[6-chloro-4-oxo-4H-1-benzopyran-3-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 142917-63-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(6-methyl-4-oxo-4H-1-benzopyran-3-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)



RN 142917-64-4 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[(6-chloro-5-methyl-4-oxo-4H-1-benzopyran-3-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)



L85 ANSWER 42 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:122242 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 114:122242

ORIGINAL REFERENCE NO.: 114:20821a, 20824a

TITLE: Non-steroidal antiinflammatory agents. III: Synthesis of pyrazole derivatives of 4(3H)-quinazolinones

Farghaly, Ahmed M.; Chaaban, Ibrahim; Khalil, Mounir A.; Bekhit, Adnan A.

CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt

SOURCE: Alexandria Journal of Pharmaceutical Sciences (1996), 4(1), 52-6


CODEN: AJPSER; ISSN: 1110-1792

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:122242

GI




II




III


- AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methinamino, ethenyl, iminomethyl, aminomethyl or methinehydrazino grouping. Thus, acetanthranil (I) was treated with aminoantipyrine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.
- IT 132088-37-0P 132088-39-2P 132088-40-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
- RN 132088-37-0 HCAPLUS
- CN 4(3H)-Quinazolinone, 3-[[[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)




- RN 132088-39-2 HCAPLUS
- CN 4(3H)-Quinazolinone, 3-[[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)




- RN 132088-40-5 HCAPLUS
- CN 4(3H)-Quinazolinone, 3-[[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (CA INDEX NAME)



L85 ANSWER 43 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1987:102212 HCAPLUS Full-text
 DOCUMENT NUMBER: 106:102212
 ORIGINAL REFERENCE NO.: 106:16747a,16750a
 TITLE: Synthesis and biological activities of
 3-(2-aryl-4-oxothiazolidin-3-yl)-2-phenylquinazolin-
 4(3H)-ones
 AUTHOR(S): Husain, M. I.; Shukla, Sarveshwar
 CORPORATE SOURCE: Chem. Dep., Lucknow Univ., Lucknow, 226 007, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic
 Chemistry Including Medicinal Chemistry (1986
), 25B(5), 545-8
 CODEN: IJSBDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106:102212
 GI



I



II


AB The title compds. I (R = substituted Ph) were prepared in 62-74% yield by cyclization of the benzylideneaminoquinazolines II with HSCH₂CO₂H. I were screened for possible antibacterial activity and central nervous system activity on albino mice. Some chemical leads towards structure-activity relationship were established.

IT 56158-76-0P 106873-08-9P 106873-13-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and cyclization with mercaptoacetic acid)


RN 56158-76-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-nitrophenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 106873-08-9 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[[4-(dimethylamino)phenyl]methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 106873-13-6 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(4-fluorophenyl)methylene]amino]-2-phenyl- (CA
 INDEX NAME)




IT 73861-05-9P 73861-06-0P 76716-06-8P
 106873-11-4P 106873-12-5P 106873-14-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, cyclization with mercaptoacetic acid, and bactericidal
 activity of)


RN 73861-05-9 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(4-methylphenyl)methylene]amino]-2-phenyl- (CA
 INDEX NAME)




RN 73861-06-0 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(2-hydroxyphenyl)methylene]amino]-2-phenyl- (CA
 INDEX NAME)



RN 76716-06-8 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(3,4-dimethoxyphenyl)methylene]amino]-2-phenyl-
 (CA INDEX NAME)




RN 106873-11-4 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[[(2-fluorophenyl)methylene]amino]-2-phenyl- (CA
 INDEX NAME)




RN 106873-12-5 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-fluorophenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 106873-14-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-nitrophenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)

IT 56158-77-1P 73861-04-8P 106873-09-0P
106873-10-3PRL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, cyclization with mercaptoacetic acid, and bactericidal and central nervous system activity of)


RN 56158-77-1 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-hydroxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 73861-04-8 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-methoxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




RN 106873-09-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(3-hydroxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)



RN 106873-10-3 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(4-hydroxy-3-methoxyphenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)




IT 73861-03-7F

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, cyclization with mercaptoacetic acid, and central nervous system activity of)

RN 73861-03-7 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[(2-chlorophenyl)methylene]amino]-2-phenyl- (CA INDEX NAME)



L85 ANSWER 44 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:120999 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 100:120999


ORIGINAL REFERENCE NO.: 100:18413a,18416a

TITLE: Synthesis of some N1-(2'-alkyl or aryl-6',8'-substituted quinazolinone-3'-ylaminoacetyl)-N3-arylsureas and their in vivo action on cecal amebiasis of rats
Misra, V. S.; Saxena, V. K.; Srivastava, Rashmi
Dep. Chem., Univ. Lucknow, Lucknow, 226 007, India


AUTHOR(S):

CORPORATE SOURCE:


SOURCE: Journal of the Indian Chemical Society (1983
, 60(6), 610-11
CODEN: JICSAH; ISSN: 0019-4522
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB The title compds. I [X = NNHCH₂CONHCONHC₆H₄R₃ (II); R = Me, Ph; R₁, R₂ = H, Br; R₃ = 4-Me, 2-Me, 4-OMe, 2-OMe] were prepared by treating I (X = O) with N₂H₄ and treating I (X = NNH₂) with ClCH₂CONHCONHC₆H₄R₃. I are ineffective against *Entamoeba histolytica* in rats.
IT 89258-34-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and amebicidal activity of)
RN 89258-34-4 HCAPLUS
CN Acetamide, N-[[(2-methylphenyl)amino]carbonyl]-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



IT 89258-26-6P 89258-40-2P 89258-46-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 89258-28-6 HCAPLUS
CN Acetamide, N-[[(4-methylphenyl)amino]carbonyl]-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)




RN 89258-40-2 HCAPLUS
CN Acetamide, N-[[(4-methoxyphenyl)amino]carbonyl]-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



RN 89258-46-8 HCAPLUS

CN Acetamide, N-[(2-methoxyphenyl)amino]carbonyl]-2-[(4-oxo-2-phenyl-3(4H)-quinazolinyl)amino]- (CA INDEX NAME)



L85 ANSWER 45 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1981:462253 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 95:62253

ORIGINAL REFERENCE NO.: 95:10519a,10522a

TITLE: 3-Alkenyloxy-4(3H)-quinazolinone derivatives

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56026881	A	19810316	JP 1979-102384	19790810 <--
JP 01034988	B	19890721		

PRIORITY APPLN. INFO.: JP 1979-102384 A 19790810 <--

GI



I



II

AB Thirteen title derivs. I (R = H, alkyl, cycloalkyl; R1-R5 = H, halo, alkyl; R6 = halo, alkyl, NO2, alkoxy; n = 0-2) were prepared by treating II with R⁷CR1R2CR3:CR4R5 (R⁷ = halo). Thus, 12.1 g BrCH2CH:CH2 was added to a mixture of 4 g NaOH and 17.6 g II (R = Me, R6 = H) in MeOH with reflux to give, after 1 h, 18 g I (R = Me, R1-R6 = H) (III). III showed acaricidal and insecticidal activity at 0.2%.


IT 79490-45-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and insecticidal activity of)

RN 78490-45-6 HCAPLUS

CN 4(3H)-Quinazolinone, 2-cyclohexyl-3-(2-propen-1-yloxy)- (CA INDEX NAME)



L85 ANSWER 46 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1980:158265 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 92:158265

ORIGINAL REFERENCE NO.: 92:25574h,25575a

TITLE: Some reactions with 4H-3,1-benzoxazin-4-one and some studies on the growth of bacteria

AUTHOR(S): Mahmoud, M.; El-Hashash, M.

CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt

SOURCE: Revue Roumaine de Chimie (1979), 24(6), 849-58


CODEN: RRCHAX; ISSN: 0035-3930

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 92:158265

GI



I



II

AB Some 2-substituted-3,1(4H)benzoxazin-4-ones were reacted with Grignard reagents, primary amines sulfamidic compds., NaN₃, aldehydes, Pils, or malononitrile, and the resulting products were tested for their inhibitory effects on 2 strains of Bacillus. I [72756-63-9] and II [72756-64-0] were among the most active antibacterial compds. obtained.


IT 72756-56-0F 72756-64-0P

RL: EAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and bactericidal activity of)

RN 72756-56-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[[4-(4-chlorophenyl)methylene]amino]-2-cyclohexyl- (CA INDEX NAME)



RN 72756-64-0 HCAPLUS

CN 4(3H)-Quinazolinone, 3-[(1,3-benzodioxol-5-ylmethylene)amino]-2-cyclohexyl-
(CA INDEX NAME)

L85 ANSWER 47 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1979:152111 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 90:152111

ORIGINAL REFERENCE NO.: 90:24185a,24188a

TITLE: Syntheses and anti-tumor activity of N-heterocyclic

compounds having the cyclic hydrazide structure
 AUTHOR(S): Hayashi, Eisaku; Higashino, Takeo; Oishi, Etsuo;
 Iijima, Chihoko; Yamagishi, Masaaki; Ota, Chieko;
 Miwa, Yoshio; Nakajima, Atsuko; Iwata, Shigeko; et al.
 CORPORATE SOURCE: Shizuoka Coll. Pharm., Shizuoka, Japan
 SOURCE: Yakugaku Zasshi (1978), 98(11), 1560-5
 CODEN: YKKZAJ; ISSN: 0031-6903


DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB Compds. containing a cyclic hydrazide structure in their mol., 2-amino-3-phenyl-1(2H)-isoquinolinone, 3-amino-2-(4-methoxyphenyl)-4(3H)-quinazolinone, 5-amino-1,5-dihydro-1-phenyl-4H-pyrazolo[3,4-d]pyrimidin-4-one, 5-amino-1,5-dihydro-1-(2-pyridyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, and 30 of their derivs. were prepared for antitumor screening. 1,5-Dihydro-1-phenyl-4H-pyrazolo[3,4-d]pyrimidin-4-one had anti-tumor activity against Sarcoma-180A.


IT 69722-14-1P 69722-15-2P 69722-16-3P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation and antitumor activity of)


RN 69722-14-1 HCAPLUS

CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[(phenylmethylene)amino]- (CA
INDEX NAME)

RN 69722-15-2 HCAPLUS
 CN 4(3H)-Quinazolinone, 2-(4-methoxyphenyl)-3-[[4-methoxyphenyl)methylene]amino]- (CA INDEX NAME)



RN 69722-16-3 HCAPLUS
 CN 4(3H)-Quinazolinone, 3-[[4-chlorophenyl)methylene]amino]-2-(4-methoxyphenyl)- (CA INDEX NAME)



L85 ANSWER 48 OF 48 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1974:47670 HCAPLUS Full-text
 DOCUMENT NUMBER: 80:47670
 ORIGINAL REFERENCE NO.: 80:7761a,7764a
 TITLE: Substituted o-aminobenzoylhydrazone derivatives
 PATENT ASSIGNEE(S): FERLUI
 SOURCE: Fr. Demande, 19 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2168136	A1	19730831	FR 1972-1397	19720117 <--
FR 2168136	B1	19750801		
PRIORITY APPLN. INFO.:			FR 1972-1397	19720117 <--

GI For diagram(s), see printed CA Issue.

AB Thirty-three benzoylhydrazones (I; R = phenethyl or substituted phenyl, benzoyl, or phenethyl; R1 = Cl, H, NO2; R2 = H, Me; R3 = Me, H; R4 = Ph, substituted phenyl, CO2H, pyridyl), useful as analgesic, antiinflammatory, and


antipyretic agents, are prepared by condensation of R3CHO and R3COR4 with the benzohydrazides.

IT 50919-16-3P 50919-18-1F 50919-20-5P
50919-22-7P 50919-24-9P 50919-25-8P
50919-26-1P 50919-27-2P 50919-28-3P
50919-29-4F 50919-30-7P 50919-31-8F
50919-34-3F 50919-37-4P 50919-38-5P
50919-39-6F 50919-40-9P 51098-37-4F
51098-38-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)


RN 50919-16-9 HCAPLUS

CN Benzoic acid, 5-methyl-2-[(4-methylbenzoyl)amino]-,
2-(1-methylethylidene)hydrazide (CA INDEX NAME)




RN 50919-18-1 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-(1-methylethylidene)hydrazide (CA INDEX NAME)




RN 50919-20-5 HCAPLUS

CN Benzoic acid, 2-[(4-bromobenzoyl)amino]-5-methyl-,
2-(1-methylethylidene)hydrazide (CA INDEX NAME)




RN 50919-22-7 HCAPLUS

CN Benzoic acid, 2-[(2-methoxybenzoyl)amino]-,
2-(1-methylethylidene)hydrazide (CA INDEX NAME)




RN 50919-24-9 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-, 2-(1-methylethylidene)hydrazide
(CA INDEX NAME)




RN 50919-25-0 HCAPLUS

CN Benzoic acid, 4-chloro-2-[(4-methylbenzoyl)amino]-,
2-(1-methylethylidene)hydrazide (CA INDEX NAME)




RN 50919-26-1 HCAPLUS

CN Benzoic acid, 2-[(4-methylbenzoyl)amino]-, 2-(1-methylethylidene)hydrazide
(CA INDEX NAME)




RN 50919-27-2 HCAPLUS

CN Benzoic acid, 2-[(2-fluorobenzoyl)amino]-5-methyl-,
2-(1-methylethylidene)hydrazide (CA INDEX NAME)




RN 50919-28-3 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-(phenylmethylene)hydrazide (CA INDEX NAME)




RN 50919-29-4 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-(1-phenylethylidene)hydrazide (CA INDEX NAME)




RN 50919-30-7 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-[(2-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)





RN 50919-31-8 HCAPLUS

CN Benzoic acid, 2-[(4-nitrobenzoyl)amino]-, 2-(phenylmethylene)hydrazide
(CA INDEX NAME)




RN 50919-36-3 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-[4-(dimethylamino)phenyl]methylenehydrazide (CA INDEX NAME)





RN 50919-37-4 HCAPLUS

CN Benzoic acid, 2-[(4-nitrobenzoyl)amino]-,
2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)




RN 50919-38-5 HCAPLUS


CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-(3-pyridinylmethylene)hydrazide (CA INDEX NAME)




RN 50919-39-6 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-(4-pyridinylmethylene)hydrazide (CA INDEX NAME)

RN 50919-40-9 HCAPLUS



CN Benzoic acid, 2-[(4-nitrobenzoyl)amino]-,
2-(4-pyridinylmethylene)hydrazide (CA INDEX NAME)

RN 51098-37-4 HCAPLUS

CN Benzoic acid, 2-[(4-fluorobenzoyl)amino]-5-methyl-,
2-[1-(3,5-dichloro-2-hydroxyphenyl)ethylidene]hydrazide (CA INDEX NAME)


RN 51098-38-5 HCAPLUS

CN Benzoic acid, 2-[(4-nitrobenzoyl)amino]-,
2-[(2-hydroxyphenyl)methylene]hydrazide (CA INDEX NAME)



FILE 'HOME' ENTERED AT 10:30:25 ON 20 MAR 2009


=> d stat que 15; d stat que 19; d stat que 164; d his nofile
L1 STR



VAR G1=11/13/15
VAR G5=C/CY/17/19/21/23/25/27
REP G10=(3-7) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28


STEREO ATTRIBUTES: NONE
L2 (23983)SEA FILE=REGISTRY SSS FUL L1
L3 STR



VAR G1=11/13/15
VAR G5=C/CY/17/19/21/23/25/27
REP G10=(3-7) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE
L4 STR




VAR G1=11/13/15
 VAR G5=C/CY/17/19/21/23/25/27
 REP G10=(3-7) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
 L5 20832 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)

100.0% PROCESSED 22461 ITERATIONS 20832 ANSWERS
 SEARCH TIME: 00.00.03

L6 STR




VAR G1=11/13/15
 VAR G5=C/CY/17/19/21/23/25/27
 REP G10=(3-7) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L7 (23983)SEA FILE=REGISTRY SSS FUL L6
L8 STR




NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE
L9 8 SEA FILE=REGISTRY SUB=L7 SSS FUL L8

100.0% PROCESSED 13 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

L1 STR



VAR G1=11/13/15
VAR G5=C/CY/17/19/21/23/25/27
REP G10=(3-7) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L2 (23983)SEA FILE=REGISTRY SSS FUL L1

L3 STR



VAR G1=11/13/15

VAR G5=C/CY/17/19/21/23/25/27

REP G10=(3-7) A

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L4 STR



VAR G1=11/13/15

VAR G5=C/CY/17/19/21/23/25/27

REP G10=(3-7) A

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:






RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE



L5 20832 SEA FILE=REGISTRY SUB=L2 SSS FUL (L3 OR L4)

L58 STR



N @76 Ak @82

Page 1-A



Page 2-A

VAR G1=11/13/15

VAR G2=H/X/OH/82/69/77/74/76/77/80/71

REP G3=(1-3) C

VAR G10=32-7 31-4/38-7 37-4/52-7 53-4/53-7 54-4/53-7 52-4/47-7 48-4

NODE ATTRIBUTES:

NSPEC IS R AT 76

CONNECT IS E1 RC AT 70

CONNECT IS E1 RC AT 78

CONNECT IS E1 RC AT 79

CONNECT IS E1 RC AT 81

CONNECT IS E1 RC AT 82

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 58

STEREO ATTRIBUTES: NONE

L60 STR



VAR G1=11/13/15/20/17/23/26/29/32

VAR G6=H/38/CY/39

REP G10=(3-7) A

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 38

CONNECT IS E2 RC AT 39

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 40

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L64 9996 SEA FILE=REGISTRY SUB=L5 SSS FUL L58 AND L60

100.0% PROCESSED 20819 ITERATIONS

9996 ANSWERS

SEARCH TIME: 00.00.04

(FILE 'HOME' ENTERED AT 08:44:00 ON 20 MAR 2009)

D SAVED

FILE 'REGISTRY' ENTERED AT 08:44:39 ON 20 MAR 2009

ACT ROB857SUB1/A

L1

STR

L2 (23983)SEA SSS FUL L1

L3

STR

L4

STR

L5 20832 SEA SUB=L2 SSS FUL (L3 OR L4)

FILE 'STNGUIDE' ENTERED AT 08:44:43 ON 20 MAR 2009

FILE 'REGISTRY' ENTERED AT 08:45:23 ON 20 MAR 2009

ACT ROB857SUB2/A

```

-----
L6          STR
L7 (        23983)SEA SSS FUL L6
L8          STR
L9          8 SEA SUB=L7 SSS FUL L8
-----

```

FILE 'STNGUIDE' ENTERED AT 08:45:23 ON 20 MAR 2009

```

FILE 'HCAPLUS' ENTERED AT 08:46:23 ON 20 MAR 2009
L10         1 SEA SPE=ON ABB=ON L9
L11        695 SEA SPE=ON ABB=ON L5
           ACT ROB857HCAAU/A
-----
L12         STR
L13 (        23983)SEA SSS FUL L12
L14         STR
L15         STR
L16 (        20832)SEA SUB=L13 SSS FUL (L14 OR L15)
L17 (        695)SEA SPE=ON ABB=ON L16
L18 (         1)SEA SPE=ON ABB=ON US2006-550857/AP
L19 (        163)SEA SPE=ON ABB=ON ETO N7/AU
L20 (        114)SEA SPE=ON ABB=ON NAGAO R7/AU
L21 (        361)SEA SPE=ON ABB=ON KAZAMA T7/AU
L22         2 SEA SPE=ON ABB=ON (L18 OR L19 OR L20 OR L21) AND L17
-----
D SCAN

```

FILE 'STNGUIDE' ENTERED AT 08:46:57 ON 20 MAR 2009

```

FILE 'REGISTRY' ENTERED AT 09:06:37 ON 20 MAR 2009
L23         1 SEA SPE=ON ABB=ON 7723-14-0
-----
FILE 'HCAPLUS' ENTERED AT 09:06:37 ON 20 MAR 2009
L24        3439 SEA SPE=ON ABB=ON PRURITUS/CT
L25        7680 SEA SPE=ON ABB=ON IMMUNODEFICIENCY/CT
L26        1825 SEA SPE=ON ABB=ON SKIN/OBI(L) ULCER7/OBI
L27        6853 SEA SPE=ON ABB=ON HYPERLIPIDEMIA/CT
L28        30922 SEA SPE=ON ABB=ON ANEMIA/OBI
L29        7980 SEA SPE=ON ABB=ON SEX7/OBI(L) (DISORDER#/OBI OR DYSFUNCTION7/O
           BI)
L30         299 SEA SPE=ON ABB=ON RED/OBI(L) EYE7/OBI
L31         227 SEA SPE=ON ABB=ON (BIOLOGICAL TRANSPORT/CT OR BLOOD/OBI OR
           SERUM/OBI) (L) PHOSPHOROUS/OBI
L32         7512 SEA SPE=ON ABB=ON CALCIFICATION/OBI
L33         2484 SEA SPE=ON ABB=ON GROWTH/CW(L) (RETARD7/OBI OR DELAY7/OBI)
L34         6287 SEA SPE=ON ABB=ON BONE7/OBI(L) (FRACTURE/OBI OR DEFORM7/OBI)
L35         1236 SEA SPE=ON ABB=ON (CARDIAC/OBI OR HEART/OBI) (L) CONDUCTION/OBI
-----
L36        1695 SEA SPE=ON ABB=ON PAIN/OBI(L) (BONE/OBI OR JOINT7/OBI)
L37        287 SEA SPE=ON ABB=ON (NERVE/CT OR CENTRAL NERVOUS SYSTEM+NT/CT) (
           L) (PTH/OBI OR VITAMIN D/OBI OR PARATHYROID HORMONE/OBI)
L38         6 SEA SPE=ON ABB=ON PERIPHERAL NERVOUS SYSTEM+NT/CT(L) (PTH/OBI
           OR VITAMIN D/OBI OR PARATHYROID HORMONE/OBI)
L39        23531 SEA SPE=ON ABB=ON (KIDNEY7/OBI OR RENAL/OBI) (L) FAILURE/OBI
L40        75591 SEA SPE=ON ABB=ON HEART, DISEASE/CT OR CARDIOMYOPATH7/OBI
L41        3608 SEA SPE=ON ABB=ON HYPERPARATHYROID7/OBI
L42         593 SEA SPE=ON ABB=ON HYPERPHOSPHATEMI7/OBI
L43         829 SEA SPE=ON ABB=ON OSTEALGIA/OBI OR ARTHRALGIA/OBI
L44        2493 SEA SPE=ON ABB=ON CARBOHYDRATE METABOLISM/CT

```


L45 197 SEA SPE=ON ABB=ON TENDON/CT(L) (TORN/OBI OR RUPTURE#/OBI OR
 INJUR?/OBI OR TEAR?/OBI)
 L46 21292 SEA SPE=ON ABB=ON BONE/CT(L) (DISEASE/OBI OR DISORDER#/OBI)
 L47 1114 SEA SPE=ON ABB=ON OSTEODYSTROPH?/OBI OR OSTEOPATH?/OBI
 L48 10271 SEA SPE=ON ABB=ON ARTERIOSCLEROSIS/CT
 L49 170 SEA SPE=ON ABB=ON VASCULOPATH?/OBI(L) DIABET?/OBI
 L50 225 SEA SPE=ON ABB=ON (LUNG/OBI OR PULMONARY/OBI) (L) (EXPANSION/OB
 I OR DIFFUS?/OBI) (L) (DISEASE#/OBI OR DISORDER#/OBI OR IMPAIR?/O
 BI)
 L51 46938 SEA SPE=ON ABB=ON (HEART/OBI OR CARDIAC/OBI) (L) (INFARCT?/OBI
 OR FAILURE/OBI OR MURMUR/OBI)
 L52 344 SEA SPE=ON ABB=ON NERVOUS SYSTEM+NT/CT(L) (PTH/OBI OR VITAMIN
 D/OBI OR PARATHYROID HORMONE/OBI)
 L53 203624 SEA SPE=ON ABB=ON L23
 L54 1477 SEA SPE=ON ABB=ON L53 (L) (TRANSPORT?/OBI)
 L55 16 SEA SPE=ON ABB=ON L11 AND (L24 OR L25 OR L26 OR L27 OR L28
 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37
 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46
 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR L54)

FILE 'REGISTRY' ENTERED AT 09:50:46 ON 20 MAR 2009

FILE 'REGISTRY' ENTERED AT 09:51:04 ON 20 MAR 2009

L56 STR L1
 L57 50 SEA SUB=L5 SSS SAM L56
 D STAT QUE
 L58 STR L56
 L59 50 SEA SUB=L5 SSS SAM L58
 L60 STR L1
 L61 50 SEA SUB=L5 SSS SAM (L58 OR L60)
 L62 50 SEA SUB=L5 SSS SAM L58 AND L60

FILE 'ZCAPLUS' ENTERED AT 10:20:00 ON 20 MAR 2009

L63 8 SEA SPE=ON ABB=ON L62

FILE 'REGISTRY' ENTERED AT 10:20:05 ON 20 MAR 2009

L64 9996 SEA SUB=L5 SSS FUL L58 AND L60
 SAVE TEMP L64 ROB857SUB3/A

FILE 'HCAPLUS' ENTERED AT 10:20:39 ON 20 MAR 2009

L65 122 SEA SPE=ON ABB=ON L64
 L66 ANALYZE L65 1- RN HIT : 1979 TERMS
 D 1-20
 L67 27 SEA SPE=ON ABB=ON L65 AND PATENT/DT
 L68 0 SEA SPE=ON ABB=ON L65 AND REVIEW/DT
 L69 95 SEA SPE=ON ABB=ON L65 NOT L67
 L70 86 SEA SPE=ON ABB=ON L69 AND PY<2007
 L71 81 SEA SPE=ON ABB=ON L69 AND PY<2006
 L72 47 SEA SPE=ON ABB=ON L65 AND PHARMAC?/SC, SX
 L73 44 SEA SPE=ON ABB=ON L65 (L) (THU OR BAC OR PAC OR PKT OR DMA)/RL
 L74 59 SEA SPE=ON ABB=ON (L72 OR L73)
 L75 15 SEA SPE=ON ABB=ON L72 NOT L73
 D SCAN TI HITIND
 L76 19 SEA SPE=ON ABB=ON L74 AND PATENT/DT
 L77 40 SEA SPE=ON ABB=ON L74 NOT L76
 L78 33 SEA SPE=ON ABB=ON L77 AND PY<2007
 L79 19 SEA SPE=ON ABB=ON L76 AND (PD<20070620 OR AD<20070620 OR
 PRD<20070620)

```

L80          52 SEA SPE=ON  ABB=ON  (L78 OR L79)

FILE 'STINGUIDE' ENTERED AT 10:25:01 ON 20 MAR 2009

FILE 'HCAPLUS' ENTERED AT 10:25:28 ON 20 MAR 2009
  D QUE NOS L22
L81          2 SEA SPE=ON  ABB=ON  L22 OR (L22 AND (L24 OR L25 OR L26 OR L27
    OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36
    OR L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45
    OR L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR L54))
  D QUE NOS L81
  D IBIB ABS HITIND HITSTR L81 1-2

FILE 'REGISTRY' ENTERED AT 10:27:52 ON 20 MAR 2009
  D STAT QUE L9

FILE 'HCAPLUS' ENTERED AT 10:28:00 ON 20 MAR 2009
  D QUE NOS L10
L82          0 SEA SPE=ON  ABB=ON  L10 NOT L81
L83          1 SEA SPE=ON  ABB=ON  L10 AND L81
  D SCAN TI

FILE 'REGISTRY' ENTERED AT 10:28:31 ON 20 MAR 2009
  D STAT QUE L5

FILE 'HCAPLUS' ENTERED AT 10:28:31 ON 20 MAR 2009
  D QUE NOS L55
L84          14 SEA SPE=ON  ABB=ON  L55 NOT L81
  D IBIB ABS HITIND HITSTR L84 1-14

FILE 'REGISTRY' ENTERED AT 10:29:26 ON 20 MAR 2009
  D STAT QUE L64

FILE 'HCAPLUS' ENTERED AT 10:29:27 ON 20 MAR 2009
  D QUE NOS L80
L85          48 SEA SPE=ON  ABB=ON  L80 NOT (L81 OR L84)
  D IBIB ABS HITSTR 1-48

FILE 'HOME' ENTERED AT 10:30:25 ON 20 MAR 2009
  D STAT QUE L5
  D STAT QUE L9
  D STAT QUE L64

```

=>